

Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The present invention relates to several novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses, or as targets for the development of pharmaceutically / immunologically active compounds and cells.

BACKGROUND OF THE INVENTION

According to the World Health Organization (WHO), cancer ranged among the four major non-communicable deadly diseases worldwide in 2012. For the same year, colorectal cancer, breast cancer and respiratory tract cancers were listed within the top 10 causes of death in high income countries (<http://www.who.int/mediacentre/factsheets/fs310/en/>).

Epidemiology

In 2012, 14.1 million new cancer cases, 32.6 million patients suffering from cancer (within 5 years of diagnosis) and 8.2 million cancer deaths were estimated worldwide (Ferlay et al., 2013; Bray et al., 2013).

- 2 -

Within the groups of brain cancer, leukemia and lung cancer, the present application particularly focuses on glioblastoma (GB), chronic lymphocytic leukemia (CLL), and non-small cell and small cell lung cancer (NSCLC and SCLC).

Lung cancer is the most common type of cancer worldwide and the leading cause of death from cancer in many countries.

Breast cancer is an immunogenic cancer entity and different types of infiltrating immune cells in primary tumors exhibit distinct prognostic and predictive significance. A large number of early phase immunotherapy trials have been conducted in breast cancer patients. Most of the completed vaccination studies targeted HER2 and carbohydrate antigens like MUC-1 and revealed rather disappointing results. Clinical data on the effects of immune checkpoint modulation with ipilimumab and other T cell-activating antibodies in breast cancer patients are emerging (Emens, 2012).

Chronic lymphocytic leukemia

While CLL is not curable at present, many patients show only slow progression of the disease or worsening of symptoms. As patients do not benefit from an early onset of treatment, the initial approach is “watch and wait” (Richards et al., 1999). For patients with symptomatic or rapidly progressing disease, several treatment options are available. These include chemotherapy, targeted therapy, immune-based therapies like monoclonal antibodies, chimeric antigen-receptors (CARs) and active immunotherapy, and stem cell transplants.

Monoclonal antibodies are widely used in hematologic malignancies. This is due to the knowledge of suitable antigens based on the good characterization of immune cell surface molecules and the accessibility of tumor cells in blood or bone marrow. Common monoclonal antibodies used in CLL therapy target either CD20 or CD52. Rituximab, the first monoclonal anti-CD20 antibody originally approved by the FDA for treatment of NHLs, is now widely used in CLL therapy. Combinational treatment with rituxi-

mab/fludarabine/cyclophosphamide leads to higher CR rates and improved overall survival (OS) compared to the combination fludarabine/cyclophosphamide and has become the preferred treatment option (Hallek et al., 2008). Ofatumomab targets CD20 and is used for therapy of refractory CLL patients (Wierda et al., 2011). Obinutuzumab is another monoclonal anti-CD20 antibody used in first-line treatment in combination with chlorambucil (Goede et al., 2014).

Alemtuzumab is an anti-CD52 antibody used for treatment of patients with chemotherapy-resistant disease or patients with poor prognostic factors as del 17p or p53 mutations (Parikh et al., 2011).

Novel monoclonal antibodies target CD37 (otlertuzumab, BI 836826, IMGN529 and (177)Lu-tetulumab) or CD40 (dacetuzumab and lucatumumab) and are tested in pre-clinical settings (Robak and Robak, 2014).

Several completed and ongoing trials are based on engineered autologous chimeric antigen receptor (CAR)-modified T cells with CD19 specificity (Maus et al., 2014). So far, only the minority of patients showed detectable or persistent CARs. One partial response (PR) and two complete responses (CR) have been detected in the CAR T-cell trials by Porter et al. and Kalos et al. (Kalos et al., 2011; Porter et al., 2011).

Active immunotherapy includes the following strategies: gene therapy, whole modified tumor cell vaccines, DC-based vaccines and tumor associated antigen (TAA)-derived peptide vaccines.

Approaches in gene therapy make use of autologous genetically modified tumor cells. These B-CLL cells are transfected with immuno-(co-)stimulatory genes like IL-2, IL-12, TNF-alpha, GM-CSF, CD80, CD40L, LFA-3 and ICAM-1 to improve antigen presentation and T cell activation (Carballido et al., 2012). While specific T-cell responses and reduction in tumor cells are readily observed, immune responses are only transient.

Several studies have used autologous DCs as antigen presenting cells to elicit anti-tumor responses. DCs have been loaded *ex vivo* with tumor associated peptides, whole tumor cell lysate and tumor-derived RNA or DNA. Another strategy uses whole tumor cells for fusion with DCs and generation of DC-B-CLL-cell hybrids. Transfected DCs initiated both CD4+ and CD8+ T-cell responses (Muller et al., 2004). Fusion hybrids and DCs loaded with tumor cell lysate or apoptotic bodies increased tumor-specific CD8+ T-cell responses. Patients that showed a clinical response had increased IL-12 serum levels and reduced numbers of Tregs (Palma et al., 2008).

Different approaches use altered tumor cells to initiate or increase CLL-specific immune responses. An example for this strategy is the generation of trioma cells: B-CLL cells are fused to anti-Fc receptor expressing hybridoma cells that have anti-APC specificity. Trioma cells induced CLL-specific T-cell responses *in vitro* (Kronenberger et al., 2008).

Another strategy makes use of irradiated autologous CLL cells with Bacillus Calmette-Guérin as an adjuvant as a vaccine. Several patients showed a reduction in leukocyte levels or stable disease (Hus et al., 2008).

Besides isolated CLL cells, whole blood from CLL patients has been used as a vaccine after preparation in a blood treatment unit. The vaccine elicited CLL-specific T-cell responses and led to partial clinical responses or stable disease in several patients (Spaner et al., 2005).

Several TAAs are over-expressed in CLL and are suitable for vaccinations. These include fibromodulin (Mayr et al., 2005), RHAMM/CD168 (Giannopoulos et al., 2006), MDM2 (Mayr et al., 2006), hTERT (Counter et al., 1995), the oncofetal antigen-immature laminin receptor protein (OFAiLRP) (Siegel et al., 2003), adipophilin (Schmidt et al., 2004), survivin (Granziero et al., 2001), KW1 to KW14 (Krackhardt et al., 2002) and the tumor-derived IgVHCDR3 region (Harig et al., 2001; Carballido et al., 2012). A phase I clinical trial was conducted using the RHAMM-derived R3 peptide as a vaccine.

5 of 6 patients had detectable R3-specific CD8+ T-cell responses (Giannopoulos et al., 2010).

Colorectal cancer

Depending on the colorectal cancer (CRC) stage, different standard therapies are available for colon and rectal cancer. Standard procedures include surgery, radiation therapy, chemotherapy and targeted therapy for CRC (Berman et al., 2015a; Berman et al., 2015b).

In addition to chemotherapeutic drugs, several monoclonal antibodies targeting the epidermal growth factor receptor (EGFR, cetuximab, panitumumab) or the vascular endothelial growth factor-A (VEGF-A, bevacizumab) are administered to patients with high stage disease. For second-line and later treatment the inhibitor for VEGF aflibercept, the tyrosine kinase inhibitor regorafenib and the thymidylate-synthetase inhibitor TAS-102 and the dUTPase inhibitor TAS-114 can be used (Stintzing, 2014; Wilson et al., 2014).

The most recent clinical trials analyze active immunotherapy as a treatment option against CRC. Those strategies include the vaccination with peptides from tumor-associated antigens (TAAs), whole tumor cells, dendritic cell (DC) vaccines and viral vectors (Koido et al., 2013).

Peptide vaccines have so far been directed against carcinoembryonic antigen (CEA), mucin 1, EGFR, squamous cell carcinoma antigen recognized by T cells 3 (SART3), beta-human chorionic gonadotropin (beta-hCG), Wilms' Tumor antigen 1 (WT1), Survivin-2B, MAGE3, p53, ring finger protein 43 and translocase of the outer mitochondrial membrane 34 (TOMM34), or mutated KRAS. In several phase I and II clinical trials patients showed antigen-specific CTL responses or antibody production. In contrast to immunological responses, many patients did not benefit from peptide vaccines on the clinical level (Koido et al., 2013; Miyagi et al., 2001; Moulton et al., 2002; Okuno et al., 2011).

Dendritic cell vaccines comprise DCs pulsed with either TAA-derived peptides, tumor cell lysates, apoptotic tumor cells, or tumor RNA or DC-tumor cell fusion products. While many patients in phase I/II trials showed specific immunological responses, only the minority had a clinical benefit (Koido et al., 2013).

Whole tumor cell vaccines consist of autologous tumor cells modified to secrete GM-CSF, modified by irradiation or virus-infected, irradiated cells. Most patients showed no clinical benefit in several phase II/ III trials (Koido et al., 2013).

Vaccinia virus or replication-defective avian poxvirus encoding CEA as well as B7.1, ICAM-1 and LFA-3 have been used as vehicles in viral vector vaccines in phase I clinical trials. A different study used nonreplicating canarypox virus encoding CEA and B7.1. Besides the induction of CEA-specific T cell responses 40% of patients showed objective clinical responses (Horig et al., 2000; Kaufman et al., 2008).

Esophageal cancer

The primary treatment strategy for esophageal cancer depends on tumor stage and location, histological type and the medical condition of the patient. Surgery alone is not sufficient, except in a small subgroup of patients with squamous cell carcinoma.

Data on immunotherapeutic approaches in esophageal cancer are scarce, as only a very limited number of early phase clinical trials have been performed. A vaccine consisting of three peptides derived from three different cancer-testis antigens (TTK protein kinase, lymphocyte antigen 6 complex locus K and insulin-like growth factor (IGF)-II mRNA binding protein 3) was administered to patients with advanced esophageal cancer in a phase I trial with moderate results. Intra-tumoral injection of activated T cells after *in vitro* challenge with autologous malignant cells elicited complete or partial tumor responses in four of eleven patients in a phase I/II study (Toomey et al., 2013).

Gastric cancer

Gastric cancer (GC) begins in the cells lining the mucosal layer and spreads through the outer layers as it grows. Surgery is the primary treatment and the only curative treatment for gastric cancer. The efficacy of current therapeutic regimens for advanced GC is poor, resulting in low 5-year survival rates. Immunotherapy might be an alternative approach to ameliorate the survival of GC patients. Adoptive transfer of tumor-associated lymphocytes and cytokine induced killer cells, peptide-based vaccines targeting HER2/neu, MAGE-3 or vascular endothelial growth factor receptor 1 and 2 and dendritic cell-based vaccines targeting HER2/neu showed promising results in clinical GC trials. Immune checkpoint inhibition and engineered T cells might represent additional therapeutic options, which is currently evaluated in pre-clinical and clinical studies (Matsueda and Graham, 2014).

Glioblastoma

The therapeutic options for glioblastoma (WHO grade IV) are very limited. According to the guidelines released by the German Society for Neurology the standard therapy in young patients includes resection or biopsy of the tumor, focal radiation therapy and chemotherapy with temozolomide or CCNU/lomustine or a combination of procarbazine with CCNU and vincristine (PCV). In the USA, Canada and Switzerland treatment with bevacizumab (anti-VEGF-antibody) is also approved for relapse therapy (Leitlinien für Diagnostik und Therapie in der Neurologie, 2014).

Different immunotherapeutic approaches are investigated for the treatment of GB, including immune-checkpoint inhibition, vaccination and adoptive transfer of engineered T cells.

Antibodies directed against inhibitory T cell receptors or their ligands were shown to efficiently enhance T cell-mediated anti-tumor immune responses in different cancer types, including melanoma and bladder cancer. The effects of T cell activating antibodies like ipilimumab and nivolumab are therefore assessed in clinical GB trials, but preliminary data indicate autoimmune-related adverse events.

Different vaccination strategies for GB patients are currently investigated, including peptide-based vaccines, heat-shock protein vaccines, autologous tumor cell vaccines, dendritic cell-based vaccines and viral protein-based vaccines. In these approaches peptides derived from GB-associated proteins like epidermal growth factor receptor variant III (EGFRvIII) or heat shock proteins or dendritic cells pulsed with autologous tumor cell lysate or cytomegalo virus components are applied to induce an anti-tumor immune response in GB patients. Several of these studies reveal good safety and tolerability profiles as well as promising efficacy data.

Adoptive transfer of genetically modified T cells is an additional immunotherapeutic approach for the treatment of GB. Different clinical trials currently evaluate the safety and efficacy of chimeric antigen receptor bearing T cells directed against HER2, IL-13 receptor alpha 2 and EGFRvIII (Ampie et al., 2015).

Liver cancer

Disease management depends on the tumor stage at the time of diagnosis and the overall condition of the liver. If surgery is not a treatment option, different other therapies are available at hand.

Lately, a limited number of immunotherapy trials for HCC have been conducted. Cytokines have been used to activate subsets of immune cells and/or increase the tumor immunogenicity (Reinisch et al., 2002; Sangro et al., 2004). Other trials have focused on the infusion of Tumor-infiltrating lymphocytes or activated peripheral blood lymphocytes (Shi et al., 2004; Takayama et al., 1991; Takayama et al., 2000b).

So far, a small number of therapeutic vaccination trials have been executed. Butterfield et al. conducted two trials using peptides derived from alpha-fetoprotein (AFP) as a vaccine or DCs loaded with AFP peptides *ex vivo* (Butterfield et al., 2003; Butterfield et al., 2006). In two different studies, autologous dendritic cells (DCs) were pulsed *ex vivo* with autologous tumor lysate (Lee et al., 2005) or lysate of the hepatoblastoma cell line

HepG2 (Palmer et al., 2009). So far, vaccination trials have only shown limited improvements in clinical outcomes.

Melanoma

The standard therapy in melanoma is complete surgical resection with surrounding healthy tissue. If resection is not complete or not possible at all, patients receive primary radiation therapy, which can be combined with interferon-alpha administration in advanced stages (stages IIB/C and IIIA-C).

Enhancing the anti-tumor immune responses appears to be a promising strategy for the treatment of advanced melanoma. In the United States the immune checkpoint inhibitor ipilimumab as well as the BRAF kinase inhibitors vemurafenib and dabrafenib and the MEK inhibitor trametinib are already approved for the treatment of advanced melanoma. Both approaches increase the patient's anti-tumor immunity - ipilimumab directly by reducing T cell inhibition and the kinase inhibitors indirectly by enhancing the expression of melanocyte differentiation antigens. Additional checkpoint inhibitors (nivolumab and lambrolizumab) are currently investigated in clinical studies with first encouraging results. Additionally, different combination therapies targeting the anti-tumor immune response are tested in clinical trials including ipilimumab plus nivolumab, ipilimumab plus a gp100-derived peptide vaccine, ipilimumab plus dacarbazine, ipilimumab plus IL-2 and ipilimumab plus GM-CSF (Srivastava and McDermott, 2014).

Several different vaccination approaches have already been evaluated in patients with advanced melanoma. So far, phase III trials revealed rather disappointing results and vaccination strategies clearly need to be improved. Therefore, new clinical trials, like the OncoVEX GM-CSF trial or the DERMA trial, aim at improving clinical efficacy without reducing tolerability (<http://www.cancerresearchuk.org>).

Adoptive T cell transfer shows great promise for the treatment of advanced stage melanoma. *In vitro* expanded autologous tumor infiltrating lymphocytes as well as T cells harboring a high affinity T cell receptor for the cancer-testis antigen NY-ESO-1 had sig-

- 10 -

nificant beneficial and low toxic effects upon transfer into melanoma patients. Unfortunately, T cells with high affinity T cell receptors for the melanocyte specific antigens MART1 and gp100 and the cancer-testis antigen MAGEA3 induced considerable toxic effects in clinical trials. Thus, adoptive T cell transfer has high therapeutic potential, but safety and tolerability of these treatments needs to be further increased (Phan and Rosenberg, 2013; Hinrichs and Restifo, 2013).

Non-small cell lung cancer

Treatment options are determined by the type (small cell or non-small cell) and stage of cancer and include surgery, radiation therapy, chemotherapy, and targeted biological therapies such as bevacizumab, erlotinib and gefitinib.

To expand the therapeutic options for NSCLC, different immunotherapeutic approaches have been studied or are still under investigation. While vaccination with L-BLP25 or MAGEA3 failed to demonstrate a vaccine-mediated survival advantage in NSCLC patients, an allogeneic cell line-derived vaccine showed promising results in clinical studies. Additionally, further vaccination trials targeting gangliosides, the epidermal growth factor receptor and several other antigens are currently ongoing. An alternative strategy to enhance the patient's anti-tumor T cell response consists of blocking inhibitory T cell receptors or their ligands with specific antibodies. The therapeutic potential of several of these antibodies, including ipilimumab, nivolumab, pembrolizumab, MPDL3280A and MEDI-4736, in NSCLC is currently evaluated in clinical trials (Reinmuth et al., 2015).

Ovarian cancer

Surgical resection is the primary therapy in early as well as advanced stage ovarian carcinoma. Surgical removal is followed by systemic chemotherapy with platinum analogs, except for very low grade ovarian cancers (stage IA, grade 1), where post-operative chemotherapy is not indicated.

Immunotherapy appears to be a promising strategy to ameliorate the treatment of ovarian cancer patients, as the presence of pro-inflammatory tumor infiltrating lymphocytes,

especially CD8-positive T cells, correlates with good prognosis and T cells specific for tumor-associated antigens can be isolated from cancer tissue.

Therefore, a lot of scientific effort is put into the investigation of different immunotherapies in ovarian cancer. A considerable number of pre-clinical and clinical studies has already been performed and further studies are currently ongoing. Clinical data are available for cytokine therapy, vaccination, monoclonal antibody treatment, adoptive cell transfer and immunomodulation.

Cytokine therapy with interleukin-2, interferon-alpha, interferon-gamma or granulocyte-macrophage colony stimulating factor aims at boosting the patient's own anti-tumor immune response and these treatments have already shown promising results in small study cohorts.

Phase I and II vaccination studies, using single or multiple peptides, derived from several tumor-associated proteins (Her2/neu, NY-ESO-1, p53, Wilms tumor-1) or whole tumor antigens, derived from autologous tumor cells revealed good safety and tolerability profiles, but only low to moderate clinical effects.

Monoclonal antibodies that specifically recognize tumor-associated proteins are thought to enhance immune cell-mediated killing of tumor cells. The anti-CA-125 antibodies or egovomab and abagovomab as well as the anti-EpCAM antibody catumaxomab achieved promising results in phase II and III studies. In contrast, the anti-MUC1 antibody HMFG1 failed to clearly enhance survival in a phase III study.

An alternative approach uses monoclonal antibodies to target and block growth factor and survival receptors on tumor cells. While administration of trastuzumab (anti-HER2/neu antibody) and MOv18 and MORAb-003 (anti-folate receptor alpha antibodies) only conferred limited clinical benefit to ovarian cancer patients, addition of bevacizumab (anti-VEGF antibody) to the standard chemotherapy in advanced ovarian cancer appears to be advantageous.

Adoptive transfer of immune cells achieved heterogeneous results in clinical trials. Adoptive transfer of autologous, *in vitro* expanded tumor infiltrating T cells was shown to be a promising approach in a pilot trial. In contrast, transfer of T cells harboring a chimeric antigen receptor specific for folate receptor alpha did not induce a significant clinical response in a phase I trial. Dendritic cells pulsed with tumor cell lysate or tumor-associated proteins *in vitro* were shown to enhance the anti-tumor T cell response upon transfer, but the extent of T cell activation did not correlate with clinical effects. Transfer of natural killer cells caused significant toxicities in a phase II study.

Intrinsic anti-tumor immunity as well as immunotherapy are hampered by an immunosuppressive tumor microenvironment. To overcome this obstacle immunomodulatory drugs, like cyclophosphamide, anti-CD25 antibodies and pegylated liposomal doxorubicin are tested in combination with immunotherapy. Most reliable data are currently available for ipilimumab, an anti-CTLA4 antibody, which enhances T cell activity. Ipilimumab was shown to exert significant anti-tumor effects in ovarian cancer patients (Mantia-Smaldone et al., 2012).

Pancreatic cancer

Therapeutic options for pancreatic cancer patients are very limited. One major problem for effective treatment is the typically advanced tumor stage at diagnosis. Additionally, pancreatic cancer is rather resistant to chemotherapeutics, which might be caused by the dense and hypovascular desmoplastic tumor stroma.

According to the guidelines released by the German Cancer Society, the German Cancer Aid and the Association of the Scientific Medical Societies in Germany, resection of the tumor is the only available curative treatment option.

Vaccination strategies are investigated as further innovative and promising alternative for the treatment of pancreatic cancer. Peptide-based vaccines targeting KRAS mutations, reactive telomerase, gastrin, survivin, CEA and MUC1 have already been evalu-

ated in clinical trials, partially with promising results. Furthermore, clinical trials for dendritic cell-based vaccines, allogeneic GM-CSF-secreting vaccines and algenpantucel-L in pancreatic cancer patients also revealed beneficial effects of immunotherapy. Additional clinical trials further investigating the efficiency of different vaccination protocols are currently ongoing (Salman et al., 2013).

Prostate cancer

The therapeutic strategy for prostate cancer mainly depends on the cancer stage. The dendritic cell-based vaccine sipuleucel-T was the first anti-cancer vaccine to be approved by the FDA. Due to its positive effect on survival in patients with CRPC, much effort is put into the development of further immunotherapies. Regarding vaccination strategies, the peptide vaccine prostate-specific antigen (PSA)-TRICOM, the personalized peptide vaccine PPV, the DNA vaccine pTVG-HP and the whole cell vaccine expressing GM-CSF GVAX showed promising results in different clinical trials. Furthermore, dendritic cell-based vaccines other than sipuleucel-T, namely BPX-101 and DCVAC/Pa were shown to elicit clinical responses in prostate cancer patients. Immune checkpoint inhibitors like ipilimumab and nivolumab are currently evaluated in clinical studies as monotherapy as well as in combination with other treatments, including androgen deprivation therapy, local radiation therapy, PSA-TRICOM and GVAX. The immunomodulatory substance tasquinimod, which significantly slowed progression and increased progression free survival in a phase II trial, is currently further investigated in a phase III trial. Lenalidomide, another immunomodulator, induced promising effects in early phase clinical studies, but failed to improve survival in a phase III trial. Despite these disappointing results further lenalidomide trials are ongoing (Quinn et al., 2015).

Renal cell carcinoma

Initial treatment is most commonly either partial or complete removal of the affected kidney(s) and remains the mainstay of curative treatment (Rini et al., 2008). The known immunogenicity of RCC has represented the basis supporting the use of immunotherapy and cancer vaccines in advanced RCC. The interesting correlation between

lymphocytes PD-1 expression and RCC advanced stage, grade and prognosis, as well as the selective PD-L1 expression by RCC tumor cells and its potential association with worse clinical outcomes, have led to the development of new anti PD-1/PD-L1 agents, alone or in combination with anti-angiogenic drugs or other immunotherapeutic approaches, for the treatment of RCC (Massari et al., 2015). In advanced RCC, a phase III cancer vaccine trial called TRIST study evaluates whether TroVax (a vaccine using a tumor-associated antigen, 5T4, with a pox virus vector), added to first-line standard of care therapy, prolongs survival of patients with locally advanced or mRCC. Median survival had not been reached in either group with 399 patients (54%) remaining on study however analysis of the data confirms prior clinical results, demonstrating that TroVax is both immunologically active and that there is a correlation between the strength of the 5T4-specific antibody response and improved survival. Further there are several studies searching for peptide vaccines using epitopes being over-expressed in RCC.

Various approaches of tumor vaccines have been under investigation. Studies using whole-tumor approaches, including tumor cell lysates, fusions of dendritic cells with tumor cells, or whole-tumor RNA were done in RCC patients, and remissions of tumor lesions were reported in some of these trials (Avigan et al., 2004; Holth et al., 2002; Marten et al., 2002; Su et al., 2003; Wittig et al., 2001).

Small cell lung cancer

The treatment and prognosis of SCLC depend strongly on the diagnosed cancer stage. Immune therapy presents an excessively investigated field of cancer therapy. Various approaches are studied in the treatment of SCLC. One of the approaches targets the blocking of CTLA-4, a natural human immune suppressor. The inhibition of CTLA-4 intends to boost the immune system to combat the cancer. Recently, the development of promising immune check point inhibitors for treatment of SCLC has been started. Another approach is based on anti-cancer vaccines which is currently available for treatment of SCLC in clinical studies (American Cancer Society, 2015; National Cancer Institute, 2015).

Acute myeloid leukemia

One treatment option for AML is targeting CD33 with antibody-drug conjugates (anti-CD33 + calechiamicin, SGN-CD33a, anti-CD33 + actinium-225), bispecific antibodies (recognition of CD33 + CD3 (AMG 330) or CD33 + CD16) and chimeric antigen receptors (CARs) (Estey, 2014).

Non-Hodgkin lymphoma

Treatment of NHL depends on the histologic type and stage (National Cancer Institute, 2015): Spontaneous tumor regression can be observed in lymphoma patients. Therefore, active immunotherapy is a therapy option (Palomba, 2012).

An important vaccination option includes Id vaccines. B lymphocytes express surface immunoglobulins with a specific amino acid sequence in the variable regions of their heavy and light chains, unique to each cell clone (= idiotype, Id). The idiotype functions as a tumor associated antigen.

Passive immunization includes the injection of recombinant murine anti-Id monoclonal antibodies alone or in combination with IFN α , IL2 or chlorambucil.

Active immunization includes the injection of recombinant protein (Id) conjugated to an adjuvant (KLH), given together with GM-CSF as an immune adjuvant. Tumor-specific Id is produced by hybridoma cultures or using recombinant DNA technology (plasmids) by bacterial, insect or mammalian cell culture.

Three phase III clinical trials have been conducted (Biovest, Genitope, Favril). In two trials patients had received rituximab. GM-CSF was administered in all three trials. Biovest used hybridoma-produced protein, Genitope and Favril used recombinant protein. In all three trials Id was conjugated to KLH. Only Biovest had a significant result.

- 16 -

Vaccines other than Id include the cancer-testis antigens MAGE, NY-ESO1 and PASD-1, the B-cell antigen CD20 or cellular vaccines. The latest mentioned consist of DCs pulsed with apoptotic tumor cells, tumor cell lysate, DC-tumor cell fusion or DCs pulsed with tumor-derived RNA.

In situ vaccination involves the vaccination with intra-tumoral CpG in combination with chemotherapy or irradiated tumor cells grown in the presence of GM-CSF and collection/ expansion/ re-infusion of T cells.

Vaccination with antibodies that alter immunologic checkpoints are comprised of anti-CD40, anti-OX40, anti-41BB, anti-CD27, anti-GITR (agonist antibodies that directly enhance anti-tumor response) or anti-PD1, anti-CTLA-4 (blocking antibodies that inhibit the checkpoint that would hinder the immune response). Examples are ipilimumab (anti-CTLA-4) and CT-011 (anti-PD1) (Palomba, 2012).

Uterine cancer

Treatment of endometrial carcinomas is stage-dependent. The majority of endometrial carcinomas comprises of well to moderately differentiated endometrioid adenocarcinomas which are usually confined to the corpus uteri at diagnosis and can be cured by hysterectomy (World Cancer Report, 2014).

Also therapies for cervical cancer depend on the stage. In early stages, excision is the standard therapy which might be combined with radio-(chemo-)therapy. Primary radio-(chemo-)therapy is chosen at late stages (Stage III and higher), in cases with lymph node infiltration or in cases in which the tumor cannot be excised.

There are also some immunotherapeutic approaches that are currently being tested. In a Phase I/II Clinical Trial patients suffering from uterine cancer were vaccinated with autologous dendritic cells (DCs) electroporated with Wilms' tumor gene 1 (WT1) mRNA. Besides one case of local allergic reaction to the adjuvant, no adverse side effects were

- 17 -

observed and 3 out of 6 patients showed an immunological response (Coosemans et al., 2013).

As stated above, HPV infections provoke lesions that may ultimately lead to cervical cancer. Therefore, the HPV viral oncoproteins E6 and E7 that are constitutively expressed in high-grade lesions and cancer and are required for the onset and maintenance of the malignant phenotype are considered promising targets for immunotherapeutic approaches (Hung et al., 2008; Vici et al., 2014). One study performed Adoptive T-cell therapy (ACT) in patients with metastatic cervical cancer. Patients receive an infusion with E6 and E7 reactive tumor-infiltrating T cells (TILs) resulting in complete regression in 2 and a partial response in 1 out of 9 patients (Stevanovic et al., 2015). Furthermore, an intracellular antibody targeting E7 was reported to block tumor growth in mice (Accardi et al., 2014). Also peptide, DNA and DC-based vaccines targeting HPV E6 and E7 are in clinical trials (Vici et al., 2014).

Gallbladder adenocarcinoma and cholangiocarcinoma

Cholangiocarcinoma is mostly identified in advanced stages because it is difficult to diagnose. Cholangiocarcinoma is difficult to treat and is usually lethal.

Gallbladder cancer is the most common and aggressive malignancy of the biliary tract worldwide.

Urinary bladder cancer

The standard treatment for bladder cancer includes surgery, radiation therapy, chemotherapy and immunotherapy.

At stage 0 and I, the bladder cancer is typically treated by transurethral resection potentially followed by intravesical chemotherapy and optionally combined with intravesical immunotherapeutic treatment with BCG (*bacillus Calmette-Guérin*).

An effective immunotherapeutic approach is established in the treatment of aggressive non-muscle invasive bladder cancer (NMIBC). Thereby, a weakened form of the bacterium *Mycobacterium bovis* (*bacillus Calmette-Guérin* = BCG) is applied as an intravesical solution. The major effect of BCG treatment is a significant long-term (up to 10 years) protection from cancer recurrence and reduced progression rate. In principle, the treatment with BCG induces a local inflammatory response which stimulates the cellular immune response. The immune response to BCG is based on the following key steps: infection of urothelial and bladder cancer cells by BCG, followed by increased expression of antigen-presenting molecules, induction of immune response mediated via cytokine release, induction of antitumor activity via involvement of various immune cells (thereunder cytotoxic T lymphocytes, neutrophils, natural killer cells, and macrophages) (Fuge et al., 2015; Gandhi et al., 2013).

BCG treatment is in general well tolerated by patients but can be fatal especially by the immunocompromised patients. BCG refractory is observed in about 30-40% of patients (Fuge et al., 2015; Steinberg et al., 2016a). The treatment of patients who failed the BCG therapy is challenging. The patients who failed the BCG treatment are at high risk for developing of muscle-invasive disease. Radical cystectomy is the preferable treatment option for non-responders (Steinberg et al., 2016b; von Rundstedt and Lerner, 2015). The FDA approved second line therapy of BCG-failed NMIBC for patients who desire the bladder preservation is the chemotherapeutic treatment with valrubicin. A number of other second line therapies are available or being currently under investigation as well, thereunder immunotherapeutic approaches like combined BCG-interferon or BCG-check point inhibitor treatments, pre-BCG transdermal vaccination, treatment with *Mycobacterium phlei* cell wall-nucleic acid (MCNA) complex, mono- or combination chemotherapy with various agents like mitomycin C, gemcitabine, docetaxel, nab-paclitaxel, epirubicin, mitomycin/gemcitabine, gemcitabine/docetaxel, and device-assisted chemotherapies like thermochemo-, radiochemo-, electromotive or photodynamic therapies (Fuge et al., 2015; Steinberg et al., 2016b; von Rundstedt and Lerner, 2015). Further evaluation of available therapies in clinical trials is still required.

The alternative treatment options for advanced bladder cancer are being investigated in ongoing clinical trials. The current clinical trials focused on the development of molecularly targeted therapies and immunotherapies. The targeted therapies investigate the effects of cancerogenesis related pathway inhibitors (i.e. mTOR, vascular endothelial, fibroblast, or epidermal growth factor receptors, anti-angiogenesis or cell cycle inhibitors) in the treatment of bladder cancer. The development of molecularly targeted therapies remains challenging due to high degree of genetic diversity of bladder cancer. The main focus of the current immunotherapy is the development of checkpoint blockade agents like anti-PD1 monoclonal antibody and adoptive T-cell transfer (Knollman et al., 2015b; Grivas et al., 2015; Jones et al., 2016; Rouanne et al., 2016).

Head and neck squamous cell carcinoma

Head and neck squamous cell carcinomas (HNSCC) are heterogeneous tumors with differences in epidemiology, etiology and treatment (Economopoulou et al., 2016).

HNSCC is considered an immunosuppressive disease, characterized by the dysregulation of immunocompetent cells and impaired cytokine secretion (Economopoulou et al., 2016). Immunotherapeutic strategies differ between HPV-negative and HPV-positive tumors.

In HPV-positive tumors, the viral oncoproteins E6 and E7 represent good targets, as they are continuously expressed by tumor cells and are essential to maintain the transformation status of HPV-positive cancer cells. Several vaccination therapies are currently under investigation in HPV-positive HNSCC, including DNA vaccines, peptide vaccines and vaccines involving dendritic cells (DCs). Additionally, an ongoing phase II clinical trial investigates the efficacy of lymphodepletion followed by autologous infusion of TILs in patients with HPV-positive tumors (Economopoulou et al., 2016).

In HPV-negative tumors, several immunotherapeutic strategies are currently used and under investigation. The chimeric IgG1 anti-EGFR monoclonal antibody cetuximab has been approved by the FDA in combination with chemotherapy as standard first line

- 20 -

treatment for recurring/metastatic HNSCC. Other anti-EGFR monoclonal antibodies, including panitumumab, nimotuzumab and zalutumumab, are evaluated in HNSCC. Several immune checkpoint inhibitors are investigated in clinical trials for their use in HNSCC. They include the following antibodies: Ipilimumab (anti-CTLA-4), tremelimumab (anti-CTLA-4), pembrolizumab (anti-PD-1), nivolumab (anti-PD-1), durvalumab (anti-PD-1), anti-KIR, urelumab (anti-CD137), and anti-LAG-3.

Two clinical studies with HNSCC patients evaluated the use of DCs loaded with p53 peptides or apoptotic tumor cells. The immunological responses were satisfactory and side effects were acceptable.

Several studies have been conducted using adoptive T cell therapy (ACT). T cells were induced against either irradiated autologous tumor cells or EBV. Results in disease control and overall survival were promising (Economopoulou et al., 2016).

Considering the severe side-effects and expense associated with treating cancer, there is a need to identify factors that can be used in the treatment of cancer in general and hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, non-small cell lung cancer (NSCLC), pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer, chronic lymphocytic leukemia (CLL), Merkel cell carcinoma (MCC), small cell lung cancer (SCLC), Non-Hodgkin lymphoma (NHL), acute myeloid leukemia (AML), gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), uterine cancer (UEC), head and neck squamous cell carcinoma (HNSCC), in particular. There is also a need to identify factors representing biomarkers for cancer in general and the above-mentioned cancer types in particular, leading to better diagnosis of cancer, assessment of prognosis, and prediction of treatment success.

Immunotherapy of cancer represents an option of specific targeting of cancer cells while minimizing side effects. Cancer immunotherapy makes use of the existence of tumor associated antigens.

The current classification of tumor associated antigens (TAAs) comprises the following major groups:

- a) Cancer-testis antigens: The first TAAs ever identified that can be recognized by T cells belong to this class, which was originally called cancer-testis (CT) antigens because of the expression of its members in histologically different human tumors and, among normal tissues, only in spermatocytes/spermatogonia of testis and, occasionally, in placenta. Since the cells of testis do not express class I and II HLA molecules, these antigens cannot be recognized by T cells in normal tissues and can therefore be considered as immunologically tumor-specific. Well-known examples for CT antigens are the MAGE family members and NY-ESO-1.
- b) Differentiation antigens: These TAAs are shared between tumors and the normal tissue from which the tumor arose. Most of the known differentiation antigens are found in melanomas and normal melanocytes. Many of these melanocyte lineage-related proteins are involved in biosynthesis of melanin and are therefore not tumor specific but nevertheless are widely used for cancer immunotherapy. Examples include, but are not limited to, tyrosinase and Melan-A/MART-1 for melanoma or PSA for prostate cancer.
- c) Over-expressed TAAs: Genes encoding widely expressed TAAs have been detected in histologically different types of tumors as well as in many normal tissues, generally with lower expression levels. It is possible that many of the epitopes processed and potentially presented by normal tissues are below the threshold level for T-cell recognition, while their over-expression in tumor cells can trigger an anticancer response by breaking previously established tolerance. Prominent examples for this class of TAAs are Her-2/neu, survivin, telomerase, or WT1.
- d) Tumor-specific antigens: These unique TAAs arise from mutations of normal genes (such as β -catenin, CDK4, etc.). Some of these molecular changes are associated with neoplastic transformation and/or progression. Tumor-specific antigens are generally able to induce strong immune responses without bearing the risk for autoimmune reac-

tions against normal tissues. On the other hand, these TAAs are in most cases only relevant to the exact tumor on which they were identified and are usually not shared between many individual tumors. Tumor-specificity (or -association) of a peptide may also arise if the peptide originates from a tumor- (-associated) exon in case of proteins with tumor-specific (-associated) isoforms.

e) TAAs arising from abnormal post-translational modifications: Such TAAs may arise from proteins which are neither specific nor overexpressed in tumors but nevertheless become tumor associated by posttranslational processes primarily active in tumors. Examples for this class arise from altered glycosylation patterns leading to novel epitopes in tumors as for MUC1 or events like protein splicing during degradation which may or may not be tumor specific.

f) Oncoviral proteins: These TAAs are viral proteins that may play a critical role in the oncogenic process and, because they are foreign (not of human origin), they can evoke a T-cell response. Examples of such proteins are the human papilloma type 16 virus proteins, E6 and E7, which are expressed in cervical carcinoma.

T-cell based immunotherapy targets peptide epitopes derived from tumor-associated or tumor-specific proteins, which are presented by molecules of the major histocompatibility complex (MHC). The antigens that are recognized by the tumor specific T lymphocytes, that is, the epitopes thereof, can be molecules derived from all protein classes, such as enzymes, receptors, transcription factors, etc. which are expressed and, as compared to unaltered cells of the same origin, usually up-regulated in cells of the respective tumor.

There are two classes of MHC-molecules, MHC class I and MHC class II. MHC class I molecules are composed of an alpha heavy chain and beta-2-microglobulin, MHC class II molecules of an alpha and a beta chain. Their three-dimensional conformation results in a binding groove, which is used for non-covalent interaction with peptides.

MHC class I molecules can be found on most nucleated cells. They present peptides that result from proteolytic cleavage of predominantly endogenous proteins, defective ribosomal products (DRIPs) and larger peptides. However, peptides derived from endo-

- 23 -

somal compartments or exogenous sources are also frequently found on MHC class I molecules. This non-classical way of class I presentation is referred to as cross-presentation in the literature (Brossart and Bevan, 1997; Rock et al., 1990). MHC class II molecules can be found predominantly on professional antigen presenting cells (APCs), and primarily present peptides of exogenous or transmembrane proteins that are taken up by APCs e.g. during endocytosis, and are subsequently processed.

Complexes of peptide and MHC class I are recognized by CD8-positive T cells bearing the appropriate T-cell receptor (TCR), whereas complexes of peptide and MHC class II molecules are recognized by CD4-positive-helper-T cells bearing the appropriate TCR. It is well known that the TCR, the peptide and the MHC are thereby present in a stoichiometric amount of 1:1:1.

CD4-positive helper T cells play an important role in inducing and sustaining effective responses by CD8-positive cytotoxic T cells. The identification of CD4-positive T-cell epitopes derived from tumor associated antigens (TAA) is of great importance for the development of pharmaceutical products for triggering anti-tumor immune responses (Gnjatic et al., 2003). At the tumor site, T helper cells, support a cytotoxic T cell- (CTL-) friendly cytokine milieu (Mortara et al., 2006) and attract effector cells, e.g. CTLs, natural killer (NK) cells, macrophages, and granulocytes (Hwang et al., 2007).

In the absence of inflammation, expression of MHC class II molecules is mainly restricted to cells of the immune system, especially professional antigen-presenting cells (APC), e.g., monocytes, monocyte-derived cells, macrophages, dendritic cells. In cancer patients, cells of the tumor have been found to express MHC class II molecules (Dengjel et al., 2006).

Elongated peptides of the invention can act as MHC class II active epitopes.

T-helper cells, activated by MHC class II epitopes, play an important role in orchestrating the effector function of CTLs in anti-tumor immunity. T-helper cell epitopes that trig-

ger a T-helper cell response of the TH1 type support effector functions of CD8-positive killer T cells, which include cytotoxic functions directed against tumor cells displaying tumor-associated peptide/MHC complexes on their cell surfaces. In this way tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides, can serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses.

It was shown in mammalian animal models, e.g., mice, that even in the absence of CD8-positive T lymphocytes, CD4-positive T cells are sufficient for inhibiting manifestation of tumors via inhibition of angiogenesis by secretion of interferon-gamma (IFN γ) (Beatty and Paterson, 2001; Mumberg et al., 1999). There is evidence for CD4 T cells as direct anti-tumor effectors (Braumuller et al., 2013; Tran et al., 2014).

Since the constitutive expression of HLA class II molecules is usually limited to immune cells, the possibility of isolating class II peptides directly from primary tumors was previously not considered possible. However, Dengjel et al. were successful in identifying a number of MHC Class II epitopes directly from tumors (WO 2007/028574, EP 1 760 088 B1).

Since both types of response, CD8 and CD4 dependent, contribute jointly and synergistically to the anti-tumor effect, the identification and characterization of tumor-associated antigens recognized by either CD8+ T cells (ligand: MHC class I molecule + peptide epitope) or by CD4-positive T-helper cells (ligand: MHC class II molecule + peptide epitope) is important in the development of tumor vaccines.

For an MHC class I peptide to trigger (elicit) a cellular immune response, it also must bind to an MHC-molecule. This process is dependent on the allele of the MHC-molecule and specific polymorphisms of the amino acid sequence of the peptide. MHC-class-I-binding peptides are usually 8-12 amino acid residues in length and usually contain two conserved residues ("anchors") in their sequence that interact with the corresponding

binding groove of the MHC-molecule. In this way each MHC allele has a "binding motif" determining which peptides can bind specifically to the binding groove.

In the MHC class I dependent immune reaction, peptides not only have to be able to bind to certain MHC class I molecules expressed by tumor cells, they subsequently also have to be recognized by T cells bearing specific T cell receptors (TCR).

For proteins to be recognized by T-lymphocytes as tumor-specific or -associated antigens, and to be used in a therapy, particular prerequisites must be fulfilled. The antigen should be expressed mainly by tumor cells and not, or in comparably small amounts, by normal healthy tissues. In a preferred embodiment, the peptide should be over-presented by tumor cells as compared to normal healthy tissues. It is furthermore desirable that the respective antigen is not only present in a type of tumor, but also in high concentrations (i.e. copy numbers of the respective peptide per cell). Tumor-specific and tumor-associated antigens are often derived from proteins directly involved in transformation of a normal cell to a tumor cell due to their function, e.g. in cell cycle control or suppression of apoptosis. Additionally, downstream targets of the proteins directly causative for a transformation may be up-regulated and thus may be indirectly tumor-associated. Such indirect tumor-associated antigens may also be targets of a vaccination approach (Singh-Jasuja et al., 2004). It is essential that epitopes are present in the amino acid sequence of the antigen, in order to ensure that such a peptide ("immunogenic peptide"), being derived from a tumor associated antigen, leads to an *in vitro* or *in vivo* T-cell-response.

Basically, any peptide able to bind an MHC molecule may function as a T-cell epitope. A prerequisite for the induction of an *in vitro* or *in vivo* T-cell-response is the presence of a T cell having a corresponding TCR and the absence of immunological tolerance for this particular epitope.

Therefore, TAAs are a starting point for the development of a T cell based therapy including but not limited to tumor vaccines. The methods for identifying and characterizing

- 26 -

the TAAs are usually based on the use of T-cells that can be isolated from patients or healthy subjects, or they are based on the generation of differential transcription profiles or differential peptide expression patterns between tumors and normal tissues. However, the identification of genes over-expressed in tumor tissues or human tumor cell lines, or selectively expressed in such tissues or cell lines, does not provide precise information as to the use of the antigens being transcribed from these genes in an immune therapy. This is because only an individual subpopulation of epitopes of these antigens are suitable for such an application since a T cell with a corresponding TCR has to be present and the immunological tolerance for this particular epitope needs to be absent or minimal. In a very preferred embodiment of the invention it is therefore important to select only those over- or selectively presented peptides against which a functional and/or a proliferating T cell can be found. Such a functional T cell is defined as a T cell, which upon stimulation with a specific antigen can be clonally expanded and is able to execute effector functions ("effector T cell").

In case of targeting peptide-MHC by specific TCRs (e.g. soluble TCRs) and antibodies or other binding molecules (scaffolds) according to the invention, the immunogenicity of the underlying peptides is secondary. In these cases, the presentation is the determining factor.

SUMMARY OF THE INVENTION

In a first aspect of the present invention, the present invention relates to a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 388 or a variant sequence thereof which is at least 77%, preferably at least 88%, homologous (preferably at least 77% or at least 88% identical) to SEQ ID NO: 1 to SEQ ID NO: 388, wherein said variant binds to MHC and/or induces T cells cross-reacting with said peptide, or a pharmaceutical acceptable salt thereof, wherein said peptide is not the underlying full-length polypeptide.

While the most important criterion for a peptide to function as cancer therapy target is its over-presentation on primary tumor tissues as compared to normal tissues, also the

- 27 -

RNA expression profile of the corresponding gene can help to select appropriate peptides. Particularly, some peptides are hard to detect by mass spectrometry, either due to their chemical properties or to their low copy numbers on cells, and a screening approach focusing on detection of peptide presentation may fail to identify these targets. However, these targets may be detected by an alternative approach starting with analysis of gene expression in normal tissues and secondarily assessing peptide presentation and gene expression in tumors. This approach was realized in this invention using an mRNA database (Lonsdale, 2013) in combination with further gene expression data (including tumor samples), as well as peptide presentation data. If the mRNA of a gene is nearly absent in normal tissues, especially in vital organ systems, targeting the corresponding peptides by even very potent strategies (such as bispecific affinity-optimized antibodies or T-cell receptors), is more likely to be safe. Such peptides, even if identified on only a small percentage of tumor tissues, represent interesting targets. Routine mass spectrometry analysis is not sensitive enough to assess target coverage on the peptide level. Rather, tumor mRNA expression can be used to assess coverage. For detection of the peptide itself, a targeted mass spectrometry approach with higher sensitivity than in the routine screening may be necessary and may lead to a better estimation of coverage on the level of peptide presentation.

The present invention further relates to a peptide of the present invention comprising a sequence that is selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 388 or a variant thereof, which is at least 77%, preferably at least 88%, homologous (preferably at least 77% or at least 88% identical) to SEQ ID NO: 1 to SEQ ID NO: 388, wherein said peptide or variant thereof has an overall length of between 8 and 100, preferably between 8 and 30, and most preferred of between 8 and 14 amino acids.

The following tables show the peptides according to the present invention, their respective SEQ ID NOs, and the prospective source (underlying) genes for these peptides. All peptides in Table 1A and Table 2A bind to HLA-A*02. Peptides in Table 1C and Table 2B bind to HLA-A*24. Peptides in Table 1B bind to HLA class II alleles. The peptides in

- 28 -

Table 3 are additional peptides that are HLA-A*24 binding and may be useful in combination with the other peptides of the invention.

Table 1A: Peptides according to the present invention, HLA-A*02-binding.

SEQ ID No.	Sequence	GeneID(s)	Official Gene Symbol(s)
1	PLWGKVFYL	10926	DBF4
2	ALYGKLLKL	157680	VPS13B
3	TLLGKQVTL	157680	VPS13B
4	ELAEIVFKV	203427,349075,51373	SLC25A43, ZNF713, MRPS17
5	SLFGQEVYC	10840	ALDH1L1
6	FLDPAQRDL	57677	ZFP14
7	AAAAKVPEV	23382	AHCYL2
8	KLGPFLNA	100508781,653199,9747	FAM115B, FAM115A
9	FLGDYVENL	54832	VPS13C
10	KTLDFVNIIL	54832	VPS13C
11	GVLKVFLENV	121504,554313,8294,8359,8360,8361,8362,8363,8364,8365,8366,8367,8368,8370	HIST4H4, HIST2H4B, HIST1H4I, HIST1H4A, HIST1H4D, HIST1H4F, HIST1H4K, HIST1H4J, HIST1H4C, HIST1H4H, HIST1H4B, HIST1H4E, HIST1H4L, HIST2H4A
12	GLIYEETRGV		
13	VLRDNIQGI		
14	LLDHLSFINKI	64863	METTTL4
15	ALGDYVHAC	4588	MUC6
16	HLYNNEEQV	101060798,1645,8644	AKR1C1, AKR1C3
17	ILHEHHIFL	4233	MET
18	YVLNEEDLQKV	4233	MET
19	TLLPTVLTL	127707	KLHDC7A
20	ALDGHLIAI	127707	KLHDC7A
21	SLYHRVLLY	57221	KIAA1244
22	MLSDLTLQL	57221	KIAA1244
23	AQTVVVIKA	101059911,4586,727897	MUC5AC, MUC5B
24	FLWNGEDSAL	4586,727897	MUC5AC, MUC5B
25	IQADDFRTL	101059911,4586,727897	MUC5AC, MUC5B
26	KVDGVVIQL	101059911,4586,727897	MUC5AC, MUC5B

- 29 -

SEQ ID No.	Sequence	GeneID(s)	Official Gene Symbol(s)
27	KVFGDLDQV	169611	OLFML2A
28	TLYSMDLMKV	169611	OLFML2A
29	TLCNKTFTA	26137	ZBTB20
30	TVIDECTRI	26137	ZBTB20
31	ALSDETKNNWE V	5591	PRKDC
32	ILADEAFFSV	5591	PRKDC
33	LLLPLLPPLSPS LG	347252	IGFBPL1
34	LLPKKTESHKK T	8330,8331	HIST1H2AK, HIST1H2AJ
35	YVLPKLYVKL	100128168,100996 747,441502,6231,6 43003,644166,644 928,644934,64675 3,728937,729188	RPS26P39, RPS26P11, RPS26, RPS26P28, RPS26P20,RPS26P15, RPS26P50, RPS26P2, RPS26P25, RPS26P58
36	KLYGIEIEV	56107	PCDHGA9
37	ALINDILGELVKL	85463	ZC3H12C
38	KMQEDLVTL	781	CACNA2D1
39	ALMAVVSGL	55103	RALGPS2
40	SLLALPQDLQA	1364,1365,23562,9 074,9080	CLDN4, CLDN3, CLDN14, CLDN6, CLDN9
41	FVLPLVVTL	2848	GPR25
42	VLSPFILTL	113730	KLHDC7B
43	LLWAGPVTA	28603	TRBV6-4
44	GLLWQIIKV	5357	PLS1
45	VLGPTPELV	100124692	
46	SLAKHGIVAL	10693	CCT6B
47	GLYQAQVNL	89886	SLAMF9
48	TLDHKPVTV	203447	NRK
49	LLDESKLTL	64097	EPB41L4A
50	EYALLYHTL	26	ABP1
51	LLLDGDFTL	347051	SLC10A5
52	ELLSSIFFL	160418	TMTC3
53	SLLSHVIVA	545	ATR
54	FINPKGNWLL	3673	ITGA2
55	IASAIVNEL	57448	BIRC6
56	KILDLTRVL	79783	C7orf10
57	VLISSTVRL	166379	BBS12
58	ALDDSLTSL	2302	FOXJ1
59	ALTKILAEI	339766	MROH2A

- 30 -

SEQ ID No.	Sequence	GeneID(s)	Official Gene Symbol(s)
60	FLIDTSASM	203522,26512	DDX26B, INTS6
61	HLPDFVKQL	9857	CEP350
62	SLFNQEVQI	100528032,22914,8302	KLRK1, KLRC4
63	TLSSERDFAL	100293534,720,721	C4A,C4B
64	GLSSSSYEL	89866	SEC16B
65	KLDGICWQV	733	C8G
66	FITDFYTTV	80055	PGAP1
67	GVIETVTSL	79895	ATP8B4
68	ALYGFFFKI	118663	BTBD16
69	GIYDGILHSI	158809,392433	MAGEB6, MAGEB6P1
70	GLFSQHFNL	1789	DNMT3B
71	GLITVDIAL	84162	KIAA1109
72	GMIGFQVLL	6006,6007	RHCE,RHD
73	GVPDTIATL	23120	ATP10B
74	ILDETLNV	167227	DCP2
75	ILDNVKNLL	4602	MYB
76	ILLDESNFNHFL	222584	FAM83B
77	IVLSTIASV	10559,154313	SLC35A1, C6orf165
78	LLWGHPRVA	25878	MXRA5
79	SLVPLQILL	101060288,101060295,101060308,343068,343070,400735,440560,440561,441873,645359,653619,729368	PRAMEF5, PRAMEF9, PRAMEF4, PRAMEF11, PRAMEF6, PRAMEF15, PRAMEF23
80	TLDEYLTYL	101060308,343068,343070,653619	PRAMEF5, PRAMEF9, PRAMEF15
81	VLFLGKLLV	204962	SLC44A5
82	VLLRVLIL	102	ADAM10
83	ELLEYPQL	5288	PIK3C2G
84	FLEEEITRV	6570	SLC18A1
85	STLDGSLHAV	2081	ERN1
86	LLVTSLVVV	118471,118472	PRAP1, ZNF511
87	YLTEVFLHVV	55024	BANK1
88	ILLNTEDLASL	388015	RTL1
89	YLVAHNLLL	9365	KL
90	GAVAAEVLSSI	340273	ABCB5
91	SSLEPQIQPV	23029	RBM34
92	LLRGPPVARA	3486	IGFBP3

- 31 -

SEQ ID No.	Sequence	GeneID(s)	Official Gene Symbol(s)
93	SLLTQPIFL	151295	SLC23A3

Table 1B: Peptides according to the present invention, HLA class II binding.

SEQ ID No.	Sequence	GeneID(s)	Official Gene Symbol(s)
94	LKMENKEVLPQLVDAVTS	4547	MTTP
95	GLYLPLFKPSVSTSKAIGGG P	10165	SLC25A13

Table 1C: Peptides according to the present invention, HLA-A*24 binding.

SEQ ID No.	Sequence	GeneID(s)	Official Gene Symbol(s)
96	YYTQYSQTI	25878	MXRA5
97	TYTFLKETF	203238	CCDC171
98	VFPRLHNVLF	9816	URB2
99	QYILAVPVL	91147	TMEM67
100	VYIESRIGTSTSF	10112	KIF20A
101	IYIPVLPPHL	163486	DENND1B
102	VYPFENFEF	127700	OSCP1
103	NYIPVKNGKQF	3096	HIVEP1
104	SYLTWHQQI	125919	ZNF543
105	IYNETITDLL	1062	CENPE
106	IYNETVRDLL	3833	KIFC1
107	KYFPYLVVI	80131	LRRC8E
108	PYLVVIHTL	80131	LRRC8E
109	LFITGGQFF	114134	SLC2A13
110	SYPKIIEEF	2177	FANCD2
111	VYVQILQKL	4998	ORC1
112	IYNFVESKL	4998	ORC1
113	IYSFHTLSF	55183	RIF1
114	QYLDGTWSL	55083	KIF26B
115	RYLNKSFVL	63926	ANKRD5
116	AYVIAVHLF	10178	TENM1
117	IYLSDLTYI	55103	RALGPS2
118	KYLNSVQYI	55103	RALGPS2
119	VYRVYVTTTF	57089	ENTPD7
120	GYIEHFSWL	5069	PAPPA
121	RYGLPAAWSTF	79713	IGFLR1
122	EYQARIPEF	55758	RCOR3

- 32 -

123	VYTPVLEHL	5591	PRKDC
124	TYKDYVDLF	5591	PRKDC
125	VFSRDFGLLVF	5591	PRKDC
126	PYDPALGSPSRLF	389058	SP5
127	QYFTGNPLF	3237	HOXD11
128	VYPFDWQYI	7941	PLA2G7
129	KYIDYLMTW	55233,92597	MOB1A, MOB1B
130	VYAHYHQHF	55233,92597	MOB1A, MOB1B
131	EYLDRIQLFF	51608	GET4
132	RYPALFPVL	11237	RNF24
133	KYLEDMKTYF	5273	SERPINB10
134	AYIPTPIYF	81796	SLCO5A1
135	VYEAMVPLF	85465	EPT1
136	IYPEWPVVFF	51146	A4GNT
137	EYLNCSYF	25909,285116	AHCTF1, AHCTF1P1
138	VYNAVSTSF	79915	ATAD5
139	IFGIFPNQF	79895	ATP8B4
140	RYLINSYDF	84002	B3GNT5
141	SYNGHLTIWF	56245	C21orf62
142	VYVDDIYVI	57082	CASC5
143	KYIFQLNEI	347475	CCDC160
144	VFASLPGFLF	1233	CCR4
145	VYALKVRTI	1237	CCR8
146	NYERIHAL	8832	CD84
147	LYLAFPLAF	253782	CERS6
148	SYGTVSQIF	23601	CLEC5A
149	SYGTVSQI	23601	CLEC5A
150	IYITRQFVQF	81501	DCSTAMP
151	AYISGLDVF	8632	DNAH17
152	KFFDDLGDLELF	8632	DNAH17
153	VYVPFGGKSMITF	146754	DNAH2
154	VYGVPTPHF	151651	EFHB
155	IYKWITDNF	2302	FOXJ1
156	YYMELTKLLL	51659	GINS2
157	DYIPASGFALF	84059	GPR98
158	IYEETRGVLKVF	121504, 554313, 8294, 8359, 8360, 8361, 8362, 8363, 8364, 8365, 8366, 8367, 8368, 8370	HIST4H4, HIST2H4B, HIST1H4I, HIST1H4A, HIST1H4D, HIST1H4F, HIST1H4K, HIST1H4J, HIST1H4C, HIST1H4H, HIST1H4B, HIST1H4E, HIST1H4L, HIST2H4A
159	IYEETRGVL		

160	RYGDGGSSF	3188	HNRNPH2
161	KYPDIVQQF	29851	ICOS
162	KYTSYILAF	3458	IFNG
163	RYLTISNLQF	28785	IGLV4-60
164	HYVPATKVF	259307	IL4I1
165	EYFTPLLSGQF	55175	KLHL11
166	FYTLPFHLI	55175	KLHL11
167	RYGFYYVEF	197021	LCTL
168	RYLEAALRL	10609	LEPREL4
169	NYITGKGDVF	84125	LRRIQ1
170	QYPFHVPLL	4049	LTA
171	NYEDHFPLL	4109	MAGEA10
172	VFIFKGNEF	4319	MMP10
173	QYLEKYYNL	4319	MMP10
174	VYEKNGYIYF	4322	MMP13
175	LYSPVPFTL	387521	TMEM189
176	FYINGQYQF	55728	N4BP2
177	VYFKAGLDVF	254827	NAALADL2
178	NYSSAVQKF	4983	OPHN1
179	TYIPVGLGRLL	58495	OVOL2
180	KYLQVVGMF	5021	OXTR
181	VYPPYLNLY	5241	PGR
182	AYAQLGYLLF	9033	PKD2L1
183	PYLQDVPRI	92340	C17orf72
184	IYSVGAFENF	389677	RBM12B
185	QYLVHVNDL	23322	RPGRIP1L
186	VFTTSSNIF	10371	SEMA3A
187	AYAANVHYL	151473	SLC16A14
188	GYKTFFNEF	64078	SLC28A3
189	AYFKQSSVF	54790	TET2
190	LYSELTETL	54790	TET2
191	TYPDGTYTGRIF	201633	TIGIT
192	RYSTFSEIF	8277	TKTL1
193	YLENNAQTQF	8626	TP63
194	VYQSLSNSL	286827	TRIM59
195	AYIKGGWIL	125488	TTC39C
196	GYIRGSWQF	79465	ULBP3
197	IFTDIFHYL	54464	XRN1
198	DYVGFTLKI	19	ABCA1
199	SYLNHLNNL	154664	ABCA13
200	VFIHHL PQF	116285	ACSM1

- 34 -

201	GYNPNRVFF	158067	AK8
202	RYVEGIVSL	246	ALOX15
203	VYNVEVKNAEF	84250	ANKRD32
204	EYLSTCSKL	196528	ARID2
205	VYPVVLNQI	79798	ARMC5
206	NYLDVATFL	10973	ASCC3
207	LYSDAFKFIVF	344905	ATP13A5
208	TYLEKIDGF	100526740,26024,9551	ATP5J2-PTCD1, PTCD1, ATP5J2
209	AFIETPIPLF	631	BFSP1
210	IYAGVGESFS	701	BUB1B
211	VFKSEGAYF	375444	C5orf34
212	SYAPPSEDLF	100533105,23678	SGK3
213	SYAPPSEDLFL	100533105,23678	SGK3
214	KYLMELTLI	9133	CCNB2
215	SYVASFFLL	9398	CD101
216	FYVNVKEQF	79682	MLF1IP
217	IYISNSIYF	54967	CXorf48
218	LYSELNKWSF	1591	CYP24A1
219	SYLKAVFNL	163720,199974	CYP4Z2P, CYP4Z1
220	SYSEIKDFL	64421	DCLRE1C
221	KYIGNLDLL	8701	DNAH11
222	HYSTLVHMF	8701	DNAH11
223	TFITQSPLL	1767	DNAH5
224	PYFFANQEF	79843	FAM124B
225	TYTNTLERL	55719	FAM178A
226	MYLKLVQLF	2175	FANCA
227	IYRFITERF	2301	FOXO3
228	IYQYVADNF	2299	FOXO1
229	IYQFVADSF	344167	FOXO3
230	TYGMVMVTF	84059	GPR98
231	AFADVSVKF	84059	GPR98
232	YYLSDSPLL	51512	GTSE1
233	QYLTAALHNL	3552	IL1A
234	SYLPAIWLL	3641	INSL4
235	VYKDSIYYI	84541	KBTD8
236	VYLPKIPSW	157855	KCNU1
237	KYVGQLAVL	9928	KIF14
238	SYLEKVRQL	100653049,3881,3883,3884,3885,3886	KRT31, KRT33A, KRT33B, KRT34, KRT35
239	VYAIFRILL	987	LRBA

- 35 -

240	YYFFVQEKI	84944	MAEL
241	SYVKVLHHL	101060230,4111	MAGEA12
242	VYGEPRELL	392555,51438	MAGEC2
243	SYLELANTL	4163	MCC
244	VHFEDTGKTLF	4322	MMP13
245	LYPQLFVVL	377711,727957	MROH1
246	KYLSVQLTL	339766	MROH2A
247	SFTKTSPNF	200958	MUC20
248	AFPTFSVQL	4588	MUC6
249	RYHPTTCTI	4608	MYBPH
250	KYPDIASPTF	89795	NAV3
251	VYTKALSSL	64151	NCAPG
252	AFGQETNVPLNNF	4695	NDUFA2
253	IYGFFNENF	10886	NPFFR2
254	KYLESSATF	91181	NUP210L
255	VYQKIILKF	139135	PASD1
256	VFGKSAYLF	118987	PDZD8
257	IFIDNSTQPLHF	5288	PIK3C2G
258	AYAQLGYLL	9033	PKD2L1
259	YFIKSPPSQLF	79949	PLEKHS1
260	VYMNVMTRL	5523	PPP2R3A
261	GYIKLINFI	10196	PRMT3
262	VYSSQFETI	23362	PSD3
263	RYILENHDF	442247	RFPL4B
264	LYTETRLQF	26150	RIBC2
265	SYLNEAFSF	286205	SCAI
266	KYTDWTEFL	57713	SFMBT2
267	SFLNIEKTEILF	347051	SLC10A5
268	IFITKALQI	159371	SLC35G1
269	QYPYLQAFF	146857	SLFN13
270	YYSQESKVLYL	55181	SMG8
271	RFLMKSYSF	8435	SOAT2
272	RYVFPLPYL	8403	SOX14
273	IYGEKLQFIF	57405	SPC25
274	KQLDIANYELF	51430	SUCO
275	KYGTLDVTF	255928	SYT14
276	QYLDVLHAL	51256	TBC1D7
277	FYTFPFQQL	6996	TDG
278	KYVNLVMYF	116238	TLCD1
279	VWLPASVLF	85019	TMEM241
280	TYNPNLQDKL	5651	TMPRSS15

- 36 -

281	NYSPGLVSLIL	28677	TRAV9-2
282	NYLVDPVTI	129868,653192	TRIM43, TRIM43B
283	EYQEIFQQL	129868,653192	TRIM43, TRIM43B
284	DYLKDPVTI	391712,653794	TRIM61, TRIM60P14
285	VYVGDALLHAI	7223	TRPC4
286	SYGTILSHI	54986	ULK4
287	IYNPNLLTASKF	81839	VANGL1
288	VYPDTVALTF	284403	WDR62
289	FFHEGQYVF	389668	XKR9
290	KYGDFKLLEF	143570	XRRA1
291	YYLGSGRETF	152002	XXYLT1
292	FYPQIINTF	79776	ZFHX4
293	VYPHFSTTNLI	79776	ZFHX4
294	RFPVQGTVTF	79818	ZNF552
295	SYLVIHERI	84775	ZNF607
296	SYQVIFQHF	344905	ATP13A5
297	TYIDTRTVF	827	CAPN6
298	AYKSEVVYF	441402,728577,79937	CNTNAP3B, CNTNAP3
299	KYQYVLNEF	400823	FAM177B
300	TYPSQLPSL	26290	GALNT8
301	KFDDVTMLF	2977	GUCY1A2
302	LYLPVHYGF	253012	HEPACAM2
303	LYSVIKEDF	285600	KIAA0825
304	EYNEVANLF	57097	PARP11
305	NYENKQYLF	144406	WDR66
306	VYPAEQPQI	2334	AFF2
307	GYAFTLPLF	440138	ALG11
308	TFDGHGVFF	29785	CYP2S1
309	KYYRQTLLF	27042	DIEXF
310	IYAPTLLVF	23341	DNAJC16
311	EYLQNLNHI	79659	DYNC2H1
312	SYTSVLSRL	57724	EPG5
313	KYTHFIQSF	26301	GBGT1
314	RYFKGDYSI	3709	ITPR2
315	FYIPHVPVSF	89866	SEC16B
316	VYFEGSDFKF	55164	SHQ1
317	VFDTSIAQLF	6477	SIAH1
318	TYSNSAFQYF	28672	TRAV12-3
319	KYSDVKNLI	57623	ZFAT
320	KFILALKVLF	6790	AURKA

- 37 -

Table 2A: Additional peptides according to the present invention, HLA-A*02-binding.

SEQ ID No.	Sequence	GeneID(s)	Official Gene Symbol(s)
321	SLWFKPEEL	4831,654364	NME2, NME1-NME2
322	ALVSGGVAQA	64326	RFWD2
323	ILSVVNSQL	80183	KIAA0226L
324	AIFDFCPSV	23268	DNMBP
325	RLLPKVQEV	168417,89958	ZNF679, SAPCD2
326	SLLPLVWKI	1130	LYST
327	SIGDIFLKY	1894	ECT2
328	SVDSAPAAV	10635	RAD51AP1
329	FAWEPSFRDQV	1244	ABCC2
330	FLWPKEVEL	146206	RLTPR
331	AIWKELISL	55183	RIF1
332	AVTKYTSAK	54145,85236,8970	H2BFS, HIST1H2BK, HIST1H2BJ
333	GTFLEGVAK	126328	NDUFA11
334	GRADALRVL	79713	IGFLR1
335	VLLAAGPSAA	23225	NUP210
336	GLMDGSPHFL	157680	VPS13B
337	KVLGKIEKV	987	LRBA
338	LLYDGKLSSA	987	LRBA
339	VLGPGPPPL	254359	ZDHHC24
340	SVAKTILKR	55233,92597	MOB1A, MOB1B

Table 2B: Additional peptides according to the present invention, HLA-A*24-binding.

SEQ ID No.	Sequence	GeneID(s)	Official Gene Symbol(s)
341	SYLTQHQRI	162655,344065,9422	ZNF519, ZNF264
342	NYAFLHRTL	200316,9582	APOBEC3F, APOBEC3B
343	NYLGGTSTI	367	AR
344	EYNSDLHQF	699	BUB1
345	EYNSDLHQFF	699	BUB1
346	IYVIPQPHF	57082	CASC5
347	VYAEVNSL	1459	CSNK2A2
348	IYLEHTESI	2177	FANCD2
349	QYSIISNVF	28982	FLVCR1
350	KYGNFIDKL	85865	GTPBP10
351	IFHEVPLKF	728432,79664	NARG2
352	QYGGDLTNTF	3673	ITGA2
353	TYGKIDLGF	57650	KIAA1524

SEQ ID No.	Sequence	GeneID(s)	Official Gene Symbol(s)
354	VYNEQIRDLL	81930	KIF18A
355	IYVTGGHLF	113730	KLHDC7B
356	NYMPGQLTI	346389	MACC1
357	QFITSTNTF	94025	MUC16
358	YYSEVPVKL	25878	MXRA5
359	NYGVLHVTF	204801	NLRP11
360	VFSPDGHLF	143471,5688	PSMA8, PSMA7
361	TYADIGGLDNQI	5700	PSMC1
362	VYNYAEQTL	100526737,10432,5936	RBM14-RBM4, RBM14, RBM4
363	SYAELGTTI	23657	SLC7A11
364	KYLNENQLSQL	6491	STIL
365	VFIDHPVHL	26011	TENM4
366	QYLELAHSL	4796	TONSL
367	LYQDHMQYI	7474	WNT5A
368	KYQNVKHNL	79830	ZMYM1
369	VYTDEVVTL	983	CDK1
370	RFIGIPNQF	79659	DYNC2H1
371	AYSHLRVVF	2195	FAT1
372	VYVIEPHSMEF	23225	NUP210
373	GYISNGELF	116143,5534,5535	WDR92, PPP3R1, PPP3R2
374	VFLPRVTEL	5591	PRKDC
375	KYTDYILKI	374462	PTPRQ
376	VYTPVASRQSL	56852	RAD18
377	QYTPHSHQF	57521	RPTOR
378	VYIAELEKI	27127	SMC1B
379	VFIAQGYTL	160418	TMTC3
380	VYTGIDHHW	25879	DCAF13
381	KYPASSSVF	3217	HOXB7
382	AYLPPLQQVF	26523	EIF2C1
383	RYKPGEPITF	163486	DENND1B
384	RYFDVGLHNF	55733	HHAT
385	QYIEELQKF	55103	RALGPS2
386	TFSDVEAHF	55609	ZNF280C
387	KYTEKLEEI	95681	CEP41
388	IYGEKTYAF	5273	SERPINB10

Table 3: Peptides useful for cancer therapies according to the invention, e.g. personalized cancer therapies.

SEQ ID No.	Sequence	GeneID(s)	Official Gene Symbol(s)
------------	----------	-----------	-------------------------

SEQ No.	ID	Sequence	GeneID(s)	Official Gene Symbol(s)
389		EYLPEFLHTF	154664	ABCA13
390		RYLWATVTI	259266	ASPM
391		LYQILQGIVF	983	CDK1
392		RYLDSLKAIVF	55839	CENPN
393		KYIEAIQWI	81501	DCSTAMP
394		FYQPKIQQF	55215	FANCI
395		LYINKANIW	55632	G2E3
396		YYHFIFTTL	2899	GRIK3
397		IYNGKLFDL	11004	KIF2C
398		IYNGKLFDLL	11004	KIF2C
399		SYIDVLPEF	4233	MET
400		KYLEKYYNL	4312	MMP1
401		VFMKDGFFYF	4312	MMP1
402		VWSDVTPLTF	4320	MMP11
403		TYKYVDINTF	4321	MMP12
404		RYLEKFYGL	4321	MMP12
405		NYPKSIHSF	4321	MMP12
406		TYSEKTTLF	94025	MUC16
407		VYGIRLEHF	83540	NUF2
408		QYASRFVQL	10733	PLK4
409		YFISHVLAF	6241	RRM2
410		RFLSGIINF	83540	NUF2
411		VYIGHTSTI	23499,93035	MACF1, PKHD1L1
412		SYNPLWLRI	259266	ASPM
413		NYLLYVSNF	4486	MST1R
414		MYPYIYHVL	54954	FAM120C
415		SYQKVIELF	55872	PBK
416		AYSDBGHFLF	26011	TENM4
417		VYKVVGNNLL	128239	IQGAP3

The present invention furthermore generally relates to the peptides according to the present invention for use in the treatment of proliferative diseases, such as, for example, glioblastoma (GB), breast cancer (BRCA), colorectal cancer (CRC), renal cell carcinoma (RCC), chronic lymphocytic leukemia (CLL), hepatocellular carcinoma (HCC), non-small cell and small cell lung cancer (NSCLC, SCLC), Non-Hodgkin lymphoma (NHL), acute myeloid leukemia (AML), ovarian cancer (OC), pancreatic cancer (PC), prostate cancer (PCA), esophageal cancer including cancer of the gastric-esophageal junction (OSCAR), gallbladder cancer and cholangiocarcinoma (GBC, CCC), melanoma

- 40 -

(MEL), gastric cancer (GC), testis cancer (TC), urinary bladder cancer (UBC), head-and neck squamous cell carcinoma (HNSCC), and uterine cancer (UEC).

Particularly preferred are the peptides – alone or in combination - according to the present invention selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 388. More preferred are the peptides – alone or in combination - selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 295 (see Table 1A, B, C), and their uses in the immunotherapy of glioblastoma, breast cancer, colorectal cancer, renal cell carcinoma, chronic lymphocytic leukemia, hepatocellular carcinoma, non-small cell and small cell lung cancer, Non-Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, pancreatic cancer, prostate cancer, esophageal cancer including cancer of the gastric-esophageal junction, gallbladder cancer and cholangiocarcinoma, melanoma, gastric cancer, testis cancer, urinary bladder cancer, head-and neck squamous cell carcinoma, or uterine cancer.

Particularly preferred are the peptides – alone or in combination - according to the present invention selected from the group consisting of SEQ ID NO: 70, 80, 323, and 325. More preferred are the peptides – alone or in combination - selected from the group consisting of SEQ ID NO: 70, 80, 323, and 325, and their uses in the immunotherapy of glioblastoma, breast cancer, colorectal cancer, renal cell carcinoma, chronic lymphocytic leukemia, hepatocellular carcinoma, non-small cell and small cell lung cancer, Non-Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, pancreatic cancer, prostate cancer, esophageal cancer including cancer of the gastric-esophageal junction, gallbladder cancer and cholangiocarcinoma, melanoma, gastric cancer, testis cancer, urinary bladder cancer, head-and neck squamous cell carcinoma, or uterine cancer.

Also preferred are the peptides – alone or in combination - according to the present invention selected from the group consisting of SEQ ID NO: 391, and 403. More preferred are the peptides – alone or in combination - selected from the group consisting of SEQ ID NO: 391, and 403, and their uses in the immunotherapy of glioblastoma, breast cancer, colorectal cancer, renal cell carcinoma, chronic lymphocytic leukemia, hepatocellu-

- 41 -

lar carcinoma, non-small cell and small cell lung cancer, Non-Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, pancreatic cancer, prostate cancer, esophageal cancer including cancer of the gastric-esophageal junction, gallbladder cancer and cholangiocarcinoma, melanoma, gastric cancer, testis cancer, urinary bladder cancer, head-and neck squamous cell carcinoma, or uterine cancer.

As shown in Example 1, many of the peptides according to the present invention are found on various tumor types and can, thus, also be used in the immunotherapy of a variety of indications. Over-expression of the underlying polypeptides in a variety of cancers, as shown in Example 2, hints towards the usefulness of these peptides in various other oncological indications.

Thus, another aspect of the present invention relates to the use of the peptides according to the present invention for the - preferably combined - treatment of a proliferative disease selected from the group of glioblastoma, breast cancer, colorectal cancer, renal cell carcinoma, chronic lymphocytic leukemia, hepatocellular carcinoma, non-small cell and small cell lung cancer, Non-Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, pancreatic cancer, prostate cancer, esophageal cancer including cancer of the gastric-esophageal junction, gallbladder cancer and cholangiocarcinoma, melanoma, gastric cancer, testis cancer, urinary bladder cancer, head-and neck squamous cell carcinoma, or uterine cancer.

The present invention furthermore relates to peptides according to the present invention that have the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or - in an elongated form, such as a length-variant - MHC class -II.

The present invention further relates to the peptides according to the present invention wherein said peptides (each) consist or consist essentially of an amino acid sequence according to SEQ ID NO: 1 to SEQ ID NO: 388.

The present invention further relates to the peptides according to the present invention, wherein said peptide is modified and/or includes non-peptide bonds.

The present invention further relates to the peptides according to the present invention, wherein said peptide is part of a fusion protein, in particular fused to the N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii), or fused to (or into the sequence of) an antibody, such as, for example, an antibody that is specific for dendritic cells.

Another embodiment of the present invention relates to a non-naturally occurring peptide wherein said peptide consists or consists essentially of an amino acid sequence according to SEQ ID No: 1 to SEQ ID No: 48 and has been synthetically produced (e.g. synthesized) as a pharmaceutically acceptable salt. Methods to synthetically produce peptides are well known in the art. The salts of the peptides according to the present invention differ substantially from the peptides in their state(s) *in vivo*, as the peptides as generated *in vivo* are no salts. The non-natural salt form of the peptide mediates the solubility of the peptide, in particular in the context of pharmaceutical compositions comprising the peptides, e.g. the peptide vaccines as disclosed herein. A sufficient and at least substantial solubility of the peptide(s) is required in order to efficiently provide the peptides to the subject to be treated. Preferably, the salts are pharmaceutically acceptable salts of the peptides. These salts according to the invention include alkaline and earth alkaline salts such as salts of the Hofmeister series comprising as anions PO_4^{3-} , SO_4^{2-} , CH_3COO^- , Cl^- , Br^- , NO_3^- , ClO_4^- , I^- , SCN^- and as cations NH_4^+ , Rb^+ , K^+ , Na^+ , Cs^+ , Li^+ , Zn^{2+} , Mg^{2+} , Ca^{2+} , Mn^{2+} , Cu^{2+} and Ba^{2+} . Particularly salts are selected from $(\text{NH}_4)_3\text{PO}_4$, $(\text{NH}_4)_2\text{HPO}_4$, $(\text{NH}_4)\text{H}_2\text{PO}_4$, $(\text{NH}_4)_2\text{SO}_4$, $\text{NH}_4\text{CH}_3\text{COO}$, NH_4Cl , NH_4Br , NH_4NO_3 , NH_4ClO_4 , NH_4I , NH_4SCN , Rb_3PO_4 , Rb_2HPO_4 , RbH_2PO_4 , Rb_2SO_4 , $\text{Rb}_4\text{CH}_3\text{COO}$, Rb_4Cl , Rb_4Br , Rb_4NO_3 , Rb_4ClO_4 , Rb_4I , Rb_4SCN , K_3PO_4 , K_2HPO_4 , KH_2PO_4 , K_2SO_4 , KCH_3COO , KCl , KBr , KNO_3 , KClO_4 , KI , KSCN , Na_3PO_4 , Na_2HPO_4 , NaH_2PO_4 , Na_2SO_4 , NaCH_3COO , NaCl , NaBr , NaNO_3 , NaClO_4 , NaI , NaSCN , ZnCl_2 , Cs_3PO_4 , Cs_2HPO_4 , CsH_2PO_4 , Cs_2SO_4 , CsCH_3COO , CsCl , CsBr , CsNO_3 , CsClO_4 , CsI , CsSCN , Li_3PO_4 , Li_2HPO_4 , LiH_2PO_4 , Li_2SO_4 , LiCH_3COO , LiCl , LiBr , LiNO_3 , LiClO_4 , LiI ,

- 43 -

LiSCN, Cu₂SO₄, Mg₃(PO₄)₂, Mg₂HPO₄, Mg(H₂PO₄)₂, Mg₂SO₄, Mg(CH₃COO)₂, MgCl₂, MgBr₂, Mg(NO₃)₂, Mg(ClO₄)₂, MgI₂, Mg(SCN)₂, MnCl₂, Ca₃(PO₄)₂, Ca₂HPO₄, Ca(H₂PO₄)₂, CaSO₄, Ca(CH₃COO)₂, CaCl₂, CaBr₂, Ca(NO₃)₂, Ca(ClO₄)₂, CaI₂, Ca(SCN)₂, Ba₃(PO₄)₂, Ba₂HPO₄, Ba(H₂PO₄)₂, BaSO₄, Ba(CH₃COO)₂, BaCl₂, BaBr₂, Ba(NO₃)₂, Ba(ClO₄)₂, BaI₂, and Ba(SCN)₂. Particularly preferred are NH acetate, MgCl₂, KH₂PO₄, Na₂SO₄, KCl, NaCl, and CaCl₂, such as, for example, the chloride or acetate (trifluoroacetate) salts.

Generally, peptides and variants (at least those containing peptide linkages between amino acid residues) may be synthesized by the Fmoc-polyamide mode of solid-phase peptide synthesis as disclosed by Lukas et al. (Lukas et al., 1981) and by references as cited therein. Temporary N-amino group protection is afforded by the 9-fluorenylmethyloxycarbonyl (Fmoc) group. Repetitive cleavage of this highly base-labile protecting group is done using 20% piperidine in N, N-dimethylformamide. Side-chain functionalities may be protected as their butyl ethers (in the case of serine threonine and tyrosine), butyl esters (in the case of glutamic acid and aspartic acid), butyloxycarbonyl derivative (in the case of lysine and histidine), trityl derivative (in the case of cysteine) and 4-methoxy-2,3,6-trimethylbenzenesulphonyl derivative (in the case of arginine). Where glutamine or asparagine are C-terminal residues, use is made of the 4,4'-dimethoxybenzhydryl group for protection of the side chain amido functionalities. The solid-phase support is based on a polydimethyl-acrylamide polymer constituted from the three monomers dimethylacrylamide (backbone-monomer), bisacryloylethylene diamine (cross linker) and acryloylsarcosine methyl ester (functionalizing agent). The peptide-to-resin cleavable linked agent used is the acid-labile 4-hydroxymethyl-phenoxyacetic acid derivative. All amino acid derivatives are added as their preformed symmetrical anhydride derivatives with the exception of asparagine and glutamine, which are added using a reversed N, N-dicyclohexyl-carbodiimide/1hydroxybenzotriazole mediated coupling procedure. All coupling and deprotection reactions are monitored using ninhydrine, trinitrobenzene sulphonic acid or isotin test procedures. Upon completion of synthesis, peptides are cleaved from the resin support with concomitant removal of side-chain protecting groups by treatment with 95% trifluoroacetic acid containing a 50 % scavenger

- 44 -

mix. Scavengers commonly used include ethanedithiol, phenol, anisole and water, the exact choice depending on the constituent amino acids of the peptide being synthesized. Also a combination of solid phase and solution phase methodologies for the synthesis of peptides is possible (see, for example, (Bruckdorfer et al., 2004), and the references as cited therein).

Trifluoroacetic acid is removed by evaporation in vacuo, with subsequent trituration with diethyl ether affording the crude peptide. Any scavengers present are removed by a simple extraction procedure which on lyophilization of the aqueous phase affords the crude peptide free of scavengers. Reagents for peptide synthesis are generally available from e.g. Calbiochem-Novabiochem (Nottingham, UK).

Purification may be performed by any one, or a combination of, techniques such as recrystallization, size exclusion chromatography, ion-exchange chromatography, hydrophobic interaction chromatography and (usually) reverse-phase high performance liquid chromatography using e.g. acetonitrile/water gradient separation.

The present invention further relates to a nucleic acid, encoding the peptides according to the present invention. The present invention further relates to the nucleic acid according to the present invention that is DNA, cDNA, PNA, RNA or combinations thereof.

The present invention further relates to an expression vector capable of expressing and/or expressing a nucleic acid according to the present invention.

The present invention further relates to a peptide according to the present invention, a nucleic acid according to the present invention or an expression vector according to the present invention for use in the treatment of diseases and in medicine, in particular in the treatment of cancer.

- 45 -

The present invention further relates to antibodies that are specific against the peptides according to the present invention or complexes of said peptides according to the present invention with MHC, and methods of making these.

The present invention further relates to T-cell receptors (TCRs), in particular soluble TCR (sTCRs) and cloned TCRs engineered into autologous or allogeneic T cells, and methods of making these, as well as NK cells or other cells bearing said TCR or cross-reacting with said TCRs.

The antibodies and TCRs are additional embodiments of the immunotherapeutic use of the peptides according to the invention at hand.

The present invention further relates to a host cell comprising a nucleic acid according to the present invention or an expression vector as described before. The present invention further relates to the host cell according to the present invention that is an antigen presenting cell, and preferably is a dendritic cell.

The present invention further relates to a method for producing a peptide according to the present invention, said method comprising culturing the host cell according to the present invention, and isolating the peptide from said host cell or its culture medium.

The present invention further relates to said method according to the present invention, wherein the antigen is loaded onto class I or II MHC molecules expressed on the surface of a suitable antigen-presenting cell or artificial antigen-presenting cell by contacting a sufficient amount of the antigen with an antigen-presenting cell.

The present invention further relates to the method according to the present invention, wherein the antigen-presenting cell comprises an expression vector capable of expressing or expressing said peptide containing SEQ ID No. 1 to SEQ ID No.: 388, preferably containing SEQ ID No. 1 to SEQ ID No. 295, or a variant amino acid sequence.

- 46 -

The present invention further relates to activated T cells, produced by the method according to the present invention, wherein said T cell selectively recognizes a cell which expresses a polypeptide comprising an amino acid sequence according to the present invention.

The present invention further relates to a method of killing target cells in a patient which target cells aberrantly express a polypeptide comprising any amino acid sequence according to the present invention, the method comprising administering to the patient an effective number of T cells as produced according to the present invention.

The present invention further relates to the use of any peptide as described, the nucleic acid according to the present invention, the expression vector according to the present invention, the cell according to the present invention, the activated T lymphocyte, the T cell receptor or the antibody or other peptide- and/or peptide-MHC-binding molecules according to the present invention as a medicament or in the manufacture of a medicament. Preferably, said medicament is active against cancer.

Preferably, said medicament is a cellular therapy, a vaccine or a protein based on a soluble TCR or antibody.

The present invention further relates to a use according to the present invention, wherein said cancer cells are glioblastoma, breast cancer, colorectal cancer, renal cell carcinoma, chronic lymphocytic leukemia, hepatocellular carcinoma, non-small cell and small cell lung cancer, Non-Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, pancreatic cancer, prostate cancer, esophageal cancer including cancer of the gastric-esophageal junction, gallbladder cancer and cholangiocarcinoma, melanoma, gastric cancer, testis cancer, urinary bladder cancer, head and neck squamous cell carcinoma, or uterine cancer.

The present invention further relates to biomarkers based on the peptides according to the present invention, herein called "targets", that can be used in the diagnosis of can-

- 47 -

cer, preferably of glioblastoma, breast cancer, colorectal cancer, renal cell carcinoma, chronic lymphocytic leukemia, hepatocellular carcinoma, non-small cell and small cell lung cancer, Non-Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, pancreatic cancer, prostate cancer, esophageal cancer including cancer of the gastric-esophageal junction, gallbladder cancer and cholangiocarcinoma, melanoma, gastric cancer, testis cancer, urinary bladder cancer, head and neck squamous cell carcinoma, or uterine cancer. The marker can be over-presentation of the peptide(s) themselves, or over-expression of the corresponding gene(s). The markers may also be used to predict the probability of success of a treatment, preferably an immunotherapy, and most preferred an immunotherapy targeting the same target that is identified by the biomarker. For example, an antibody or soluble TCR can be used to stain sections of the tumor to detect the presence of a peptide of interest in complex with MHC.

Optionally the antibody carries a further effector function such as an immune stimulating domain or toxin.

The present invention also relates to the use of these novel targets in the context of cancer treatment.

Both therapeutic and diagnostic uses against additional cancerous diseases are disclosed in the following description of the underlying expression products (polypeptides) of the peptides according to the invention.

A4GNT is frequently expressed in pancreatic cancer cells but not peripheral blood cells and quantitative analysis of A4GNT mRNA expressed in the mononuclear cell fraction of peripheral blood will contribute to the detection of pancreatic cancer (Ishizone et al., 2006). A4GNT mRNA was detectable in 80% of patients with an early stage of gastric cancer when the cancer cells were limited to the gastric mucosa, and the expression levels of A4GNT mRNA were increased in association with tumor progression (Shimizu et al., 2003).

The up-regulated expression of ABCC2 in primary fallopian tube carcinomas is associated with poor prognosis (Halon et al., 2013).

In human cancer ADAM10 is up-regulated, with levels generally correlating with parameters of tumor progression and poor outcome. In preclinical models, a selective inhibitor against ADAM10 has been shown to synergize with existing therapies in decreasing tumor growth (Duffy et al., 2009).

AHCYL2 was shown to be down-regulated in colon carcinoma and in a subset of lung carcinomas (Leonart et al., 2006). mRNA expression of AHCYL2 was described as being potentially associated with the control of p53 function as well as the ras-MAPK pathway, methylation and transcriptional cellular programs, and AHCYL2 may thus be a regulatory suppressor gene involved in human colon and lung tumors (Leonart et al., 2006).

AKR1C1 plays a role in cisplatin resistance in cervical, ovarian and lung cancer cells which includes mitochondrial membrane depolarization, ROS production and activation of the JNK pathway (Chen et al., 2015). Significantly higher intratumoral levels of AKR1C1 were found in responders to neoadjuvant chemotherapy compared with non-responders (Hlavac et al., 2014).

Expression of AKR1C3 was shown to be positively correlated with an elevated Gleason score in prostate cancer, indicating that AKR1C3 can serve as a promising biomarker for the progression of prostate cancer (Tian et al., 2014). AKR1C3 was shown to catalyze the reduction of 4-androstene-3,17-dione to testosterone and estrone to 17 β -estradiol, which promotes the proliferation of hormone dependent prostate and breast cancers, respectively (Byrns et al., 2011). AKR1C3 was shown to be up-regulated in breast cancer, prostate cancer and skin squamous cell carcinoma (Byrns et al., 2011; Mantel et al., 2014). AKR1C3 was shown to be a marker within a gene signature which is able to discriminate responder patients from non-responders upon chemoradiotherapy treatment of patients with locally advanced rectal cancer (Agostini et al.,

2015). AKR1C3 was shown to be associated with doxorubicin resistance in human breast cancer by activation of anti-apoptosis PTEN/Akt pathway via loss of the tumor suppressor PTEN (Zhong et al., 2015). AKR1C3 was shown to be associated with a higher risk of lung cancer among people from a Chinese county who were exposed to coal emissions (Li et al., 2015a). AKR1C3 was described as a potential therapeutic marker for choriocarcinoma which is also associated with the development of methotrexate resistance in this disease (Zhao et al., 2014a).

The expression of ALDH1L1 was shown to be down-regulated in HCC and gliomas. The down-regulation of ALDH1L1 in those cancers was associated with poorer prognosis and more aggressive phenotype (Chen et al., 2012; Rodriguez et al., 2008).

ALOX15 is present at high levels in prostate cancer (PCa), lung cancer, breast cancer, melanomas, and colonic adenocarcinomas when compared with normal tissues (Kelavkar et al., 2002). ALOX15 enzyme activity contributes to PCa initiation and progression (Kelavkar et al., 2007).

AR has been implicated in the development of various cancers such as prostate, castrate-resistant prostate, breast, glioblastoma multiforme, colon and gastric (Wang et al., 2009b; Yu et al., 2015b; Mehta et al., 2015; Wang et al., 2015a; Sukocheva et al., 2015). In addition to promoting prostate cancer proliferation, androgen signaling through AR leads to apoptosis via inducing the expression of p21 (WAF1/CIP1), a cyclin-dependent kinase inhibitor (Yeh et al., 2000).

Mutations in ARMC5 cause macronodular cortisol-producing neoplasias, bilateral macronodular hyperplasias, primary macronodular adrenal hyperplasia, and meningioma (Espiard and Bertherat, 2015; Kirschner and Stratakis, 2016; Elbelt et al., 2015).

Pharmacogenomic studies reveal correlations between ATAD5 and anticancer agents (Abaan et al., 2013). ATAD5 is significantly up-regulated in malignant peripheral nerve sheath tumors (Pasmant et al., 2011). Hepatitis B virus protein X significantly enhances

the expression of ATAD5 in HBV-associated hepatocellular carcinoma (Ghosh et al., 2016). Loss of ATAD5 is embryonically lethal in mice, it acts as tumor suppressor in both mice and humans, and it interacts with components of the human Fanconi Anemia pathway. Furthermore, it may be responsible for some of the phenotypes associated with neurofibromatosis, a hereditary disease with high risk of tumor growth (Gazy et al., 2015; Jenne et al., 2001). Variants of the ATAD5 gene locus are associated with epithelial ovarian cancer risk (Kuchenbaecker et al., 2015). ATAD5 has a bearing on at least one mammalian phenotype of non-small cell lung cancer (Li et al., 2014).

The expression of ATP10B is de-regulated in highly invasive glioma cells and associated with the invasive behavior (Tatenhorst et al., 2004).

ATP8B4 may be a prognostic marker and therapeutic target in multiple myeloma patients and other entities (US Patent No. 20070237770 A1) (Ni et al., 2012).

ATR encodes ATR serine/threonine kinase, which belongs to the PI3/PI4-kinase family. Copy number gain, amplification, or translocation of the ATR gene were observed in oral squamous cell carcinoma cell lines (Parikh et al., 2014). It has been demonstrated that truncating ATR mutations in endometrial cancers are associated with reduced disease-free and overall survival (Zigheboim et al., 2009).

B3GNT5 is over-expressed in acute myeloid leukemia, and mouse embryonal carcinoma and its expression is inversely correlated with promotor methylation in glioblastoma (Ogasawara et al., 2011; Etcheverry et al., 2010; Wang et al., 2012). Down-regulation of B3GNT5 through miRNA-203 may contribute to the malignancy of hypopharyngeal squamous cell carcinoma (Wang et al., 2015g). B3GNT5 is associated with breast cancer patient survival (Potapenko et al., 2015).

Bub1 expression is increased in subsets of lymphomas, breast, gastric and prostate cancers. Bub1 over-expression correlates with poor clinical prognosis (Ricke and van

Deursen, 2011). Bub1 mutations can be found in colorectal carcinomas exhibiting chromosomal instability (Williams et al., 2007).

C4A has been described as a biomarker for polycystic ovary syndrome and endometrial cancer and experimental data suggest that C4 can mediate cancer growth (Galazis et al., 2013; Rutkowski et al., 2010).

In the acute myelomonocytic leukemia cell line JIH3 a chromosome deletion includes C7orf10 (Pan et al., 2012).

C8 is constitutively expressed by the human hepatoma cell line HepG2 and expression is strongly enhanced after stimulation with the cytokines IL-6, IFN-gamma and IL-1 beta (Scheurer et al., 1997).

Cancer-testis antigen specific primers can detect CASC5 in glioblastoma multiforme, one of the most malignant and aggressive tumors with very poor prognosis. CASC5 has specific binding motifs at the N-terminus (for Bub1 and BubR1) and at the C-terminus (for Zwint-1 and hMis14/hNsl1). Disruption of this connection may be able to lead to tumorigenesis (Kiyomitsu et al., 2011; Jiang et al., 2014c). CASC5 interacts with the tumor suppressor pRb (Bogdanov and Takimoto, 2008). CASC5 is highly expressed in proliferating somatic cells, tumors and healthy human testis (Bogdanov and Takimoto, 2008; Sasao et al., 2004). CASC5 is linked to cell growth suppression and maturation enhancement and its disruption thus may be a key factor for leukemogenesis (Hayette et al., 2000; Bogdanov and Takimoto, 2008; Chinwalla et al., 2003; Kuefer et al., 2003; Yang et al., 2014a).

CCR4 has been described as a prognostic marker in various tumors such as renal cell carcinoma, head and neck squamous cell carcinoma, gastric cancer, breast cancer, colon cancer and Hodgkin lymphoma (Ishida et al., 2006; Olkhanud et al., 2009; Yang et al., 2011; Tsujikawa et al., 2013; Al-haidari et al., 2013; Liu et al., 2014a). Studies

have revealed that gastric cancer patients with CCR4-positive tumors had significantly poorer prognosis compared to those with CCR4-negative tumors (Lee et al., 2009a).

CCR8 expression is increased in monocytic and granulocytic myeloid cell subsets in peripheral blood of patients with urothelial and renal carcinomas. Up-regulated expression of CCR8 is also detected within human bladder and renal cancer tissues and primarily limited to tumor-associated macrophages. The CCL1/CCR8 axis is a component of cancer-related inflammation and may contribute to immune evasion (Eruslanov et al., 2013).

A single nucleotide polymorphism in CD101 was shown to be associated with pancreatic cancer risk, but results could not be replicated in a prostate cancer case-control and cohort population, thus, requiring future research in the possible role of CD101 in pancreatic cancer (Reid-Lombardo et al., 2011). CD101 was identified as one gene of a 6-gene signature that discriminated chronic phase from blast crisis chronic myeloid leukemia using a Bayesian model averaging approach (Oehler et al., 2009).

CD84 was described as a CD antigen which is differentially abundant in progressive chronic lymphocytic leukemia as compared to slow-progressive and stable chronic lymphocytic leukemia (Huang et al., 2014). CD84 expression was shown to be significantly elevated from the early stages of chronic lymphocytic leukemia (Binsky-Ehrenreich et al., 2014).

CENPE expression significantly correlated with glioma grade and might complement other parameters for predicting survival time for glioma patients (Bie et al., 2011). CENPE is up-regulated in chemo-resistant epithelial ovarian tumors compared to chemo-sensitive tumors (Ju et al., 2009). CENPE is up-regulated in invasive and aggressive-invasive prolactin pituitary tumors (Wierinckx et al., 2007).

CLDN14 was shown to be up-regulated in gastric cancer (Gao et al., 2013). CLDN14 expression was shown to be associated with lymphatic metastasis in gastric cancer

(Gao et al., 2013). CLDN14 was described to play a role in the regulation of tumor blood vessel integrity and angiogenesis in mice (Baker et al., 2013).

CLDN3 is highly differentially expressed in many human tumors and may provide an efficient molecular tool to specifically identify and target biologically aggressive human cancer cells as CLDN3 is a high affinity receptor of *Clostridium perfringens* enterotoxin (Black et al., 2015). CLDN3 is frequently over-expressed in several neoplasias, including ovarian, breast, pancreatic, and prostate cancers (Morin, 2005). CLDN3 was identified as prostate cancer biomarker as it is highly expressed in prostate cancer (Amaro et al., 2014). Decreased expression of CLDN3 is associated with a poor prognosis and EMT in completely resected squamous cell lung carcinoma (Che et al., 2015). CLDN3 inhibits cancer aggressiveness via Wnt-EMT signaling and is a potential prognostic biomarker for hepatocellular carcinoma (Jiang et al., 2014b).

CLDN4 is highly differentially expressed in many human tumors and may provide an efficient molecular tool to specifically identify and target biologically aggressive human cancer cells as CLDN4 is a high affinity receptor of *Clostridium perfringens* enterotoxin (Black et al., 2015). CLDN4 is frequently over-expressed in several neoplasias including ovarian, breast, pancreatic, and prostate cancers (Morin, 2005). An antibody against the extracellular domain of CLDN4 provides pro-chemotherapeutic effects in bladder cancer (Kuwada et al., 2015). High expression of CLDN4 was associated with the more differentiated intestinal-type gastric carcinoma and lost in poorly differentiated diffuse type. Low expression of CLDN4 was related to lymphangiogenesis (Shareef et al., 2015).

CLDN6 expression was shown to be associated with lymph node metastasis and TNM stage in non-small cell lung cancer (Wang et al., 2015f). Furthermore, low expression of CLDN6 was shown to be associated with significantly lower survival rates in patients with non-small cell lung cancer (Wang et al., 2015f). Thus, low CLDN6 expression is an independent prognostic biomarker that indicates worse prognosis in patients with non-small cell lung cancer (Wang et al., 2015f). CLDN6 was shown to be down-regulated in cervical carcinoma and gastric cancer (Zhang et al., 2015; Lin et al., 2013). CLDN6 was

shown to be up-regulated in BRCA1-related breast cancer and ovarian papillary serous carcinoma (Wang et al., 2013b; Heerma van Voss et al., 2014). CLDN6 was described as a tumor suppressor for breast cancer (Zhang et al., 2015). Gain of CLDN6 expression in the cervical carcinoma cell lines HeLa and C33A was shown to suppress cell proliferation, colony formation in vitro, and tumor growth in vivo, suggesting that CLDN6 may function as a tumor suppressor in cervical carcinoma cells (Zhang et al., 2015). CLDN6 may play a positive role in the invasion and metastasis of ovarian cancer (Wang et al., 2013b). CLDN6 was shown to be consistently expressed in germ cell tumors and thus is a novel diagnostic marker for primitive germ cell tumors (Ushiku et al., 2012). CLDN6 expression was shown to be positive in most tumors of an assessed set of atypical teratoid/rhabdoid tumors of the central nervous system, with strong CLDN6 positivity being a potential independent prognostic factor for outcome of the disease (Dufour et al., 2012).

CLDN9 was shown to be up-regulated in the metastatic Lewis lung carcinoma cell line p-3LL and in tumors derived from these cells and in pituitary oncocytomas (Sharma et al., 2016; Hong et al., 2014). Knock-down of CLDN9 expression in metastatic Lewis lung carcinoma p-3LL cells was shown to result in significantly reduced motility, invasiveness in vitro and metastasis in vivo, whereas transient over-expression in these cells was shown to enhance their motility (Sharma et al., 2016). Thus, CLDN9 may play an essential role in promoting lung cancer metastasis (Sharma et al., 2016). CLDN9 was shown to be down-regulated in cervical carcinoma tissues (Zhu et al., 2015a). CLDN9 expression was observed to be correlated with lymphatic metastasis of cervical carcinomas (Zhu et al., 2015a). CLDN9 was described as the most significantly altered and up-regulated gene in pituitary oncocytomas with higher expression levels in invasive compared to non-invasive oncocytomas (Hong et al., 2014). Thus, CLDN9 may be an important biomarker for invasive pituitary oncocytomas (Hong et al., 2014). Over-expression of CLDN9 in the gastric adenocarcinoma cell line AGS was shown to enhance invasive potential, cell migration and the proliferation rate and is thus sufficient to enhance tumorigenic properties of a gastric adenocarcinoma cell line (Zavala-Zendejas et al., 2011). Strong CLDN9 expression was shown to be associated with a higher mor-

tality rate in diffuse-type gastric adenocarcinomas compared to the intestinal type and its detection was described as a useful prognostic marker in “intestinal- “and “diffuse-type” gastric adenocarcinomas (Rendon-Huerta et al., 2010).

CLEC5A mRNA expression was shown to be significantly lower in primary acute myeloid leukemia patients samples than in macrophages and granulocytes from healthy donors (Batliner et al., 2011). CLEC5A was described as a novel transcriptional target of the tumor suppressor PU.1 in monocytes/macrophages and granulocytes (Batliner et al., 2011).

DCP2 was identified as miR-224 target that was differentially expressed more than 2-fold in methotrexate resistant human colon cancer cells (Mencia et al., 2011).

DCSTAMP expression is increased in papillary thyroid cancer (Lee et al., 2009b; Kim et al., 2010b). Down-regulation of DCSTAMP leads to a decreased colony formation of MCF-7 cells probably because of decreased proliferation and cell cycle progression as well as increased apoptosis (Zeng et al., 2015). DCSTAMP is over-expressed in peripheral macrophages, and dendritic cells and myeloma plasma cells show high susceptibility to DCSTAMP and are able to transdifferentiate to osteoclasts. Malignant plasma cells expressing cancer stem cell phenotype and high metastasizing capability express osteoclast markers which activate the beta3 transcriptional pathway resulting in ERK1/2 phosphorylation and initiation of bone resorbing activity (Silvestris et al., 2011). Esculetin and parthenolide suppress c-Fos and nuclear factor of activated T cell c1 signaling pathway resulting in suppressed DCSTAMP expression, a marker gene for osteoclast differentiation (Ihn et al., 2015; Baek et al., 2015; Cicek et al., 2011; Courtial et al., 2012; Kim et al., 2014a).

SNPs in DENND1B were significantly associated with pancreas cancer risk (Cotterchio et al., 2015).

DNAH17, also known as DNEL2, was described as a homologue to a tumor-antigen identified in melanoma patients (Ehlken et al., 2004). DNAH17 was described as one of several candidate genes mapped to a small chromosome interval associated with sporadic breast and ovarian tumorigenesis, and esophageal cancer in the autosomal dominant disorders hereditary neuralgic amyotrophy and tylosis (Kalikin et al., 1999).

DNAH2 is one of the genes mutated in $\geq 10\%$ of patients with chronic myelomonocytic leukemia (Mason et al., 2015). Genes encoding microtubule-associated proteins, such as DNAH2, showed a 10% or higher incidence of genetic aberrations in CpG-island methylator phenotype-positive clear renal cell carcinomas (Arai et al., 2015).

Re-expression of methylation silenced tumor suppressor genes by inhibiting DNMT3B has emerged as an effective strategy against cancer (Singh et al., 2013).

FAM83B mRNA expression was significantly higher in squamous cell carcinoma than in normal lung or adenocarcinoma and FAM83B therefore is a novel biomarker for diagnosis and prognosis (Okabe et al., 2015). FAM83B was identified as an oncogene involved in activating CRAF/MAPK signaling and driving epithelial cell transformation. Elevated expression is associated with elevated tumor grade and decreased overall survival (Cipriano et al., 2014). Elevated FAM83B expression also activates the PI3K/AKT signaling pathway and confers a decreased sensitivity to PI3K, AKT, and mTOR inhibitors (Cipriano et al., 2013).

Down-regulation or dysfunction of FANCD2 due to genetic mutations has been reported in different cancer types including breast cancer, acute lymphatic leukemia and testicular seminomas and is associated with cancer development. Otherwise also re-expression and up-regulation of FANCD2 was shown to be associated with tumor progression and metastasis in gliomas and colorectal cancer (Patil et al., 2014; Shen et al., 2015a; Shen et al., 2015b; Ozawa et al., 2010; Rudland et al., 2010; Zhang et al., 2010a; Smetsers et al., 2012). PI3K/mTOR/Akt pathway promotes FANCD2 inducing the ATM/Chk2 checkpoint as DNA damage response and monoubiquitinated FANCD2

activates the transcription of the tumor suppressor TAp63 (Shen et al., 2013; Park et al., 2013).

FOXJ1 expression is up-regulated, associated with tumor stage, histologic grade and size and correlated with prognosis in patients with clear cell renal cell carcinoma (Zhu et al., 2015b). Decreased FOXJ1 expression was significantly correlated with clinic stage, lymph node metastasis, and distant metastasis, and lower FOXJ1 expression independently predicted shorter survival time in gastric carcinoma (Wang et al., 2015c). Over-expression of FOXJ1 can promote tumor cell proliferation and cell-cycle transition in hepatocellular carcinoma and is associated with histological grade and poor prognosis (Chen et al., 2013).

High GINS2 transcript level predicts poor prognosis and correlates with high histological grade and endocrine therapy resistance through mammary cancer stem cells in breast cancer patients (Zheng et al., 2014). GINS2 was reported to be present at a high level in lung adenocarcinoma and associated with TNM stages (Liu et al., 2013b). GINS2 express abundantly and abnormally in many malignant solid tumors, such as breast cancer, melanoma and hepatic carcinoma. Further, over-expression of GINS2 could promote proliferation of leukemic cell lines (Zhang et al., 2013a).

GPR98 expression is increased in primary neuroendocrine tumors relative to normal tissue (Sherman et al., 2013). GPR98 was among the genes associated with survival of glioblastoma multiforme (Sadeque et al., 2012). GPR98 displays a transcript regulated by glucocorticoids which are used for the treatment of acute lymphoblastic leukemia as they lead to the induction of apoptosis (Rainer et al., 2012).

GTPBP10 is highly correlated with copy number variation, gene expression, and patient outcome in glioblastoma (Kong et al., 2016).

GTSE1 expression represses apoptotic signaling and confers cisplatin resistance in gastric cancer cells (Subhash et al., 2015). GTSE1 is over-expressed in uterine leiomyosarcoma (ULMS) and participated in cell cycle regulation.

H2BFS was consistently expressed as a significant cluster associated with the low-risk acute lymphoblastic leukemia subgroups (Qiu et al., 2003).

HIST1H2BJ was shown to be down-regulated in brain tumors and was described as potentially useful for developing molecular markers of diagnostic or prognostic value (Luna et al., 2015).

Acetylation of HISTH4A might be a potential target to inactivate embryonic kidney cancer (Wilms tumor) (Yan-Fang et al., 2015).

HIST1H4C may act as risk distinguishing factor for the development of treatment-related myeloid leukemia (Bogni et al., 2006).

HIST1H4F was observed to be hyper-methylated in prostate cancer which might also correlate with the aging of the patient (Kitchen et al., 2016).

A high methylation rate of HIST1H4K was observed in high-grade non-muscle invasive bladder cancer as well as in prostate cancer and is therefore representing a potential biomarker (Payne et al., 2009; Kachakova et al., 2013).

It was shown that HIST1H4L is significantly up-regulated in ERG+ prostate carcinomas (Camoës et al., 2012). HIST1H4L encodes the replication-dependent histone cluster 1, H4I that is a member of the histone H4 family (RefSeq, 2002).

HIST2H4B was identified as novel protein in key cellular pathogenic pathways in cells infected with a reovirus subtype that is presently in clinical trials as an anti-cancer oncolytic agent (Berard et al., 2015).

HIST4H4 was one of the genes which showed continuous down-regulation in gastric cancer cells after treatment with immune-conjugates composed of an alpha-emitter and the monoclonal antibody d9MAb that specifically target cells expressing mutant d9-E-cadherin (Seidl et al., 2010). Hyper-methylation of other members of the histon H4 family was significantly associated with shorter relapse-free survival in stage I non-small cell lung cancer (Sandoval et al., 2013).

HIVEP1 was identified as cellular gene disrupted by human T-lymphotropic virus type 1 integration in lymphoma cell lines (Cao et al., 2015). HIVEP1 was associated with the unfavorable 11q deletion and also with the unfavorable Binet stages B and C in chronic lymphocytic leukemia (Aalto et al., 2001).

HNRNPH2 is up-regulated in different cancer types including pancreatic, liver and gastric cancer (Honore et al., 2004; Zeng et al., 2007). HNRNPH2 is involved in splicing of the beta-deletion transcript of hTERT, which is highly expressed in cancer cells and competes and thereby inhibits endogenous telomerase activity (Listerman et al., 2013).

HOXD11 is dysregulated in head and neck squamous cell carcinoma showing strikingly high levels in cell lines and patient tumor samples. Knockdown of HOXD11 reduced invasion (Sharpe et al., 2014). HOXD11 is significantly up-regulated in oral squamous cell carcinoma (Rodini et al., 2012). HOXD11 is aberrantly methylated in human breast cancers (Miyamoto et al., 2005). The HOXD11 gene is fused to the NUP98 gene in acute myeloid leukemia with t(2;11) (q31;p15) (Taketani et al., 2002).

ICOS acts as a ligand of programmed death-1 (PD-1) on T cells, induces the immune escape of cancer cells and also acts as a receptor mediating anti-apoptotic effects on cancer cells (Yang et al., 2015c). Murine tumor models have provided significant support for the targeting of multiple immune checkpoints involving ICOS during tumor growth (Leung and Suh, 2014). ICOS+ cell infiltration correlates with adverse patient prognosis, identifying ICOS as a new target for cancer immunotherapy (Faget et al.,

2013). ICOS can enhance the cytotoxic effect of cytokine-induced killer cells against cholangiocarcinoma both in vitro and in vivo (He et al., 2011).

Intratumoral expression of IFNG was shown to be associated with expression of MHC Class II molecules and a more aggressive phenotype in human melanomas (Brocker et al., 1988). Autocrine IFNG signaling was shown to enhance experimental metastatic ability of IFNG gene-transfected mammary adenocarcinoma cells, and was attributed to increased resistance to NK cells (Lollini et al., 1993).

Triple-negative breast cancer has high tumor expression of IGFBP3 associated with markers of poor prognosis (Marzec et al., 2015). A novel cell death receptor that binds specifically to IGFBP3 was identified and might be used in breast cancer treatment (Mohanraj and Oh, 2011). IGFBP3 exhibits pro-survival and growth-promoting properties in vitro (Johnson and Firth, 2014). IGFBP3 is an independent marker of recurrence of the urothelial cell carcinomas (Phe et al., 2009).

IGFBPL1 is a regulator of insulin-growth factors and is down-regulated in breast cancer cell lines by aberrant hypermethylation. Methylation in IGFBPL1 was clearly associated with worse overall survival and disease-free survival (Smith et al., 2007).

IGFLR1 is mutated in colorectal cancer (Donnard et al., 2014). IGFLR1 has structural similarity with the tumor necrosis factor receptor family (Lobito et al., 2011).

IL4I1 protein expression is very frequent in tumors. IL4I1 was detected in tumor-associated macrophages of different tumor entities, in neoplastic cells from lymphomas and in rare cases of solid cancers mainly mesothelioma (Carbonnelle-Puscian et al., 2009). IL4I1 up-regulation in human Th17 cells limits their T-cell receptor (TCR) - mediated expansion by blocking the molecular pathway involved in the activation of the IL-2 promoter and by maintaining high levels of Tob1, which impairs entry into the cell cycle (Santarlaschi et al., 2014).

IQGAP3 is over-expressed in lung cancer and is associated with tumor cell growth, migration and invasion. Furthermore, it is up-regulated by chromosomal amplification in hepatocellular carcinoma and the expression of IQGAP3 is increased in p53-mutated colorectal cancer patients with poor survival (Katkoori et al., 2012; Yang et al., 2014b; Skawran et al., 2008). IQGAP3 is modulating the EGFR/Ras/ERK signaling cascade and interacts with Rac/Cdc42 (Yang et al., 2014b; Kunitomo et al., 2009).

Elevated levels of ITGA2 were found in the highly invasive and metastatic melanoma cell lines compared with normal cultured melanocytes and non-metastatic melanoma cell lines (van Muijen et al., 1995). The adhesion molecule ITGA2 was up-regulated by IFN-gamma, TNF-alpha, and IL-1-beta in melanoma cells (Garbe and Krasagakis, 1993). Transfection of ITGA2 into human rhabdomyosarcoma cells which do not express ITGA2, potentiated the frequency of metastases in various organs (Matsuura et al., 1995).

KCNU1 is located on chromosome 8p in an area that is frequently involved in complex chromosomal rearrangements in breast cancer (Gelsi-Boyer et al., 2005). KCNU1 is one of the top 25 over-expressed extracellular membrane proteins in hepatoblastomas of pediatric cancer samples (Orentas et al., 2012).

KIAA0226L is thought to be a tumor suppressor gene and is hyper-methylated in cervical cancer. Re-activation of KIAA0226L leads to decreased cell growth, viability, and colony formation (Huisman et al., 2015; Eijssink et al., 2012; Huisman et al., 2013). The methylation pattern of KIAA0226L can be used to differ between precursor lesions and normal cervix cancer (Milutin et al., 2015). The methylation pattern of KIAA0226L cannot be used as specific biomarker for cervical cancer (Sohrabi et al., 2014). Re-activation of KIAA0226L partially de-methylates its promotor region and also decreases repressive histone methylations (Huisman et al., 2013).

KIAA1244 over-expression is one of the important mechanisms causing the activation of the estrogen/ERalpha signaling pathway in the hormone-related growth of breast cancer

cells (Kim et al., 2009). Inhibiting the interaction between KIAA1244 and PHB2 may be a new therapeutic strategy for the treatment of luminal-type breast cancer (Yoshimaru et al., 2013).

KIAA1524 encodes Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A). A critical role of CIP2A has been shown among other for NSCLC, HCC, HNSCC, bladder, pancreatic, cervical, breast, prostate, ovarian and colorectal cancers (Ventela et al., 2015; Ma et al., 2014; Guo et al., 2015b; Rincon et al., 2015; Guo et al., 2015c; Wu et al., 2015; Peng et al., 2015; Lei et al., 2014; Liu et al., 2014c; Farrell et al., 2014; Fang et al., 2012; He et al., 2012; Bockelman et al., 2012).

KIF18A was shown to be over-expressed in hepatocellular cancer, which correlated with significantly shorter disease free and overall survival. Thus, KIF18A might be a biomarker for hepatocellular cancer diagnosis and an independent predictor of disease free and overall survival after surgical resection (Liao et al., 2014). KIF18A expression is up-regulated in specific subtypes of synovial sarcoma (Przybyl et al., 2014). Estrogen strongly induces KIF18A expression in breast cancer, which is associated with increased proliferation and reduced apoptosis (Zou et al., 2014).

Over-expression of KIF20A was detected in pancreatic ductal adenocarcinoma, melanoma, bladder cancer, non-small cell lung cancer and cholangiocellular carcinoma (Imai et al., 2011; Yamashita et al., 2012; Stangel et al., 2015). Recently, it was reported that patients with pancreatic ductal adenocarcinoma vaccinated with a KIF20A-derived peptide exhibited better prognosis compared to the control group (Asahara et al., 2013). In addition, silencing of KIF20A resulted in an inhibition of proliferation, motility, and invasion of pancreatic cancer cell lines (Stangel et al., 2015).

High expression of KIF26B in breast cancer associates with poor prognosis (Wang et al., 2013c). KIF26B up-regulation was significantly correlated with tumor size analyzing CRC tumor tissues and paired adjacent normal mucosa. KIF26B plays an important role

in colorectal carcinogenesis and functions as a novel prognostic indicator and a potential therapeutic target for CRC (Wang et al., 2015d).

KIF2C was shown to be involved in directional migration and invasion of tumor cells (Ritter et al., 2015). Over-expression of KIF2C was shown to be associated with lymphatic invasion and lymph node metastasis in gastric and colorectal cancer patients (Ritter et al., 2015). KIF2C was shown to be up-regulated in oral tongue cancer (Wang et al., 2014a). High expression of KIF2C was shown to be associated with lymph node metastasis and tumor staging in squamous cell carcinoma of the oral tongue (Wang et al., 2014a). Silencing of KIF2C was shown to result in suppressed proliferation and migration of the human oral squamous cell carcinoma cell line Tca8113 (Wang et al., 2014a). Mutation of KIF2C was described as being associated with colorectal cancer (Kumar et al., 2013).

KIFC1 was shown to be essential for proper spindle assembly, stable pole-focusing and survival of cancer cells independently from number of formed centrosomes (normal or supernumerary centrosomes). KIFC1 expression was shown to be up-regulated in breast cancer, particularly in estrogen receptor negative, progesterone receptor negative and triple negative breast cancer, and 8 human breast cancer cell lines. In estrogen receptor-positive breast cancer cells, KIFC1 was one of 19 other kinesins whose expression was strongly induced by estrogen. In breast cancer, the overexpression of KIFC1 and its nuclear accumulation was shown to correlate with histological grade and predict poor progression-free and overall survival. In breast cancer cell lines, the overexpression of KIFC1 was shown to mediate the resistance to docetaxel. The KIFC1 silencing negatively affected the breast cancer cell viability (Zou et al., 2014; Pannu et al., 2015; De et al., 2009; Li et al., 2015b). KIFC1 was shown to be overexpressed in ovarian cancer which was associated with tumor aggressiveness, advanced tumor grade and stage. KIFC1 was identified as one of three genes, whose higher expression in primary NSCLC tumors indicated the higher risk for development of brain metastasis (Grinberg-Rashi et al., 2009).

KL was described as a tumor suppressor which suppresses the epithelial to mesenchymal transition in cervical cancer and which functions as a tumor suppressor in several types of human cancers by inhibiting insulin/IGF1, p53/p21, and Wnt signaling (Xie et al., 2013; Qureshi et al., 2015). KL was described as an aberrantly expressed gene in a number of cancers, including breast cancer, lung cancer and hepatocellular carcinoma (Zhou and Wang, 2015). KL was described to be down-regulated in pancreatic cancer, hepatocellular carcinoma, and other tumors (Zhou and Wang, 2015). KL was described as a novel biomarker for cancer whose down-regulation was described to result in promoted proliferation and reduced apoptosis of cancer cells. In this context Wnt/ β -catenin signaling is one of several relevant signaling pathways (Zhou and Wang, 2015). A KL gene polymorphism was shown to be associated with increased risk of colorectal cancer (Liu et al., 2015).

KLHDC7B is associated with cervical squamous cell carcinoma and is a potential biomarker for cervical squamous cell carcinoma (Guo et al., 2015a).

KLHL genes are responsible for several Mendelian diseases and have been associated with cancer (Dhanoa et al., 2013).

Focal expression of KRT31 was observed in invasive onychocytic carcinoma originating from nail matrix keratinocytes (Wang et al., 2015e). Pilomatricomas are tumors that emulate the differentiation of matrix cells of the hair follicle, showing cortical differentiation, with sequential over-expression of KRT35 and KRT31 keratins (Battistella et al., 2014).

KRT35 was one of the most frequently and most strongly expressed hair keratins in pilomatrixomas. Pilomatricomas are tumors that emulate the differentiation of matrix cells of the hair follicle, showing cortical differentiation, with sequential over-expression of KRT35 and KRT31 keratins (Battistella et al., 2014).

Knockdown of LCTL allowed hTERT to immortalize human colonic epithelial cells (Kim et al., 2011).

Researchers have observed that inhibition of LRBA expression by RNA interference, or by a dominant-negative mutant, resulted in the growth inhibition of cancer cells. These findings imply that deregulated expression of LRBA contributes to the altered growth properties of a cancer cell (Wang et al., 2004).

LRRC8E is over-expressed in osteosarcoma and neuroblastoma tissues in comparison to normal samples (Orentas et al., 2012).

LTA polymorphisms contributed to the increased risk of cancers (Huang et al., 2013a). Bone resorbing factors like LTA are produced by certain solid and hematologic cancers and have also been implicated in tumor-induced hyper-calcemia (Goni and Tolis, 1993). There is a link between the LTA to LTbetaR signaling axis and cancer (Drutskaya et al., 2010). B-cell-derived lymphotoxin promotes castration-resistant prostate cancer (Ammirante et al., 2010).

MACC1 is over-expressed in many cancer entities including gastric, colorectal, lung and breast cancer and is associated with cancer progression, metastasis and poor survival of patients (Huang et al., 2013b; Ma et al., 2013a; Stein, 2013; Wang et al., 2015b; Wang et al., 2015h; Ilm et al., 2015). MACC1 promotes carcinogenesis through targeting beta-catenin and PI3K/AKT signaling pathways, which leads to an increase of c-Met and beta-catenin and their downstream target genes including c-Myc, cyclin D1, caspase9, BAD and MMP9 (Zhen et al., 2014; Yao et al., 2015).

MAGEA10 encodes MAGE family member A10, implicated in some hereditary disorders, such as dyskeratosis congenital (RefSeq, 2002). By a vaccine directed against MAGEA10 and two other cancer-testis antigens, all of which are known to be targets of cytotoxic-T-lymphocyte responses, more than two-thirds of breast cancers would be covered (Taylor et al., 2007). MAGEA10 was expressed in 36.7% of the tumor tissues from hepatocellular carcinoma patients; however, it was not expressed in the para-cancer tissues (Chen et al., 2003). MAGEA10 was expressed in 14% of 79 lung cancer tissues (Kim et al., 2012).

MAGEB6 was identified as new MAGE gene not expressed in normal tissues, except for testis, and expressed in tumors of different histological origins (Lucas et al., 2000). MAGEB6 was found frequently expressed in head and neck squamous cell carcinoma and mRNA positivity presented significant associations with recognized clinical features for poor outcome (Zamuner et al., 2015).

MCC interacts with beta-catenin and re-expression of MCC in colorectal cancer cells specifically inhibits Wnt signaling (Fukuyama et al., 2008). The MCC gene is in close linkage with the adenomatous polyposis coli gene on chromosome 5, in a region of frequent loss of heterozygosity (LOH) in colorectal cancer (Kohonen-Corish et al., 2007). LOH of MCC gene could be found in both early and advanced stages of gastric, lung, esophageal and breast cancers (Wang et al., 1999a; Medeiros et al., 1994).

MET was shown to be up-regulated in dedifferentiated liposarcoma and is associated with melanocytic tumors, hepatocellular carcinoma, non-small cell lung cancer, hereditary papillary kidney cancers and gastric adenocarcinomas (Petrini, 2015; Finocchiaro et al., 2015; Steinway et al., 2015; Bill et al., 2015; Yeh et al., 2015).

The expression of MMP10 in oral squamous cell carcinoma was intensive and in verrucous carcinoma was moderate (Kadeh et al., 2015). MMP10 contributes to hepatocarcinogenesis in a novel crosstalk with the stromal derived factor 1/C-X-C chemokine receptor 4 axis (Garcia-Irigoyen et al., 2015). *Helicobacter pylori* infection promotes the invasion and metastasis of gastric cancer through increasing the expression of MMP10 (Jiang et al., 2014a). MMP10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors (Zhang et al., 2014).

The elevated level of preoperative MMP-13 was found to associate with tumor progression and poor survival in patients with esophageal squamous cell carcinoma (Jiao et al., 2014). PAI-1, a target gene of miR-143, regulates invasion and lung metastasis via enhancement of MMP-13 expression and secretion in human osteosarcoma cells, sug-

gesting that these molecules could be potential therapeutic target genes for preventing lung metastasis in osteosarcoma patients (Hirahata et al., 2016). MMP13 is already up-regulated in Oral lichen planus (OLP) which has been classified as a pre-malignant condition for oral squamous cell carcinoma (OSCC) (Agha-Hosseini and Mirzaii-Dizgah, 2015). MMP-13 plays a potentially unique physiological role in the regeneration of osteoblast-like cells (Ozeki et al., 2016).

MUC5AC is de-regulated in a variety of cancer types including colorectal, gastric, lung and pancreatic cancer. Depletion or low expression in colorectal and gastric tumors is associated with a more aggressive behavior and poor prognosis. Over-expression in lung cancer results in an increased likelihood of recurrence and metastases (Yonezawa et al., 1999; Kocer et al., 2002; Kim et al., 2014b; Yu et al., 1996).

MUC5B is over-expressed in different cancer entities including colorectal, lung and breast cancer and is associated with tumor progression (Sonora et al., 2006; Valque et al., 2012; Walsh et al., 2013; Nagashio et al., 2015). MUC5B can be repressed under the influence of methylation and can be up-regulated by ATF-1, c-Myc, NFkappaB, Sp1, CREB, TTF-11 and GCR (Perrais et al., 2001; Van, I et al., 2000).

Genetic variants of MUC6 have been reported to modify the risk of developing gastric cancer (Resende et al., 2011). In salivary gland tumors the expression patterns of MUC6 appear to be very closely correlated with the histopathological tumor type indicating their potential use to improve diagnostic accuracy (Mahomed, 2011). Studies have identified a differential expression of MUC6 in breast cancer tissues when compared with the non-neoplastic breast tissues (Mukhopadhyay et al., 2011).

A Chinese study identified MXRA5 as the second most frequently mutated gene in non-small cell lung cancer (Xiong et al., 2012). In colon cancer, MXRA5 was shown to be over-expressed and might serve as a biomarker for early diagnosis and omental metastasis (Zou et al., 2002; Wang et al., 2013a).

MYB can be converted into an oncogenic transforming protein through a few mutations (Zhou and Ness, 2011). MYB is known as oncogene and is associated with apoptosis, cell cycle control, cell growth/angiogenesis and cell adhesion by regulating expression of key target genes such as cyclooxygenase-2, Bcl-2, BclX(L) and c-Myc (Ramsay et al., 2003; Stenman et al., 2010). The oncogenic fusion protein MYB-NFIB and MYB over-expression are found in adenoid cystic carcinoma of the salivary gland and breast, pediatric diffuse gliomas, acute myeloid leukemia and pancreatic cancer (Wallrapp et al., 1999; Pattabiraman and Gonda, 2013; Nobusawa et al., 2014; Chae et al., 2015; Marchio et al., 2010). By the synergy between MYB and beta-Catenin during Wnt signaling, MYB is associated with colon tumorigenesis (Burgess et al., 2011). Since MYB is a direct target of estrogen signaling anti-MYB therapy is considered for ER-positive breast tumors (Gonda et al., 2008).

N4BP2 has a potential role in the development of nasopharyngeal carcinoma. There is a statistically relevant difference in two different haplotype blocks which correlate with the risk of sporadic nasopharyngeal carcinoma. Furthermore, N4BP2 is over-expressed in these tumor tissues relative to paired normal tissues (Zheng et al., 2007).

In a multistage, case-only genome-wide association study of 12,518 prostate cancer cases, NAALADL2 was identified as a locus associated with Gleason score, a pathological measure of disease aggressiveness (Berndt et al., 2015). NAALADL2 is over-expressed in prostate and colon cancer and promotes a pro-migratory and pro-metastatic phenotype associated with poor survival (Whitaker et al., 2014).

NCAPG is down-regulated in patients with multiple myeloma, acute myeloid leukemia, and leukemic cells from blood or myeloma cells (Cohen et al., 2014). NCAPG may be a multi-drug resistant gene in colorectal cancer (Li et al., 2012a). NCAPG is highly up-regulated in the chromophobe subtype of human cell carcinoma but not in conventional human renal cell carcinoma (Kim et al., 2010a). Up-regulation of NCAPG is associated with melanoma progression (Ryu et al., 2007). NCAPG is associated with uveal mela-

noma (Van Ginkel et al., 1998). NCAPG shows variable expression in different tumor cells (Jager et al., 2000).

NRK encodes Nik related kinase, a protein kinase required for JNK activation which may be involved in the induction of actin polymerization in late embryogenesis (RefSeq, 2002). NRK activates the c-Jun N-terminal kinase signaling pathway and may be involved in the regulation of actin cytoskeletal organization in skeletal muscle cells through cofilin phosphorylation (Nakano et al., 2003).

NUP210 was shown to be a candidate gene carrying polymorphisms associated with the risk of colorectal cancer (Landi et al., 2012). NUP210 was shown to be up-regulated in cervical cancer and suggested to play a role in the early phase of tumorigenesis (Rajkumar et al., 2011).

ORC1 was shown to be over-expressed in tumor-derived cell lines and is predicted to be a biomarker in prostate cancer as well as in leukemia (Struyf et al., 2003; Zimmerman et al., 2013; Young et al., 2014). Through its interaction with histone acetyltransferases such as HBO1, ORC1 exerts oncogenic functions in breast cancer (Wang et al., 2010).

Non-carrier of heterozygous mutations in two SNPs in OSCP1 might be a biomarker for susceptibility for non-viral liver carcinoma (Toda et al., 2014).

OVOL2 induces mesenchymal-epithelial transition resulting in decreased metastasis (Roca et al., 2013). OVOL2 inhibits c-Myc and Notch1 (Wells et al., 2009). OVOL2 is hyper-methylated in colorectal cancer resulting in its inability to inhibit Wnt signaling (Ye et al., 2016). Over-expression of OVOL2 decreased cell migration and invasion, reduced markers for epithelial-mesenchymal transition, and suppressed metastasis (Ye et al., 2016). OVOL2 is down-regulated in colorectal cancer and is inversely correlated with tumor stage (Ye et al., 2016). OVOL2 is regulated by Wnt signaling pathway (Ye et al., 2016).

OXTR is significantly over-expressed in primary small bowel and pancreatic neuroendocrine tumors, small cell carcinoma of the lung, ovarian carcinoma as well as in prostate cancer, mediating cell migration and metastasis (Morita et al., 2004; Zhong et al., 2010; Carr et al., 2012; Carr et al., 2013; Pequeux et al., 2002). However, OXTR1 possesses also an inhibitory effect on proliferation of neoplastic cells of either epithelial, nervous or bone origin, which is thought to be dependent on the receptor localization on the membrane (Cassoni et al., 2004).

PAPPA represents a metastasis-related gene occurring in a range of cancer types such as NSCLC and hepatocellular carcinoma, where it is positively associated to growth (VEGF and IGF-I) and transcription factors (NF-kappaB p50, NF-kappaB p65, HIF-1alpha) (Salim et al., 2013; Iunusova et al., 2013; Engelmann et al., 2015). PAPPA regulates mitotic progression through modulating the IGF-1 signaling pathway in breast cancer and ovarian cancer cells, where it is predominantly found at the primary site (Boldt and Conover, 2011; Loddio et al., 2014; Becker et al., 2015; Iunusova et al., 2014).

PGAP1 is down-regulated in the adenocarcinoma cell line AsPC-1 (Yang et al., 2016).

PGR is highly associated with breast cancer initiation and progression, where it activates MAPK and PI3K/AKT pathways as well as the expression of Growth Factors Receptors (GFR) (Jaiswal et al., 2014; Piasecka et al., 2015). PGR (besides HER and estrogen receptor) acts as a classification factor helping to distinguish between three different subtypes of breast cancer (Safarpour and Tavassoli, 2015).

PLA2G7 has strong influence on lipid metabolism in breast, ovarian, melanoma and prostate cancer cells, where a blockage of the enzyme leads to impaired cancer pathogenicity (Vainio et al., 2011a; Massoner et al., 2013; Kohnz et al., 2015). PLA2G7 is highly associated with prostate cancer and is therefore representing a potential biomarker for this type of cancer (Vainio et al., 2011b).

PPP3R1 is up-regulated in hepatocellular carcinoma cells affecting up to 10 different signaling pathways (Zekri et al., 2008).

PRKDC is a frequently mutated gene in endometriosis-associated ovarian cancer and breast cancer (Er et al., 2016; Wheler et al., 2015). PRKDC is up-regulated in cancerous tissues compared with normal tissues in colorectal carcinoma. Patients with high PRKDC expression show poorer overall survival (Sun et al., 2016).

An up-regulated expression of PSMA7T was found in metastatic lung cancer, castration-recurrent prostate cancer (CRPC) as well as in primary colorectal cancer, where it increases the risk of liver metastasis (Hu et al., 2008; Hu et al., 2009; Romanuik et al., 2010; Cai et al., 2010). It was also shown that the amount of PSMA7T correlates with the transactivation of the androgen receptor (AR) in androgen/AR-mediated prostate tumor growth (Ogiso et al., 2002).

It was shown that PSMC1 is able to influence cell growth and is therefore representing a potential anti-cancer target in prostate cancer, multiple myeloma and glioblastoma cells (Dahlman et al., 2012; Kim et al., 2008).

RAD18 is implicated in tumorigenesis due to its well-known function in DNA damage bypass, post-replication repair and homologous recombination (Ting et al., 2010). RAD18 Arg302Gln polymorphism is associated with the risk for colorectal cancer and non-small-cell lung cancer (Kanzaki et al., 2008; Kanzaki et al., 2007). RAD18 mediates resistance to ionizing radiation in human glioma cells and knockdown of RAD18 disrupts homologous recombination-mediated repair, resulting in increased accumulation of double strand breaks (Xie et al., 2014). Using melanoma tissue microarray, it was shown that nuclear RAD18 expression was up-regulated in primary and metastatic melanoma compared to dysplastic nevi (Wong et al., 2012).

RAD51AP1 was shown to be associated with radiation exposure papillary thyroid cancer (Handkiewicz-Junak et al., 2016). Amplification of RAD51AP1 was shown to be correlated with cell immortality and a shorter survival time in ovarian cancer (Sankaranarayanan et al., 2015). RAD51AP1 was described as commonly over-expressed in tumor cells and tissues and disruption of RAD51AP1 function was suggested to be a promising approach in targeted tumor therapy (Parplys et al., 2014). RAD51AP1 transcription was shown to be directly stimulated by the tumor suppressor MEN1 (Fang et al., 2013). RAD51AP1 was shown to be up-regulated in intrahepatic cholangiocarcinoma, human papillomavirus-positive squamous cell carcinoma of the head and neck and in BRCA1-deficient compared to sporadic breast tumors (Martinez et al., 2007; Martin et al., 2007; Obama et al., 2008). Suppression of RAD51AP1 was shown to result in growth suppression in intrahepatic cholangiocarcinoma cells, suggesting its involvement in the development and/or progression of intrahepatic cholangiocarcinoma (Obama et al., 2008).

Knock-down of RBM14 was shown to block glioblastoma multiforme re-growth after irradiation in vivo (Yuan et al., 2014). RBM14 was shown to be down-regulated in renal cell carcinoma (Kang et al., 2008). RBM14 was described as a potential tumor suppressor in renal carcinoma which inhibits G(1)-S transition in human kidney cells and suppresses anchorage-independent growth and xenograft tumor formation in part by down-regulation of the proto-oncogene c-myc (Kang et al., 2008). RBM14 was shown to be involved in the migration-enhancing action of PEA3 and MCF7 human cancer cells (Verreman et al., 2011). The RBM14 gene was shown to be amplified in a subset of primary human cancers including non-small cell lung carcinoma, squamous cell skin carcinoma and lymphoma (Sui et al., 2007).

RBM4 is involved in regulatory splicing mechanisms of pre-messenger RNA suppressing proliferation and migration of various cancer cells (Lin et al., 2014; Wang et al., 2014c). Dysregulations of RBM4 activity were found in cervical, breast, lung, colon, ovarian and rectal cancers (Liang et al., 2015; Markus et al., 2016).

Serum RCOR3 levels in liver cancer patients were significantly lower than those in the patients with moderate chronic hepatitis B and with mild chronic hepatitis B (Xue et al., 2011).

Down-regulation of RFWD2 is correlated with poor prognosis in gastric cancer (Sawada et al., 2013). RFWD2 directly interacts with p27 and the de-regulation of this interaction is involved in tumorigenesis (Choi et al., 2015b; Choi et al., 2015a; Marine, 2012). Up-regulation of RFWD2 is correlated with poor prognosis in bladder cancer, gastric cancer, and triple-negative breast cancer (Ouyang et al., 2015; Li et al., 2016; Li et al., 2012c).

RIF1 is highly expressed in human breast tumors, encodes an anti-apoptotic factor required for DNA repair and is a potential target for cancer treatment (Wang et al., 2009a). The role of RIF1 in the maintenance of genomic integrity has been expanded to include the regulation of chromatin structure, replication timing and intra-S phase checkpoint (Kumar and Cheek, 2014).

In patients diagnosed with visceral multicentric infantile myofibromatosis novel homozygous variants in the RLTPR gene were identified (Linhares et al., 2014).

RNF24 was shown to be up-regulated in esophageal adenocarcinoma and plays a critical role in the progression of Barrett's esophagus to esophageal adenocarcinoma (Wang et al., 2014b). RNF24 was shown to be differentially expressed depending on certain risk factors in oral squamous cell carcinoma (Cheong et al., 2009).

RPGRIP1L suppresses anchorage-independent growth partly through the mitotic checkpoint protein Mad2 and is a candidate tumor suppressor gene in human hepatocellular carcinoma (Lin et al., 2009).

Over-expression of Rtl1 in the livers of adult mice resulted in highly penetrant tumor formation and over-expression of RTL1 was detected in 30% of analyzed human hepa-

tocellular carcinoma samples (Riordan et al., 2013). Transcriptional activity of the imprinted gene RTL1 was assessed in a panel of 32 Wilms tumors and a massive over-expression was detected compared to normal renal tissue (Hubertus et al., 2011).

SAPCD2 (also called p42.3 or C9orf140) encodes a protein initially found to be expressed in gastric cancer, but not in normal gastric mucosa (Xu et al., 2007). SAPCD2 is over-expressed in different cancer entities including colorectal, gastric, hepatocellular and brain cancer and high SAPCD2 levels are associated with tumor progression (Sun et al., 2013; Weng et al., 2014; Wan et al., 2014). The optimal pathway of SAPCD2 gene in protein regulatory network in gastric cancer is Ras protein, Raf-1 protein, MEK, MAPK kinase, MAPK, tubulin, spindle protein, centromere protein and tumor (Zhang et al., 2012a; Weng et al., 2014).

Lower expression of SEMA3A was shown to be correlated with shorter overall survival and had independent prognostic importance in patients with head and neck squamous cell carcinoma (Wang et al., 2016). Over-expression of SEMA3A was shown to suppress migration, invasion and epithelial-to-mesenchymal transition due in part to the inhibition of NF- κ B and SNAI2 in head and neck squamous cell carcinoma cell lines (Wang et al., 2016). Thus, SEMA3A serves as a tumor suppressor in head and neck squamous cell carcinoma and may be a new target for the treatment of this disease (Wang et al., 2016). SEMA3A expression was shown to be significantly reverse associated with metastasis in hepatocellular carcinoma (Yan-Chun et al., 2015). SEMA3A was described as being down-regulated in numerous types of cancer, including prostate cancer, breast cancer, glioma, epithelial ovarian carcinoma and gastric cancer (Jiang et al., 2015a; Tang et al., 2014). Low SEMA3A expression was shown to be correlated with poor differentiation, vascular invasion, depth of invasion, lymph node metastasis, distant metastasis, advanced TNM stage and poor prognosis in gastric cancer (Tang et al., 2014). SEMA3A was described as a candidate tumor suppressor and potential prognostic biomarker in gastric carcinogenesis (Tang et al., 2014).

- 75 -

It was shown that missense variations in the SERPINB10 gene possess tumorigenic features leading to an increased risk of prostate cancer (Shioji et al., 2005). In addition, SERPINB10 expression is significantly up-regulated in metastatic mammary tumors (Klopfleisch et al., 2010).

Expression level of SLC16A14 is significantly associated with progression-free survival and presents a novel putative marker for the progression of epithelial ovarian cancer (Elsnerova et al., 2016).

SLC18A1 was showing lower expression in unfavorable neuroblastoma tumor types as compared to favorable ones (Wilzen et al., 2009).

SLC25A43 was identified as a regulator of cell cycle progression and proliferation through a putative mitochondrial checkpoint in breast cancer cell lines (Gabrielson et al., 2016). SLC25A43 affects drug efficacy and cell cycle regulation following drug exposure in breast cancer cell lines (Gabrielson and Tina, 2013).

SLC28A3 was shown to be down-regulated in pancreatic ductal adenocarcinoma (Mohelnikova-Duchonova et al., 2013). SLC28A3 is associated with clinical outcome in metastatic breast cancer treated with paclitaxel and gemcitabine chemotherapy, overall survival in gemcitabine treated non-small cell lung cancer and overall survival in gemcitabine-based chemoradiation treated pancreatic adenocarcinoma (Li et al., 2012b; Lee et al., 2014b; Marechal et al., 2009). SLC28A3 is associated with fludarabine resistance in chronic lymphocytic leukemia and drug resistance in T-cell leukemia (Karim et al., 2011; Fernandez-Calotti et al., 2012).

SLC2A13 was consistently increased in the sphere-forming cells in the primary cultures of oral squamous cell carcinoma samples and confocal microscopy revealed that SLC2A13-expressing cells were embedded in the limited areas of tumor tissue as a cluster suggesting that SLC2A13 can be a potential marker for cancer stem cells (Lee et

al., 2011). SLC2A13 was identified as gene associated with non-small-cell lung cancer promotion and progression (Bankovic et al., 2010).

Inhibition of SLC35A1 was shown to reduce cancer cell sialylation and decrease the metastatic potential of cancer cells (Maggioni et al., 2014).

SLC7A11 was shown to be down-regulated in drug resistant variants of the W1 ovarian cancer cell line and thus might play a role in cancer cell drug resistance (Januchowski et al., 2013). SLC7A11 was described to modulate tumor microenvironment, leading to a growth advantage for cancer (Savaskan and Eyupoglu, 2010). SLC7A11 was described to be involved in neurodegenerative processes in glioma (Savaskan et al., 2015). SLC7A11 was shown to be repressed by p53 in the context of ferroptosis, and the p53-SLC7A11 axis was described as preserved in the p53(3KR) mutant, and contributes to its ability to suppress tumorigenesis in the absence of the classical tumor suppression mechanisms (Jiang et al., 2015b). SLC7A11 was described as the functional subunit of system Xc- whose function is increased in aggressive breast cancer cells (Linher-Melville et al., 2015). High membrane staining for SLC7A11 in cisplatin-resistant bladder cancer was shown to be associated with a poorer clinical outcome and SLC7A11 inhibition was described as a promising therapeutic approach to the treatment of this disease (Drayton et al., 2014). SLC7A11 was shown to be differentially expressed in the human promyelocytic leukemia cell line HL-60 that had been exposed to benzene and its metabolites and thus highlights a potential association of SLC7A11 with leukemogenesis (Sarma et al., 2011). Disruption of SLC7A11 was described to result in growth inhibition of a variety of carcinomas, including lymphoma, glioma, prostate and breast cancer (Chen et al., 2009). Inhibition of SLC7A11 was shown to inhibit cell invasion in the esophageal cancer cell line KYSE150 in vitro and its experimental metastasis in nude mice and thus establishes a role of SLC7A11 in tumor metastasis (Chen et al., 2009).

SLCO5A1 is located at the plasma membrane and may contribute to chemoresistance of small cell lung carcinoma by affecting the intracellular transport of drugs (Olszewski-

Hamilton et al., 2011). SLCO5A1 is the most prominent organic anion transporting polypeptide in metastatic small cell lung cancer and the mRNA level of SLCO5A1 is highly increased in hepatic tumors and breast cancer (Kindla et al., 2011; Wlcek et al., 2011; Brenner et al., 2015). Gene fusions in oropharyngeal squamous cell carcinoma are associated with down-regulation of SLCO5A1 (Guo et al., 2016).

SP5 was down-regulated after depletion of beta-catenin in colorectal cancer cell lines and is a novel direct downstream target in the Wnt signaling pathway (Takahashi et al., 2005). The over-expression of SP5 demonstrated activation of the beta-catenin pathway in rare human pancreatic neoplasms (Cavard et al., 2009). In human colorectal carcinoma cells displaying de-regulated Wnt signaling, monensin reduced the intracellular levels of β -catenin leading to a decrease in the expression of Wnt signaling target genes such as SP5 and a decreased cell proliferation rate (Tumova et al., 2014).

STIL is among the genes with copy number alterations and copy-neutral losses of heterozygosity in 15 cortisol-secreting adrenocortical adenomas (Ronchi et al., 2012). Chromosomal deletions that fuse this gene and the adjacent locus commonly occur in T cell leukemias, and are thought to arise through illegitimate V-(D)-J recombination events (Karrman et al., 2009; Alonso et al., 2012).

An elevated expression of TBC1D7 was found in the majority of lung cancers and immunohistochemical staining suggested an association of TBC1D7 expression with poor prognosis for NSCLC patients (Sato et al., 2010). Over-expression of TBC7 enhanced ubiquitination of TSC1 and increased phosphorylation of S6 protein by S6 kinase, that is located in the mTOR-signaling pathway (Nakashima et al., 2007).

TDG influences the Wnt signaling pathway in an up-regulating manner via interaction with the transcription factor TCF4 and is thought to be a potential biomarker for colorectal cancer (Xu et al., 2014). On the other hand, a reduced expression of TDG leads to an impaired base excision repair (BER) pathway with strong oncogenic features (van de Klundert et al., 2012). A down-regulation of the protein was observed in early breast

cancer esophageal squamous cell carcinoma (ESCC) as well as in gastric cancer (Li et al., 2013; Du et al., 2015; Yang et al., 2015a).

Among the four most frequently mutated genes was TENM4 showing protein-changing mutations in primary CNS lymphomas (Vater et al., 2015). MDA-MB-175 cell line contains a chromosomal translocation that leads to the fusion of TENM4 and receptors of the ErbB family. Chimeric genes were also found in neuroblastomas (Wang et al., 1999b; Boeva et al., 2013).

TET2 is a critical regulator for hematopoietic stem cell homeostasis whose functional impairment leads to hematological malignancies (Nakajima and Kunimoto, 2014). TET2 mutations have an adverse impact on prognosis and may help to justify risk-adapted therapeutic strategies for patients with acute myeloid leukemia (Liu et al., 2014b). Nuclear localization of TET2 was lost in a significant portion of colorectal cancer tissues, in association with metastasis (Huang et al., 2016).

TKTL1 is associated with the development and progression of multiple tumor types such as esophageal squamous cell carcinoma, oral squamous cell carcinoma, lung cancer, colorectal cancer and non-small cell lung cancer (Kayser et al., 2011; Bentz et al., 2013; Grimm et al., 2014).

TMEM67 functions in centriole migration to the apical membrane and formation of the primary cilium. Defects in this gene are a cause of Meckel syndrome type 3 (MKS3) and Joubert syndrome type 6 (JBTS6) (RefSeq, 2002). TMEM67 is involved in cilia formation and defective cilia may cause ocular coloboma, tongue tumors, and medulloblastoma (Yang et al., 2015b; Parisi, 2009).

TONSL is involved in lung and esophageal carcinogenesis by stabilizing the oncogenic protein MMS22L (Nguyen et al., 2012). Further interactions were shown between TONSL and BRCA1, which acts as a breast and ovarian tumor suppressor (Hill et al., 2014).

TP63 translocation was described as an event in a subset of anaplastic lymphoma kinase-positive anaplastic large cell lymphomas which is associated with an aggressive course of the disease (Hapgood and Savage, 2015). TP63 was described to play a complex role in cancer due to its involvement in epithelial differentiation, cell cycle arrest and apoptosis (Lin et al., 2015). The TP63 isoform TAp63 was described to be over-expressed in hematological malignancies while TP63 missense mutations have been reported in squamous cancers and TP63 translocations in lymphomas and some lung adenocarcinomas (Orzol et al., 2015). Aberrant splicing resulting in the over-expression of the TP63 isoform DeltaNp63 was described to be frequently found in human cancers such as cutaneous squamous cell carcinoma, where it is likely to favor tumor initiation and progression (Missero and Antonini, 2014; Inoue and Fry, 2014).

TRIM59 promotes proliferation and migration of non-small cell lung cancer cells by up-regulating cell cycle related proteins (Zhan et al., 2015). The putative ubiquitin ligase TRIM59 is up-regulated in gastric tumors compared with non-tumor tissues and levels of TRIM59 correlate with tumor progression and patient survival times. TRIM59 interacts with P53, promoting its ubiquitination and degradation, and TRIM59 might promote gastric carcinogenesis via this mechanism (Zhou et al., 2014).

TRPC4 was found to be up-regulated in lung cancer, ovarian cancer, head and neck cancer, kidney cancer and non-small cell lung cancer (Zhang et al., 2010b; Zeng et al., 2013a; Jiang et al., 2013; Park et al., 2016).

ULBP3 is expressed soluble and membrane bound isoform in many tumor cells. Pediatric acute lymphoblastic leukemia blasts express significantly higher levels of ULBP3 compared to adult blasts (Torelli et al., 2014). Much higher expression levels of ULBP3 were found in the leukemia cell line K562 compared to other leukemia cell lines. Furthermore, it can be found in both leukemia cell lines and primary malignant leukemic cells (Ma et al., 2013b). The ULBP3 locus is methylated in colorectal cancer cell lines (Bormann et al., 2011). Increased mRNA levels and surface expression levels of ULBP3

have been detected in the human lung cancer cell line SW-900 (Park et al., 2011). ULBP3 has a higher surface expression in leukemic cells (Ogbomo et al., 2008). ULBP3 levels in different tumor cell lines correlate with NK cell cytotoxicity, however, ULBP3 seems not to be suitable as biomarker (Wang et al., 2008; Linkov et al., 2009). ULBP3 is not expressed in the human nasopharyngeal carcinoma cell line CNE2 (Mei et al., 2007). ULBP3 is expressed in ovarian cancer and inversely correlated with patient survival (Carlsten et al., 2007; McGilvray et al., 2010). B cells express ULBP3 in non-Hodgkin's lymphoma or it can be found in peripheral blood, bone marrow, or lymph nodes (Catellani et al., 2007). ULBP3 is expressed in breast cancer, the glioblastoma cell line U251, human brain tumors, and in head and neck squamous cell carcinoma (Eisele et al., 2006; Butler et al., 2009; Bryant et al., 2011; de Kruijf et al., 2012). Tumor cells express soluble and surface ULBP3 to regulate NK cell activity (Mou et al., 2014). ULBP3 is over-expressed in certain epithelial tumors. Furthermore, the ULBP3 level in cancer patient sera is elevated compared to healthy donors (Mou et al., 2014).

VPS13B alleles are mutated in small cell lung cancers (Iwakawa et al., 2015). Mutations of VPS13B were observed in gastric and colorectal cancers (An et al., 2012).

Frameshift mutations of VPS13C were found in gastric and colorectal cancers with microsatellite instability (An et al., 2012).

WDR62 expression was significantly increased in gastric cancer tissues and cell lines and was associated with poor differentiation and prognosis. Further, WDR62 expression was elevated in multidrug resistant cells (Zeng et al., 2013b). WDR62 over-expression is related to centrosome amplification and may be a novel useful differentiation biomarker and a potential therapy target for ovarian cancer (Zhang et al., 2013b).

Exosome-bound WDR92 inhibits breast cancer cell invasion by degrading amphiregulin mRNA (Saeki et al., 2013). WDR92 potentiates apoptosis induced by tumor necrosis factor-alpha and cycloheximide (Ni et al., 2009).

WNT5A belongs to the WNT gene family that consists of structurally related genes which encode secreted signaling proteins. These proteins have been implicated in oncogenesis and in several developmental processes, including regulation of cell fate and patterning during embryogenesis. The WNT5A gene encodes a member of the WNT family that signals through both the canonical and non-canonical WNT pathways. This protein is a ligand for the seven transmembrane receptor frizzled-5 and the tyrosine kinase orphan receptor 2. This protein plays an essential role in regulating developmental pathways during embryogenesis. This protein may also play a role in oncogenesis (RefSeq, 2002). WNT5A is over-expressed in CRC and had a concordance rate of 76% between the primary tumor and metastatic site (Lee et al., 2014a). WNT5A is up-regulated and a key regulator of the epithelial-to-mesenchymal transition and metastasis in human gastric carcinoma cells, nasopharyngeal carcinoma and pancreatic cancer (Kanzawa et al., 2013; Zhu et al., 2014; Bo et al., 2013).

XRN1 is likely involved in a number of regulatory mRNA pathways in astrocytes and astrocytoma cells (Moser et al., 2007). Knockdown of XRN1 inhibited androgen receptor expression in prostate cancer cells and plays an important role in miR-204/XRN1 axis in prostate adenocarcinoma (Ding et al., 2015).

Genome-wide association studies identified gene polymorphisms in XXYLT1. It has been proposed that these polymorphisms are susceptibility loci for non-small cell lung cancer development (Zhang et al., 2012b).

ZBTB20 promotes cell proliferation in non-small cell lung cancer through repression of FoxO1 (Zhao et al., 2014b). ZBTB20 expression is increased in hepatocellular carcinoma and associated with poor prognosis (Wang et al., 2011c). Polymorphism in ZBTB20 gene is associated with gastric cancer (Song et al., 2013).

ZFHX4 is thought to regulate cell differentiation and its suppression is linked to glioma-free survival (Chudnovsky et al., 2014). Papillary tumors of the pineal region show high

- 82 -

expression levels of ZFHX4 (Fevre-Montange et al., 2006). ZFHX4 was found to be a basal cell carcinoma susceptibility locus (Stacey et al., 2015).

ZMYM1 is a major interactor of ZNF131 which acts in estrogen signaling and breast cancer proliferation (Oh and Chung, 2012; Kim et al., 2016).

DETAILED DESCRIPTION OF THE INVENTION

Stimulation of an immune response is dependent upon the presence of antigens recognized as foreign by the host immune system. The discovery of the existence of tumor associated antigens has raised the possibility of using a host's immune system to intervene in tumor growth. Various mechanisms of harnessing both the humoral and cellular arms of the immune system are currently being explored for cancer immunotherapy.

Specific elements of the cellular immune response are capable of specifically recognizing and destroying tumor cells. The isolation of T-cells from tumor-infiltrating cell populations or from peripheral blood suggests that such cells play an important role in natural immune defense against cancer. CD8-positive T-cells in particular, which recognize class I molecules of the major histocompatibility complex (MHC)-bearing peptides of usually 8 to 10 amino acid residues derived from proteins or defect ribosomal products (DRIPS) located in the cytosol, play an important role in this response. The MHC-molecules of the human are also designated as human leukocyte-antigens (HLA).

As used herein and except as noted otherwise all terms are defined as given below.

The term "T-cell response" shall mean that the specific proliferation and activation of effector functions induced by a peptide *in vitro* or *in vivo*. For MHC class I restricted cytotoxic T cells, effector functions may be lysis of peptide-pulsed, peptide-precursor pulsed or naturally peptide-presenting target cells, secretion of cytokines, preferably Interferon-gamma, TNF-alpha, or IL-2 induced by peptide, secretion of effector molecules, preferably granzymes or perforins induced by peptide, or degranulation.

The term “peptide” is used herein to designate a series of amino acid residues, connected one to the other typically by peptide bonds between the alpha-amino and carbonyl groups of the adjacent amino acids. The peptides are preferably 9 amino acids in length, but can be as short as 8 amino acids in length, and as long as 10, 11, 12, 13 or 14 amino acids or longer, and in case of MHC class II peptides (elongated variants of the peptides of the invention) they can be as long as 15, 16, 17, 18, 19 or 20 or more amino acids in length.

Furthermore, the term “peptide” shall include salts of a series of amino acid residues, connected one to the other typically by peptide bonds between the alpha-amino and carbonyl groups of the adjacent amino acids. Preferably, the salts are pharmaceutical acceptable salts of the peptides, such as, for example, the chloride or acetate (trifluoroacetate) salts. It has to be noted that the salts of the peptides according to the present invention differ substantially from the peptides in their state(s) *in vivo*, as the peptides are not salts *in vivo*.

The term “peptide” shall also include “oligopeptide”. The term “oligopeptide” is used herein to designate a series of amino acid residues, connected one to the other typically by peptide bonds between the alpha-amino and carbonyl groups of the adjacent amino acids. The length of the oligopeptide is not critical to the invention, as long as the correct epitope or epitopes are maintained therein. The oligopeptides are typically less than about 30 amino acid residues in length, and greater than about 15 amino acids in length.

The term “polypeptide” designates a series of amino acid residues, connected one to the other typically by peptide bonds between the alpha-amino and carbonyl groups of the adjacent amino acids. The length of the polypeptide is not critical to the invention as long as the correct epitopes are maintained. In contrast to the terms peptide or oligopeptide, the term polypeptide is meant to refer to molecules containing more than about 30 amino acid residues.

- 84 -

A peptide, oligopeptide, protein or polynucleotide coding for such a molecule is “immunogenic” (and thus is an “immunogen” within the present invention), if it is capable of inducing an immune response. In the case of the present invention, immunogenicity is more specifically defined as the ability to induce a T-cell response. Thus, an “immunogen” would be a molecule that is capable of inducing an immune response, and in the case of the present invention, a molecule capable of inducing a T-cell response. In another aspect, the immunogen can be the peptide, the complex of the peptide with MHC, oligopeptide, and/or protein that is used to raise specific antibodies or TCRs against it.

A class I T cell “epitope” requires a short peptide that is bound to a class I MHC receptor, forming a ternary complex (MHC class I alpha chain, beta-2-microglobulin, and peptide) that can be recognized by a T cell bearing a matching T-cell receptor binding to the MHC/peptide complex with appropriate affinity. Peptides binding to MHC class I molecules are typically 8-14 amino acids in length, and most typically 9 amino acids in length.

In humans there are three different genetic loci that encode MHC class I molecules (the MHC-molecules of the human are also designated human leukocyte antigens (HLA)): HLA-A, HLA-B, and HLA-C. HLA-A*01, HLA-A*02, and HLA-B*07 are examples of different MHC class I alleles that can be expressed from these loci.

Table 4: Expression frequencies F of HLA-A*02 and HLA-A*24 and the most frequent HLA-DR serotypes. Frequencies are deduced from haplotype frequencies Gf within the American population adapted from Mori et al. (Mori et al., 1997) employing the Hardy-Weinberg formula $F = 1 - (1 - Gf)^2$. Combinations of A*02 or A*24 with certain HLA-DR alleles might be enriched or less frequent than expected from their single frequencies due to linkage disequilibrium. For details refer to Chanock et al. (Chanock et al., 2004).

Allele	Population	Calculated phenotype from allele frequency
A*02	Caucasian (North America)	49.1%
A*02	African American (North America)	34.1%
A*02	Asian American (North America)	43.2%

- 85 -

Allele	Population	Calculated phenotype from allele frequency
A*02	Latin American (North American)	48.3%
DR1	Caucasian (North America)	19.4%
DR2	Caucasian (North America)	28.2%
DR3	Caucasian (North America)	20.6%
DR4	Caucasian (North America)	30.7%
DR5	Caucasian (North America)	23.3%
DR6	Caucasian (North America)	26.7%
DR7	Caucasian (North America)	24.8%
DR8	Caucasian (North America)	5.7%
DR9	Caucasian (North America)	2.1%
DR1	African (North) American	13.20%
DR2	African (North) American	29.80%
DR3	African (North) American	24.80%
DR4	African (North) American	11.10%
DR5	African (North) American	31.10%
DR6	African (North) American	33.70%
DR7	African (North) American	19.20%
DR8	African (North) American	12.10%
DR9	African (North) American	5.80%
DR1	Asian (North) American	6.80%
DR2	Asian (North) American	33.80%
DR3	Asian (North) American	9.20%
DR4	Asian (North) American	28.60%
DR5	Asian (North) American	30.00%
DR6	Asian (North) American	25.10%
DR7	Asian (North) American	13.40%
DR8	Asian (North) American	12.70%
DR9	Asian (North) American	18.60%
DR1	Latin (North) American	15.30%
DR2	Latin (North) American	21.20%
DR3	Latin (North) American	15.20%
DR4	Latin (North) American	36.80%
DR5	Latin (North) American	20.00%
DR6	Latin (North) American	31.10%
DR7	Latin (North) American	20.20%
DR8	Latin (North) American	18.60%
DR9	Latin (North) American	2.10%
A*24	Philippines	65%

Allele	Population	Calculated phenotype from allele frequency
A*24	Russia Nenets	61%
A*24:02	Japan	59%
A*24	Malaysia	58%
A*24:02	Philippines	54%
A*24	India	47%
A*24	South Korea	40%
A*24	Sri Lanka	37%
A*24	China	32%
A*24:02	India	29%
A*24	Australia West	22%
A*24	USA	22%
A*24	Russia Samara	20%
A*24	South America	20%
A*24	Europe	18%

The peptides of the invention, preferably when included into a vaccine of the invention as described herein preferably bind to A*02, A*24 or class II alleles, as specified. A vaccine may also include pan-binding MHC class II peptides. Therefore, the vaccine of the invention can be used to treat cancer in patients that are A*02 positive, whereas no selection for MHC class II allotypes is necessary due to the pan-binding nature of these peptides.

If A*02 peptides of the invention are combined with peptides binding to another allele, for example A*24, a higher percentage of any patient population can be treated compared with addressing either MHC class I allele alone. While in most populations less than 50% of patients could be addressed by either allele alone, a vaccine comprising HLA-A*24 and HLA-A*02 epitopes can treat at least 60% of patients in any relevant population. Specifically, the following percentages of patients will be positive for at least one of these alleles in various regions: USA 61%, Western Europe 62%, China 75%, South Korea 77%, Japan 86% (calculated from www.allelefrequencies.net).

In a preferred embodiment, the term “nucleotide sequence” refers to a heteropolymer of deoxyribonucleotides.

The nucleotide sequence coding for a particular peptide, oligopeptide, or polypeptide may be naturally occurring or they may be synthetically constructed. Generally, DNA segments encoding the peptides, polypeptides, and proteins of this invention are assembled from cDNA fragments and short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic gene that is capable of being expressed in a recombinant transcriptional unit comprising regulatory elements derived from a microbial or viral operon.

As used herein the term “a nucleotide coding for (or encoding) a peptide” refers to a nucleotide sequence coding for the peptide including artificial (man-made) start and stop codons compatible for the biological system the sequence is to be expressed by, for example, a dendritic cell or another cell system useful for the production of TCRs.

As used herein, reference to a nucleic acid sequence includes both single stranded and double stranded nucleic acid. Thus, for example for DNA, the specific sequence, unless the context indicates otherwise, refers to the single strand DNA of such sequence, the duplex of such sequence with its complement (double stranded DNA) and the complement of such sequence.

The term “coding region” refers to that portion of a gene which either naturally or normally codes for the expression product of that gene in its natural genomic environment, i.e., the region coding *in vivo* for the native expression product of the gene.

The coding region can be derived from a non-mutated (“normal”), mutated or altered gene, or can even be derived from a DNA sequence, or gene, wholly synthesized in the laboratory using methods well known to those of skill in the art of DNA synthesis.

The term “expression product” means the polypeptide or protein that is the natural translation product of the gene and any nucleic acid sequence coding equivalents resulting from genetic code degeneracy and thus coding for the same amino acid(s).

The term “fragment”, when referring to a coding sequence, means a portion of DNA comprising less than the complete coding region, whose expression product retains essentially the same biological function or activity as the expression product of the complete coding region.

The term “DNA segment” refers to a DNA polymer, in the form of a separate fragment or as a component of a larger DNA construct, which has been derived from DNA isolated at least once in substantially pure form, i.e., free of contaminating endogenous materials and in a quantity or concentration enabling identification, manipulation, and recovery of the segment and its component nucleotide sequences by standard biochemical methods, for example, by using a cloning vector. Such segments are provided in the form of an open reading frame uninterrupted by internal non-translated sequences, or introns, which are typically present in eukaryotic genes. Sequences of non-translated DNA may be present downstream from the open reading frame, where the same do not interfere with manipulation or expression of the coding regions.

The term “primer” means a short nucleic acid sequence that can be paired with one strand of DNA and provides a free 3'-OH end at which a DNA polymerase starts synthesis of a deoxyribonucleotide chain.

The term “promoter” means a region of DNA involved in binding of RNA polymerase to initiate transcription.

The term “isolated” means that the material is removed from its original environment (e.g., the natural environment, if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.

The polynucleotides, and recombinant or immunogenic polypeptides, disclosed in accordance with the present invention may also be in "purified" form. The term "purified" does not require absolute purity; rather, it is intended as a relative definition, and can include preparations that are highly purified or preparations that are only partially purified, as those terms are understood by those of skill in the relevant art. For example, individual clones isolated from a cDNA library have been conventionally purified to electrophoretic homogeneity. Purification of starting material or natural material to at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated. Furthermore, a claimed polypeptide which has a purity of preferably 99.999%, or at least 99.99% or 99.9%; and even desirably 99% by weight or greater is expressly encompassed.

The nucleic acids and polypeptide expression products disclosed according to the present invention, as well as expression vectors containing such nucleic acids and/or such polypeptides, may be in "enriched form". As used herein, the term "enriched" means that the concentration of the material is at least about 2, 5, 10, 100, or 1000 times its natural concentration (for example), advantageously 0.01%, by weight, preferably at least about 0.1% by weight. Enriched preparations of about 0.5%, 1%, 5%, 10%, and 20% by weight are also contemplated. The sequences, constructs, vectors, clones, and other materials comprising the present invention can advantageously be in enriched or isolated form. The term "active fragment" means a fragment, usually of a peptide, polypeptide or nucleic acid sequence, that generates an immune response (i.e., has immunogenic activity) when administered, alone or optionally with a suitable adjuvant or in a vector, to an animal, such as a mammal, for example, a rabbit or a mouse, and also including a human, such immune response taking the form of stimulating a T-cell response within the recipient animal, such as a human. Alternatively, the "active fragment" may also be used to induce a T-cell response *in vitro*.

As used herein, the terms "portion", "segment" and "fragment", when used in relation to polypeptides, refer to a continuous sequence of residues, such as amino acid residues,

- 90 -

which sequence forms a subset of a larger sequence. For example, if a polypeptide were subjected to treatment with any of the common endopeptidases, such as trypsin or chymotrypsin, the oligopeptides resulting from such treatment would represent portions, segments or fragments of the starting polypeptide. When used in relation to polynucleotides, these terms refer to the products produced by treatment of said polynucleotides with any of the endonucleases.

In accordance with the present invention, the term “percent identity” or “percent identical”, when referring to a sequence, means that a sequence is compared to a claimed or described sequence after alignment of the sequence to be compared (the “Compared Sequence”) with the described or claimed sequence (the “Reference Sequence”). The percent identity is then determined according to the following formula:

$$\text{percent identity} = 100 [1 - (C/R)]$$

wherein C is the number of differences between the Reference Sequence and the Compared Sequence over the length of alignment between the Reference Sequence and the Compared Sequence, wherein

- (i) each base or amino acid in the Reference Sequence that does not have a corresponding aligned base or amino acid in the Compared Sequence and
- (ii) each gap in the Reference Sequence and
- (iii) each aligned base or amino acid in the Reference Sequence that is different from an aligned base or amino acid in the Compared Sequence, constitutes a difference and
- (iiii) the alignment has to start at position 1 of the aligned sequences;

and R is the number of bases or amino acids in the Reference Sequence over the length of the alignment with the Compared Sequence with any gap created in the Reference Sequence also being counted as a base or amino acid.

If an alignment exists between the Compared Sequence and the Reference Sequence for which the percent identity as calculated above is about equal to or greater than a specified minimum Percent Identity then the Compared Sequence has the specified minimum percent identity to the Reference Sequence even though alignments may exist

in which the herein above calculated percent identity is less than the specified percent identity.

As mentioned above, the present invention thus provides a peptide comprising a sequence that is selected from the group of consisting of SEQ ID NO: 1 to SEQ ID NO: 388 or a variant thereof which is 88% homologous to SEQ ID NO: 1 to SEQ ID NO: 388, or a variant thereof that will induce T cells cross-reacting with said peptide. The peptides of the invention have the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or elongated versions of said peptides to class II.

In the present invention, the term "homologous" refers to the degree of identity (see percent identity above) between sequences of two amino acid sequences, i.e. peptide or polypeptide sequences. The aforementioned "homology" is determined by comparing two sequences aligned under optimal conditions over the sequences to be compared. Such a sequence homology can be calculated by creating an alignment using, for example, the ClustalW algorithm. Commonly available sequence analysis software, more specifically, Vector NTI, GENETYX or other tools are provided by public databases.

A person skilled in the art will be able to assess, whether T cells induced by a variant of a specific peptide will be able to cross-react with the peptide itself (Appay et al., 2006; Colombetti et al., 2006; Fong et al., 2001; Zaremba et al., 1997).

By a "variant" of the given amino acid sequence the inventors mean that the side chains of, for example, one or two of the amino acid residues are altered (for example by replacing them with the side chain of another naturally occurring amino acid residue or some other side chain) such that the peptide is still able to bind to an HLA molecule in substantially the same way as a peptide consisting of the given amino acid sequence in consisting of SEQ ID NO: 1 to SEQ ID NO: 388. For example, a peptide may be modified so that it at least maintains, if not improves, the ability to interact with and bind to the binding groove of a suitable MHC molecule, such as HLA-A*02 or -DR, and in that

- 92 -

way it at least maintains, if not improves, the ability to bind to the TCR of activated T cells.

These T cells can subsequently cross-react with cells and kill cells that express a polypeptide that contains the natural amino acid sequence of the cognate peptide as defined in the aspects of the invention. As can be derived from the scientific literature and databases (Rammensee et al., 1999; Godkin et al., 1997), certain positions of HLA binding peptides are typically anchor residues forming a core sequence fitting to the binding motif of the HLA receptor, which is defined by polar, electrophysical, hydrophobic and spatial properties of the polypeptide chains constituting the binding groove. Thus, one skilled in the art would be able to modify the amino acid sequences set forth in SEQ ID NO: 1 to SEQ ID NO 388, by maintaining the known anchor residues, and would be able to determine whether such variants maintain the ability to bind MHC class I or II molecules. The variants of the present invention retain the ability to bind to the TCR of activated T cells, which can subsequently cross-react with and kill cells that express a polypeptide containing the natural amino acid sequence of the cognate peptide as defined in the aspects of the invention.

The original (unmodified) peptides as disclosed herein can be modified by the substitution of one or more residues at different, possibly selective, sites within the peptide chain, if not otherwise stated. Preferably those substitutions are located at the end of the amino acid chain. Such substitutions may be of a conservative nature, for example, where one amino acid is replaced by an amino acid of similar structure and characteristics, such as where a hydrophobic amino acid is replaced by another hydrophobic amino acid. Even more conservative would be replacement of amino acids of the same or similar size and chemical nature, such as where leucine is replaced by isoleucine. In studies of sequence variations in families of naturally occurring homologous proteins, certain amino acid substitutions are more often tolerated than others, and these are often show correlation with similarities in size, charge, polarity, and hydrophobicity between the original amino acid and its replacement, and such is the basis for defining "conservative substitutions."

Conservative substitutions are herein defined as exchanges within one of the following five groups: Group 1-small aliphatic, nonpolar or slightly polar residues (Ala, Ser, Thr, Pro, Gly); Group 2-polar, negatively charged residues and their amides (Asp, Asn, Glu, Gln); Group 3-polar, positively charged residues (His, Arg, Lys); Group 4-large, aliphatic, nonpolar residues (Met, Leu, Ile, Val, Cys); and Group 5-large, aromatic residues (Phe, Tyr, Trp).

Less conservative substitutions might involve the replacement of one amino acid by another that has similar characteristics but is somewhat different in size, such as replacement of an alanine by an isoleucine residue. Highly non-conservative replacements might involve substituting an acidic amino acid for one that is polar, or even for one that is basic in character. Such "radical" substitutions cannot, however, be dismissed as potentially ineffective since chemical effects are not totally predictable and radical substitutions might well give rise to serendipitous effects not otherwise predictable from simple chemical principles.

Of course, such substitutions may involve structures other than the common L-amino acids. Thus, D-amino acids might be substituted for the L-amino acids commonly found in the antigenic peptides of the invention and yet still be encompassed by the disclosure herein. In addition, non-standard amino acids (i.e., other than the common naturally occurring proteinogenic amino acids) may also be used for substitution purposes to produce immunogens and immunogenic polypeptides according to the present invention.

If substitutions at more than one position are found to result in a peptide with substantially equivalent or greater antigenic activity as defined below, then combinations of those substitutions will be tested to determine if the combined substitutions result in additive or synergistic effects on the antigenicity of the peptide. At most, no more than 4 positions within the peptide would be simultaneously substituted.

- 94 -

A peptide consisting essentially of the amino acid sequence as indicated herein can have one or two non-anchor amino acids (see below regarding the anchor motif) exchanged without that the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or –II is substantially changed or is negatively affected, when compared to the non-modified peptide. In another embodiment, in a peptide consisting essentially of the amino acid sequence as indicated herein, one or two amino acids can be exchanged with their conservative exchange partners (see herein below) without that the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or –II is substantially changed, or is negatively affected, when compared to the non-modified peptide.

The amino acid residues that do not substantially contribute to interactions with the T-cell receptor can be modified by replacement with other amino acids whose incorporation do not substantially affect T-cell reactivity and does not eliminate binding to the relevant MHC. Thus, apart from the proviso given, the peptide of the invention may be any peptide (by which term the inventors include oligopeptide or polypeptide), which includes the amino acid sequences or a portion or variant thereof as given.

Table 5: Preferred variants and motifs of the HLA-A*02-peptides according to SEQ ID NO: 2, 4, and 6.

Position	1	2	3	4	5	6	7	8	9
SEQ ID NO. 4	E	L	A	E	I	V	F	K	V
Variants									I
									L
									A
		M							I
		M							L
		M							
		M							A
		A							I
		A							L
		A							
		A							A
		V							I

- 96 -

									I
									A
		M							V
		M							I
		M							
		M							A
		A							V
		A							I
		A							
		A							A
		V							V
		V							I
		V							
		V							A
		T							V
		T							I
		T							
		T							A
		Q							V
		Q							I
		Q							
		Q							A

Table 6: Preferred variants and motifs of the HLA-A*24-binding peptides according to SEQ ID NO: 98, 114, and 158.

Position	1	2	3	4	5	6	7	8	9	10	11	12
SEQ ID 158	I	Y	E	E	T	R	G	V	L	K	V	F
Variant												I
												L
		F										
		F										I
		F										L
Position	1	2	3	4	5	6	7	8	9	10	11	12
SEQ ID 114	Q	Y	L	D	G	T	W	S	L			
Variant									I			
									F			
		F										
		F							I			
		F							F			
Position	1	2	3	4	5	6	7	8	9	10	11	12

- 97 -

SEQ ID 98	V	F	P	R	L	H	N	V	L	F		
Variant		Y								I		
		Y								L		
		Y										
										I		
										L		

Longer (elongated) peptides may also be suitable. It is possible that MHC class I epitopes, although usually between 8 and 11 amino acids long, are generated by peptide processing from longer peptides or proteins that include the actual epitope. It is preferred that the residues that flank the actual epitope are residues that do not substantially affect proteolytic cleavage necessary to expose the actual epitope during processing.

The peptides of the invention can be elongated by up to four amino acids, that is 1, 2, 3 or 4 amino acids can be added to either end in any combination between 4:0 and 0:4. Combinations of the elongations according to the invention can be found in Table 7.

Table 7: Combinations of the elongations of peptides of the invention

C-terminus	N-terminus
4	0
3	0 or 1
2	0 or 1 or 2
1	0 or 1 or 2 or 3
0	0 or 1 or 2 or 3 or 4
N-terminus	C-terminus
4	0
3	0 or 1
2	0 or 1 or 2
1	0 or 1 or 2 or 3
0	0 or 1 or 2 or 3 or 4

The amino acids for the elongation/extension can be the peptides of the original sequence of the protein or any other amino acid(s). The elongation can be used to enhance the stability or solubility of the peptides.

Thus, the epitopes of the present invention may be identical to naturally occurring tumor-associated or tumor-specific epitopes or may include epitopes that differ by no

- 98 -

more than four residues from the reference peptide, as long as they have substantially identical antigenic activity.

In an alternative embodiment, the peptide is elongated on either or both sides by more than four amino acids, preferably to a total length of up to 30 amino acids. This may lead to MHC class II binding peptides. Binding to MHC class II can be tested by methods known in the art.

Accordingly, the present invention provides peptides and variants of MHC class I epitopes, wherein the peptide or variant has an overall length of between 8 and 100, preferably between 8 and 30, and most preferred between 8 and 14, namely 8, 9, 10, 11, 12, 13, 14 amino acids, in case of the elongated class II binding peptides the length can also be 15, 16, 17, 18, 19, 20, 21 or 22 amino acids.

Of course, the peptide or variant according to the present invention will have the ability to bind to a molecule of the human major histocompatibility complex (MHC) class I or II. Binding of a peptide or a variant to a MHC complex may be tested by methods known in the art.

Preferably, when the T cells specific for a peptide according to the present invention are tested against the substituted peptides, the peptide concentration at which the substituted peptides achieve half the maximal increase in lysis relative to background is no more than about 1 mM, preferably no more than about 1 μ M, more preferably no more than about 1 nM, and still more preferably no more than about 100 pM, and most preferably no more than about 10 pM. It is also preferred that the substituted peptide be recognized by T cells from more than one individual, at least two, and more preferably three individuals.

In a particularly preferred embodiment of the invention the peptide consists or consists essentially of an amino acid sequence according to SEQ ID NO: 1 to SEQ ID NO: 388.

“Consisting essentially of” shall mean that a peptide according to the present invention, in addition to the sequence according to any of SEQ ID NO: 1 to SEQ ID NO 388 or a variant thereof contains additional N- and/or C-terminally located stretches of amino acids that are not necessarily forming part of the peptide that functions as an epitope for MHC molecules epitope.

Nevertheless, these stretches can be important to provide an efficient introduction of the peptide according to the present invention into the cells. In one embodiment of the present invention, the peptide is part of a fusion protein which comprises, for example, the 80 N-terminal amino acids of the HLA-DR antigen-associated invariant chain (p33, in the following “Ii”) as derived from the NCBI, GenBank Accession number X00497. In other fusions, the peptides of the present invention can be fused to an antibody as described herein, or a functional part thereof, in particular into a sequence of an antibody, so as to be specifically targeted by said antibody, or, for example, to or into an antibody that is specific for dendritic cells as described herein.

In addition, the peptide or variant may be modified further to improve stability and/or binding to MHC molecules in order to elicit a stronger immune response. Methods for such an optimization of a peptide sequence are well known in the art and include, for example, the introduction of reverse peptide bonds or non-peptide bonds.

In a reverse peptide bond amino acid residues are not joined by peptide (-CO-NH-) linkages but the peptide bond is reversed. Such retro-inverso peptidomimetics may be made using methods known in the art, for example such as those described in Meziere et al (1997) (Meziere et al., 1997), incorporated herein by reference. This approach involves making pseudopeptides containing changes involving the backbone, and not the orientation of side chains. Meziere et al. (Meziere et al., 1997) show that for MHC binding and T helper cell responses, these pseudopeptides are useful. Retro-inverse peptides, which contain NH-CO bonds instead of CO-NH peptide bonds, are much more resistant to proteolysis.

- 100 -

A non-peptide bond is, for example, $-\text{CH}_2\text{-NH}$, $-\text{CH}_2\text{S-}$, $-\text{CH}_2\text{CH}_2\text{-}$, $-\text{CH=CH-}$, $-\text{COCH}_2\text{-}$, $-\text{CH(OH)CH}_2\text{-}$, and $-\text{CH}_2\text{SO-}$. US 4,897,445 provides a method for the solid phase synthesis of non-peptide bonds ($-\text{CH}_2\text{-NH}$) in polypeptide chains which involves polypeptides synthesized by standard procedures and the non-peptide bond synthesized by reacting an amino aldehyde and an amino acid in the presence of NaCNBH_3 .

Peptides comprising the sequences described above may be synthesized with additional chemical groups present at their amino and/or carboxy termini, to enhance the stability, bioavailability, and/or affinity of the peptides. For example, hydrophobic groups such as carbobenzoxy, dansyl, or t-butyloxycarbonyl groups may be added to the peptides' amino termini. Likewise, an acetyl group or a 9-fluorenylmethoxy-carbonyl group may be placed at the peptides' amino termini. Additionally, the hydrophobic group, t-butyloxycarbonyl, or an amido group may be added to the peptides' carboxy termini.

Further, the peptides of the invention may be synthesized to alter their steric configuration. For example, the D-isomer of one or more of the amino acid residues of the peptide may be used, rather than the usual L-isomer. Still further, at least one of the amino acid residues of the peptides of the invention may be substituted by one of the well-known non-naturally occurring amino acid residues. Alterations such as these may serve to increase the stability, bioavailability and/or binding action of the peptides of the invention.

Similarly, a peptide or variant of the invention may be modified chemically by reacting specific amino acids either before or after synthesis of the peptide. Examples for such modifications are well known in the art and are summarized e.g. in R. Lundblad, *Chemical Reagents for Protein Modification*, 3rd ed. CRC Press, 2004 (Lundblad, 2004), which is incorporated herein by reference. Chemical modification of amino acids includes but is not limited to, modification by acylation, amidination, pyridoxylation of lysine, reductive alkylation, trinitrobenzylation of amino groups with 2,4,6-trinitrobenzene sulphonic acid (TNBS), amide modification of carboxyl groups and sulphydryl modification by performic acid oxidation of cysteine to cysteic acid, formation of mercurial deriva-

tives, formation of mixed disulphides with other thiol compounds, reaction with maleimide, carboxymethylation with iodoacetic acid or iodoacetamide and carbamoylation with cyanate at alkaline pH, although without limitation thereto. In this regard, the skilled person is referred to Chapter 15 of Current Protocols In Protein Science, Eds. Coligan et al. (John Wiley and Sons NY 1995-2000) (Coligan et al., 1995) for more extensive methodology relating to chemical modification of proteins.

Briefly, modification of e.g. arginyl residues in proteins is often based on the reaction of vicinal dicarbonyl compounds such as phenylglyoxal, 2,3-butanedione, and 1,2-cyclohexanedione to form an adduct. Another example is the reaction of methylglyoxal with arginine residues. Cysteine can be modified without concomitant modification of other nucleophilic sites such as lysine and histidine. As a result, a large number of reagents are available for the modification of cysteine. The websites of companies such as Sigma-Aldrich (<http://www.sigma-aldrich.com>) provide information on specific reagents.

Selective reduction of disulfide bonds in proteins is also common. Disulfide bonds can be formed and oxidized during the heat treatment of biopharmaceuticals. Woodward's Reagent K may be used to modify specific glutamic acid residues. N-(3-(dimethylamino)propyl)-N'-ethylcarbodiimide can be used to form intra-molecular cross-links between a lysine residue and a glutamic acid residue. For example, diethylpyrocarbonate is a reagent for the modification of histidyl residues in proteins. Histidine can also be modified using 4-hydroxy-2-nonenal. The reaction of lysine residues and other α -amino groups is, for example, useful in binding of peptides to surfaces or the cross-linking of proteins/peptides. Lysine is the site of attachment of poly(ethylene)glycol and the major site of modification in the glycosylation of proteins. Methionine residues in proteins can be modified with e.g. iodoacetamide, bromoethylamine, and chloramine T.

Tetranitromethane and N-acetylimidazole can be used for the modification of tyrosyl residues. Cross-linking via the formation of dityrosine can be accomplished with hydrogen peroxide/copper ions.

Recent studies on the modification of tryptophan have used N-bromosuccinimide, 2-hydroxy-5-nitrobenzyl bromide or 3-bromo-3-methyl-2-(2-nitrophenylmercapto)-3H-indole (BPNS-skatole).

Successful modification of therapeutic proteins and peptides with PEG is often associated with an extension of circulatory half-life while cross-linking of proteins with glutaraldehyde, polyethylene glycol diacrylate and formaldehyde is used for the preparation of hydrogels. Chemical modification of allergens for immunotherapy is often achieved by carbamylation with potassium cyanate.

A peptide or variant, wherein the peptide is modified or includes non-peptide bonds is a preferred embodiment of the invention. Generally, peptides and variants (at least those containing peptide linkages between amino acid residues) may be synthesized by the Fmoc-polyamide mode of solid-phase peptide synthesis as disclosed by Lukas et al. (Lukas et al., 1981) and by references as cited therein. Temporary N-amino group protection is afforded by the 9-fluorenylmethyloxycarbonyl (Fmoc) group. Repetitive cleavage of this highly base-labile protecting group is done using 20% piperidine in N, N-dimethylformamide. Side-chain functionalities may be protected as their butyl ethers (in the case of serine threonine and tyrosine), butyl esters (in the case of glutamic acid and aspartic acid), butyloxycarbonyl derivative (in the case of lysine and histidine), trityl derivative (in the case of cysteine) and 4-methoxy-2,3,6-trimethylbenzenesulphonyl derivative (in the case of arginine). Where glutamine or asparagine are C-terminal residues, use is made of the 4,4'-dimethoxybenzhydryl group for protection of the side chain amido functionalities. The solid-phase support is based on a polydimethyl-acrylamide polymer constituted from the three monomers dimethylacrylamide (backbone-monomer), bisacryloylethylene diamine (cross linker) and acryloylsarcosine methyl ester (functionalizing agent). The peptide-to-resin cleavable linked agent used is the acid-labile 4-hydroxymethyl-phenoxyacetic acid derivative. All amino acid derivatives are added as their preformed symmetrical anhydride derivatives with the exception of asparagine and glutamine, which are added using a reversed N, N-dicyclohexylcarbodiimide/1hydroxybenzotriazole mediated coupling procedure. All coupling and

deprotection reactions are monitored using ninhydrin, trinitrobenzene sulphonic acid or isotin test procedures. Upon completion of synthesis, peptides are cleaved from the resin support with concomitant removal of side-chain protecting groups by treatment with 95% trifluoroacetic acid containing a 50 % scavenger mix. Scavengers commonly used include ethanedithiol, phenol, anisole and water, the exact choice depending on the constituent amino acids of the peptide being synthesized. Also a combination of solid phase and solution phase methodologies for the synthesis of peptides is possible (see, for example, (Bruckdorfer et al., 2004), and the references as cited therein).

Trifluoroacetic acid is removed by evaporation in vacuo, with subsequent trituration with diethyl ether affording the crude peptide. Any scavengers present are removed by a simple extraction procedure which on lyophilization of the aqueous phase affords the crude peptide free of scavengers. Reagents for peptide synthesis are generally available from e.g. Calbiochem-Novabiochem (Nottingham, UK).

Purification may be performed by any one, or a combination of, techniques such as recrystallization, size exclusion chromatography, ion-exchange chromatography, hydrophobic interaction chromatography and (usually) reverse-phase high performance liquid chromatography using e.g. acetonitrile/water gradient separation.

Analysis of peptides may be carried out using thin layer chromatography, electrophoresis, in particular capillary electrophoresis, solid phase extraction (CSPE), reverse-phase high performance liquid chromatography, amino-acid analysis after acid hydrolysis and by fast atom bombardment (FAB) mass spectrometric analysis, as well as MALDI and ESI-Q-TOF mass spectrometric analysis.

For the identification of peptides of the present invention, a database of RNA expression data (Lonsdale, 2013) from about 3000 normal (healthy) tissue samples was screened for genes with near-absent expression in vital organ systems, and low expression in other important organ systems. Then, cancer-associated peptides derived from the pro-

tein products of these genes were identified by mass spectrometry using the XPRESIDENT™ platform as described herein.

In order to select over-presented peptides, a presentation profile was calculated showing the median sample presentation as well as replicate variation. The profile juxtaposes samples of the tumor entity of interest to a baseline of normal tissue samples. Each of these profiles can then be consolidated into an over-presentation score by calculating the p-value of a Linear Mixed-Effects Model (Pinheiro et al., 2015) adjusting for multiple testing by False Discovery Rate (Benjamini and Hochberg, 1995) (cf. Example 1).

For the identification and relative quantitation of HLA ligands by mass spectrometry, HLA molecules from shock-frozen tissue samples were purified and HLA-associated peptides were isolated. The isolated peptides were separated and sequences were identified by online nano-electrospray-ionization (nanoESI) liquid chromatography-mass spectrometry (LC-MS) experiments. The resulting peptide sequences were verified by comparison of the fragmentation pattern of natural tumor-associated peptides (TUMAPs) recorded from cancer samples (N = 377 A*02-positive samples from 370 donors, N = 204 A*24-positive samples) with the fragmentation patterns of corresponding synthetic reference peptides of identical sequences. Since the peptides were directly identified as ligands of HLA molecules of primary tumors, these results provide direct evidence for the natural processing and presentation of the identified peptides on primary cancer tissue obtained from 574 cancer patients.

The discovery pipeline XPRESIDENT® v2.1 (see, for example, US 2013-0096016, which is hereby incorporated by reference in its entirety) allows the identification and selection of relevant over-presented peptide vaccine candidates based on direct relative quantitation of HLA-restricted peptide levels on cancer tissues in comparison to several different non-cancerous tissues and organs. This was achieved by the development of label-free differential quantitation using the acquired LC-MS data processed by a proprietary data analysis pipeline, combining algorithms for sequence identification, spec-

tral clustering, ion counting, retention time alignment, charge state deconvolution and normalization.

Presentation levels including error estimates for each peptide and sample were established. Peptides exclusively presented on tumor tissue and peptides over-presented in tumor versus non-cancerous tissues and organs have been identified.

HLA-peptide complexes from tissue samples were purified and HLA-associated peptides were isolated and analyzed by LC-MS (see examples). All TUMAPs contained in the present application were identified with this approach on primary cancer samples, confirming their presentation on primary glioblastoma, breast cancer, colorectal cancer, renal cell carcinoma, chronic lymphocytic leukemia, hepatocellular carcinoma, non-small cell and small cell lung cancer, Non-Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, pancreatic cancer, prostate cancer, esophageal cancer including cancer of the gastric-esophageal junction, gallbladder cancer and cholangiocarcinoma, melanoma, gastric cancer, testis cancer, urinary bladder cancer, or uterine cancer.

TUMAPs as identified on multiple cancer and normal tissues were quantified using ion-counting of label-free LC-MS data. The method assumes that LC-MS signal areas of a peptide correlate with its abundance in the sample. All quantitative signals of a peptide in various LC-MS experiments were normalized based on central tendency, averaged per sample and merged into a bar plot, called presentation profile. The presentation profile consolidates different analysis methods like protein database search, spectral clustering, charge state deconvolution (decharging) and retention time alignment and normalization.

Furthermore, the discovery pipeline XPRESIDENT® v2.1 allows the direct absolute quantitation of MHC-, preferably HLA-restricted, peptide levels on cancer or other infected tissues. Briefly, the total cell count was calculated from the total DNA content of the analyzed tissue sample. The total peptide amount for a TUMAP in a tissue sample was measured by nanoLC-MS/MS as the ratio of the natural TUMAP and a known

- 106 -

amount of an isotope-labeled version of the TUMAP, the so-called internal standard. The efficiency of TUMAP isolation was determined by spiking peptide:MHC complexes of all selected TUMAPs into the tissue lysate at the earliest possible point of the TUMAP isolation procedure and their detection by nanoLC-MS/MS following completion of the peptide isolation procedure. The total cell count and the amount of total peptide were calculated from triplicate measurements per tissue sample. The peptide-specific isolation efficiencies were calculated as an average from 10 spike experiments each measured as a triplicate (see Example 6 and Table 14).

This combined analysis of RNA expression and mass spectrometry data resulted in the 417 peptides of the present invention.

The present invention provides peptides that are useful in treating cancers/tumors, preferably glioblastoma, breast cancer, colorectal cancer, renal cell carcinoma, chronic lymphocytic leukemia, hepatocellular carcinoma, non-small cell and small cell lung cancer, Non-Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, pancreatic cancer, prostate cancer, esophageal cancer including cancer of the gastric-esophageal junction, gallbladder cancer and cholangiocarcinoma, melanoma, gastric cancer, testis cancer, urinary bladder cancer, head and neck squamous cell carcinoma, and uterine cancer that over- or exclusively present the peptides of the invention. These peptides were shown by mass spectrometry to be naturally presented by HLA molecules on primary human cancer samples.

Many of the source gene/proteins (also designated “full-length proteins” or “underlying proteins”) from which the peptides are derived were shown to be highly over-expressed in cancer compared with normal tissues – “normal tissues” in relation to this invention shall mean either healthy cells or tissue derived from the same organ as the tumor, or other normal tissue cells, demonstrating a high degree of tumor association of the source genes (see Example 2). Moreover, the peptides themselves are strongly over-presented on tumor tissue – “tumor tissue” in relation to this invention shall mean a

sample from a patient suffering from cancer, but not on normal tissues (see, e.g., Example 1).

HLA-bound peptides can be recognized by the immune system, specifically T lymphocytes. T cells can destroy the cells presenting the recognized HLA/peptide complex, e.g. glioblastoma, breast cancer, colorectal cancer, renal cell carcinoma, chronic lymphocytic leukemia, hepatocellular carcinoma, non-small cell and small cell lung cancer, Non-Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, pancreatic cancer, prostate cancer, esophageal cancer including cancer of the gastric-esophageal junction, gallbladder cancer and cholangiocarcinoma, melanoma, gastric cancer, testis cancer, urinary bladder cancer, head and neck squamous cell carcinoma, or uterine cancer cells presenting the derived peptides.

The peptides of the present invention have been shown to be capable of stimulating T cell responses and/or are over-presented and thus can be used for the production of antibodies and/or TCRs, such as soluble TCRs, according to the present invention (see Example 3). Furthermore, the peptides when complexed with the respective MHC can be used for the production of antibodies and/or TCRs, in particular sTCRs, according to the present invention, as well. Respective methods are well known to the person of skill, and can be found in the respective literature as well. Thus, the peptides of the present invention are useful for generating an immune response in a patient by which tumor cells can be destroyed. An immune response in a patient can be induced by direct administration of the described peptides or suitable precursor substances (e.g. elongated peptides, proteins, or nucleic acids encoding these peptides) to the patient, ideally in combination with an agent enhancing the immunogenicity (i.e. an adjuvant). The immune response originating from such a therapeutic vaccination can be expected to be highly specific against tumor cells because the target peptides of the present invention are not presented on normal tissues in comparable copy numbers, preventing the risk of undesired autoimmune reactions against normal cells in the patient.

The present description further relates to T-cell receptors (TCRs) comprising an alpha chain and a beta chain ("alpha/beta TCRs"). Also provided are peptides capable of binding to TCRs and antibodies when presented by an MHC molecule. The present description also relates to nucleic acids, vectors and host cells for expressing TCRs and peptides of the present description; and methods of using the same.

The term "T-cell receptor" (abbreviated TCR) refers to a heterodimeric molecule comprising an alpha polypeptide chain (alpha chain) and a beta polypeptide chain (beta chain), wherein the heterodimeric receptor is capable of binding to a peptide antigen presented by an HLA molecule. The term also includes so-called gamma/delta TCRs.

In one embodiment the description provides a method of producing a TCR as described herein, the method comprising culturing a host cell capable of expressing the TCR under conditions suitable to promote expression of the TCR.

The description in another aspect relates to methods according to the description, wherein the antigen is loaded onto class I or II MHC molecules expressed on the surface of a suitable antigen-presenting cell or artificial antigen-presenting cell by contacting a sufficient amount of the antigen with an antigen-presenting cell or the antigen is loaded onto class I or II MHC tetramers by tetramerizing the antigen/class I or II MHC complex monomers.

The alpha and beta chains of alpha/beta TCR's, and the gamma and delta chains of gamma/delta TCRs, are generally regarded as each having two "domains", namely variable and constant domains. The variable domain consists of a concatenation of variable region (V), and joining region (J). The variable domain may also include a leader region (L). Beta and delta chains may also include a diversity region (D). The alpha and beta constant domains may also include C-terminal transmembrane (TM) domains that anchor the alpha and beta chains to the cell membrane.

- 109 -

With respect to gamma/delta TCRs, the term "TCR gamma variable domain" as used herein refers to the concatenation of the TCR gamma V (TRGV) region without leader region (L), and the TCR gamma J (TRGJ) region, and the term TCR gamma constant domain refers to the extracellular TRGC region, or to a C-terminal truncated TRGC sequence. Likewise the term "TCR delta variable domain" refers to the concatenation of the TCR delta V (TRDV) region without leader region (L) and the TCR delta D/J (TRDD/TRDJ) region, and the term "TCR delta constant domain" refers to the extracellular TRDC region, or to a C-terminal truncated TRDC sequence.

TCRs of the present description preferably bind to a peptide-HLA molecule complex with a binding affinity (KD) of about 100 μ M or less, about 50 μ M or less, about 25 μ M or less, or about 10 μ M or less. More preferred are high affinity TCRs having binding affinities of about 1 μ M or less, about 100 nM or less, about 50 nM or less, about 25 nM or less. Non-limiting examples of preferred binding affinity ranges for TCRs of the present invention include about 1 nM to about 10 nM; about 10 nM to about 20 nM; about 20 nM to about 30 nM; about 30 nM to about 40 nM; about 40 nM to about 50 nM; about 50 nM to about 60 nM; about 60 nM to about 70 nM; about 70 nM to about 80 nM; about 80 nM to about 90 nM; and about 90 nM to about 100 nM.

As used herein in connect with TCRs of the present description, "specific binding" and grammatical variants thereof are used to mean a TCR having a binding affinity (KD) for a peptide-HLA molecule complex of 100 μ M or less.

Alpha/beta heterodimeric TCRs of the present description may have an introduced disulfide bond between their constant domains. Preferred TCRs of this type include those which have a TRAC constant domain sequence and a TRBC1 or TRBC2 constant domain sequence except that Thr 48 of TRAC and Ser 57 of TRBC1 or TRBC2 are replaced by cysteine residues, the said cysteines forming a disulfide bond between the TRAC constant domain sequence and the TRBC1 or TRBC2 constant domain sequence of the TCR.

With or without the introduced inter-chain bond mentioned above, alpha/beta heterodimeric TCRs of the present description may have a TRAC constant domain sequence and a TRBC1 or TRBC2 constant domain sequence, and the TRAC constant domain sequence and the TRBC1 or TRBC2 constant domain sequence of the TCR may be linked by the native disulfide bond between Cys4 of exon 2 of TRAC and Cys2 of exon 2 of TRBC1 or TRBC2.

TCRs of the present description may comprise a detectable label selected from the group consisting of a radionuclide, a fluorophore and biotin. TCRs of the present description may be conjugated to a therapeutically active agent, such as a radionuclide, a chemotherapeutic agent, or a toxin.

In an embodiment, a TCR of the present description having at least one mutation in the alpha chain and/or having at least one mutation in the beta chain has modified glycosylation compared to the unmutated TCR.

In an embodiment, a TCR comprising at least one mutation in the TCR alpha chain and/or TCR beta chain has a binding affinity for, and/or a binding half-life for, a peptide-HLA molecule complex, which is at least double that of a TCR comprising the unmutated TCR alpha chain and/or unmutated TCR beta chain. Affinity-enhancement of tumor-specific TCRs, and its exploitation, relies on the existence of a window for optimal TCR affinities. The existence of such a window is based on observations that TCRs specific for HLA-A2-restricted pathogens have KD values that are generally about 10-fold lower when compared to TCRs specific for HLA-A2-restricted tumor-associated self-antigens. It is now known, although tumor antigens have the potential to be immunogenic, because tumors arise from the individual's own cells only mutated proteins or proteins with altered translational processing will be seen as foreign by the immune system. Antigens that are upregulated or overexpressed (so called self-antigens) will not necessarily induce a functional immune response against the tumor: T-cells expressing TCRs that are highly reactive to these antigens will have been negatively selected within the thymus in a process known as central tolerance, meaning that only T-cells with

low-affinity TCRs for self-antigens remain. Therefore, affinity of TCRs or variants of the present description to the peptides according to the invention can be enhanced by methods well known in the art.

The present description further relates to a method of identifying and isolating a TCR according to the present description, said method comprising incubating PBMCs from HLA-A*02-negative healthy donors with A2/peptide monomers, incubating the PBMCs with tetramer-phycoerythrin (PE) and isolating the high avidity T-cells by fluorescence activated cell sorting (FACS)–Calibur analysis.

The present description further relates to a method of identifying and isolating a TCR according to the present description, said method comprising obtaining a transgenic mouse with the entire human TCR $\alpha\beta$ gene loci (1.1 and 0.7 Mb), whose T-cells express a diverse human TCR repertoire that compensates for mouse TCR deficiency, immunizing the mouse with peptide of interest, incubating PBMCs obtained from the transgenic mice with tetramer-phycoerythrin (PE), and isolating the high avidity T-cells by fluorescence activated cell sorting (FACS)–Calibur analysis.

In one aspect, to obtain T-cells expressing TCRs of the present description, nucleic acids encoding TCR-alpha and/or TCR-beta chains of the present description are cloned into expression vectors, such as gamma retrovirus or lentivirus. The recombinant viruses are generated and then tested for functionality, such as antigen specificity and functional avidity. An aliquot of the final product is then used to transduce the target T-cell population (generally purified from patient PBMCs), which is expanded before infusion into the patient. In another aspect, to obtain T-cells expressing TCRs of the present description, TCR RNAs are synthesized by techniques known in the art, e.g., in vitro transcription systems. The in vitro-synthesized TCR RNAs are then introduced into primary CD8+ T-cells obtained from healthy donors by electroporation to re-express tumor specific TCR-alpha and/or TCR-beta chains.

To increase the expression, nucleic acids encoding TCRs of the present description may be operably linked to strong promoters, such as retroviral long terminal repeats (LTRs), cytomegalovirus (CMV), murine stem cell virus (MSCV) U3, phosphoglycerate kinase (PGK), β -actin, ubiquitin, and a simian virus 40 (SV40)/CD43 composite promoter, elongation factor (EF)-1a and the spleen focus-forming virus (SFFV) promoter. In a preferred embodiment, the promoter is heterologous to the nucleic acid being expressed. In addition to strong promoters, TCR expression cassettes of the present description may contain additional elements that can enhance transgene expression, including a central polypurine tract (cPPT), which promotes the nuclear translocation of lentiviral constructs (Follenzi et al., 2000), and the woodchuck hepatitis virus posttranscriptional regulatory element (wPRE), which increases the level of transgene expression by increasing RNA stability (Zufferey et al., 1999).

The alpha and beta chains of a TCR of the present invention may be encoded by nucleic acids located in separate vectors, or may be encoded by polynucleotides located in the same vector.

Achieving high-level TCR surface expression requires that both the TCR-alpha and TCR-beta chains of the introduced TCR be transcribed at high levels. To do so, the TCR-alpha and TCR-beta chains of the present description may be cloned into bicistronic constructs in a single vector, which has been shown to be capable of overcoming this obstacle. The use of a viral intraribosomal entry site (IRES) between the TCR-alpha and TCR-beta chains results in the coordinated expression of both chains, because the TCR-alpha and TCR-beta chains are generated from a single transcript that is broken into two proteins during translation, ensuring that an equal molar ratio of TCR-alpha and TCR-beta chains are produced. (Schmitt et al. 2009).

Nucleic acids encoding TCRs of the present description may be codon optimized to increase expression from a host cell. Redundancy in the genetic code allows some amino acids to be encoded by more than one codon, but certain codons are less "optimal" than others because of the relative availability of matching tRNAs as well as other fac-

tors (Gustafsson et al., 2004). Modifying the TCR-alpha and TCR-beta gene sequences such that each amino acid is encoded by the optimal codon for mammalian gene expression, as well as eliminating mRNA instability motifs or cryptic splice sites, has been shown to significantly enhance TCR-alpha and TCR-beta gene expression (Scholten et al., 2006).

Furthermore, mispairing between the introduced and endogenous TCR chains may result in the acquisition of specificities that pose a significant risk for autoimmunity. For example, the formation of mixed TCR dimers may reduce the number of CD3 molecules available to form properly paired TCR complexes, and therefore can significantly decrease the functional avidity of the cells expressing the introduced TCR (Kuball et al., 2007).

To reduce mispairing, the C-terminus domain of the introduced TCR chains of the present description may be modified in order to promote interchain affinity, while decreasing the ability of the introduced chains to pair with the endogenous TCR. These strategies may include replacing the human TCR-alpha and TCR-beta C-terminus domains with their murine counterparts (murinized C-terminus domain); generating a second interchain disulfide bond in the C-terminus domain by introducing a second cysteine residue into both the TCR-alpha and TCR-beta chains of the introduced TCR (cysteine modification); swapping interacting residues in the TCR-alpha and TCR-beta chain C-terminus domains ("knob-in-hole"); and fusing the variable domains of the TCR-alpha and TCR-beta chains directly to CD3 ζ (CD3 ζ fusion). (Schmitt et al. 2009).

In an embodiment, a host cell is engineered to express a TCR of the present description. In preferred embodiments, the host cell is a human T-cell or T-cell progenitor. In some embodiments the T-cell or T-cell progenitor is obtained from a cancer patient. In other embodiments the T-cell or T-cell progenitor is obtained from a healthy donor. Host cells of the present description can be allogeneic or autologous with respect to a patient to be treated. In one embodiment, the host is a gamma/delta T-cell transformed to express an alpha/beta TCR.

A "pharmaceutical composition" is a composition suitable for administration to a human being in a medical setting. Preferably, a pharmaceutical composition is sterile and produced according to GMP guidelines.

The pharmaceutical compositions comprise the peptides either in the free form or in the form of a pharmaceutically acceptable salt (see also above). As used herein, "a pharmaceutically acceptable salt" refers to a derivative of the disclosed peptides wherein the peptide is modified by making acid or base salts of the agent. For example, acid salts are prepared from the free base (typically wherein the neutral form of the drug has a neutral $-NH_2$ group) involving reaction with a suitable acid. Suitable acids for preparing acid salts include both organic acids, e.g., acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methane sulfonic acid, ethane sulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like, as well as inorganic acids, e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid phosphoric acid and the like. Conversely, preparation of basic salts of acid moieties which may be present on a peptide are prepared using a pharmaceutically acceptable base such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, trimethylamine or the like.

In an especially preferred embodiment, the pharmaceutical compositions comprise the peptides as salts of acetic acid (acetates), trifluoro acetates or hydrochloric acid (chlorides).

Preferably, the medicament of the present invention is an immunotherapeutic, such as a vaccine. It may be administered directly into the patient, into the affected organ or systemically i.d., i.m., s.c., i.p. and i.v., or applied *ex vivo* to cells derived from the patient or a human cell line which are subsequently administered to the patient, or used *in vitro* to select a subpopulation of immune cells derived from the patient, which are then re-administered to the patient. If the nucleic acid is administered to cells *in vitro*, it may be

- 115 -

useful for the cells to be transfected so as to co-express immune-stimulating cytokines, such as interleukin-2. The peptide may be substantially pure, or combined with an immune-stimulating adjuvant (see below) or used in combination with immune-stimulatory cytokines, or be administered with a suitable delivery system, for example liposomes. The peptide may also be conjugated to a suitable carrier such as keyhole limpet haemocyanin (KLH) or mannan (see WO 95/18145 and (Longenecker et al., 1993)). The peptide may also be tagged, may be a fusion protein, or may be a hybrid molecule. The peptides whose sequence is given in the present invention are expected to stimulate CD4 or CD8 T cells. However, stimulation of CD8 T cells is more efficient in the presence of help provided by CD4 T-helper cells. Thus, for MHC Class I epitopes that stimulate CD8 T cells the fusion partner or sections of a hybrid molecule suitably provide epitopes which stimulate CD4-positive T cells. CD4- and CD8-stimulating epitopes are well known in the art and include those identified in the present invention.

In one aspect, the vaccine comprises at least one peptide having the amino acid sequence set forth SEQ ID No. 1 to SEQ ID No. 388, and at least one additional peptide, preferably two to 50, more preferably two to 25, even more preferably two to 20 and most preferably two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen or eighteen peptides. The peptide(s) may be derived from one or more specific TAAs and may bind to MHC class I molecules.

A further aspect of the invention provides a nucleic acid (for example a polynucleotide) encoding a peptide or peptide variant of the invention. The polynucleotide may be, for example, DNA, cDNA, PNA, RNA or combinations thereof, either single- and/or double-stranded, or native or stabilized forms of polynucleotides, such as, for example, polynucleotides with a phosphorothioate backbone and it may or may not contain introns so long as it codes for the peptide. Of course, only peptides that contain naturally occurring amino acid residues joined by naturally occurring peptide bonds are encodable by a polynucleotide. A still further aspect of the invention provides an expression vector capable of expressing a polypeptide according to the invention.

A variety of methods have been developed to link polynucleotides, especially DNA, to vectors for example via complementary cohesive termini. For instance, complementary homopolymer tracts can be added to the DNA segment to be inserted to the vector DNA. The vector and DNA segment are then joined by hydrogen bonding between the complementary homopolymeric tails to form recombinant DNA molecules.

Synthetic linkers containing one or more restriction sites provide an alternative method of joining the DNA segment to vectors. Synthetic linkers containing a variety of restriction endonuclease sites are commercially available from a number of sources including International Biotechnologies Inc. New Haven, CN, USA.

A desirable method of modifying the DNA encoding the polypeptide of the invention employs the polymerase chain reaction as disclosed by Saiki RK, et al. (Saiki et al., 1988). This method may be used for introducing the DNA into a suitable vector, for example by engineering in suitable restriction sites, or it may be used to modify the DNA in other useful ways as is known in the art. If viral vectors are used, pox- or adenovirus vectors are preferred.

The DNA (or in the case of retroviral vectors, RNA) may then be expressed in a suitable host to produce a polypeptide comprising the peptide or variant of the invention. Thus, the DNA encoding the peptide or variant of the invention may be used in accordance with known techniques, appropriately modified in view of the teachings contained herein, to construct an expression vector, which is then used to transform an appropriate host cell for the expression and production of the polypeptide of the invention. Such techniques include those disclosed, for example, in US 4,440,859, 4,530,901, 4,582,800, 4,677,063, 4,678,751, 4,704,362, 4,710,463, 4,757,006, 4,766,075, and 4,810,648.

The DNA (or in the case of retroviral vectors, RNA) encoding the polypeptide constituting the compound of the invention may be joined to a wide variety of other DNA sequences for introduction into an appropriate host. The companion DNA will depend up-

on the nature of the host, the manner of the introduction of the DNA into the host, and whether episomal maintenance or integration is desired.

Generally, the DNA is inserted into an expression vector, such as a plasmid, in proper orientation and correct reading frame for expression. If necessary, the DNA may be linked to the appropriate transcriptional and translational regulatory control nucleotide sequences recognized by the desired host, although such controls are generally available in the expression vector. The vector is then introduced into the host through standard techniques. Generally, not all of the hosts will be transformed by the vector. Therefore, it will be necessary to select for transformed host cells. One selection technique involves incorporating into the expression vector a DNA sequence, with any necessary control elements, that codes for a selectable trait in the transformed cell, such as antibiotic resistance.

Alternatively, the gene for such selectable trait can be on another vector, which is used to co-transform the desired host cell.

Host cells that have been transformed by the recombinant DNA of the invention are then cultured for a sufficient time and under appropriate conditions known to those skilled in the art in view of the teachings disclosed herein to permit the expression of the polypeptide, which can then be recovered.

Many expression systems are known, including bacteria (for example *E. coli* and *Bacillus subtilis*), yeasts (for example *Saccharomyces cerevisiae*), filamentous fungi (for example *Aspergillus spec.*), plant cells, animal cells and insect cells. Preferably, the system can be mammalian cells such as CHO cells available from the ATCC Cell Biology Collection.

A typical mammalian cell vector plasmid for constitutive expression comprises the CMV or SV40 promoter with a suitable poly A tail and a resistance marker, such as neomycin. One example is pSVL available from Pharmacia, Piscataway, NJ, USA. An example of

- 118 -

an inducible mammalian expression vector is pMSG, also available from Pharmacia. Useful yeast plasmid vectors are pRS403-406 and pRS413-416 and are generally available from Stratagene Cloning Systems, La Jolla, CA 92037, USA. Plasmids pRS403, pRS404, pRS405 and pRS406 are Yeast Integrating plasmids (YIps) and incorporate the yeast selectable markers HIS3, TRP1, LEU2 and URA3. Plasmids pRS413-416 are Yeast Centromere plasmids (Ycps). CMV promoter-based vectors (for example from Sigma-Aldrich) provide transient or stable expression, cytoplasmic expression or secretion, and N-terminal or C-terminal tagging in various combinations of FLAG, 3xFLAG, c-myc or MAT. These fusion proteins allow for detection, purification and analysis of recombinant protein. Dual-tagged fusions provide flexibility in detection.

The strong human cytomegalovirus (CMV) promoter regulatory region drives constitutive protein expression levels as high as 1 mg/L in COS cells. For less potent cell lines, protein levels are typically ~0.1 mg/L. The presence of the SV40 replication origin will result in high levels of DNA replication in SV40 replication permissive COS cells. CMV vectors, for example, can contain the pMB1 (derivative of pBR322) origin for replication in bacterial cells, the b-lactamase gene for ampicillin resistance selection in bacteria, hGH polyA, and the f1 origin. Vectors containing the pre-pro-trypsin leader (PPT) sequence can direct the secretion of FLAG fusion proteins into the culture medium for purification using ANTI-FLAG antibodies, resins, and plates. Other vectors and expression systems are well known in the art for use with a variety of host cells.

In another embodiment two or more peptides or peptide variants of the invention are encoded and thus expressed in a successive order (similar to "beads on a string" constructs). In doing so, the peptides or peptide variants may be linked or fused together by stretches of linker amino acids, such as for example LLLLLL, or may be linked without any additional peptide(s) between them. These constructs can also be used for cancer therapy, and may induce immune responses both involving MHC I and MHC II.

The present invention also relates to a host cell transformed with a polynucleotide vector construct of the present invention. The host cell can be either prokaryotic or eukary-

otic. Bacterial cells may be preferred prokaryotic host cells in some circumstances and typically are a strain of *E. coli* such as, for example, the *E. coli* strains DH5 available from Bethesda Research Laboratories Inc., Bethesda, MD, USA, and RR1 available from the American Type Culture Collection (ATCC) of Rockville, MD, USA (No ATCC 31343). Preferred eukaryotic host cells include yeast, insect and mammalian cells, preferably vertebrate cells such as those from a mouse, rat, monkey or human fibroblastic and colon cell lines. Yeast host cells include YPH499, YPH500 and YPH501, which are generally available from Stratagene Cloning Systems, La Jolla, CA 92037, USA. Preferred mammalian host cells include Chinese hamster ovary (CHO) cells available from the ATCC as CCL61, NIH Swiss mouse embryo cells NIH/3T3 available from the ATCC as CRL 1658, monkey kidney-derived COS-1 cells available from the ATCC as CRL 1650 and 293 cells which are human embryonic kidney cells. Preferred insect cells are Sf9 cells which can be transfected with baculovirus expression vectors. An overview regarding the choice of suitable host cells for expression can be found in, for example, the textbook of Paulina Balbás and Argelia Lorence "Methods in Molecular Biology Recombinant Gene Expression, Reviews and Protocols," Part One, Second Edition, ISBN 978-1-58829-262-9, and other literature known to the person of skill.

Transformation of appropriate cell hosts with a DNA construct of the present invention is accomplished by well-known methods that typically depend on the type of vector used. With regard to transformation of prokaryotic host cells, see, for example, Cohen et al. (Cohen et al., 1972) and (Green and Sambrook, 2012) . Transformation of yeast cells is described in Sherman et al. (Sherman et al., 1986). The method of Beggs (Beggs, 1978) is also useful. With regard to vertebrate cells, reagents useful in transfecting such cells, for example calcium phosphate and DEAE-dextran or liposome formulations, are available from Stratagene Cloning Systems, or Life Technologies Inc., Gaithersburg, MD 20877, USA. Electroporation is also useful for transforming and/or transfecting cells and is well known in the art for transforming yeast cell, bacterial cells, insect cells and vertebrate cells.

- 120 -

Successfully transformed cells, i.e. cells that contain a DNA construct of the present invention, can be identified by well-known techniques such as PCR. Alternatively, the presence of the protein in the supernatant can be detected using antibodies.

It will be appreciated that certain host cells of the invention are useful in the preparation of the peptides of the invention, for example bacterial, yeast and insect cells. However, other host cells may be useful in certain therapeutic methods. For example, antigen-presenting cells, such as dendritic cells, may usefully be used to express the peptides of the invention such that they may be loaded into appropriate MHC molecules. Thus, the current invention provides a host cell comprising a nucleic acid or an expression vector according to the invention.

In a preferred embodiment the host cell is an antigen presenting cell, in particular a dendritic cell or antigen presenting cell. APCs loaded with a recombinant fusion protein containing prostatic acid phosphatase (PAP) were approved by the U.S. Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic HRPC (Sipuleucel-T) (Rini et al., 2006; Small et al., 2006).

A further aspect of the invention provides a method of producing a peptide or its variant, the method comprising culturing a host cell and isolating the peptide from the host cell or its culture medium.

In another embodiment the peptide, the nucleic acid or the expression vector of the invention are used in medicine. For example, the peptide or its variant may be prepared for intravenous (i.v.) injection, sub-cutaneous (s.c.) injection, intradermal (i.d.) injection, intraperitoneal (i.p.) injection, intramuscular (i.m.) injection. Preferred methods of peptide injection include s.c., i.d., i.p., i.m., and i.v. Preferred methods of DNA injection include i.d., i.m., s.c., i.p. and i.v. Doses of e.g. between 50 µg and 1.5 mg, preferably 125 µg to 500 µg, of peptide or DNA may be given and will depend on the respective peptide or DNA. Dosages of this range were successfully used in previous trials (Walter et al., 2012).

The polynucleotide used for active vaccination may be substantially pure, or contained in a suitable vector or delivery system. The nucleic acid may be DNA, cDNA, PNA, RNA or a combination thereof. Methods for designing and introducing such a nucleic acid are well known in the art. An overview is provided by e.g. Teufel et al. (Teufel et al., 2005). Polynucleotide vaccines are easy to prepare, but the mode of action of these vectors in inducing an immune response is not fully understood. Suitable vectors and delivery systems include viral DNA and/or RNA, such as systems based on adenovirus, vaccinia virus, retroviruses, herpes virus, adeno-associated virus or hybrids containing elements of more than one virus. Non-viral delivery systems include cationic lipids and cationic polymers and are well known in the art of DNA delivery. Physical delivery, such as via a "gene-gun", may also be used. The peptide or peptides encoded by the nucleic acid may be a fusion protein, for example with an epitope that stimulates T cells for the respective opposite CDR as noted above.

The medicament of the invention may also include one or more adjuvants. Adjuvants are substances that non-specifically enhance or potentiate the immune response (e.g., immune responses mediated by CD8-positive T cells and helper-T (TH) cells to an antigen, and would thus be considered useful in the medicament of the present invention. Suitable adjuvants include, but are not limited to, 1018 ISS, aluminum salts, AMPLIVAX®, AS15, BCG, CP-870,893, CpG7909, CyaA, dSLIM, flagellin or TLR5 ligands derived from flagellin, FLT3 ligand, GM-CSF, IC30, IC31, Imiquimod (ALDARA®), resiquimod, ImuFact IMP321, Interleukins as IL-2, IL-13, IL-21, Interferon-alpha or -beta, or pegylated derivatives thereof, IS Patch, ISS, ISCOMATRIX, ISCOMs, JuvImmune®, LipoVac, MALP2, MF59, monophosphoryl lipid A, Montanide IMS 1312, Montanide ISA 206, Montanide ISA 50V, Montanide ISA-51, water-in-oil and oil-in-water emulsions, OK-432, OM-174, OM-197-MP-EC, ONTAK, OspA, PepTel® vector system, poly(lactid co-glycolid) [PLG]-based and dextran microparticles, talactoferrin SRL172, Virosomes and other Virus-like particles, YF-17D, VEGF trap, R848, beta-glucan, Pam3Cys, Aquila's QS21 stimulon, which is derived from saponin, mycobacterial extracts and synthetic bacterial cell wall mimics, and other proprietary adjuvants such as

Ribi's Detox, Quil, or Superfos. Adjuvants such as Freund's or GM-CSF are preferred. Several immunological adjuvants (e.g., MF59) specific for dendritic cells and their preparation have been described previously (Allison and Krummel, 1995). Also cytokines may be used. Several cytokines have been directly linked to influencing dendritic cell migration to lymphoid tissues (e.g., TNF-), accelerating the maturation of dendritic cells into efficient antigen-presenting cells for T-lymphocytes (e.g., GM-CSF, IL-1 and IL-4) (U.S. Pat. No. 5,849,589, specifically incorporated herein by reference in its entirety) and acting as immunoadjuvants (e.g., IL-12, IL-15, IL-23, IL-7, IFN-alpha, IFN-beta) (Gabrilovich et al., 1996).

CpG immunostimulatory oligonucleotides have also been reported to enhance the effects of adjuvants in a vaccine setting. Without being bound by theory, CpG oligonucleotides act by activating the innate (non-adaptive) immune system via Toll-like receptors (TLR), mainly TLR9. CpG triggered TLR9 activation enhances antigen-specific humoral and cellular responses to a wide variety of antigens, including peptide or protein antigens, live or killed viruses, dendritic cell vaccines, autologous cellular vaccines and polysaccharide conjugates in both prophylactic and therapeutic vaccines. More importantly it enhances dendritic cell maturation and differentiation, resulting in enhanced activation of TH1 cells and strong cytotoxic T-lymphocyte (CTL) generation, even in the absence of CD4 T cell help. The TH1 bias induced by TLR9 stimulation is maintained even in the presence of vaccine adjuvants such as alum or incomplete Freund's adjuvant (IFA) that normally promote a TH2 bias. CpG oligonucleotides show even greater adjuvant activity when formulated or co-administered with other adjuvants or in formulations such as microparticles, nanoparticles, lipid emulsions or similar formulations, which are especially necessary for inducing a strong response when the antigen is relatively weak. They also accelerate the immune response and enable the antigen doses to be reduced by approximately two orders of magnitude, with comparable antibody responses to the full-dose vaccine without CpG in some experiments (Krieg, 2006). US 6,406,705 B1 describes the combined use of CpG oligonucleotides, non-nucleic acid adjuvants and an antigen to induce an antigen-specific immune response. A CpG TLR9 antagonist is dSLIM (double Stem Loop Immunomodulator) by Mologen (Berlin, Germany) which is a

preferred component of the pharmaceutical composition of the present invention. Other TLR binding molecules such as RNA binding TLR 7, TLR 8 and/or TLR 9 may also be used.

Other examples for useful adjuvants include, but are not limited to chemically modified CpGs (e.g. CpR, Idera), dsRNA analogues such as Poly(I:C) and derivatives thereof (e.g. AmpliGen®, Hiltonol®, poly-(ICLC), poly(IC-R), poly(I:C12U), non-CpG bacterial DNA or RNA as well as immunoactive small molecules and antibodies such as cyclophosphamide, sunitinib, Bevacizumab®, celebrex, NCX-4016, sildenafil, tadalafil, vardenafil, sorafenib, temozolomide, temsirolimus, XL-999, CP-547632, pazopanib, VEGF Trap, ZD2171, AZD2171, anti-CTLA4, other antibodies targeting key structures of the immune system (e.g. anti-CD40, anti-TGFβ, anti-TNFα receptor) and SC58175, which may act therapeutically and/or as an adjuvant. The amounts and concentrations of adjuvants and additives useful in the context of the present invention can readily be determined by the skilled artisan without undue experimentation.

Preferred adjuvants are anti-CD40, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, and particulate formulations with PLG or virosomes.

In a preferred embodiment, the pharmaceutical composition according to the invention the adjuvant is selected from the group consisting of colony-stimulating factors, such as Granulocyte Macrophage Colony Stimulating Factor (GM-CSF, sargramostim), cyclophosphamide, imiquimod, resiquimod, and interferon-alpha.

In a preferred embodiment, the pharmaceutical composition according to the invention the adjuvant is selected from the group consisting of colony-stimulating factors, such as Granulocyte Macrophage Colony Stimulating Factor (GM-CSF, sargramostim), cyclophosphamide, imiquimod and resiquimod. In a preferred embodiment of the pharmaceutical composition according to the invention, the adjuvant is cyclophosphamide,

imiquimod or resiquimod. Even more preferred adjuvants are Montanide IMS 1312, Montanide ISA 206, Montanide ISA 50V, Montanide ISA-51, poly-ICLC (Hiltonol®) and anti-CD40 mAB, or combinations thereof.

This composition is used for parenteral administration, such as subcutaneous, intradermal, intramuscular or oral administration. For this, the peptides and optionally other molecules are dissolved or suspended in a pharmaceutically acceptable, preferably aqueous carrier. In addition, the composition can contain excipients, such as buffers, binding agents, blasting agents, diluents, flavors, lubricants, etc. The peptides can also be administered together with immune stimulating substances, such as cytokines. An extensive listing of excipients that can be used in such a composition, can be, for example, taken from A. Kibbe, Handbook of Pharmaceutical Excipients (Kibbe, 2000). The composition can be used for a prevention, prophylaxis and/or therapy of adenomatous or cancerous diseases. Exemplary formulations can be found in, for example, EP2112253.

It is important to realize that the immune response triggered by the vaccine according to the invention attacks the cancer in different cell-stages and different stages of development. Furthermore different cancer associated signaling pathways are attacked. This is an advantage over vaccines that address only one or few targets, which may cause the tumor to easily adapt to the attack (tumor escape). Furthermore, not all individual tumors express the same pattern of antigens. Therefore, a combination of several tumor-associated peptides ensures that every single tumor bears at least some of the targets. The composition is designed in such a way that each tumor is expected to express several of the antigens and cover several independent pathways necessary for tumor growth and maintenance. Thus, the vaccine can easily be used "off-the-shelf" for a larger patient population. This means that a pre-selection of patients to be treated with the vaccine can be restricted to HLA typing, does not require any additional biomarker assessments for antigen expression, but it is still ensured that several targets are simultaneously attacked by the induced immune response, which is important for efficacy (Banchereau et al., 2001; Walter et al., 2012).

As used herein, the term "scaffold" refers to a molecule that specifically binds to an (e.g. antigenic) determinant. In one embodiment, a scaffold is able to direct the entity to which it is attached (e.g. a (second) antigen binding moiety) to a target site, for example to a specific type of tumor cell or tumor stroma bearing the antigenic determinant (e.g. the complex of a peptide with MHC, according to the application at hand). In another embodiment a scaffold is able to activate signaling through its target antigen, for example a T cell receptor complex antigen. Scaffolds include but are not limited to antibodies and fragments thereof, antigen binding domains of an antibody, comprising an antibody heavy chain variable region and an antibody light chain variable region, binding proteins comprising at least one ankyrin repeat motif and single domain antigen binding (SDAB) molecules, aptamers, (soluble) TCRs and (modified) cells such as allogenic or autologous T cells. To assess whether a molecule is a scaffold binding to a target, binding assays can be performed.

"Specific" binding means that the scaffold binds the peptide-MHC-complex of interest better than other naturally occurring peptide-MHC-complexes, to an extent that a scaffold armed with an active molecule that is able to kill a cell bearing the specific target is not able to kill another cell without the specific target but presenting other peptide-MHC complex(es). Binding to other peptide-MHC complexes is irrelevant if the peptide of the cross-reactive peptide-MHC is not naturally occurring, i.e. not derived from the human HLA-peptidome. Tests to assess target cell killing are well known in the art. They should be performed using target cells (primary cells or cell lines) with unaltered peptide-MHC presentation, or cells loaded with peptides such that naturally occurring peptide-MHC levels are reached.

Each scaffold can comprise a labelling which provides that the bound scaffold can be detected by determining the presence or absence of a signal provided by the label. For example, the scaffold can be labelled with a fluorescent dye or any other applicable cellular marker molecule. Such marker molecules are well known in the art. For example a fluorescence-labelling, for example provided by a fluorescence dye, can provide a visu-

alization of the bound aptamer by fluorescence or laser scanning microscopy or flow cytometry.

Each scaffold can be conjugated with a second active molecule such as for example IL-21, anti-CD3, anti-CD28.

For further information on polypeptide scaffolds see for example the background section of WO 2014/071978A1 and the references cited therein.

The present invention further relates to aptamers. Aptamers (see for example WO 2014/191359 and the literature as cited therein) are short single-stranded nucleic acid molecules, which can fold into defined three-dimensional structures and recognize specific target structures. They have appeared to be suitable alternatives for developing targeted therapies. Aptamers have been shown to selectively bind to a variety of complex targets with high affinity and specificity.

Aptamers recognizing cell surface located molecules have been identified within the past decade and provide means for developing diagnostic and therapeutic approaches. Since aptamers have been shown to possess almost no toxicity and immunogenicity they are promising candidates for biomedical applications. Indeed aptamers, for example prostate-specific membrane-antigen recognizing aptamers, have been successfully employed for targeted therapies and shown to be functional in xenograft *in vivo* models. Furthermore, aptamers recognizing specific tumor cell lines have been identified.

DNA aptamers can be selected to reveal broad-spectrum recognition properties for various cancer cells, and particularly those derived from solid tumors, while non-tumorigenic and primary healthy cells are not recognized. If the identified aptamers recognize not only a specific tumor sub-type but rather interact with a series of tumors, this renders the aptamers applicable as so-called broad-spectrum diagnostics and therapeutics.

Further, investigation of cell-binding behavior with flow cytometry showed that the aptamers revealed very good apparent affinities that are within the nanomolar range.

Aptamers are useful for diagnostic and therapeutic purposes. Further, it could be shown that some of the aptamers are taken up by tumor cells and thus can function as molecular vehicles for the targeted delivery of anti-cancer agents such as siRNA into tumor cells.

Aptamers can be selected against complex targets such as cells and tissues and complexes of the peptides comprising, preferably consisting of, a sequence according to any of SEQ ID NO 1 to SEQ ID NO 388, according to the invention at hand with the MHC molecule, using the cell-SELEX (Systematic Evolution of Ligands by Exponential enrichment) technique.

The peptides of the present invention can be used to generate and develop specific antibodies against MHC/peptide complexes. These can be used for therapy, targeting toxins or radioactive substances to the diseased tissue. Another use of these antibodies can be targeting radionuclides to the diseased tissue for imaging purposes such as PET. This use can help to detect small metastases or to determine the size and precise localization of diseased tissues.

Therefore, it is a further aspect of the invention to provide a method for producing a recombinant antibody specifically binding to a human major histocompatibility complex (MHC) class I or II being complexed with a HLA-restricted antigen, the method comprising: immunizing a genetically engineered non-human mammal comprising cells expressing said human major histocompatibility complex (MHC) class I or II with a soluble form of a MHC class I or II molecule being complexed with said HLA-restricted antigen; isolating mRNA molecules from antibody producing cells of said non-human mammal; producing a phage display library displaying protein molecules encoded by said mRNA molecules; and isolating at least one phage from said phage display library, said at least

one phage displaying said antibody specifically binding to said human major histocompatibility complex (MHC) class I or II being complexed with said HLA-restricted antigen.

It is a further aspect of the invention to provide an antibody that specifically binds to a human major histocompatibility complex (MHC) class I or II being complexed with a HLA-restricted antigen, wherein the antibody preferably is a polyclonal antibody, monoclonal antibody, bi-specific antibody and/or a chimeric antibody.

Respective methods for producing such antibodies and single chain class I major histocompatibility complexes, as well as other tools for the production of these antibodies are disclosed in WO 03/068201, WO 2004/084798, WO 01/72768, WO 03/070752, and in publications (Cohen et al., 2003a; Cohen et al., 2003b; Denkberg et al., 2003), which for the purposes of the present invention are all explicitly incorporated by reference in their entireties.

Preferably, the antibody is binding with a binding affinity of below 20 nanomolar, preferably of below 10 nanomolar, to the complex, which is also regarded as "specific" in the context of the present invention.

The present invention relates to a peptide comprising a sequence that is selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 388, or a variant thereof which is at least 88% homologous (preferably identical) to SEQ ID NO: 1 to SEQ ID NO: 388 or a variant thereof that induces T cells cross-reacting with said peptide, wherein said peptide is not the underlying full-length polypeptide.

The present invention further relates to a peptide comprising a sequence that is selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 388 or a variant thereof which is at least 88% homologous (preferably identical) to SEQ ID NO: 1 to SEQ ID NO: 388, wherein said peptide or variant has an overall length of between 8 and 100, preferably between 8 and 30, and most preferred between 8 and 14 amino acids.

- 129 -

The present invention further relates to the peptides according to the invention that have the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or -II.

The present invention further relates to the peptides according to the invention wherein the peptide consists or consists essentially of an amino acid sequence according to SEQ ID NO: 1 to SEQ ID NO: 388.

The present invention further relates to the peptides according to the invention, wherein the peptide is (chemically) modified and/or includes non-peptide bonds.

The present invention further relates to the peptides according to the invention, wherein the peptide is part of a fusion protein, in particular comprising N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii), or wherein the peptide is fused to (or into) an antibody, such as, for example, an antibody that is specific for dendritic cells.

The present invention further relates to a nucleic acid, encoding the peptides according to the invention, provided that the peptide is not the complete (full) human protein.

The present invention further relates to the nucleic acid according to the invention that is DNA, cDNA, PNA, RNA or combinations thereof.

The present invention further relates to an expression vector capable of expressing or expressing a nucleic acid according to the present invention.

The present invention further relates to a peptide according to the present invention, a nucleic acid according to the present invention or an expression vector according to the present invention for use in medicine, in particular in the treatment of cancers such as glioblastoma, breast cancer, colorectal cancer, renal cell carcinoma, chronic lymphocytic leukemia, hepatocellular carcinoma, non-small cell and small cell lung cancer, Non-

- 130 -

Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, pancreatic cancer, prostate cancer, esophageal cancer including cancer of the gastric-esophageal junction, gallbladder cancer and cholangiocarcinoma, melanoma, gastric cancer (GC), testis cancer (TC), urinary bladder cancer (UBC), head and neck squamous cell carcinoma (HNSCC), or uterine cancer (UEC).

The present invention further relates to a host cell comprising a nucleic acid according to the invention or an expression vector according to the invention.

The present invention further relates to the host cell according to the present invention that is an antigen presenting cell, and preferably a dendritic cell.

The present invention further relates to a method of producing a peptide according to the present invention, said method comprising culturing the host cell according to the present invention, and isolating the peptide from said host cell or its culture medium.

The present invention further relates to the method according to the present invention, where-in the antigen is loaded onto class I or II MHC molecules expressed on the surface of a suitable antigen-presenting cell by contacting a sufficient amount of the antigen with an antigen-presenting cell.

The present invention further relates to the method according to the invention, wherein the antigen-presenting cell comprises an expression vector capable of expressing said peptide containing SEQ ID NO: 1 to SEQ ID NO: 388 or said variant amino acid sequence.

The present invention further relates to activated T cells, produced by the method according to the present invention, wherein said T cells selectively recognizes a cell which aberrantly expresses a polypeptide comprising an amino acid sequence according to the present invention.

- 131 -

The present invention further relates to a method of killing target cells in a patient which target cells aberrantly express a polypeptide comprising any amino acid sequence according to the present invention, the method comprising administering to the patient an effective number of T cells as according to the present invention.

The present invention further relates to the use of any peptide described, a nucleic acid according to the present invention, an expression vector according to the present invention, a cell according to the present invention, or an activated cytotoxic T lymphocyte according to the present invention as a medicament or in the manufacture of a medicament. The present invention further relates to a use according to the present invention, wherein the medicament is active against cancer.

The present invention further relates to a use according to the invention, wherein the medicament is a vaccine. The present invention further relates to a use according to the invention, wherein the medicament is active against cancer.

The present invention further relates to a use according to the invention, wherein said cancer cells are solid or hematological tumor cells such as glioblastoma, breast cancer, colorectal cancer, renal cell carcinoma, chronic lymphocytic leukemia, hepatocellular carcinoma, non-small cell and small cell lung cancer, Non-Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, pancreatic cancer, prostate cancer, esophageal cancer including cancer of the gastric-esophageal junction, gallbladder cancer and cholangiocarcinoma, melanoma, gastric cancer, testis cancer, urinary bladder cancer, head and neck squamous cell carcinoma (HNSCC), or uterine cancer.

The present invention further relates to particular marker proteins and biomarkers based on the peptides according to the present invention, herein called "targets" that can be used in the diagnosis and/or prognosis of glioblastoma, breast cancer, colorectal cancer, renal cell carcinoma, chronic lymphocytic leukemia, hepatocellular carcinoma, non-small cell and small cell lung cancer, Non-Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, pancreatic cancer, prostate cancer, esophageal cancer including cancer

- 132 -

of the gastric-esophageal junction, gallbladder cancer and cholangiocarcinoma, melanoma, gastric cancer, testis cancer, urinary bladder cancer, head and neck squamous cell carcinoma (HNSCC), or uterine cancer. The present invention also relates to the use of these novel targets for cancer treatment.

The term "antibody" or "antibodies" is used herein in a broad sense and includes both polyclonal and monoclonal antibodies. In addition to intact or "full" immunoglobulin molecules, also included in the term "antibodies" are fragments (e.g. CDRs, Fv, Fab and Fc fragments) or polymers of those immunoglobulin molecules and humanized versions of immunoglobulin molecules, as long as they exhibit any of the desired properties (e.g., specific binding of a glioblastoma, breast cancer, colorectal cancer, renal cell carcinoma, chronic lymphocytic leukemia, hepatocellular carcinoma, non-small cell and small cell lung cancer, Non-Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, pancreatic cancer, prostate cancer, esophageal cancer including cancer of the gastric-esophageal junction, gallbladder cancer and cholangiocarcinoma, melanoma, gastric cancer, testis cancer, urinary bladder cancer, head and neck squamous cell carcinoma (HNSCC), or uterine cancer marker (poly)peptide, delivery of a toxin to a cancer cell expressing a cancer marker gene at an increased level, and/or inhibiting the activity of a cancer marker polypeptide) according to the invention.

Whenever possible, the antibodies of the invention may be purchased from commercial sources. The antibodies of the invention may also be generated using well-known methods. The person of skill will understand that either full length glioblastoma, breast cancer, colorectal cancer, renal cell carcinoma, chronic lymphocytic leukemia, hepatocellular carcinoma, non-small cell and small cell lung cancer, Non-Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, pancreatic cancer, prostate cancer, esophageal cancer including cancer of the gastric-esophageal junction, gallbladder cancer and cholangiocarcinoma, melanoma, gastric cancer, testis cancer, urinary bladder cancer, head and neck squamous cell carcinoma (HNSCC), or uterine cancer marker polypeptides or fragments thereof may be used to generate the antibodies of the invention. A polypeptide to be used for generating an antibody of the invention may be partially or

fully purified from a natural source, or may be produced using recombinant DNA techniques.

For example, a cDNA encoding a peptide according to the present invention, such as a peptide according to SEQ ID NO: 1 to SEQ ID NO: 388 polypeptide, or a variant or fragment thereof, can be expressed in prokaryotic cells (e.g., bacteria) or eukaryotic cells (e.g., yeast, insect, or mammalian cells), after which the recombinant protein can be purified and used to generate a monoclonal or polyclonal antibody preparation that specifically bind the marker polypeptide for above-mentioned cancers used to generate the antibody according to the invention.

One of skill in the art will realize that the generation of two or more different sets of monoclonal or polyclonal antibodies maximizes the likelihood of obtaining an antibody with the specificity and affinity required for its intended use (e.g., ELISA, immunohistochemistry, *in vivo* imaging, immunotoxin therapy). The antibodies are tested for their desired activity by known methods, in accordance with the purpose for which the antibodies are to be used (e.g., ELISA, immunohistochemistry, immunotherapy, etc.; for further guidance on the generation and testing of antibodies, see, e.g., Greenfield, 2014 (Greenfield, 2014)). For example, the antibodies may be tested in ELISA assays or, Western blots, immunohistochemical staining of formalin-fixed cancers or frozen tissue sections. After their initial *in vitro* characterization, antibodies intended for therapeutic or *in vivo* diagnostic use are tested according to known clinical testing methods.

The term "monoclonal antibody" as used herein refers to an antibody obtained from a substantially homogeneous population of antibodies, i.e.; the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. The monoclonal antibodies herein specifically include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies de-

rived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired antagonistic activity (US 4,816,567, which is hereby incorporated in its entirety).

Monoclonal antibodies of the invention may be prepared using hybridoma methods. In a hybridoma method, a mouse or other appropriate host animal is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized *in vitro*.

The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in US 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies).

In vitro methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly Fab fragments, can be accomplished using routine techniques known in the art. For instance, digestion can be performed using papain. Examples of papain digestion are described in WO 94/29348 and US 4,342,566. Papain digestion of antibodies typically produces two identical antigen binding fragments, called Fab fragments, each with a single antigen binding site, and a residual Fc fragment. Pepsin treatment yields a F(ab')₂ fragment and a pFc' fragment.

The antibody fragments, whether attached to other sequences or not, can also include insertions, deletions, substitutions, or other selected modifications of particular regions or specific amino acids residues, provided the activity of the fragment is not significantly altered or impaired compared to the non-modified antibody or antibody fragment. These modifications can provide for some additional property, such as to remove/add amino acids capable of disulfide bonding, to increase its bio-longevity, to alter its secretory characteristics, etc. In any case, the antibody fragment must possess a bioactive prop-

erty, such as binding activity, regulation of binding at the binding domain, etc. Functional or active regions of the antibody may be identified by mutagenesis of a specific region of the protein, followed by expression and testing of the expressed polypeptide. Such methods are readily apparent to a skilled practitioner in the art and can include site-specific mutagenesis of the nucleic acid encoding the antibody fragment.

The antibodies of the invention may further comprise humanized antibodies or human antibodies. Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab' or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.

Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "human-

ized" antibodies are chimeric antibodies (US 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

Transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production can be employed. For example, it has been described that the homozygous deletion of the antibody heavy chain joining region gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge. Human antibodies can also be produced in phage display libraries.

Antibodies of the invention are preferably administered to a subject in a pharmaceutically acceptable carrier. Typically, an appropriate amount of a pharmaceutically-acceptable salt is used in the formulation to render the formulation isotonic. Examples of the pharmaceutically-acceptable carrier include saline, Ringer's solution and dextrose solution. The pH of the solution is preferably from about 5 to about 8, and more preferably from about 7 to about 7.5. Further carriers include sustained release preparations such as semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, liposomes or microparticles. It will be apparent to those persons skilled in the art that certain carriers may be more preferable depending upon, for instance, the route of administration and concentration of antibody being administered.

The antibodies can be administered to the subject, patient, or cell by injection (e.g., intravenous, intraperitoneal, subcutaneous, intramuscular), or by other methods such as infusion that ensure its delivery to the bloodstream in an effective form. The antibodies

may also be administered by intratumoral or peritumoral routes, to exert local as well as systemic therapeutic effects. Local or intravenous injection is preferred.

Effective dosages and schedules for administering the antibodies may be determined empirically, and making such determinations is within the skill in the art. Those skilled in the art will understand that the dosage of antibodies that must be administered will vary depending on, for example, the subject that will receive the antibody, the route of administration, the particular type of antibody used and other drugs being administered. A typical daily dosage of the antibody used alone might range from about 1 ($\mu\text{g/kg}$ to up to 100 mg/kg of body weight or more per day, depending on the factors mentioned above. Following administration of an antibody, preferably for treating glioblastoma, breast cancer, colorectal cancer, renal cell carcinoma, chronic lymphocytic leukemia, hepatocellular carcinoma, non-small cell and small cell lung cancer, Non-Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, pancreatic cancer, prostate cancer, esophageal cancer including cancer of the gastric-esophageal junction, gallbladder cancer and cholangiocarcinoma, melanoma, gastric cancer, testis cancer, urinary bladder cancer, head and neck squamous cell carcinoma (HNSCC), or uterine cancer, the efficacy of the therapeutic antibody can be assessed in various ways well known to the skilled practitioner. For instance, the size, number, and/or distribution of cancer in a subject receiving treatment may be monitored using standard tumor imaging techniques. A therapeutically-administered antibody that arrests tumor growth, results in tumor shrinkage, and/or prevents the development of new tumors, compared to the disease course that would occur in the absence of antibody administration, is an efficacious antibody for treatment of cancer.

It is a further aspect of the invention to provide a method for producing a soluble T-cell receptor (sTCR) recognizing a specific peptide-MHC complex. Such soluble T-cell receptors can be generated from specific T-cell clones, and their affinity can be increased by mutagenesis targeting the complementarity-determining regions. For the purpose of T-cell receptor selection, phage display can be used (US 2010/0113300, (Liddy et al., 2012)). For the purpose of stabilization of T-cell receptors during phage display and in

case of practical use as drug, alpha and beta chain can be linked e.g. by non-native disulfide bonds, other covalent bonds (single-chain T-cell receptor), or by dimerization domains (Boulter et al., 2003; Card et al., 2004; Willcox et al., 1999). The T-cell receptor can be linked to toxins, drugs, cytokines (see, for example, US 2013/0115191), domains recruiting effector cells such as an anti-CD3 domain, etc., in order to execute particular functions on target cells. Moreover, it could be expressed in T cells used for adoptive transfer. Further information can be found in WO 2004/033685A1 and WO 2004/074322A1. A combination of sTCRs is described in WO 2012/056407A1. Further methods for the production are disclosed in WO 2013/057586A1.

In addition, the peptides and/or the TCRs or antibodies or other binding molecules of the present invention can be used to verify a pathologist's diagnosis of a cancer based on a biopsied sample.

The antibodies or TCRs may also be used for *in vivo* diagnostic assays. Generally, the antibody is labeled with a radionucleotide (such as ^{111}In , ^{99}Tc , ^{14}C , ^{131}I , ^3H , ^{32}P or ^{35}S) so that the tumor can be localized using immunoscintigraphy. In one embodiment, antibodies or fragments thereof bind to the extracellular domains of two or more targets of a protein selected from the group consisting of the above-mentioned proteins, and the affinity value (K_d) is less than $1 \times 10\mu\text{M}$.

Antibodies for diagnostic use may be labeled with probes suitable for detection by various imaging methods. Methods for detection of probes include, but are not limited to, fluorescence, light, confocal and electron microscopy; magnetic resonance imaging and spectroscopy; fluoroscopy, computed tomography and positron emission tomography. Suitable probes include, but are not limited to, fluorescein, rhodamine, eosin and other fluorophores, radioisotopes, gold, gadolinium and other lanthanides, paramagnetic iron, fluorine-18 and other positron-emitting radionuclides. Additionally, probes may be bi- or multi-functional and be detectable by more than one of the methods listed. These antibodies may be directly or indirectly labeled with said probes. Attachment of probes to the antibodies includes covalent attachment of the probe, incorporation of the probe into

the antibody, and the covalent attachment of a chelating compound for binding of probe, amongst others well recognized in the art. For immunohistochemistry, the disease tissue sample may be fresh or frozen or may be embedded in paraffin and fixed with a preservative such as formalin. The fixed or embedded section contains the sample are contacted with a labeled primary antibody and secondary antibody, wherein the antibody is used to detect the expression of the proteins in situ.

Another aspect of the present invention includes an *in vitro* method for producing activated T cells, the method comprising contacting *in vitro* T cells with antigen loaded human MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate the T cell in an antigen specific manner, wherein the antigen is a peptide according to the invention. Preferably a sufficient amount of the antigen is used with an antigen-presenting cell.

Preferably the mammalian cell lacks or has a reduced level or function of the TAP peptide transporter. Suitable cells that lack the TAP peptide transporter include T2, RMA-S and Drosophila cells. TAP is the transporter associated with antigen processing.

The human peptide loading deficient cell line T2 is available from the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852, USA under Catalogue No CRL 1992; the Drosophila cell line Schneider line 2 is available from the ATCC under Catalogue No CRL 19863; the mouse RMA-S cell line is described in Ljunggren et al. (Ljunggren and Karre, 1985).

Preferably, before transfection the host cell expresses substantially no MHC class I molecules. It is also preferred that the stimulator cell expresses a molecule important for providing a co-stimulatory signal for T-cells such as any of B7.1, B7.2, ICAM-1 and LFA 3. The nucleic acid sequences of numerous MHC class I molecules and of the co-stimulator molecules are publicly available from the GenBank and EMBL databases.

In case of a MHC class I epitope being used as an antigen, the T cells are CD8-positive T cells.

If an antigen-presenting cell is transfected to express such an epitope, preferably the cell comprises an expression vector capable of expressing a peptide containing SEQ ID NO: 1 to SEQ ID NO: 388, or a variant amino acid sequence thereof.

A number of other methods may be used for generating T cells in vitro. For example, autologous tumor-infiltrating lymphocytes can be used in the generation of CTL. Plebanski et al. (Plebanski et al., 1995) made use of autologous peripheral blood lymphocytes (PLBs) in the preparation of T cells. Furthermore, the production of autologous T cells by pulsing dendritic cells with peptide or polypeptide, or via infection with recombinant virus is possible. Also, B cells can be used in the production of autologous T cells. In addition, macrophages pulsed with peptide or polypeptide, or infected with recombinant virus, may be used in the preparation of autologous T cells. S. Walter et al. (Walter et al., 2003) describe the in vitro priming of T cells by using artificial antigen presenting cells (aAPCs), which is also a suitable way for generating T cells against the peptide of choice. In the present invention, aAPCs were generated by the coupling of preformed MHC:peptide complexes to the surface of polystyrene particles (microbeads) by biotin:streptavidin biochemistry. This system permits the exact control of the MHC density on aAPCs, which allows to selectively elicit high- or low-avidity antigen-specific T cell responses with high efficiency from blood samples. Apart from MHC:peptide complexes, aAPCs should carry other proteins with co-stimulatory activity like anti-CD28 antibodies coupled to their surface. Furthermore such aAPC-based systems often require the addition of appropriate soluble factors, e. g. cytokines, like interleukin-12.

Allogeneic cells may also be used in the preparation of T cells and a method is described in detail in WO 97/26328, incorporated herein by reference. For example, in addition to *Drosophila* cells and T2 cells, other cells may be used to present antigens such as CHO cells, baculovirus-infected insect cells, bacteria, yeast, vaccinia-infected target cells. In addition, plant viruses may be used (see, for example, Porta et al. (Porta et al.,

1994) which describes the development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides.

The activated T cells that are directed against the peptides of the invention are useful in therapy. Thus, a further aspect of the invention provides activated T cells obtainable by the foregoing methods of the invention.

Activated T cells, which are produced by the above method, will selectively recognize a cell that aberrantly expresses a polypeptide that comprises an amino acid sequence of SEQ ID NO: 1 to SEQ ID NO 388.

Preferably, the T cell recognizes the cell by interacting through its TCR with the HLA/peptide-complex (for example, binding). The T cells are useful in a method of killing target cells in a patient whose target cells aberrantly express a polypeptide comprising an amino acid sequence of the invention wherein the patient is administered an effective number of the activated T cells. The T cells that are administered to the patient may be derived from the patient and activated as described above (i.e. they are autologous T cells). Alternatively, the T cells are not from the patient but are from another individual. Of course, it is preferred if the individual is a healthy individual. By "healthy individual" the inventors mean that the individual is generally in good health, preferably has a competent immune system and, more preferably, is not suffering from any disease that can be readily tested for, and detected.

In vivo, the target cells for the CD8-positive T cells according to the present invention can be cells of the tumor (which sometimes express MHC class II) and/or stromal cells surrounding the tumor (tumor cells) (which sometimes also express MHC class II; (Dengjel et al., 2006)).

The T cells of the present invention may be used as active ingredients of a therapeutic composition. Thus, the invention also provides a method of killing target cells in a patient whose target cells aberrantly express a polypeptide comprising an amino acid se-

quence of the invention, the method comprising administering to the patient an effective number of T cells as defined above.

By "aberrantly expressed" the inventors also mean that the polypeptide is over-expressed compared to levels of expression in normal tissues or that the gene is silent in the tissue from which the tumor is derived but in the tumor it is expressed. By "over-expressed" the inventors mean that the polypeptide is present at a level at least 1.2-fold of that present in normal tissue; preferably at least 2-fold, and more preferably at least 5-fold or 10-fold the level present in normal tissue.

T cells may be obtained by methods known in the art, e.g. those described above.

Protocols for this so-called adoptive transfer of T cells are well known in the art. Reviews can be found in: Gattinoni et al. and Morgan et al. (Gattinoni et al., 2006; Morgan et al., 2006).

Another aspect of the present invention includes the use of the peptides complexed with MHC to generate a T-cell receptor whose nucleic acid is cloned and is introduced into a host cell, preferably a T cell. This engineered T cell can then be transferred to a patient for therapy of cancer.

Any molecule of the invention, i.e. the peptide, nucleic acid, antibody, expression vector, cell, activated T cell, T-cell receptor or the nucleic acid encoding it, is useful for the treatment of disorders, characterized by cells escaping an immune response. Therefore any molecule of the present invention may be used as medicament or in the manufacture of a medicament. The molecule may be used by itself or combined with other molecule(s) of the invention or (a) known molecule(s).

The present invention is further directed at a kit comprising:

(a) a container containing a pharmaceutical composition as described above, in solution or in lyophilized form;

- 143 -

- (b) optionally a second container containing a diluent or reconstituting solution for the lyophilized formulation; and
- (c) optionally, instructions for (i) use of the solution or (ii) reconstitution and/or use of the lyophilized formulation.

The kit may further comprise one or more of (iii) a buffer, (iv) a diluent, (v) a filter, (vi) a needle, or (vii) a syringe. The container is preferably a bottle, a vial, a syringe or test tube; and it may be a multi-use container. The pharmaceutical composition is preferably lyophilized.

Kits of the present invention preferably comprise a lyophilized formulation of the present invention in a suitable container and instructions for its reconstitution and/or use. Suitable containers include, for example, bottles, vials (e.g. dual chamber vials), syringes (such as dual chamber syringes) and test tubes. The container may be formed from a variety of materials such as glass or plastic. Preferably the kit and/or container contain/s instructions on or associated with the container that indicates directions for reconstitution and/or use. For example, the label may indicate that the lyophilized formulation is to be reconstituted to peptide concentrations as described above. The label may further indicate that the formulation is useful or intended for subcutaneous administration.

The container holding the formulation may be a multi-use vial, which allows for repeat administrations (e.g., from 2-6 administrations) of the reconstituted formulation. The kit may further comprise a second container comprising a suitable diluent (e.g., sodium bicarbonate solution).

Upon mixing of the diluent and the lyophilized formulation, the final peptide concentration in the reconstituted formulation is preferably at least 0.15 mg/mL/peptide (=75 µg) and preferably not more than 3 mg/mL/peptide (=1500 µg). The kit may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.

- 144 -

Kits of the present invention may have a single container that contains the formulation of the pharmaceutical compositions according to the present invention with or without other components (e.g., other compounds or pharmaceutical compositions of these other compounds) or may have distinct container for each component.

Preferably, kits of the invention include a formulation of the invention packaged for use in combination with the co-administration of a second compound (such as adjuvants (e.g. GM-CSF), a chemotherapeutic agent, a natural product, a hormone or antagonist, an anti-angiogenesis agent or inhibitor, an apoptosis-inducing agent or a chelator) or a pharmaceutical composition thereof. The components of the kit may be pre-complexed or each component may be in a separate distinct container prior to administration to a patient. The components of the kit may be provided in one or more liquid solutions, preferably, an aqueous solution, more preferably, a sterile aqueous solution. The components of the kit may also be provided as solids, which may be converted into liquids by addition of suitable solvents, which are preferably provided in another distinct container.

The container of a therapeutic kit may be a vial, test tube, flask, bottle, syringe, or any other means of enclosing a solid or liquid. Usually, when there is more than one component, the kit will contain a second vial or other container, which allows for separate dosing. The kit may also contain another container for a pharmaceutically acceptable liquid. Preferably, a therapeutic kit will contain an apparatus (e.g., one or more needles, syringes, eye droppers, pipette, etc.), which enables administration of the agents of the invention that are components of the present kit.

The present formulation is one that is suitable for administration of the peptides by any acceptable route such as oral (enteral), nasal, ophthal, subcutaneous, intradermal, intramuscular, intravenous or transdermal. Preferably, the administration is s.c., and most preferably i.d. administration may be by infusion pump.

Since the peptides of the invention were isolated from glioblastoma, breast cancer, colorectal cancer, renal cell carcinoma, chronic lymphocytic leukemia, hepatocellular carcinoma, non-small cell and small cell lung cancer, Non-Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, pancreatic cancer, prostate cancer, esophageal cancer including cancer of the gastric-esophageal junction, gallbladder cancer and cholangiocarcinoma, melanoma, gastric cancer, testis cancer, urinary bladder cancer, or uterine cancer, the medicament of the invention is preferably used to treat glioblastoma, breast cancer, colorectal cancer, renal cell carcinoma, chronic lymphocytic leukemia, hepatocellular carcinoma, non-small cell and small cell lung cancer, Non-Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, pancreatic cancer, prostate cancer, esophageal cancer including cancer of the gastric-esophageal junction, gallbladder cancer and cholangiocarcinoma, melanoma, gastric cancer, testis cancer, urinary bladder cancer, head and neck squamous cell carcinoma (HNSCC), or uterine cancer.

The present invention further relates to a method for producing a personalized pharmaceutical for an individual patient comprising manufacturing a pharmaceutical composition comprising at least one peptide selected from a warehouse of pre-screened TUMAPs, wherein the at least one peptide used in the pharmaceutical composition is selected for suitability in the individual patient. In one embodiment, the pharmaceutical composition is a vaccine. The method could also be adapted to produce T cell clones for down-stream applications, such as TCR isolations, or soluble antibodies, and other treatment options.

A “personalized pharmaceutical” shall mean specifically tailored therapies for one individual patient that will only be used for therapy in such individual patient, including actively personalized cancer vaccines and adoptive cellular therapies using autologous patient tissue.

As used herein, the term “warehouse” shall refer to a group or set of peptides that have been pre-screened for immunogenicity and/or over-presentation in a particular tumor type. The term “warehouse” is not intended to imply that the particular peptides included

in the vaccine have been pre-manufactured and stored in a physical facility, although that possibility is contemplated. It is expressly contemplated that the peptides may be manufactured *de novo* for each individualized vaccine produced, or may be pre-manufactured and stored. The warehouse (e.g. in the form of a database) is composed of tumor-associated peptides which were highly overexpressed in the tumor tissue of glioblastoma, breast cancer, colorectal cancer, renal cell carcinoma, chronic lymphocytic leukemia, hepatocellular carcinoma, non-small cell and small cell lung cancer, Non-Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, pancreatic cancer, prostate cancer, esophageal cancer including cancer of the gastric-esophageal junction, gallbladder cancer and cholangiocarcinoma, melanoma, gastric cancer, testis cancer, urinary bladder cancer, head and neck squamous cell carcinoma (HNSCC), or uterine cancer patients with various HLA-A HLA-B and HLA-C alleles. It may contain MHC class I and MHC class II peptides or elongated MHC class I peptides. In addition to the tumor associated peptides collected from several cancer tissues, the warehouse may contain HLA-A*02 and HLA-A*24 marker peptides. These peptides allow comparison of the magnitude of T-cell immunity induced by TUMAPS in a quantitative manner and hence allow important conclusion to be drawn on the capacity of the vaccine to elicit anti-tumor responses. Secondly, they function as important positive control peptides derived from a "non-self" antigen in the case that any vaccine-induced T-cell responses to TUMAPs derived from "self" antigens in a patient are not observed. And thirdly, it may allow conclusions to be drawn, regarding the status of immunocompetence of the patient.

TUMAPs for the warehouse are identified by using an integrated functional genomics approach combining gene expression analysis, mass spectrometry, and T-cell immunology (XPresident®). The approach assures that only TUMAPs truly present on a high percentage of tumors but not or only minimally expressed on normal tissue, are chosen for further analysis. For initial peptide selection, glioblastoma, breast cancer, colorectal cancer, renal cell carcinoma, chronic lymphocytic leukemia, hepatocellular carcinoma, non-small cell and small cell lung cancer, Non-Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, pancreatic cancer, prostate cancer, esophageal cancer including

cancer of the gastric-esophageal junction, gallbladder cancer and cholangiocarcinoma, melanoma, gastric cancer, testis cancer, urinary bladder cancer, head and neck squamous cell carcinoma (HNSCC), and uterine cancer samples from patients and blood from healthy donors were analyzed in a stepwise approach:

1. HLA ligands from the malignant material were identified by mass spectrometry
2. Genome-wide messenger ribonucleic acid (mRNA) expression analysis was used to identify genes over-expressed in the malignant tissue compared with a range of normal organs and tissues
3. Identified HLA ligands were compared to gene expression data. Peptides over-presented or selectively presented on tumor tissue, preferably encoded by selectively expressed or over-expressed genes as detected in step 2 were considered suitable TUMAP candidates for a multi-peptide vaccine.
4. Literature research was performed in order to identify additional evidence supporting the relevance of the identified peptides as TUMAPs
5. The relevance of over-expression at the mRNA level was confirmed by redetection of selected TUMAPs from step 3 on tumor tissue and lack of (or infrequent) detection on healthy tissues.
6. In order to assess, whether an induction of *in vivo* T-cell responses by the selected peptides may be feasible, *in vitro* immunogenicity assays were performed using human T cells from healthy donors as well as from cancer patients.

In an aspect, the peptides are pre-screened for immunogenicity before being included in the warehouse. By way of example, and not limitation, the immunogenicity of the peptides included in the warehouse is determined by a method comprising *in vitro* T-cell priming through repeated stimulations of CD8⁺ T cells from healthy donors with artificial antigen presenting cells loaded with peptide/MHC complexes and anti-CD28 antibody.

This method is preferred for rare cancers and patients with a rare expression profile. In contrast to multi-peptide cocktails with a fixed composition as currently developed, the warehouse allows a significantly higher matching of the actual expression of antigens in the tumor with the vaccine. Selected single or combinations of several "off-the-shelf"

peptides will be used for each patient in a multitarget approach. In theory an approach based on selection of e.g. 5 different antigenic peptides from a library of 50 would already lead to approximately 17 million possible drug product (DP) compositions.

In an aspect, the peptides are selected for inclusion in the vaccine based on their suitability for the individual patient based on the method according to the present invention as described herein, or as below.

The HLA phenotype, transcriptomic and peptidomic data is gathered from the patient's tumor material, and blood samples to identify the most suitable peptides for each patient containing "warehouse" and patient-unique (i.e. mutated) TUMAPs. Those peptides will be chosen, which are selectively or over-expressed in the patients tumor and, where possible, show strong *in vitro* immunogenicity if tested with the patients' individual PBMCs.

Preferably, the peptides included in the vaccine are identified by a method comprising: (a) identifying tumor-associated peptides (TUMAPs) presented by a tumor sample from the individual patient; (b) comparing the peptides identified in (a) with a warehouse (database) of peptides as described above; and (c) selecting at least one peptide from the warehouse (database) that correlates with a tumor-associated peptide identified in the patient. For example, the TUMAPs presented by the tumor sample are identified by: (a1) comparing expression data from the tumor sample to expression data from a sample of normal tissue corresponding to the tissue type of the tumor sample to identify proteins that are over-expressed or aberrantly expressed in the tumor sample; and (a2) correlating the expression data with sequences of MHC ligands bound to MHC class I and/or class II molecules in the tumor sample to identify MHC ligands derived from proteins over-expressed or aberrantly expressed by the tumor. Preferably, the sequences of MHC ligands are identified by eluting bound peptides from MHC molecules isolated from the tumor sample, and sequencing the eluted ligands. Preferably, the tumor sample and the normal tissue are obtained from the same patient.

In addition to, or as an alternative to, selecting peptides using a warehousing (database) model, TUMAPs may be identified in the patient *de novo*, and then included in the vaccine. As one example, candidate TUMAPs may be identified in the patient by (a1) comparing expression data from the tumor sample to expression data from a sample of normal tissue corresponding to the tissue type of the tumor sample to identify proteins that are over-expressed or aberrantly expressed in the tumor sample; and (a2) correlating the expression data with sequences of MHC ligands bound to MHC class I and/or class II molecules in the tumor sample to identify MHC ligands derived from proteins over-expressed or aberrantly expressed by the tumor. As another example, proteins may be identified containing mutations that are unique to the tumor sample relative to normal corresponding tissue from the individual patient, and TUMAPs can be identified that specifically target the mutation. For example, the genome of the tumor and of corresponding normal tissue can be sequenced by whole genome sequencing: For discovery of non-synonymous mutations in the protein-coding regions of genes, genomic DNA and RNA are extracted from tumor tissues and normal non-mutated genomic germline DNA is extracted from peripheral blood mononuclear cells (PBMCs). The applied NGS approach is confined to the re-sequencing of protein coding regions (exome re-sequencing). For this purpose, exonic DNA from human samples is captured using vendor-supplied target enrichment kits, followed by sequencing with e.g. a HiSeq2000 (Illumina). Additionally, tumor mRNA is sequenced for direct quantification of gene expression and validation that mutated genes are expressed in the patients' tumors. The resultant millions of sequence reads are processed through software algorithms. The output list contains mutations and gene expression. Tumor-specific somatic mutations are determined by comparison with the PBMC-derived germline variations and prioritized. The *de novo* identified peptides can then be tested for immunogenicity as described above for the warehouse, and candidate TUMAPs possessing suitable immunogenicity are selected for inclusion in the vaccine.

In one exemplary embodiment, the peptides included in the vaccine are identified by: (a) identifying tumor-associated peptides (TUMAPs) presented by a tumor sample from the individual patient by the method as described above; (b) comparing the peptides identi-

- 150 -

fied in a) with a warehouse of peptides that have been prescreened for immunogenicity and overpresentation in tumors as compared to corresponding normal tissue; (c) selecting at least one peptide from the warehouse that correlates with a tumor-associated peptide identified in the patient; and (d) optionally, selecting at least one peptide identified de novo in (a) confirming its immunogenicity.

In one exemplary embodiment, the peptides included in the vaccine are identified by: (a) identifying tumor-associated peptides (TUMAPs) presented by a tumor sample from the individual patient; and (b) selecting at least one peptide identified de novo in (a) and confirming its immunogenicity.

Once the peptides for a personalized peptide based vaccine are selected, the vaccine is produced. The vaccine preferably is a liquid formulation consisting of the individual peptides dissolved in between 20-40% DMSO, preferably about 30-35% DMSO, such as about 33% DMSO.

Each peptide to be included into a product is dissolved in DMSO. The concentration of the single peptide solutions has to be chosen depending on the number of peptides to be included into the product. The single peptide-DMSO solutions are mixed in equal parts to achieve a solution containing all peptides to be included in the product with a concentration of ~2.5 mg/ml per peptide. The mixed solution is then diluted 1:3 with water for injection to achieve a concentration of 0.826 mg/ml per peptide in 33% DMSO. The diluted solution is filtered through a 0.22 μ m sterile filter. The final bulk solution is obtained.

Final bulk solution is filled into vials and stored at -20°C until use. One vial contains 700 μ L solution, containing 0.578 mg of each peptide. Of this, 500 μ L (approx. 400 μ g per peptide) will be applied for intradermal injection.

In addition to being useful for treating cancer, the peptides of the present invention are also useful as diagnostics. Since the peptides were generated from glioblastoma, breast

- 151 -

cancer, colorectal cancer, renal cell carcinoma, chronic lymphocytic leukemia, hepatocellular carcinoma, non-small cell and small cell lung cancer, Non-Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, pancreatic cancer, prostate cancer, esophageal cancer including cancer of the gastric-esophageal junction, gallbladder cancer and cholangiocarcinoma, melanoma, gastric cancer, testis cancer, urinary bladder cancer, head and neck squamous cell carcinoma (HNSCC), or uterine cancer samples and since it was determined that these peptides are not or at lower levels present in normal tissues, these peptides can be used to diagnose the presence of a cancer.

The presence of claimed peptides on tissue biopsies in blood samples can assist a pathologist in diagnosis of cancer. Detection of certain peptides by means of antibodies, mass spectrometry or other methods known in the art can tell the pathologist that the tissue sample is malignant or inflamed or generally diseased, or can be used as a biomarker for glioblastoma, breast cancer, colorectal cancer, renal cell carcinoma, chronic lymphocytic leukemia, hepatocellular carcinoma, non-small cell and small cell lung cancer, Non-Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, pancreatic cancer, prostate cancer, esophageal cancer including cancer of the gastric-esophageal junction, gallbladder cancer and cholangiocarcinoma, melanoma, gastric cancer, testis cancer, urinary bladder cancer, head and neck squamous cell carcinoma (HNSCC), or uterine cancer. Presence of groups of peptides can enable classification or subclassification of diseased tissues.

The detection of peptides on diseased tissue specimen can enable the decision about the benefit of therapies involving the immune system, especially if T-lymphocytes are known or expected to be involved in the mechanism of action. Loss of MHC expression is a well described mechanism by which infected or malignant cells escape immunosurveillance. Thus, presence of peptides shows that this mechanism is not exploited by the analyzed cells.

The peptides of the present invention might be used to analyze lymphocyte responses against those peptides such as T cell responses or antibody responses against the pep-

tide or the peptide complexed to MHC molecules. These lymphocyte responses can be used as prognostic markers for decision on further therapy steps. These responses can also be used as surrogate response markers in immunotherapy approaches aiming to induce lymphocyte responses by different means, e.g. vaccination of protein, nucleic acids, autologous materials, adoptive transfer of lymphocytes. In gene therapy settings, lymphocyte responses against peptides can be considered in the assessment of side effects. Monitoring of lymphocyte responses might also be a valuable tool for follow-up examinations of transplantation therapies, e.g. for the detection of graft versus host and host versus graft diseases.

The present invention will now be described in the following examples which describe preferred embodiments thereof, and with reference to the accompanying figures, nevertheless, without being limited thereto. For the purposes of the present invention, all references as cited herein are incorporated by reference in their entireties.

FIGURES

Figure 1 shows the over-presentation of various peptides in normal tissues (white bars) and different cancers (black bars). Figure 1A) Gene symbol: IGFBPL1, Peptide: LLPLLPLSPSLG (SEQ ID NO: 33) - Tissues from left to right: 1 cell line (1 pancreatic), 1 normal tissue (1 thyroid gland), 22 cancer tissues (5 brain cancers, 1 breast cancer, 1 colon cancer, 1 esophageal cancer, 1 gallbladder cancer, 1 liver cancer, 10 lung cancers, 1 pancreas cancer, 1 stomach cancer); Figure 1B) Gene symbol: HIVEP1, Peptide: NYIPVKNGKQF (SEQ ID NO: 103) - Tissues from left to right: 11 cancer tissues (1 brain cancer, 1 liver cancer, 8 lung cancers, 1 prostate cancer); Figure 1C) Gene symbol: GET4, Peptide: EYLDRIGQLFF (SEQ ID NO: 131) - Tissues from left to right: 2 normal tissues (1 kidney, 1 lung), 41 cancer tissues (2 brain cancers, 1 kidney cancer, 3 liver cancers, 29 lung cancers, 2 prostate cancers, 4 stomach cancers); Figure 1D) Gene symbol: N4BP2, Peptide: FYINGQYQF (SEQ ID NO: 176) - Tissues from left to right: 1 cell line (1 prostate), 3 normal tissues (1 kidney, 1 pituitary gland, 1 skin), 67 cancer tissues (4 brain cancers, 2 liver cancers, 42 lung cancers, 12 prostate cancers, 7 stomach cancers). Figures 1E) to Z) show the over-presentation of various peptides in

different cancer tissues compared to normal tissues. The analyses included data from more than 440 normal tissue samples, and 526 cancer samples. Shown are only samples where the peptide was found to be presented. Figure 1E) Gene symbol: AKR1C1, AKR1C3, Peptide: HLYNNEEQV (SEQ ID NO: 16) - Tissues from left to right: 1 cell line (pancreas), 15 cancer tissues (1 bile duct cancer, 1 esophageal cancer, 6 liver cancers, 5 lung cancers, 2 urinary bladder cancers); Figure 1F) Gene symbol: RPS26P39, RPS26P11, RPS26, RPS26P28, RPS26P20, RPS26P15, RPS26P50, RPS26P2, RPS26P25, RPS26P58, Peptide: YVLPKLYVKL (SEQ ID NO: 35) - Tissues from left to right: 1 normal tissue (1 leukocyte sample), 8 cancer tissues (1 head-and-neck cancer, 3 leukocytic leukemia cancers, 1 myeloid cells cancer, 1 gallbladder cancer, 1 colon cancer, 1 lymph node cancer); Figure 1G) Gene symbol: CLDN4, CLDN3, CLDN14, CLDN6, CLDN9, Peptide: SLLALPQDLQA (SEQ ID NO: 40) - Tissues from left to right: 21 cancer tissues (1 bile duct cancer, 1 breast cancer, 3 colon cancers, 1 rectum cancer, 6 lung cancers, 2 ovarian cancers, 1 prostate cancer, 3 urinary bladder cancers, 3 uterus cancers); Figure 1H) Gene symbol: KLHDC7B, Peptide: VLSPFILTL (SEQ ID NO: 42) - Tissues from left to right: 18 cancer tissues (1 leukocytic leukemia cancer, 1 myeloid cells cancer, 1 breast cancer, 1 kidney cancer, 6 lung cancers, 3 lymph node cancers, 2 ovarian cancers, 2 urinary bladder cancers, 1 uterus cancer); Figure 1I) Gene symbol: ATR, Peptide: SLLSHVIVA (SEQ ID NO: 53) - Tissues from left to right: 3 cell lines (1 blood cell, 2 pancreas), 21 cancer tissues (1 head-and-neck cancer, 1 bile duct cancer, 2 leukocytic leukemia cancers, 1 breast cancer, 2 esophageal cancers, 1 gallbladder cancer, 1 kidney cancer, 1 liver cancer, 2 lung cancers, 4 lymph node cancers, 1 ovarian cancer, 3 skin cancers, 1 urinary bladder cancer); Figure 1J) Gene symbol: PGAP1, Peptide: FITDFYTTV (SEQ ID NO: 66) - Tissues from left to right: 1 cell line (skin), 1 normal tissue (1 colon), 13 cancer tissues (1 head-and-neck cancer, 6 brain cancers, 1 colon cancer, 1 liver cancer, 2 skin cancers, 2 urinary bladder cancers); Figure 1K) Gene symbol: ZNF679, SAPCD2, Peptide: RLLPKVQEV (SEQ ID NO: 325) - Tissues from left to right: 4 cell lines (2 blood cells, 1 kidney, 1 large intestine), 22 cancer tissues (1 myeloid cells cancer, 1 breast cancer, 1 esophageal cancer, 4 colon cancers, 1 rectum cancer, 10 lung cancers, 2 ovarian cancers, 1 stomach cancer, 1 urinary bladder cancer); Figure 1L) Gene symbol: ZDHHC24, Peptide: VLGPGPPL (SEQ ID

- 154 -

NO: 339) - Tissues from left to right: 2 cell lines (1 kidney, 1 pancreas), 19 cancer tissues (4 leukocytic leukemia cancers, 1 myeloid cells cancer, 1 bone marrow cancer, 2 brain cancers, 1 liver cancer, 2 lung cancers, 6 lymph node cancers, 1 skin cancer, 1 uterus cancer); Figure 1M) Gene symbol: ORC1, Peptide: VYVQILQKL (SEQ ID NO: 111) - Tissues from left to right: 1 normal tissue (1 liver), 32 cancer tissues (2 liver cancers, 24 lung cancers, 6 stomach cancers); Figure 1N) Gene symbol: RIF1, Peptide: IYSFHTLSF (SEQ ID NO: 113) - Tissues from left to right: 28 cancer tissues (1 prostate, 1 brain cancer, 25 lung cancers, 2 stomach cancers); Figure 1O) Gene symbol: ANKRD5, Peptide: RYLNKSFVL (SEQ ID NO: 115) - Tissues from left to right: 1 normal tissue (1 stomach), 25 cancer tissues (1 brain cancer, 2 liver cancers, 17 lung cancers, 2 prostate cancers, 3 stomach cancers); Figure 1P) Gene symbol: IGFLR1, Peptide: RYGLPAAWSTF (SEQ ID NO: 121) - Tissues from left to right: 20 cancer tissues (2 liver cancers, 17 lung cancers, 1 stomach cancer); Figure 1Q) Gene symbol: CCR8, Peptide: VYALKVRTI (SEQ ID NO: 145) - Tissues from left to right: 25 cancer tissues (25 lung cancers); Figure 1R) Gene symbol: CLEC5A, Peptide: SYGTVSQIF (SEQ ID NO: 148) - Tissues from left to right: 5 normal tissues (1 liver, 3 lungs, 1 pituitary gland), 100 cancer tissues (10 brain cancers, 4 liver cancers, 74 lung cancers, 1 prostate cancer, 11 stomach cancers); Figure 1S) Gene symbol: FOXJ1, Peptide: IYKWITDNF (SEQ ID NO: 155) - Tissues from left to right: 4 normal tissues (4 kidneys), 53 cancer tissues (10 brain cancers, 1 liver cancer, 26 lung cancers, 1 prostate cancer, 15 stomach cancers); Figure 1T) Gene symbol: IFNG, Peptide: KYTSYILAF (SEQ ID NO: 162) - Tissues from left to right: 3 cell lines (3 prostates), 4 normal tissues (1 liver, 1 lung, 1 pancreas, 1 stomach), 95 cancer tissues (1 kidney cancer, 5 liver cancers, 71 lung cancers, 2 prostate cancers, 16 stomach cancers); Figure 1U) Gene symbol: KLHL11, Peptide: EYFTPLLSGQF (SEQ ID NO: 165) - Tissues from left to right: 10 cancer tissues (10 lung cancers); Figure 1V) Gene symbol: TMEM189, Peptide: LYSPVPFTL (SEQ ID NO: 175) - Tissues from left to right: 42 cancer tissues (4 brain cancers, 1 liver cancer, 30 lung cancers, 7 stomach cancers); Figure 1W) Gene symbol: BUB1, Peptide: EYNSDLHQFF (SEQ ID NO: 345) - Tissues from left to right: 13 cancer tissues (3 brain cancers, 10 lung cancers); Figure 1X) Gene symbol: CASC5, Peptide: IYVIPQPHF (SEQ ID NO: 346) - Tissues from left to right: 21 cancer tissues (3 brain cancers, 1 kid-

- 155 -

ney cancer, 1 liver cancer, 14 lung cancers, 2 stomach cancers); Figure 1Y) Gene symbol: KIF18A, Peptide: VYNEQIRDLL (SEQ ID NO: 354) - Tissues from left to right: 13 cancer tissues (1 brain cancer, 11 lung cancers, 1 stomach cancer); and Figure 1Z) Gene symbol: PSMA8, PSMA7, Peptide: VFSPDGHLF (SEQ ID NO: 360) - Tissues from left to right: 33 cancer tissues (4 liver cancers, 27 lung cancers, 1 prostate cancer, 1 stomach cancer).

Figure 2 shows exemplary expression profiles of source genes of the present invention that are highly over-expressed or exclusively expressed in different cancers in a panel of normal tissues (white bars) and different cancer samples (black bars). Figure 2A) Gene symbol: MXRA5 - Tissues from left to right: 61 normal tissue samples (6 arteries, 1 brain, 1 heart, 2 livers, 2 lungs, 2 veins, 1 adipose tissue, 1 adrenal gland, 5 bone marrows, 1 cartilage, 1 colon, 1 esophagus, 2 gallbladders, 1 kidney, 6 lymph nodes, 1 pancreas, 1 pituitary gland, 1 rectum, 1 skeletal muscle, 1 skin, 1 small intestine, 1 spleen, 1 stomach, 1 thymus, 1 thyroid gland, 5 tracheas, 1 urinary bladder, 1 breast, 5 ovaries, 3 placentas, 1 prostate, 1 testis, 1 uterus) and 70 cancer samples (10 breast cancers, 11 lung cancers, 12 ovary cancers, 11 esophageal cancers, 26 pancreas cancers); Figure 2B) Gene symbol: KIF26B - Tissues from left to right: 61 normal tissue samples (6 arteries, 1 brain, 1 heart, 2 livers, 2 lungs, 2 veins, 1 adipose tissue, 1 adrenal gland, 5 bone marrows, 1 cartilage, 1 colon, 1 esophagus, 2 gallbladders, 1 kidney, 6 lymph nodes, 1 pancreas, 1 pituitary gland, 1 rectum, 1 skeletal muscle, 1 skin, 1 small intestine, 1 spleen, 1 stomach, 1 thymus, 1 thyroid gland, 5 tracheas, 1 urinary bladder, 1 breast, 5 ovaries, 3 placentas, 1 prostate, 1 testis, 1 uterus) and 58 cancer samples (10 breast cancers, 11 lung cancers, 11 esophageal cancers, 26 pancreas cancers); Figure 2C) Gene symbol: IL4I1 - Tissues from left to right: 61 normal tissue samples (6 arteries, 1 brain, 1 heart, 2 livers, 2 lungs, 2 veins, 1 adipose tissue, 1 adrenal gland, 5 bone marrows, 1 cartilage, 1 colon, 1 esophagus, 2 gallbladders, 1 kidney, 6 lymph nodes, 1 pancreas, 1 pituitary gland, 1 rectum, 1 skeletal muscle, 1 skin, 1 small intestine, 1 spleen, 1 stomach, 1 thymus, 1 thyroid gland, 5 tracheas, 1 urinary bladder, 1 breast, 5 ovaries, 3 placentas, 1 prostate, 1 testis, 1 uterus) and 34 cancer samples (11 lung cancers, 12 ovary cancers, 11 esophageal cancers); Figure 2D) Gene

symbol: TP63 - Tissues from left to right: 61 normal tissue samples (6 arteries, 1 brain, 1 heart, 2 livers, 2 lungs, 2 veins, 1 adipose tissue, 1 adrenal gland, 5 bone marrows, 1 cartilage, 1 colon, 1 esophagus, 2 gallbladders, 1 kidney, 6 lymph nodes, 1 pancreas, 1 pituitary gland, 1 rectum, 1 skeletal muscle, 1 skin, 1 small intestine, 1 spleen, 1 stomach, 1 thymus, 1 thyroid gland, 5 tracheas, 1 urinary bladder, 1 breast, 5 ovaries, 3 placentas, 1 prostate, 1 testis, 1 uterus) and 11 esophageal cancer samples

Figure 3 shows exemplary immunogenicity data: flow cytometry results after peptide-specific multimer staining.

Figure 4 shows exemplary results of peptide-specific in vitro CD8⁺ T cell responses of a healthy HLA-A*02⁺ donor. CD8⁺ T cells were primed using artificial APCs coated with anti-CD28 mAb and HLA-A*02 in complex with SEQ ID NO: 2 peptide (A, left panel), SEQ ID NO: 9 peptide (B, left panel) and SEQ ID NO: 331 peptide (C, left panel), respectively. After three cycles of stimulation, the detection of peptide-reactive cells was performed by 2D multimer staining with A*02/ SEQ ID NO: 2 (A), A*02/ SEQ ID NO: 9 (B) or A*02/ SEQ ID NO: 331 (C). Right panels (A, B and C) show control staining of cells stimulated with irrelevant A*02/peptide complexes. Viable singlet cells were gated for CD8⁺ lymphocytes. Boolean gates helped excluding false-positive events detected with multimers specific for different peptides. Frequencies of specific multimer⁺ cells among CD8⁺ lymphocytes are indicated.

Figure 5 shows exemplary results of peptide-specific in vitro CD8⁺ T cell responses of a healthy HLA-A*24⁺ donor. CD8⁺ T cells were primed using artificial APCs coated with anti-CD28 mAb and HLA-A*24 in complex with SEQ ID NO: 99 peptide (A, left panel), SEQ ID NO: 119 peptide (B, left panel), SEQ ID NO: 142 peptide (C, left panel) and SEQ ID NO: 174 peptide (D, left panel), respectively. After three cycles of stimulation, the detection of peptide-reactive cells was performed by 2D multimer staining with A*24/ SEQ ID NO: 99 (A), A*24/ SEQ ID NO: 119 (B), A*24/ SEQ ID NO: 142 (C) or A*24/ SEQ ID NO: 174 (D). Right panels (A, B, C and D) show control staining of cells stimulated with irrelevant A*24/peptide complexes. Viable singlet cells were gated for CD8⁺

- 157 -

lymphocytes. Boolean gates helped excluding false-positive events detected with multimers specific for different peptides. Frequencies of specific multimer+ cells among CD8+ lymphocytes are indicated.

EXAMPLES

EXAMPLE 1

Identification and quantitation of tumor associated peptides presented on the cell surface

Tissue samples

Patients' tumor tissues were obtained under written informed consents of all patients had been given before surgery or autopsy. Tissues were shock-frozen immediately after excision and stored until isolation of TUMAPs at -70°C or below.

Peptides were selected if two conditions were true: (1) Its underlying transcript(s) and/or exon(s) are expressed at very low levels, i.e. the median reads per Kilobase per million reads (RPKM) was required to be less than two, and the 75% quartile was required to be less than 5 for the following organs: brain, blood vessel, heart, liver, lung, blood. In addition, the median RPKM was required to be less than 10 for the following organs: urinary bladder, salivary gland, stomach, adrenal gland, colon, small intestine, spleen, bone marrow, pancreas, muscle, adipose tissue, skin, esophagus, kidney, thyroid gland, pituitary gland, nerve. (2) The peptide was tumor-associated, i.e. found specifically or on tumors or over-expressed compared to a baseline of normal tissues (cf. Example 1).

Sample numbers for HLA-A*02 TUMAP selection were: for pancreatic cancer N=16, for renal cancer N= 20, for colorectal cancer N=28, for esophageal carcinoma including cancer of the gastric-esophageal junction N= 15, for prostate tumors N=35, for hepatocellular carcinoma N=16, for non-small cell lung cancer N=88, for gastric cancer N=29, for breast cancer N=9, for melanoma N=3, for ovarian cancer N=20, for chronic lymphocytic leukemia N=13 (of 12 donors), for urinary bladder cancer N=5, for testis cancer

N=1, for small-cell lung cancer N=18 (of 13 donors), for gallbladder cancer and cholangiocarcinoma N=3, for acute myeloid leukemia N=5 (of 4 donors), for glioblastoma N=40, and for uterine cancer N=5.

Sample numbers for HLA-A*24 TUMAP selection were: for gastric cancer N=44, for prostate tumors N=37, for non-small cell lung cancer N=88, for hepatocellular carcinoma N=15, for renal cancer N=2, for colorectal cancer N=1, and for glioblastoma N=17.

Isolation of HLA peptides from tissue samples

HLA peptide pools from shock-frozen tissue samples were obtained by immune precipitation from solid tissues according to published protocols (Falk et al., 1991; Seeger et al., 1999) with minor modifications using the HLA-A*02-specific antibody BB7.2, the HLA-A, -B, -C-specific antibody W6/32, the HLA class II-specific antibody L243, CNBr-activated sepharose, acid treatment, and ultrafiltration.

Mass spectrometry analyses

The HLA peptide pools as obtained were separated according to their hydrophobicity by reversed-phase chromatography (nanoAcquity UPLC system, Waters) and the eluting peptides were analyzed in LTQ-velos and fusion hybrid mass spectrometers (ThermoElectron) equipped with an ESI source. Peptide pools were loaded directly onto the analytical fused-silica micro-capillary column (75 μm i.d. x 250 mm) packed with 1.7 μm C18 reversed-phase material (Waters) applying a flow rate of 400 nL per minute. Subsequently, the peptides were separated using a two-step 180 minute-binary gradient from 10% to 33% B at a flow rate of 300 nL per minute. The gradient was composed of Solvent A (0.1% formic acid in water) and solvent B (0.1% formic acid in acetonitrile). A gold coated glass capillary (PicoTip, New Objective) was used for introduction into the nanoESI source. The LTQ-Orbitrap mass spectrometers were operated in the data-dependent mode using a TOP5 strategy. In brief, a scan cycle was initiated with a full scan of high mass accuracy in the orbitrap ($R = 30\,000$), which was followed by MS/MS scans also in the orbitrap ($R = 7500$) on the 5 most abundant precursor ions with dynamic exclusion of previously selected ions. Tandem mass spectra were interpreted by

SEQUEST and additional manual control. The identified peptide sequence was assured by comparison of the generated natural peptide fragmentation pattern with the fragmentation pattern of a synthetic sequence-identical reference peptide.

Label-free relative LC-MS quantitation was performed by ion counting i.e. by extraction and analysis of LC-MS features (Mueller et al., 2007). The method assumes that the peptide's LC-MS signal area correlates with its abundance in the sample. Extracted features were further processed by charge state deconvolution and retention time alignment (Mueller et al., 2008; Sturm et al., 2008). Finally, all LC-MS features were cross-referenced with the sequence identification results to combine quantitative data of different samples and tissues to peptide presentation profiles. The quantitative data were normalized in a two-tier fashion according to central tendency to account for variation within technical and biological replicates. Thus each identified peptide can be associated with quantitative data allowing relative quantification between samples and tissues. In addition, all quantitative data acquired for peptide candidates was inspected manually to assure data consistency and to verify the accuracy of the automated analysis. For each peptide a presentation profile was calculated showing the mean sample presentation as well as replicate variations. The profiles juxtapose different cancer samples to a baseline of normal tissue samples. Presentation profiles of exemplary over-presented peptides are shown in Figure 1.

Tables 8 (A and B) and 9 (A and B) show the presentation on various cancer entities for selected peptides, and thus the particular relevance of the peptides as mentioned for the diagnosis and/or treatment of the cancers as indicated (e.g. peptide SEQ ID No. 1 for urinary bladder cancer, esophageal cancer, including cancer of the gastric-esophageal junction, hepatocellular carcinoma, non-small cell lung cancer, and pancreatic cancer, peptide SEQ ID No. 2 for renal cancer, esophageal cancer, including cancer of the gastric-esophageal, glioblastoma, ... etc.).

Table 8A: Overview of presentation of selected HLA-A*02-binding tumor-associated peptides of the present invention across entities. GB = glioblastoma, BRCA = breast

- 160 -

cancer, CRC = colorectal cancer, RCC = renal cell carcinoma, CLL = chronic lymphocytic leukemia, HCC = hepatocellular carcinoma, NSCLC = non-small cell lung cancer, SCLC = small cell lung cancer, NHL = non-Hodgkin lymphoma (8 samples), AML = acute myeloid leukemia, OC = ovarian cancer, PC = pancreatic cancer, cIPC = pancreatic cancer cell lines, PCA = prostate cancer and benign prostate hyperplasia, OSCAR = esophageal cancer, including cancer of the gastric-esophageal junction, GBC_CCC = gallbladder adenocarcinoma and cholangiocarcinoma, MEL = melanoma, GC = gastric cancer, TC = testis cancer, UBC = urinary bladder cancer, UEC = uterine cancer.

SEQ ID No.	Sequence	Peptide Presentation on cancer entities
1	HLYNNEEQV	UBC, OSCAR, HCC, NSCLC, cIPC
2	ALYGKLLKL	RCC, OSCAR, GB, BRCA, CLL, UBC, HCC, SCLC, NSCLC, CRC, OC, GC, NHL
4	ELAEIVFKV	CRC, CLL, NSCLC, GB
5	SLFGQEVYC	HCC, GB, CRC
6	FLDPAQRDL	UBC, NSCLC, GB, AML, cIPC
7	AAAAKVPEV	NSCLC, GB, CRC
8	KLGPFLNNA	GC, GB, cIPC, NSCLC
9	FLGDYVENL	CLL, CRC, UBC
10	KTLDFVNIIL	CLL, GC, GBC_CCC, OSCAR
11	GVLKVFLNV	HCC, NSCLC, GC, OC, OSCAR
12	GLIYEETRGV	GC, OSCAR, NSCLC, NHL
13	VLRDNIQGI	NSCLC, GBC_CCC, OC, GC, BRCA, OSCAR, CRC, GB, UEC, CLL, RCC, UBC, HCC, MEL, SCLC, NHL
15	ALGDYVHAC	HCC, GC
16	PLWGKVFYL	GBC_CCC, NSCLC, GB, cIPC, CRC
17	ILHEHHIFL	RCC, NSCLC
19	TLLPTVLT	RCC, UBC, SCLC
20	ALDGHLYAI	RCC, UBC, GC
21	SLYHRVLLY	RCC, OSCAR, NSCLC
22	MLSDLTLQL	CRC, PCA, RCC, NSCLC, BRCA, GC, SCLC, PC, OSCAR
23	AQTVVVIKA	GC
24	FLWNGEDSAL	PC, CRC
25	IQADDFRTL	GC
26	KVDGVVIQL	OSCAR, GC
27	KVFGDLDQV	OSCAR, GC
29	TLCNKTFTA	PCA, GB
30	TVIDECTRI	GC

- 161 -

31	ALSDETKNNWE V	AML, CLL
32	ILADEAFFSV	CLL, PC, GB, UBC, PCA, CRC, SCLC, HCC, RCC, OC, NSCLC, MEL, OSCAR, cIPC, GC, BRCA, NHL
34	LLPKKTESHKK T	CRC, HCC, NSCLC, GB
35	YVLPKLYVKL	CLL, CRC, NSCLC, GBC_CCC, UBC, OSCAR
36	KLYGIEIEV	NSCLC, GB, RCC
37	ALINDILGELVKL	cIPC, CRC, RCC, HCC
38	KMQEDLVTL	NSCLC, RCC, OC, GC, GBC_CCC, OSCAR, cIPC, GB, BRCA, PCA, PC, UEC, HCC, CRC, SCLC, NHL
39	ALMAVVSGL	OSCAR, GBC_CCC, CLL, BRCA, HCC, UBC, NSCLC, OC, GC, MEL
40	SLLALPQDLQA	PCA, NSCLC, CRC, UBC, OC
41	FVLPLVVTL	OC, OSCAR, CLL, PCA, SCLC, NSCLC, NHL
42	VLSPFILTL	NSCLC, RCC, BRCA, UBC, OC, NHL
43	LLWAGPVTA	CLL, HCC, CRC, NSCLC, RCC, UBC, NHL, TC
44	GLLWQIIKV	CRC, NSCLC, GC
45	VLGPTPELV	CRC, SCLC, GC, cIPC, PC
46	SLAKHGIVAL	PC, NSCLC, CRC, RCC, OC, cIPC, PCA, NHL
47	GLYQAQVNL	NSCLC, SCLC
48	TLDHKPVTV	OC, PCA, NSCLC
49	LLDESKLTL	UBC, OC, PCA, NSCLC, RCC
50	EYALLYHTL	CRC, GC
51	LLLDGDFTL	SCLC, HCC
52	ELLSSIFFL	UBC, NSCLC, CRC, RCC
53	SLLSHVIVA	cIPC, RCC, GBC_CCC, UBC, NSCLC
54	FINPKGWNLL	UBC, NSCLC, cIPC
55	IASAIVNEL	BRCA, GC
56	KILDLTRVL	CRC, NSCLC
57	VLISSTVRL	cIPC, RCC, CLL, NHL
58	ALDDSLTSL	cIPC, PC, GB
59	ALTKILAEI	UBC, NSCLC
60	FLIDTSASM	UBC, SCLC, RCC
61	HLPDFVKQL	BRCA, CLL, GBC_CCC
62	SLFNQEVQI	CLL, NHL
63	TLSSERDFAL	NSCLC, GC
66	FITDFYTTV	GB
67	GVIETVTSI	NSCLC, GC, CRC
68	ALYGFFFKI	UBC
69	GIYDGILHSI	UEC, GB
70	GLFSQHFNL	HCC, NSCLC
71	GLITVDIAL	SCLC, PCA

- 162 -

72	GMIGFQVLL	UBC, OC, CLL, GB, GBC_CCC
74	ILDETLNV	UBC, SCLC, NHL
76	ILLDESNFNHFL	NSCLC
77	IVLSTIASV	cIPc, CRC, PCA
81	VLFLGKLLV	CRC, UBC
82	VLLRVLIL	NSCLC, TC
83	ELLEYPQL	PC, GBC_CCC
84	FLEEEITRV	CRC, GC
85	STLDGSLHAV	OSCAR, PCA, GC
87	YLTEVFLHVV	CLL, NHL
89	YLVAHNLLL	RCC
90	GAVAEVLSSI	GB
92	LLRGPPVARA	cIPc, PC, RCC, UBC, OSCAR
93	SLLTQPIFL	RCC, HCC
321	SLWFKPEEL	GC, BRCA, CLL, PC, GB, UBC, PCA, CRC, SCLC, HCC, MEL, OC, NSCLC, GBC_CCC, OSCAR, cIPc, NHL
322	ALVSGGVAQA	GBC_CCC, OSCAR, BRCA, CLL, UBC, HCC, PC, SCLC, NSCLC, CRC, OC, NHL
323	ILSVVNSQL	CRC, GC, BRCA, OC, CLL, NSCLC, NHL
324	AIFDFCPSV	NSCLC, CRC, GC, MEL, GB, OSCAR, CLL
325	RLLPKVQEV	OSCAR, NSCLC, CRC, SCLC, OC
326	SLLPLVWKI	NSCLC, CRC, GB, RCC, MEL, CLL, TC
327	SIGDIFLKY	GC, GB, CRC, RCC, NSCLC
328	SVDSAPAAV	SCLC, OC, PC, OSCAR, RCC, NSCLC, UBC
329	FAWEPSFRDQV	SCLC, HCC
330	FLWPKEVEL	NSCLC, BRCA, SCLC, OC, CLL, NHL
331	AIWKELISL	GB, CRC
332	AVTKYTSAK	CLL, NSCLC, MEL, NHL
333	GTFLEGVAK	RCC, CLL, HCC
334	GRADALRVL	BRCA, SCLC, CLL
335	VLLAAGPSAA	UBC, CLL, NSCLC, GC, cIPc
336	GLMDGSPHFL	PC, NSCLC
337	KVLGKIEKV	RCC, CRC
339	VLGPGPPPL	NSCLC, cIPc, CLL, NHL
340	SVAKTILKR	NSCLC, OSCAR

Table 8B shows the presentation on additional cancer entities for selected peptides, and thus the particular relevance of the peptides as mentioned for the diagnosis and/or treatment of the cancers as indicated.

Table 8B: Overview of presentation of selected HLA-A*02 peptides across entities. GB = glioblastoma, BRCA = breast cancer, CRC = colorectal cancer, RCC = renal cell carcinoma, CLL = chronic lymphocytic leukaemia, HCC = hepatocellular carcinoma, NSCLC = non-small cell lung cancer, SCLC = small cell lung cancer, NHL = non-Hodgkin lymphoma, AML = acute myeloid leukaemia, OC = ovarian cancer, PC = pancreatic cancer, BPH = prostate cancer and benign prostate hyperplasia, OSCAR = oesophageal cancer, including cancer of the gastric-oesophageal junction, GBC_CCC = gallbladder adenocarcinoma and cholangiocarcinoma, MEL = melanoma, GC = gastric cancer, UBC = urinary bladder cancer, UTC = uterine cancer, HNSCC = head and neck squamous cell carcinoma.

SEQ ID No.	Sequence	Peptide Presentation on cancer entities
1	HLYNNEEQV	GBC_CCC
2	ALYGKLLKL	cIPC, UTC, PCA, MEL, AML
3	TLLGKQVTL	CLL, NSCLC, NHL, AML
5	SLFGQEVYC	GBC_CCC, PCA
6	FLDPAQRDL	MEL
7	AAAQKVPEV	MEL, HNSCC, NHL
8	KLGPFLNA	UTC, HCC
9	FLGDYVENL	UTC, AML, OC, cIPC
12	GLIYEETRGV	AML, UTC, HNSCC
13	VLRDNIQGI	AML, HNSCC
17	ILHEHHIFL	UTC
18	YVLNEEDLQKV	UTC, NSCLC
19	TLLPTVLT	GBC_CCC, BRCA, UTC
22	MLSDLTLQL	MEL
24	FLWNGEDSAL	NSCLC, GC, UTC
28	TLYSMDLMKV	HNSCC, RCC
32	ILADEAFFSV	HNSCC, UTC, AML, GBC_CCC
33	LLLPLLPLSPSLG	MEL, NSCLC, GBC_CCC, GC, cIPC, SCLC, GB, PC, MCC, CRC, HCC
34	LLPKKTESHHKT	UTC
35	YVLPKLYVKL	HNSCC, NHL, AML
36	KLYGIEIEV	UTC
37	ALINDILGELVKL	MEL, UTC
38	KMQEDLVTL	MEL, AML

- 164 -

SEQ ID No.	Sequence	Peptide Presentation on cancer entities
39	ALMAVVSGL	HNSCC, NHL, UTC, AML
40	SLLALPQDLQA	GBC_CCC, BRCA, UTC
41	FVLPLVVT	AML, CRC, BRCA, HNSCC, UTC
42	VLSPFILTL	AML, CLL, UTC
43	LLWAGPVTA	HNSCC
45	VLGPTPELV	OSCAR, GBC_CCC, BRCA
46	SLAKHGIVAL	UBC, HNSCC, GB, CLL, MEL, UTC, HCC
47	GLYQAQVNL	OSCAR
50	EYALLYHTL	GBC_CCC
51	LLLDGDFTL	OSCAR
53	SLLSHVIVA	HCC, AML, OC, OSCAR, HNSCC, MEL, CLL, NHL, BRCA
54	FINPKGWNLL	UTC, HNSCC
55	IASAIVNEL	HCC, GBC_CCC
56	KILDLTRVL	GBC_CCC
57	VLISSTVRL	MEL
59	ALTKILAE	HCC
60	FLIDTSASM	AML, CLL, BRCA, HNSCC, UTC, NHL
61	HLPDFVKQL	MEL, AML
64	GLSSSSYEL	GBC_CCC, HCC
65	KLDGICWQV	GBC_CCC, HCC
66	FITDFYTTV	MEL, UBC, HCC, HNSCC, CRC
67	GVIETVTS	AML
70	GLFSQHFNL	BRCA, UTC, HNSCC, UBC, AML, OSCAR, cIP
71	GLITVDIAL	AML, MEL, UTC
72	GMIGFQVLL	HNSCC, AML
73	GVPDTIATL	GC
74	ILDETLNV	AML, BRCA
75	ILDNVKNLL	AML
77	IVLSTIASV	AML
78	LLWGHPRVA	NSCLC
79	SLVPLQILL	HCC
80	TLDEYLTYL	HCC
81	VLFLGKLLV	HNSCC
86	LLVTSLVVV	HCC, GBC_CCC
88	ILLNTEDLASL	RCC
91	SSLEPQIQPV	MEL, CLL

SEQ ID No.	Sequence	Peptide Presentation on cancer entities
93	SLLTQPIFL	GBC_CCC
321	SLWFKPEEL	UTC, HNSCC, AML
322	ALVSGGVAQA	AML, GC, dPC, UTC, MEL
323	ILSVVNSQL	MEL, GBC_CCC, AML, OSCAR
324	AIFDFCPSV	BRCA, NHL, UTC, AML, HNSCC
325	RLLPKVQEV	AML, BRCA, UBC, GC
326	SLLPLVWKI	AML
327	SIGDIFLKY	MEL, AML
328	SVDSAPAAV	NHL, BRCA, AML, UTC, CLL, HNSCC, MEL
329	FAWEPSFRDQV	GBC_CCC
330	FLWPKEVEL	AML
331	AIWKELISL	MEL, CLL, NSCLC
333	GTFLEGVAK	MEL, NSCLC
334	GRADALRVL	MEL, GBC_CCC, AML
335	VLLAAGPSAA	AML, CRC, UTC, NHL
336	GLMDGSPHFL	MEL
338	LLYDGKLSSA	CRC, UBC, OC
339	VLGPGPPPL	MEL, GB, UTC, AML, HCC
340	SVAKTILKR	NHL

Table 9A: Overview of presentation of selected HLA-A*24-binding tumor-associated peptides of the present invention across entities. GB = glioblastoma, HCC = hepatocellular carcinoma, NSCLC = non-small cell lung cancer, PCA = prostate cancer, GC = gastric cancer, CRC = colorectal cancer, RCC = renal cell carcinoma.

SEQ ID NO.	Sequence	ENTITIES
96	LYSPVPFTL	HCC, NSCLC, GC, GB
97	TYTFLKETF	PCA, HCC, NSCLC, GB
98	VFPRLHNVLF	HCC, NSCLC, GC
99	QYILAVPVL	NSCLC, GC, GB, PCA
100	VYIESRIGTSTSF	GB, HCC, NSCLC, GC
101	IYIPVLPPHL	HCC, NSCLC
102	VYPFENFEF	GC, NSCLC
103	NYIPVKNGKQF	PCA, HCC, NSCLC, GB
104	SYLTWHQQI	PCA, HCC, NSCLC
105	IYNETITDLL	GC, GB, HCC, NSCLC
106	IYNETVRDLL	GC, GB, NSCLC

- 166 -

107	KYFPYLVI	HCC, NSCLC, GC
109	LFITGGQFF	HCC, NSCLC, GC
110	SYPKIIEEF	GB, HCC, NSCLC, GC
111	VYVQILQKL	GC, HCC, NSCLC
112	IYNFVESKL	NSCLC, GC
113	IYSFHTLSF	NSCLC, GC, GB
114	QYLDGTWSL	NSCLC, GC, GB
115	RYLNKSFVL	NSCLC, GC, GB, PCA, HCC
116	AYVIAVHLF	GB, PCA, HCC, NSCLC
117	IYLSDLTYI	HCC, NSCLC, GC, PCA
118	KYLNSVQYI	HCC, NSCLC, GC, GB, PCA
119	VYRVYVTF	NSCLC, GC
120	GYIEHFSWL	HCC, NSCLC, GC
121	RYGLPAAWSTF	HCC, NSCLC, GC
122	EYQARIPEF	NSCLC, GC, GB, PCA, HCC
123	VYTPVLEHL	NSCLC, GC, GB, HCC
124	TYKDYVDLF	GC, RCC, GB, PCA, HCC, NSCLC
125	VFSRDFGLLVF	GC, HCC, NSCLC
126	PYDPALGSPSRLF	NSCLC, GC, PCA, HCC
127	QYFTGNPLF	NSCLC, GC, GB, RCC, PCA
128	VYPFDWQYI	GB, PCA, HCC, NSCLC, GC
129	KYIDYLMTW	NSCLC, GC, GB, PCA, HCC
130	VYAHYHQHF	NSCLC, GC, PCA, HCC
131	EYLDRIGQLFF	NSCLC, GC, RCC, GB, PCA, HCC
132	RYPALFPVL	HCC, NSCLC, GC, GB, PCA
133	KYLEDMKTYF	HCC, NSCLC, GC, GB
134	AYIPTPIYF	PCA, NSCLC, GB
135	VYEAMVPLF	GC, NSCLC
136	IYPEWPVVF	GC
137	EYLHNCSYF	GC, PCA, HCC, NSCLC
138	VYNAVSTSF	NSCLC, GC
139	IFGIFPNQF	PCA, NSCLC
142	VYVDDIYVI	NSCLC, GC
143	KYIFQLNEI	GB, NSCLC
144	VFASLPGFLF	NSCLC, GC
145	VYALKVRTI	NSCLC
147	LYLAFPLAF	NSCLC, GC, PCA, HCC
148	SYGTVSQIF	PCA, HCC, NSCLC, GC, GB
149	SYGTVSQI	HCC, NSCLC, GB
150	IYITRQFVQF	PCA, HCC, NSCLC, GB
151	AYISGLDVF	HCC, NSCLC, PCA
153	VYVPFGGKSMITF	NSCLC

- 167 -

154	VYGVPTPHF	GB, NSCLC
155	IYKWITDNF	HCC, NSCLC, GC, GB
156	YYMELTKLLL	NSCLC, GC, HCC
157	DYIPASGFALF	NSCLC, GB
158	IYEETRGLKVF	HCC, NSCLC, GC
159	IYEETRGL	HCC, NSCLC
160	RYGDGGSSF	PCA, NSCLC, GC
161	KYPDIVQQF	PCA, HCC, NSCLC, GC
162	KYTSYLAF	NSCLC, GC, PCA, HCC
163	RYLTISNLQF	NSCLC
165	EYFTPLLSGQF	NSCLC
166	FYTLPFHLI	HCC, NSCLC
168	RYLEAALRL	NSCLC, GC, GB, PCA, HCC
169	NYITGKGDF	NSCLC, PCA
170	QYPFHVPLL	GC, PCA, HCC, NSCLC
174	VYEKNGYIYF	NSCLC, GB
175	YYTQYSQTI	GB, NSCLC
176	FYINGQYQF	GB, PCA, HCC, NSCLC, GC
177	VYFKAGLDVF	PCA, NSCLC
178	NYSSAVQKF	PCA, HCC, NSCLC, GB
179	TYIPVGLGRLL	NSCLC, GC
180	KYLQVVGMF	NSCLC, GB
182	AYAQLGYLLF	NSCLC
183	PYLQDVPRI	NSCLC, GB
186	VFTTSSNIF	NSCLC, GB
187	AYAANVHYL	NSCLC
188	GKTFNEF	NSCLC
192	RYSTFSEIF	HCC, NSCLC, GC
194	VYQSLNSL	NSCLC
195	AYIKGGWIL	RCC, HCC, NSCLC, GC
196	GYIRGSWQF	NSCLC, GC
197	IFTDIFHYL	HCC, NSCLC, GC, GB
199	SYLNHLNNL	NSCLC
201	GYNPNRVFF	GB, NSCLC
202	RYVEGIVSL	NSCLC
204	EYLSTCSKL	NSCLC, HCC
206	NYLDVATFL	NSCLC, GC, GB, PCA, HCC
207	LYSDAFKFIVF	NSCLC
209	AFIETPIPLF	NSCLC
210	IYAGVGEFSF	NSCLC, GC
215	SYVASFFLL	GC, NSCLC
217	IYISNSIYF	NSCLC, GC
221	KYIGNLDLL	NSCLC, GB
223	TFITQSPLL	NSCLC

- 168 -

225	TYTNTLERL	NSCLC
226	MYLKLVLQF	HCC, GC
228	IYQYVADNF	NSCLC
229	IYQFVADSF	NSCLC
232	YYLSDSPLL	NSCLC, GC
234	SYLPAIWLL	GC
235	VYKDSIYYI	GB, PCA, HCC, NSCLC, GC
236	VYLPKIPSW	HCC, NSCLC
238	SYLEKVRQL	NSCLC
240	YYFFVQEKI	HCC, NSCLC
243	SYLELANTL	PCA, NSCLC
248	AFPTFSVQL	NSCLC
249	RYHPTTCTI	NSCLC
250	KYPDIASPTF	HCC
251	VYTKALSSL	NSCLC, HCC
252	AFGQETNVPLNNF	HCC
253	IYGFFNENF	HCC
254	KYLESSATF	NSCLC
255	VYQKIILKF	HCC
257	IFIDNSTQPLHF	HCC
259	YFIKSPPSQLF	NSCLC, GC
260	VYMNVMTRL	NSCLC
261	GYIKLINFI	GC
262	VYSSQFETI	GB
264	LYTETRLQF	NSCLC
265	SYLNEAFSF	PCA
266	KYTDWTEFL	HCC, NSCLC, GC, GB, PCA
268	IFITKALQI	GC
269	QYPYLQAFF	NSCLC
271	RFLMKSYSF	HCC
274	KQLDIANYELF	NSCLC, GB, HCC
275	KYGTLDVTF	NSCLC
276	QYLDVLHAL	GC, RCC
277	FYTFFPFQQL	GC, RCC, PCA, HCC, NSCLC
280	TYNPNLQDKL	HCC
281	NYSPGLVSLIL	NSCLC
284	DYLKDPVTI	NSCLC
285	VYVGDALLHAI	PCA
286	SYGTILSHI	NSCLC
288	VYPDTVALTF	NSCLC, GC
289	FFHEGQYVF	GC
290	KYGDFKLLEF	PCA, GB
295	SYLVIHERI	NSCLC, GC
296	SYQVIFQHF	NSCLC, GC

297	TYIDTRTVF	PCA, HCC, NSCLC, GC
298	AYKSEVVYF	NSCLC, GB
299	KYQYVLNEF	NSCLC, GC, GB
300	TYP SQLPSL	CRC, GC
301	KFDDVTMLF	NSCLC, GC, HCC
303	LYSVIKEDF	GB, PCA, HCC, NSCLC, GC
304	EYNEVANLF	HCC, NSCLC, GC, RCC, GB, PCA
305	NYENKQYLF	NSCLC, GB, HCC
306	VYP AEQPQI	NSCLC
307	GYAFTLPLF	NSCLC, GC
308	TFDGHGVFF	NSCLC, GC
309	KYYRQTLLF	PCA, HCC, NSCLC, GC, GB
310	IYAPTLLVF	GC, GB, RCC, HCC, NSCLC
311	EYLQNLNHI	PCA
312	SYTSVLSRL	PCA, HCC, NSCLC
313	KYTHFIQSF	NSCLC, GC, RCC, GB, PCA, HCC
314	RYFKGDYSI	GB, HCC
315	FYIPHPVVSF	HCC, NSCLC
316	VYFEGSDFKF	GB, PCA, HCC, NSCLC
317	VFDT SIAQLF	GB, RCC, HCC, NSCLC, GC
318	TYSNSAFQYF	GC, RCC, PCA, HCC, NSCLC
319	KYSDVKNLI	PCA, HCC, NSCLC, GB
320	KFILALKVLF	HCC, NSCLC
341	SYLTQHQR I	PCA, NSCLC
343	NYLGGTSTI	PCA, HCC, GB
344	EYNSDLHQF	GB, RCC, HCC, NSCLC, GC
345	EYNSDLHQFF	GB, NSCLC
346	IYVIPQPHF	NSCLC, GC, GB, HCC
347	VYAEVNSL	GB, NSCLC, GC
348	IYLEHTESI	GC, HCC, NSCLC
349	QYSIISNVF	GC, HCC, NSCLC
350	KYGNFIDKL	NSCLC, GC, HCC
351	IFHEVPLKF	HCC, NSCLC
352	QYGGDLTNTF	NSCLC, GB
353	TYGKIDLGF	HCC, NSCLC, GC, GB
354	VYNEQIRDLL	NSCLC, GC, GB
355	IYVTGGHLF	HCC, NSCLC, GC, RCC, GB, PCA
356	NYMPGQLTI	RCC, NSCLC, GC
357	QFITSTNTF	NSCLC
358	YYSEVPVKL	NSCLC, GB
359	NYGVLHVTF	RCC, HCC, NSCLC

- 170 -

360	VFSPDGHLF	GB, PCA, HCC, NSCLC
361	TYADIGGLDNQI	PCA, NSCLC, GC, GB, RCC
362	VYNYAEQTL	GC, GB, NSCLC
363	SYAELGTTI	GB, NSCLC, GC
365	VFIDHPVHL	NSCLC, GB
366	QYLELAHSL	HCC, NSCLC, GC
367	LYQDHMQYI	HCC, NSCLC, GC, GB, PCA
368	KYQNVKHNL	NSCLC, HCC
369	VYTHEVVTI	NSCLC
370	RFIGIPNQF	PCA
371	AYSHLRVVF	GB, PCA, HCC, NSCLC
373	GYISNGELF	PCA, HCC
375	KYTDYILKI	NSCLC
376	VYTPVASRQSL	HCC, NSCLC, GC, GB, PCA
377	QYTPHSHQF	HCC, NSCLC
378	VYIAELEKI	HCC, NSCLC
380	VYTGIDHHW	NSCLC, GC, RCC, GB, PCA, HCC
382	AYLPPLQQVF	PCA, HCC, NSCLC, GC, RCC, GB
383	RYKPGEPITF	GB, PCA, HCC, NSCLC
384	RYFDVGLHNF	GC, GB, PCA, HCC, NSCLC
385	QYIEELQKF	NSCLC, HCC
386	TFSDVEAHF	HCC, NSCLC, GC, GB
387	KYTEKLEEI	HCC, NSCLC, GB, PCA
388	IYGEKTYAF	HCC, NSCLC, GC, RCC, GB, PCA
389	EYLPEFLHTF	NSCLC
390	RYLWATVTI	GC, HCC, NSCLC
391	LYQILQGIVF	NSCLC, GC, GB, RCC, HCC
392	RYLDLKAIVF	NSCLC, GC, RCC, HCC
393	KYIEAIQWI	HCC, NSCLC
394	FYQPKIQQF	GB, PCA, HCC, NSCLC, GC
395	LYINKANIW	NSCLC, GC, HCC
396	YYHFIFTTL	GB
397	IYNGKLFDL	GB, NSCLC, GC
398	IYNGKLFDLL	CRC, GC, RCC, GB, PCA, HCC, NSCLC
399	SYIDVLPEF	HCC, NSCLC, GC, RCC, GB, PCA
400	KYLEKYYNL	NSCLC
401	VFMKDGFFYF	NSCLC, GC, PCA
402	VWSDVTPLTF	NSCLC, CRC, GC, RCC, GB, PCA, HCC

403	TYKYVDINTF	NSCLC, GC
404	RYLEKFYGL	NSCLC, GC, HCC
405	NYPKSIHSF	NSCLC
406	TYSEKTTLF	NSCLC, GC
407	VYGIRLEHF	HCC, NSCLC, GC, GB
408	QYASRFVQL	GC, GB, HCC, NSCLC
409	YFISHVLAF	GC, NSCLC
410	RFLSGIINF	NSCLC, GC, GB, HCC
411	VYIGHTSTI	NSCLC
412	SYNPLWLRI	GB, RCC, HCC, NSCLC, GC
413	NYLLYVSNF	HCC, NSCLC, GC
414	MYPYIYHVL	HCC, NSCLC, GC, GB, PCA
415	SYQKVIELF	PCA, HCC, NSCLC, CRC, GC, RCC, GB
416	AYSDGHFLF	NSCLC, GC, RCC, GB, PCA, HCC
417	VYKVVGNNL	GB, RCC, HCC, NSCLC, GC

Table 9B shows the presentation on additional cancer entities for selected peptides, and thus the particular relevance of the peptides as mentioned for the diagnosis and/or treatment of the cancers as indicated.

Table 9B: Overview of presentation of selected HLA-A*24 peptides across cancer entities. GB = glioblastoma, CRC = colorectal cancer, RCC = renal cell carcinoma, HCC = hepatocellular carcinoma, NSCLC = non-small cell lung cancer, PCA = prostate cancer and benign prostate hyperplasia, GC = gastric cancer.

SEQ ID No.	Sequence	Peptide Presentation on cancer entities
50	EYALLYHTL	PCA, HCC, NSCLC, CRC, GC, RCC
104	SYLTWHQQI	GB
108	PYLVIHTL	NSCLC
110	SYPKIIEEF	PCA
132	RYPALFPVL	RCC
135	VYEAMVPLF	HCC
140	RYLINSYDF	NSCLC
141	SYNGHLTIWF	GB
146	NYYERIHAI	NSCLC
148	SYGTVSQIF	CRC

- 172 -

SEQ ID No.	Sequence	Peptide Presentation on cancer entities
152	KFFDDLGDLELF	NSCLC
155	IYKWITDNF	PCA
164	HYVPATKVF	NSCLC
167	RYGFYYVEF	GB
171	NYEDHFPLL	NSCLC
172	VFIFKGNEF	NSCLC
173	QYLEKYYNL	NSCLC
181	VYPPYLYNL	PCA
184	IYSVGAFENF	NSCLC
185	QYLVHVNDL	GB
189	AYFKQSSVF	NSCLC
190	LYSELTETL	NSCLC
191	TYPDGTYTGRIF	NSCLC
193	LYLENNAAQTQF	NSCLC
198	DYVGFTLKI	NSCLC
200	VFIHHL PQF	HCC
203	VYNVEVKNAEF	NSCLC
204	EYLSTCSKL	PCA
205	VYPVVLNQL	NSCLC
208	TYLEKIDGF	NSCLC
211	VFKSEGAYF	NSCLC
212	SYAPPSEDLF	NSCLC
213	SYAPPSEDLFL	NSCLC
214	KYLMELTLI	NSCLC
216	FYVNVKEQF	NSCLC
218	LYSELNKWSF	NSCLC
219	SYLKAVFNL	NSCLC
220	SYSEIKDFL	NSCLC
222	HYSTLVHMF	NSCLC
224	PYFFANQEF	HCC
227	IYRFITERF	NSCLC
230	TYGMVMVTF	NSCLC
231	AFADVSVKF	NSCLC
233	QYLTAAALHNL	NSCLC
237	KYVGQLAVL	HCC
239	VYAIFRILL	GC
241	SYVKVLHHL	HCC
242	VYGEPRELL	HCC

SEQ ID No.	Sequence	Peptide Presentation on cancer entities
244	VHFEDTGKTLLF	NSCLC
245	LYPQLFVVL	GC
246	KYLSVQLTL	NSCLC
247	SFTKTSPNF	HCC
256	VFGKSAYLF	NSCLC
258	AYAQLGYLL	NSCLC
263	RYILENHDF	HCC
267	SFLNIEKTEILF	HCC
270	YYSQESKVLYL	HCC
272	RYVFPLPYL	NSCLC
273	IYGEKLQFIF	NSCLC
278	KYVNLVMYF	NSCLC
279	VWLPASVLF	NSCLC
282	NYLVDPVTI	NSCLC
283	EYQEIFQQL	NSCLC
287	IYNPNLLTASKF	NSCLC
291	YYLGSGRETF	NSCLC, GB, PCA, HCC
292	FYPQIINTF	NSCLC
293	VYPHFSTTNLI	HCC
294	RFPVQGTVTF	PCA
302	LYLPVHYGF	NSCLC
342	NYAFLHRTL	NSCLC
344	EYNSDLHQF	PCA
348	IYLEHTESI	GB
350	KYGNFIDKL	PCA
364	KYLNENQLSQL	NSCLC
372	VYVIEPHSMEF	NSCLC
374	VFLPRVTEL	NSCLC
379	VFIAQGYTL	NSCLC
381	KYPASSSVF	RCC, NSCLC

EXAMPLE 2

Expression profiling of genes encoding the peptides of the invention

Over-presentation or specific presentation of a peptide on tumor cells compared to normal cells is sufficient for its usefulness in immunotherapy, and some peptides are tu-

mor-specific despite their source protein occurring also in normal tissues. Still, mRNA expression profiling adds an additional level of safety in selection of peptide targets for immunotherapies. Especially for therapeutic options with high safety risks, such as affinity-matured TCRs, the ideal target peptide will be derived from a protein that is unique to the tumor and not found on normal tissues, and a high tumor-to-normal ratio of gene expression indicates a therapeutic window. Moreover, over-expression of source genes in tumor entities that were not yet analyzed for peptide presentation indicates that a certain peptide may be of importance in the respective entity.

For HLA class I-binding peptides of this invention, normal tissue expression of all source genes was shown to be minimal based on a database of RNASeq data covering around 3000 normal tissue samples (Lonsdale, 2013). In addition, gene expression data from tumors vs normal tissues were analyzed to assess target coverage in various tumor entities.

RNA sources and preparation

Surgically removed tissue specimens were provided as indicated above (see Example 1) after written informed consent had been obtained from each patient. Tumor tissue specimens were snap-frozen immediately after surgery and later homogenized with mortar and pestle under liquid nitrogen. Total RNA was prepared from these samples using TRI Reagent (Ambion, Darmstadt, Germany) followed by a cleanup with RNeasy (QIAGEN, Hilden, Germany); both methods were performed according to the manufacturer's protocol.

Total RNA from healthy human tissues for RNASeq experiments was obtained from: Asterand (Detroit, MI, USA and Royston, Herts, UK); Bio-Options Inc. (Brea, CA, USA); ProteoGenex Inc. (Culver City, CA, USA); Geneticist Inc. (Glendale, CA, USA); Istituto Nazionale Tumori "Pascale" (Naples, Italy); University Hospital of Heidelberg (Heidelberg, Germany); BioCat GmbH (Heidelberg, Germany), BioServe (Beltsville, MD, USA), Capital BioScience Inc. (Rockville, MD, USA).

Total RNA from tumor tissues for RNASeq experiments was obtained from: Asterand (Detroit, MI, USA & Royston, Herts, UK), Bio-Options Inc. (Brea, CA, USA), BioServe (Beltsville, MD, USA), Geneticist Inc. (Glendale, CA, USA), ProteoGenex Inc. (Culver City, CA, USA), Tissue Solutions Ltd (Glasgow, UK), University Hospital Bonn (Bonn, Germany), University Hospital Heidelberg (Heidelberg, Germany), University Hospital Tübingen (Tübingen, Germany)

Quality and quantity of all RNA samples were assessed on an Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany) using the RNA 6000 Pico LabChip Kit (Agilent).

RNAseq experiments

Gene expression analysis of tumor and normal tissue RNA samples was performed by next generation sequencing (RNAseq) by CeGaT (Tübingen, Germany). Briefly, sequencing libraries are prepared using the Illumina HiSeq v4 reagent kit according to the provider's protocol (Illumina Inc., San Diego, CA, USA), which includes RNA fragmentation, cDNA conversion and addition of sequencing adaptors. Libraries derived from multiple samples are mixed equimolar and sequenced on the Illumina HiSeq 2500 sequencer according to the manufacturer's instructions, generating 50 bp single end reads. Processed reads are mapped to the human genome (GRCh38) using the STAR software. Expression data are provided on transcript level as RPKM (Reads Per Kilobase per Million mapped reads, generated by the software Cufflinks) and on exon level (total reads, generated by the software Bedtools), based on annotations of the ensembl sequence database (Ensembl77). Exon reads are normalized for exon length and alignment size to obtain RPKM values.

Exemplary expression profiles of source genes of the present invention that are highly over-expressed or exclusively expressed in different cancers are shown in Figure 2. Expression scores for further exemplary targets are shown in Table 10 (A and B), based on in-house RNASeq analyses. Expression data for other entities and further exemplary peptides are summarized in Table 11, based on data generated by the TCGA Research Network: <http://cancergenome.nih.gov/>.

Table 10A: Target coverage within various tumor entities, for expression of source genes of selected peptides. Over-expression was defined as more than 1.5-fold higher expression on a tumor compared to the relevant normal tissue that showed highest expression of the gene. <19% over-expression = I, 20-49% = II, 50-69% = III, >70% = IV. If a peptide could be derived from several source genes, the gene with minimal coverage was decisive. The baseline included the following relevant normal tissues: adipose tissue, adrenal gland, artery, bone marrow, brain, cartilage, colon, esophagus, gallbladder, heart, kidney, liver, lung, lymph node, pancreas, pituitary, rectum, skeletal muscle, skin, small intestine, spleen, stomach, thymus, thyroid gland, trachea, urinary bladder and vein. In case expression data for several samples of the same tissue type were available, the arithmetic mean of all respective samples was used for the calculation.

[illegible]

- 177 -

SEQ ID NO.	Sequence	AML (N=7)	BRCA (N=10)	CLL (N=10)	CRC (N=20)	GB (N=24)	HCC (N=15)	pNSCLC (N=11)	OC (N=12)	OSCAR (N=11)	PC (N=26)	RCC (N=10)	SCLC (N=10)
36	KLYGIEIEV	I	I	I	I	II	I	I	I	I	I	I	I
39	ALMAVVSGL	I	I	IV	I	I	I	I	I	I	I	I	I
42	VLSPFILTL	I	I	I	I	I	I	I	I	II	I	I	I
44	GLLWQIIKV	I	I	I	III	I	I	I	I	I	I	I	I
45	VLGPTPELV	I	I	I	I	I	I	I	I	I	II	I	I
46	SLAKHGIVAL	I	II	I	I	I	I	I	I	I	I	I	I
47	GLYQAQVNL	I	I	I	II	II	II	III	I	IV	II	I	II
49	LLDESKLTL	I	I	I	I	I	I	I	I	I	I	III	I
50	EYALLYHTL	I	I	I	II	I	I	I	I	I	I	II	I
51	LLLDGDFTL	I	I	I	I	I	III	I	I	I	I	I	I
52	ELLSSIFFL	I	I	I	I	I	I	II	I	II	I	II	II
53	SLLSHVIVA	I	II	I	II	I	I	II	II	II	I	I	II
54	FINPKGWNLL	I	I	I	I	I	I	II	I	I	II	I	I
55	IASAIVNEL	I	II	II	I	II	I	II	II	I	I	I	II
59	ALTKILAEI	I	I	I	I	I	I	I	I	I	I	I	II
63	TLSSERDFAL	I	I	I	I	I	III	I	I	I	I	II	I
64	GLSSSSYEL	I	I	I	I	I	III	I	I	I	I	I	I
65	KLDGICWQV	I	I	I	I	I	II	I	I	I	I	I	I
67	GVIETVTSI	IV	I	I	I	I	I	I	I	I	I	I	I
69	GIYDGILHSI	I	I	I	II	II	II	II	II	II	I	I	II
70	GLFSQHFNL	III	I	I	I	I	I	I	I	II	I	I	I
73	GVPDTIATL	I	I	I	II	I	I	I	I	I	I	I	I
75	ILDNVKNLL	IV	I	I	I	I	I	I	I	I	I	I	I
78	LLWGHPRVA	I	IV	I	II	I	I	III	III	IV	III	I	I
79	SLVPLQILL	I	I	I	I	I	II	I	I	I	I	I	I
80	TLDEYLTYL	I	I	I	I	I	II	I	II	I	I	I	I
81	VLFLGKLLV	I	I	II	II	III	II	I	II	II	II	II	IV
84	FLEEEITRV	I	I	I	I	I	I	I	I	I	I	I	II
86	LLVTSLVVV	I	I	I	I	I	III	I	I	I	I	I	I
88	ILLNTEDLASL	I	I	I	I	I	I	I	I	I	I	II	II
91	SSLEPQIQPV	I	II	II	I	II	I	I	II	III	I	II	I
322	ALVSGGVAQA	I	III	I	I	I	I	I	III	III	II	I	I
323	ILSVVNSQL	I	I	IV	II	I	I	I	I	I	I	I	I
324	AIFDFCPSV	I	I	IV	I	I	I	I	I	I	I	I	I
325	RLLPKVQEV	I	I	I	I	II	I	I	I	I	I	I	I
327	SIGDIFLKY	I	II	I	III	II	I	IV	III	III	II	I	IV

- 178 -

SEQ ID NO.	Sequence	AML (N=7)	BRCA (N=10)	CLL (N=10)	CRC (N=20)	GB (N=24)	HCC (N=15)	pNSCLC (N=11)	OC (N=12)	OSCAR (N=11)	PC (N=26)	RCC (N=10)	SCLC (N=10)
328	SVDSAPAAV	I	I	I	I	I	I	I	I	I	I	I	II
329	FAWEPSFRDQV	I	I	I	I	I	III	I	I	I	I	I	I
331	AIWKELISL	I	I	I	I	II	I	I	I	I	I	I	III
332	AVTKYTSK	I	II	I	I	I	II	I	I	I	I	I	II
334	GRADALRVL	I	I	IV	I	I	I	I	I	I	I	I	I
335	VLLAAGPSAA	I	I	II	I	I	I	I	I	I	I	I	II
336	GLMDGSPHFL	I	II	I	I	I	I	I	I	I	I	I	I
337	KVLGKIEKV	I	II	I	I	I	I	I	I	I	I	I	II
338	LLYDGLSSA	I	II	I	I	I	I	I	I	I	I	I	II
96	YYTQYSQTI	I	IV	I	II	I	I	III	III	IV	III	I	I
98	VFPRLHNVLF	I	I	I	I	I	I	I	I	I	I	I	II
100	VYIESRIGTSTSF	I	II	I	I	I	I	I	II	II	I	I	II
101	IYIPVLPPHL	I	IV	I	I	I	I	IV	III	III	I	I	I
103	NYIPVKNGKQF	I	I	III	I	I	I	I	I	I	I	I	I
106	IYNETVRDLL	I	I	I	I	I	I	I	II	I	I	I	I
107	KYFPYLVVI	I	II	I	I	I	I	I	II	III	I	II	I
108	PYLVIHTL	I	II	I	I	I	I	I	II	III	I	II	I
110	SYPKIIIEEF	I	I	III	I	I	I	I	I	I	I	I	I
113	IYSFHTLSF	I	I	I	I	II	I	I	I	I	I	I	III
114	QYLDGTWSL	I	IV	I	II	II	I	IV	II	IV	III	I	II
115	RYLNKSFVL	I	II	I	II	I	I	I	III	I	I	I	II
117	IYLSDLTYI	I	I	IV	I	I	I	I	I	I	I	I	I
118	KYLNSVQYI	I	I	IV	I	I	I	I	I	I	I	I	I
119	VYRVYVTF	I	I	I	I	I	I	II	I	II	I	I	I
121	RYGLPAAWSTF	I	I	IV	I	I	I	I	I	I	I	I	I
123	VYTPVLEHL	I	III	I	II	III	I	III	III	II	I	I	IV
124	TYKDYVDLF	I	III	I	II	III	I	III	III	II	I	I	IV
125	VFSRDFGLLVF	I	III	I	II	III	I	III	III	II	I	I	IV
126	PYDPALGSPSRLF	I	I	I	II	I	III	I	II	I	I	I	I
127	QYFTGNPLF	I	I	I	I	I	I	I	I	I	I	I	II
132	RYPALFPVL	I	I	I	I	I	I	I	II	I	I	I	I
135	VYEAMVPLF	I	I	I	I	I	I	I	I	I	I	I	II
138	VYNAVSTSF	I	I	I	I	I	I	I	I	I	I	I	II
139	IFGIFPNQF	IV	I	I	I	I	I	I	I	I	I	I	I
140	RYLINSYDF	I	I	I	I	I	I	II	I	I	I	I	II
141	SYNGHLTIWF	I	I	I	I	III	I	I	I	I	I	I	I

[illegible]

[illegible]

- 181 -

SEQ ID NO.	Sequence	AML (N=7)	BRCA (N=10)	CLL (N=10)	CRC (N=20)	GB (N=24)	HCC (N=15)	pNSCLC (N=11)	OC (N=12)	OSCAR (N=11)	PC (N=26)	RCC (N=10)	SCLC (N=10)
274	KQLDIANYELF	I	III	I	I	II	I	I	II	I	I	I	II
276	QYLDVLHAL	I	II	I	I	I	I	I	II	II	I	II	II
277	FYTFPFQQL	I	I	I	I	I	I	I	I	I	I	I	II
278	KYVNLVMYF	I	I	I	I	I	I	I	II	I	I	I	I
279	VWLPASVLF	I	I	I	I	I	I	I	I	I	I	I	II
282	NYLVDPVTI	I	II	I	I	I	I	I	III	I	I	I	I
283	EYQEIFQQL	I	II	I	I	I	I	I	III	I	I	I	I
287	IYNPNLLTASKF	I	III	I	I	I	I	I	III	III	I	I	I
291	YYLGSGRETF	I	I	I	I	II	I	II	II	III	I	I	II
292	FYPQIINTF	I	I	I	I	II	I	I	I	I	I	I	I
293	VYPHFSTTNLI	I	I	I	I	II	I	I	I	I	I	I	I
294	RFPVQGTVTF	I	IV	I	I	I	I	I	II	I	I	I	I
295	SYLVIHERI	I	I	II	I	II	I	I	III	I	I	I	II
300	TYPESQLPSL	I	I	I	II	I	I	I	I	I	I	I	I
302	LYLPVHYGF	I	I	I	II	I	I	I	I	I	I	I	II
304	EYNEVANLF	I	I	I	I	II	I	I	I	I	I	I	I
307	GYAFTLPLF	I	II	I	II	II	I	I	II	I	I	II	II
308	TFDGHGVFF	I	I	I	II	I	I	I	I	II	I	I	I
309	KYYRQTLLF	I	I	I	I	I	I	I	III	IV	I	II	II
310	IYAPTLLVF	I	II	II	I	I	I	I	I	I	I	I	I
314	RYFKGDYSI	I	I	I	I	II	I	I	I	I	I	I	I
315	FYIPHPVVSF	I	I	I	I	I	III	I	I	I	I	I	I
320	KFILALKVLF	I	I	I	I	I	I	I	I	I	I	I	II
342	NYAFLHRTL	II	I	I	I	I	I	I	II	III	I	I	I
343	NYLGGTSTI	I	II	I	I	I	II	I	I	I	I	I	II
344	EYNSDLHQF	I	I	I	I	I	I	I	I	I	I	I	II
345	EYNSDLHQFF	I	I	I	I	I	I	I	I	I	I	I	II
348	IYLEHTESI	I	I	II	I	I	I	I	I	I	I	I	I
350	KYGNFIDKL	I	I	I	I	I	I	I	II	I	I	I	I
351	IFHEVPLKF	I	I	I	I	I	I	I	I	I	I	I	II
352	QYGGDLTNTF	I	I	I	I	I	I	II	I	I	II	I	I
353	TYGKIDLGF	I	I	I	I	I	I	I	I	I	I	I	II
354	VYNEQIRDLL	I	I	I	I	I	I	I	I	I	I	I	II
355	IYVTGGHLF	I	I	I	I	I	I	I	I	II	I	I	I
356	NYMPGQLTI	I	I	I	II	I	I	II	II	I	II	II	I
358	YYSEVPVKL	I	IV	I	II	I	I	III	III	IV	III	I	I

SEQ ID NO.	Sequence	AML (N=7)	BRCA (N=10)	CLL (N=10)	CRC (N=20)	GB (N=24)	HCC (N=15)	pNSCLC (N=11)	OC (N=12)	OSCAR (N=11)	PC (N=26)	RCC (N=10)	SCLC (N=10)
359	NYGVLHVTF	II	I	II	II	II	III	I	I	I	I	II	II
360	VFSPDGHLF	I	II	I	I	I	I	I	I	I	I	I	I
361	TYADIGGLDNQI	II	I	I	I	I	I	I	I	I	I	I	I
363	SYAELGTTI	I	I	I	I	II	I	I	I	II	I	I	I
364	KYLNENQLSQL	I	I	I	I	I	I	I	I	I	I	I	III
365	VFIDHPVHL	I	I	I	I	II	I	I	I	I	I	I	II
366	QYLELAHSL	I	I	I	I	I	I	I	II	I	I	I	II
367	LYQDHMQYI	I	I	I	I	I	I	I	I	II	I	I	I
368	KYQNVKHNL	I	I	I	I	I	I	I	I	I	I	I	II
371	AYSHLRYVF	I	I	I	IV	III	I	IV	II	IV	III	III	II
372	VYVIEPHSMEF	I	I	II	I	I	I	I	I	I	I	I	II
374	VFLPRVTEL	I	III	I	II	III	I	III	III	II	I	I	IV
376	VYTPVASRQSL	I	I	I	I	II	I	I	I	I	I	I	II
377	QYTPHSHQF	I	I	I	I	II	I	II	I	I	I	I	III
378	VYIAELEKI	I	II	I	I	I	I	I	I	I	I	I	II
379	VFIAQGYTL	I	I	I	I	I	I	II	I	II	I	II	II
380	VYTGIDHHW	I	II	I	II	I	I	II	III	IV	I	I	III
381	KYPASSSVF	I	I	I	I	I	I	I	II	I	I	III	I
382	AYLPPLQQVF	I	I	I	I	I	I	I	I	I	I	I	II
383	RYKPGEPITF	II	IV	I	II	I	I	IV	II	II	I	I	II
385	QYIEELQKF	I	I	IV	I	I	I	I	I	I	I	I	I
386	TFSDVEAHF	I	I	I	I	I	I	I	I	I	I	I	II
387	KYTEKLEEI	I	I	I	I	IV	I	I	II	I	I	I	III

Table 10B: Target coverage for source genes of selected peptides. Over-expression was defined as more than 1.5-fold higher expression on a tumor compared to the relevant normal tissue that showed highest expression of the gene. <19% over-expression = I, 20-49% = II, 50-69% = III, >70% = IV. If a peptide could be derived from several source genes, the gene with minimal coverage was decisive. The baseline included the following relevant normal tissues: adipose tissue, adrenal gland, artery, bone marrow, brain, cartilage, colon, esophagus, gallbladder, heart, kidney, liver, lung, lymph node, pancreas, pituitary, rectum, skeletal muscle, skin, small intestine, spleen, stomach, thy-

mus, thyroid gland, trachea, urinary bladder and vein. In case expression data for several samples of the same tissue type were available, the arithmetic mean of all respective samples was used for the calculation. NHL = non-Hodgkin lymphoma, PCA = prostate cancer and benign prostate hyperplasia, GC = gastric cancer, GBC_CCC = gallbladder adenocarcinoma and cholangiocarcinoma, MEL = melanoma, UBC = urinary bladder cancer, UTC = uterine cancer, HNSCC = head and neck small cell carcinoma.

SEQ ID NO.	Sequence	NHL (N=10)	PCA (n=10)	GC (N=11)	GBC_CCC (N=10)	MEL (N=10)	UBC (N=10)	UTC (N=10)	HNSCC (N=10)
2	ALYGKLLKL	I	I	I	I	I	I	I	I
3	TLLGKQVTL	I	I	I	I	I	I	I	I
4	ELAEIVFKV	I	I	I	I	I	I	I	II
9	FLGDYVENL	I	I	I	I	I	I	I	I
12	GLIYEETRGV	II	II	I	I	II	I	I	I
13	VLRDNIQGI	II	II	I	I	II	I	I	I
19	TLLPTVLT	I	I	I	I	I	III	I	I
32	ILADEAFFSV	II	I	I	I	II	I	I	I
34	LLPKKTESHKT	II	I	I	I	I	I	I	I
35	YVLPKLYVKL	I	I	I	I	I	I	I	I
37	ALINDILGELVKL	I	I	I	I	I	I	I	I
39	ALMAVVSGL	II	I	I	I	I	I	I	I
41	FVLPLVVT	I	I	I	I	I	I	I	I
42	VLSPFILTL	I	I	I	II	I	II	I	II
45	VLGPTPELV	I	I	II	II	I	I	I	I
46	SLAKHGIVAL	I	I	I	I	I	I	II	I
47	GLYQAQVNL	I	I	I	II	IV	II	I	III
51	LLLDGDFTL	I	I	I	I	I	I	I	I
53	SLLSHVIVA	III	I	I	II	I	I	II	I
55	IASAIVNEL	II	I	I	II	I	I	I	I
60	FLIDTSASM	I	I	I	I	I	I	I	I
61	HLPDFVKQL	I	I	I	I	I	I	I	I
70	GLFSQHFNL	I	I	I	II	I	II	III	II
96	YYTQYSQTI	I	I	I	II	I	I	I	II
98	VFPRLHNVLF	I	I	I	I	I	I	I	I

- 184 -

SEQ ID NO.	Sequence	NHL (N=10)	PCA (n=10)	GC (N=11)	GBC_CCC (N=10)	MEL (N=10)	UBC (N=10)	UTC (N=10)	HNSSC (N=10)
99	QYILAVPVL	I	I	I	I	I	I	I	I
100	VYIESRIGTSTSF	I	I	I	I	II	I	I	I
101	IYIPVLPPHL	III	III	I	III	I	II	III	III
103	NYIPVKNGKQF	I	I	I	I	I	I	I	I
104	SYLTWHQQI	I	I	I	I	I	I	I	I
105	IYNETITDLL	I	I	I	I	I	I	I	I
110	SYPKIIEEF	II	I	I	I	I	I	I	I
113	IYSFHTLSF	I	I	I	I	I	I	I	II
114	QYLDGTWSL	II	I	II	IV	IV	III	IV	III
116	AYVIAVHLF	I	I	I	I	I	I	I	I
117	IYLSDLTYI	II	I	I	I	I	I	I	I
118	KYLNSVQYI	II	I	I	I	I	I	I	I
119	VYRVYVTTF	I	I	I	I	I	I	II	I
121	RYGLPAAWSTF	I	I	I	I	I	I	I	I
123	VYTPVLEHL	II	I	I	I	II	I	I	I
124	TYKDYVDLF	II	I	I	I	II	I	I	I
126	PYDPALGSPSRLF	I	II	II	II	I	I	III	I
127	QYFTGNPLF	I	I	I	I	I	I	I	I
128	VYPFDWQYI	I	I	I	I	I	I	I	I
132	RYPALFPVL	I	I	I	I	I	I	I	I
135	VYEAMVPLF	I	I	I	I	I	I	I	I
144	VFASLPGLFLF	III	I	I	I	I	I	I	I
145	VYALKVRTI	II	I	I	II	II	II	I	II
147	LYLAFPLAF	I	I	I	I	I	I	I	I
150	IYITRQFVQF	I	I	I	I	II	I	I	I
151	AYISGLDVF	I	I	I	I	I	I	I	III
155	IYKWITDNF	I	I	I	I	I	I	II	I
156	YYMELTKLLL	II	I	I	II	I	I	I	I
158	IYEETRGVLKVF	II	II	I	I	II	I	I	I
161	KYPDIVQQF	II	I	I	I	I	I	I	I
162	KYTSYILAF	II	I	I	II	I	I	I	I
163	RYLTISNLQF	I	I	I	I	I	I	I	I
165	EYFTPLLSGQF	I	I	I	I	I	I	I	I

- 185 -

SEQ ID NO.	Sequence	NHL (N=10)	PCA (n=10)	GC (N=11)	GBC_CCC (N=10)	MEL (N=10)	UBC (N=10)	UTC (N=10)	HNSCC (N=10)
166	FYTLPFHLI	I	I	I	I	I	I	I	I
168	RYLEAALRL	I	I	I	I	II	I	I	I
170	QYPFHVPLL	III	I	I	I	I	I	I	I
171	NYEDHFPLL	I	I	II	I	IV	II	I	II
172	VFIFKGNF	I	I	I	I	I	I	I	I
175	LYSPVPFTL	I	I	I	II	I	I	I	II
176	FYINGQYQF	I	II	I	I	I	I	I	II
177	VYFKAGLDVF	I	III	I	II	I	II	II	I
178	NYSSAVQKF	I	III	I	I	II	I	I	I
179	TYIPVGLGRLL	I	I	I	I	I	I	III	II
180	KYLQVVGMF	I	I	I	I	I	I	I	I
191	TYPDGTYTGRIF	II	I	I	I	I	I	I	I
195	AYIKGGWIL	I	I	I	I	I	I	I	I
197	IFTDIFHYL	I	I	I	I	I	I	I	I
204	EYLSTCSKL	II	II	I	I	I	I	IV	II
206	NYLDVATFL	I	I	I	I	I	I	II	I
235	VYKDSIYYI	IV	I	I	I	I	I	I	I
277	FYTFFPFQQL	I	I	I	I	I	I	I	II
291	YYLGSGRETF	I	I	I	II	II	II	III	III
296	SYQVIFQHF	I	I	I	I	I	I	I	II
297	TYIDTRTVF	I	I	I	I	I	I	III	I
304	EYNEVANLF	I	III	I	I	I	I	I	I
307	GYAFTLPLF	I	II	I	I	I	I	II	I
309	KYYRQTLLF	I	I	I	I	I	I	II	I
312	SYTSVLSRL	II	I	I	I	II	I	I	I
316	VYFEGSDFKF	II	I	I	I	I	I	I	I
317	VFDTSIAQLF	I	I	I	I	I	I	I	I
318	TYSNSAFQYF	I	I	I	I	I	I	I	I
319	KYSDVKNLI	I	I	I	I	I	I	I	I
326	SLLPLVWKI	I	I	I	I	I	I	I	I
327	SIGDIFLKY	I	I	II	III	I	I	III	II
328	SVDSAPAAV	II	I	I	I	I	I	I	I
330	FLWPKEVEL	II	I	I	I	I	I	I	I

- 186 -

SEQ ID NO.	Sequence	NHL (N=10)	PCA (n=10)	GC (N=11)	GBC_CCC (N=10)	MEL (N=10)	UBC (N=10)	UTC (N=10)	HNSCC (N=10)
331	AIWKELISL	I	I	I	I	I	I	I	II
332	AVTKYTSK	I	I	I	I	I	I	I	I
333	GTFLEGVAK	I	I	I	I	I	I	I	I
334	GRADALRVL	I	I	I	I	I	I	I	I
335	VLLAAGPSAA	III	I	I	I	I	I	I	I
342	NYAFLHRTL	I	I	I	I	I	II	I	I
343	NYLGGTSTI	I	IV	I	I	I	I	II	I
344	EYNSDLHQF	II	I	I	I	I	I	I	I
345	EYNSDLHQFF	II	I	I	I	I	I	I	I
347	VYAEVNSL	I	I	I	I	I	I	I	I
348	IYLEHTESI	I	I	I	I	I	I	I	I
350	KYGNFIDKL	I	I	I	I	I	I	I	I
352	QYGGDLTNTF	I	I	I	II	I	II	I	I
353	TYGKIDLGF	II	I	I	I	I	I	I	I
354	VYNEQIRDLL	I	I	I	I	I	I	I	I
355	IYVTGGHLF	I	I	I	II	I	II	I	II
356	NYMPGQLTI	I	I	II	II	I	I	I	I
359	NYGVLHVTF	IV	I	I	I	II	I	I	I
360	VFSPDGHLF	II	I	I	I	I	I	I	I
361	TYADIGGLDNQI	I	I	I	I	I	I	I	I
362	VYNYAEQTL	I	I	I	I	I	I	I	I
363	SYAELGTTI	I	I	I	I	I	I	I	I
365	VFIDHPVHL	I	I	I	I	I	I	I	I
366	QYLELAHSL	I	I	I	I	I	I	I	I
367	LYQDHMQYI	I	I	I	I	I	I	I	I
371	AYSHLRYVF	I	I	III	II	I	IV	I	II
376	VYTPVASRQSL	II	I	I	II	I	II	I	I
380	VYTGIDHHW	II	I	I	II	I	I	I	II
383	RYKPGEPITF	II	III	I	III	I	II	III	II
386	TFSDVEAHF	II	I	I	I	I	I	I	I
387	KYTEKLEEI	I	I	I	I	I	I	I	I

Table 11: Target coverage within various tumor entities, for expression of source genes of selected peptides. A gene was considered over-expressed if its expression level in a tumor sample was more than 2-fold above the highest 75% percentile of expression levels determined from samples of the following normal organs (adjacent to tumors): rectum (n=10), esophagus (n=11), bladder (n=19), kidney (n=129), stomach (n=35), colon (n=41), head and neck (n=43), liver (n=50), lung (n=51), thyroid (n=59), lung (n=59).

Over-expression categories are indicated as "A" (>=50% of tumors above the cutoff), "B" (>= 20% of tumors above the cutoff, but <50%), and "C" (>=5% of tumors above the cutoff, but <20%).

ACC=Adrenocortical carcinoma (N=79), BLCA=Bladder urothelial carcinoma (N=408), LGG=Lower grade glioma (N=534), CESC=Cervical squamous cell carcinoma and endocervical adenocarcinoma (N=307), STAD=Stomach adenocarcinoma (N=415), CHOL=Cholangiocarcinoma (N=36), MESO=Mesothelioma (N=87), KICH=Kidney chromophobe (N=66), PRAD=Prostate adenocarcinoma (N=498), DLBC=Lymphoid neoplasm diffuse large B-cell lymphoma (N=48), PCPG=Pheochromocytoma and paraganglioma (N=184), KIRP=Kidney renal papillary cell carcinoma (N=291), SKCM=Skin cutaneous melanoma (N=473), SARC=Sarcoma (N=263), THCA=Thyroid carcinoma (N=513), THYM=Thymoma (N=120), UCS=Uterine carcinosarcoma (N=57), UCEC=Uterine corpus endometrial carcinoma (N=546), UVM=Uveal melanoma (N=80), TGCT=Testicular germ cell tumors (N=156), HNSC=Head and neck squamous cell carcinoma (N=521)

SEQ CD NO.	ACC(N=79)	BLCA(N=408)	CESC(N=307)	CHOL(N=36)	DLBC(N=48)	HNSC(N=521)	KICH(N=66)	KIRP(N=291)	LGG(N=534)	MESO(N=87)	PCPG(N=184)	PRAD(N=498)	SARC(N=263)	SKCM(N=473)	STAD(N=415)	TGCT(N=156)	THCA(N=513)	THYM(N=120)	UCEC(N=546)	UCS(N=57)	UVM(N=80)
16		C	C	C		C		C													
2																					
3																					
4		B	C		B	B							C		C	A			C	C	

SEQ CD NO.	ACG(N=79)	BLCA(N=408)	CESC(N=307)	CHOL(N=36)	DLBC(N=48)	HNSC(N=521)	KICH(N=66)	KIRP(N=291)	LG(N=534)	MESO(N=87)	PCPG(N=184)	PRAD(N=498)	SARC(N=263)	SKCM(N=473)	STAD(N=415)	TGCT(N=156)	THCA(N=513)	THYM(N=120)	UCEC(N=546)	UCS(N=57)	UVM(N=80)
5												C									
6	C								C												
8																					
9																					
10																					
11	C	B	B	B	A	C	C		C	C	B	A	C	B	B	B	C	A	A	B	C
12	C	B	B	B	A	C	C		C	C	B	A	C	B	B	B	C	A	A	B	C
13	C	B	B	B	A	C	C		C	C	B	A	C	B	B	B	C	A	A	B	C
1		C	B		B	C			C	C			C	C	C	A		B	C	B	
17							B	A		C				C	C		A				B
18							B	A		C				C	C		A				B
21											C	B									
22											C	B									
24			C								C	B							C		
27																					
28													C								
29													C								
30																					
31		C	C			B							C	C	C	B				B	C
32		C	C			B							C	C	B	B				B	C
34		C	C		B										C	B		B	B	C	
35																					
36				C				C	B	C											
37																					
38											C										
39				C	B																
40		C	C	A		C				C	C				C	A	A	C	B	A	
42		A	A		B	B	B	C		C			C	C	C		C	A	C		
45															B						
47		C	C	C	C	B				C			C	B	C	C					C

SEQ CD NO.	ACC(N=79)	BLCA(N=408)	CESC(N=307)	CHOL(N=36)	DLBC(N=48)	HNSC(N=521)	KICH(N=66)	KIRP(N=291)	LG(N=534)	MESO(N=87)	PCPG(N=184)	PRAD(N=498)	SARC(N=263)	SKCM(N=473)	STAD(N=415)	TGCT(N=156)	THCA(N=513)	THYM(N=120)	UCEC(N=546)	UCS(N=57)	UVM(N=80)
237	C	A	A	C	A	A			C	B			B	A	A	A		A	B	A	
238		C	C			B			C	C			C			B		B			
240						C		C	C				C	C	B	C			C	C	
241	C	B	C			C					C		C	A	B	C			C	C	
242	C	C				C							C	B	C	B				C	
243						C							C	C	C	C					
244		B	B		C	A				C			B	B	C	C	C	C		C	
247		C	C	C		A	A														
249						C															
250	C								A	C	C		B	B		C				B	
251	C	B	A	C	A	B			C	C	B		A	B	B	A		C	B	B	
253		C								B	B		C			C	C	C	A	A	
255													C	C		B				C	
256				C											B						
258								C							B						
259			C	C								C	C		B				B		
262	C								B				C			B					
263													C								
264		C	A			C							C		C			C	B	C	
265													C								
266				C	C				B												
267												C									
268																					
269		C	A	A		C		B		C			B		B		C	B	C	C	
270																C					
271															C	A					
272												B			C			C			
273	C	C	B		A	C			C				C	C	B	A		A	C	C	B
274				C						C			C								
276													C	A		C				C	A

SEQ CD NO.	ACC(N=79)	BLCA(N=408)	CESC(N=307)	CHOL(N=36)	DLBC(N=48)	HNSC(N=521)	KICH(N=66)	KIRP(N=291)	LG(N=534)	MESO(N=87)	PCPG(N=184)	PRAD(N=498)	SARC(N=263)	SKCM(N=473)	STAD(N=415)	TGCT(N=156)	THCA(N=513)	THYM(N=120)	UCEC(N=546)	UCS(N=57)	UVM(N=80)
315				C												C					
316																					
317																B					C
319					B	B															
320	C	B	B		B				B				B	B	B	A		C	C	A	
341									B				C						C	C	
342		C	C		C	C													C		
343								C				B									
344		B	B		A	B				C			B	B	A	A		B	B	A	
345		B	B		A	B				C			B	B	A	A		B	B	A	
346		C	B		B	B			C				B	C	A	A		C	C		
347													B								C
348		B	A		A	C				C			C	B	C	A		B	B	B	
349															C	B					
350															C	C					
351																					
352		C	C	C		C									C		C	C			
353	C	B	A	C	A	A			C	B			B	B	A	A		B	B	A	
354	C	B	A	C	B	B				B			B	B	A	A		B	B	A	
355		A	A		B	B		C		C			C	C	C		C	A	C		
356								B													
357		C	B	C	C	C		C		B					C				A	C	
358	C		C			C				B			B		B		C	C		C	
359	C				B	C							C	C						C	
360		C	C		B	C							C	C						B	
361		C	C		C	C				C			C	C		B		C	B	C	
363		C	C	C		C			B				C		C						
364		B	A	C	C	B							B	C	A	A		C	B	C	
365									C												
366	C	B	A	C	B	B							C	B	A	A		C	B	A	C

SEQ CD NO.	ACC(N=79)	BLCA(N=408)	CESC(N=307)	CHOL(N=36)	DLBC(N=48)	HNSC(N=521)	KICH(N=66)	KIRP(N=291)	LG(N=534)	MESO(N=87)	PCPG(N=184)	PRAD(N=498)	SARC(N=263)	SKCM(N=473)	STAD(N=415)	TGCT(N=156)	THCA(N=513)	THYM(N=120)	UCEC(N=546)	UCS(N=57)	UVM(N=80)
367																C					
368					B	B									B	C		B	B	B	
369	C	B	A			C		B					C	C	C	C		A	B	C	
371					A	C			C			C	C	B	B	C					
372		B	A	C									C	C	B	C					
373						B			C				C	C	B	B				B	C
374		C	C							B			C	B	C	B					C
375						C				C			C	B	C	B					
376		C	C		C	C							C	C	C	C					
377	C												C	C	C	C			C	C	
378		C	A			C								C	C	C					
379						C							C	C	C	B			C	B	C
380		C	C			C							C	C	C	C					C
382																C					
383																					
385				C	B										C						
386			C		C	C					B		C	C	B	C			C	C	
387									B				C	C		C					
388						C															
389		C	B			B											C	C			
390	C	B	A	C	B	B				A			B	B	A	A		B	C	B	
391	C	B	A		B	B							B	C	B	C		B	B	B	
392	B	B	A	C	B	B				C		A	B	B	B	A		B	C	B	
393													B	C	C		A				
394		B	A	C	A	B			C	C			B	B	B	A		A	B	B	
395									A		B		C	C	C	B					
396									A				C	C	B	A					C
397		A	A	C	A	A			C	C			B	B	B	A		A	B	A	
398		A	A	C	A	A			C	C			B	B	B	A		A	B	A	
399							B	A	C	C				C	C	C	A				B

SEQ CD NO.	ACC(N=79)	BLCA(N=408)	CESC(N=307)	CHOL(N=36)	DLBC(N=48)	HNSC(N=521)	KICH(N=66)	KIRP(N=291)	LG(N=534)	MESO(N=87)	PCPG(N=184)	PRAD(N=498)	SARC(N=263)	SKCM(N=473)	STAD(N=415)	TGCT(N=156)	THCA(N=513)	THYM(N=120)	UCEC(N=546)	UCS(N=57)	UVM(N=80)
400			B		B	A				C			C	C	A				C	C	
401		B	B		B	A	C	A		C		C	C	C	A	B	B		C	C	
402	C	A	A	A	C	A				A	C	C	A	B	A	B	B		A	A	
403		C	B		B	B									B	B					
404		C	B		B	B									B	B					
405		C	B		B	B									B	B					
406		C	B	C	C	C				B					C	A			A	C	
407	C	A	A	C	A	B			C	C			B	B	B	A		A	B	A	
408		B	A		B	B							B	C	B	A		B	B	B	
409		B	A		B	B							C	C	B	B		B	C		
410	C	A	A	C	A	B			C	C			B	B	B	A		A	B	A	
412	C	B	A	C	B	B				A			B	B	A	A		B	C	B	
413															C						
414									A				C			C					
415	C	C	B		C	C			C				C	B	B	C		C	C	C	
416									C					B							
417	C	B	A	B		B			C	C			B	B	A	A			B	B	

EXAMPLE 3

In vitro immunogenicity for MHC class I presented peptides

In order to obtain information regarding the immunogenicity of the TUMAPs of the present invention, the inventors performed investigations using an *in vitro* T-cell priming assay based on repeated stimulations of CD8⁺ T cells with artificial antigen presenting cells (aAPCs) loaded with peptide/MHC complexes and anti-CD28 antibody. This way the inventors could show immunogenicity for HLA-A*02:01 restricted TUMAPs of the invention, demonstrating that these peptides are T-cell epitopes against which CD8⁺ precursor T cells exist in humans (Table 9).

In vitro priming of CD8⁺ T cells

In order to perform *in vitro* stimulations by artificial antigen presenting cells loaded with peptide-MHC complex (pMHC) and anti-CD28 antibody, the inventors first isolated CD8⁺ T cells from fresh HLA-A*02 leukapheresis products via positive selection using CD8 microbeads (Miltenyi Biotec, Bergisch-Gladbach, Germany) of healthy donors obtained from the University clinics Mannheim, Germany, after informed consent.

PBMCs and isolated CD8⁺ lymphocytes were incubated in T-cell medium (TCM) until use consisting of RPMI-Glutamax (Invitrogen, Karlsruhe, Germany) supplemented with 10% heat inactivated human AB serum (PAN-Biotech, Aidenbach, Germany), 100 U/ml Penicillin/100 µg/ml Streptomycin (Cambrex, Cologne, Germany), 1 mM sodium pyruvate (CC Pro, Oberdorla, Germany), 20 µg/ml Gentamycin (Cambrex), 2.5 ng/ml IL-7 (PromoCell, Heidelberg, Germany) and 10 U/ml IL-2 (Novartis Pharma, Nürnberg, Germany) were also added to the TCM at this step.

Generation of pMHC/anti-CD28 coated beads, T-cell stimulations and readout was performed in a highly defined *in vitro* system using four different pMHC molecules per stimulation condition and 8 different pMHC molecules per readout condition.

The purified co-stimulatory mouse IgG2a anti human CD28 Ab 9.3 (Jung et al., 1987) was chemically biotinylated using Sulfo-N-hydroxysuccinimidobiotin as recommend-

ed by the manufacturer (Perbio, Bonn, Germany). Beads used were 5.6 µm diameter streptavidin coated polystyrene particles (Bangs Laboratories, Illinois, USA).

pMHC used for positive and negative control stimulations were A*0201/MLA-001 (peptide ELAGIGILTV (SEQ ID NO. 418) from modified Melan-A/MART-1) and A*0201/DDX5-001 (YLLPAIVHI from DDX5, SEQ ID NO. 419), respectively.

800.000 beads / 200 µl were coated in 96-well plates in the presence of 4 x 12.5 ng different biotin-pMHC, washed and 600 ng biotin anti-CD28 were added subsequently in a volume of 200 µl. Stimulations were initiated in 96-well plates by co-incubating 1×10^6 CD8+ T cells with 2×10^5 washed coated beads in 200 µl TCM supplemented with 5 ng/ml IL-12 (PromoCell) for 3 days at 37°C. Half of the medium was then exchanged by fresh TCM supplemented with 80 U/ml IL-2 and incubating was continued for 4 days at 37°C. This stimulation cycle was performed for a total of three times. For the pMHC multimer readout using 8 different pMHC molecules per condition, a two-dimensional combinatorial coding approach was used as previously described (Andersen et al., 2012) with minor modifications encompassing coupling to 5 different fluorochromes. Finally, multimeric analyses were performed by staining the cells with Live/dead near IR dye (Invitrogen, Karlsruhe, Germany), CD8-FITC antibody clone SK1 (BD, Heidelberg, Germany) and fluorescent pMHC multimers. For analysis, a BD LSRII SORP cytometer equipped with appropriate lasers and filters was used. Peptide specific cells were calculated as percentage of total CD8+ cells. Evaluation of multimeric analysis was done using the FlowJo software (Tree Star, Oregon, USA). *In vitro* priming of specific multimer+ CD8+ lymphocytes was detected by comparing to negative control stimulations. Immunogenicity for a given antigen was detected if at least one evaluable *in vitro* stimulated well of one healthy donor was found to contain a specific CD8+ T-cell line after *in vitro* stimulation (i.e. this well contained at least 1% of specific multimer+ among CD8+ T-cells and the percentage of specific multimer+ cells was at least 10x the median of the negative control stimulations).

In vitro immunogenicity for different cancer peptides

For tested HLA class I peptides, *in vitro* immunogenicity could be demonstrated by generation of peptide specific T-cell lines. Exemplary flow cytometry results after

TUMAP-specific multimer staining for 2 peptides of the invention are shown in Figure 3 together with corresponding negative controls. Results for 5 peptides from the invention are summarized in Table 12A. Exemplary flow cytometry results after TUMAP-specific multimer staining for 7 peptides of the invention are shown in Figure 4 and 5 together with corresponding negative controls. Results for 74 peptides from the invention are summarized in Table 12B.

Table 8A: *in vitro* immunogenicity of HLA class I peptides of the invention

Exemplary results of *in vitro* immunogenicity experiments conducted by the applicant for the peptides of the invention. <20 % = +; 20 % - 49 % = ++; 50 % - 69 % = +++; >= 70 % = ++++

Seq ID	Sequence	wells
393	KYIEAIQWI	++
399	SYIDVLPEF	++
400	KYLEKYYNL	++
407	VYGIRLEHF	+++
414	MYPYIYHVL	++

Table 12B: *in vitro* immunogenicity of HLA class I peptides of the invention

Exemplary results of *in vitro* immunogenicity experiments conducted by the applicant for the peptides of the invention. <20 % = +; 20 % - 49 % = ++; 50 % - 69 % = +++; >= 70 % = ++++

Seq ID	Sequence	Wells positive [%]
2	ALYGKLLKL	++++
7	AAAQKVPEV	+
8	KLGPFLNA	+++
9	FLGDYVENL	+
17	ILHEHHIFL	+
43	LLWAGPVTA	++++
322	ALVSGGVAQA	+
331	AIWKELISL	++
96	YYTQYSQTI	+
98	VFPRLHNVLF	+
99	QYILAVPVL	+++
102	VYPFENFEF	+++
103	NYIPVKNGKQF	+
104	SYLTWHQQI	+
105	IYNETITDLL	+
106	IYNETVRDLL	+

Seq ID	Sequence	Wells positive [%]
107	KYFPYLVVI	++
109	LFITGGQFF	++
110	SYPKIIEEF	++
111	VYVQILQKL	+
112	IYNFVESKL	+++
114	QYLDGTWSL	+++
115	RYLNKSFVL	+
119	VYRVYVTTF	+++
120	GYIEHFSLW	++
122	EYQARIPEF	++
132	RYPALFPVL	+
137	EYLNCSYF	+
139	IFGIFPNQF	++
140	RYLINSYDF	+++
142	VYVDDIYVI	++++
144	VFASLPGFLF	++
155	IYKWITDNF	++
156	YYMELTKLLL	+
157	DYIPASGFALF	+
158	IYEETRGVLKVF	+
160	RYGDGGSSF	+
161	KYPDIVQQF	+
162	KYTSYILAF	+
163	RYLTISNLQF	+
164	HYVPATKVF	+
166	FYTLPFHLI	++++
167	RYGFYYVEF	++++
168	RYLEAALRL	+++
170	QYPFHVPLL	+++
171	NYEDHFPLL	++
172	VFIFKGNEF	+
174	VYEKNGYIYF	++++
175	LYSPVPFTL	+
177	VYFKAGLDVF	+
179	TYIPVGLGRLL	+++
180	KYLQVVGMF	+
181	VYPPYLNLY	++++
182	AYAQLGYLLF	+++
186	VFTTSSNIF	+
190	LYSELTETL	++++
277	FYTFPFQQL	+++
344	EYNSDLHQF	+

Seq ID	Sequence	Wells positive [%]
345	EYNSDLHQFF	++
349	QYSIISNVF	++
350	KYGNFIDKL	+++
351	IFHEVPLKF	++
353	TYGKIDLGF	+
354	VYNEQIRDLL	+
356	NYMPGQLTI	+
358	YYSEVPVKL	++++
359	NYGVLHVTF	+
360	VFSPDGHLF	++
363	SYAELGTTI	+
365	VFIDHPVHL	+
366	QYLELAHSL	++
367	LYQDHMQYI	++
371	AYSHLRYVF	++
380	VYTGIDHHW	+

EXAMPLE 4

Synthesis of peptides

All peptides were synthesized using standard and well-established solid phase peptide synthesis using the Fmoc-strategy. Identity and purity of each individual peptide have been determined by mass spectrometry and analytical RP-HPLC. The peptides were obtained as white to off-white lyophilizates (trifluoro acetate salt) in purities of >50%. All TUMAPs are preferably administered as trifluoro-acetate salts or acetate salts, other salt-forms are also possible.

EXAMPLE 5

MHC Binding Assays

Candidate peptides for T cell based therapies according to the present invention were further tested for their MHC binding capacity (affinity). The individual peptide-MHC complexes were produced by UV-ligand exchange, where a UV-sensitive peptide is cleaved upon UV-irradiation, and exchanged with the peptide of interest as analyzed. Only peptide candidates that can effectively bind and stabilize the peptide-receptive MHC molecules prevent dissociation of the MHC complexes. To determine the yield of the exchange reaction, an ELISA was performed based on the detection

of the light chain ($\beta 2m$) of stabilized MHC complexes. The assay was performed as generally described in Rodenko et al. (Rodenko et al., 2006).

96 well MAXISorp plates (NUNC) were coated over night with 2ug/ml streptavidin in PBS at room temperature, washed 4x and blocked for 1h at 37°C in 2% BSA containing blocking buffer. Refolded HLA-A*02:01/MLA-001 monomers served as standards, covering the range of 15-500 ng/ml. Peptide-MHC monomers of the UV-exchange reaction were diluted 100 fold in blocking buffer. Samples were incubated for 1h at 37°C, washed four times, incubated with 2ug/ml HRP conjugated anti- $\beta 2m$ for 1h at 37°C, washed again and detected with TMB solution that is stopped with NH_4SO_4 . Absorption was measured at 450nm. Candidate peptides that show a high exchange yield (preferably higher than 50%, most preferred higher than 75%) are generally preferred for a generation and production of antibodies or fragments thereof, and/or T cell receptors or fragments thereof, as they show sufficient avidity to the MHC molecules and prevent dissociation of the MHC complexes.

Table 13: MHC class I binding scores. Binding of HLA-class I restricted peptides to HLA-A*02 was ranged by peptide exchange yield: <20 % = +; 20 % - 49 % = ++; 50 % - 75 % = +++; >= 75 % = ++++

Seq ID	Sequence	Peptide exchange
1	PLWGKVFYL	++
2	ALYGKLLKL	+++
3	TLLGKQVTL	+++
4	ELAEIVFKV	+++
5	SLFGQEVYC	+++
6	FLDPAQRDL	+++
7	AAAAKVPEV	+++
8	KLGPFLNA	+++
9	FLGDYVENL	++
10	KTLDVFNIL	++
11	GVLKVFLNV	++
12	GLIYEETRGV	++
13	VLRDNIQGI	+++
14	LLDHLSFINKI	++
16	HLYNNEEQV	++
17	ILHEHHIFL	+++
18	YVLNEEDLQKV	+++
19	TLLPTVLT	+++

Seq ID	Sequence	Peptide exchange
20	ALDGHLYAI	+++
21	SLYHRVLLY	++++
22	MLSDLTLQL	++++
23	AQTVVVIKA	+
24	FLWNGEDSAL	+++
25	IQADDFRTL	++
26	KVDGVVIQL	+++
27	KVFGDLDQV	+++
28	TLYSMDLMKV	+++
29	TLCNKTFTA	+++
31	ALSDETKNNWEV	++++
32	ILADEAFFSV	+++
33	LLLPLLPLPSLGL	+++
35	YVLPKLYVKL	++
36	KLYGIEIEV	++++
37	ALINDILGELVKL	+++
38	KMQEDLVTL	+++
39	ALMAVVSGL	+++
40	SLLALPQDLQA	+++
41	FVLPLVVTI	+++
42	VLSPFILTL	+++
43	LLWAGPVTA	+++
44	GLLWQIIKV	++
45	VLGPTPELV	+++
46	SLAKHGIVAL	+++
47	GLYQAQVNL	+++
48	TLDHKPVTI	++
49	LLDESKLTI	+++
50	EYALLYHTI	++
51	LLLDGDFTI	+++
52	ELLSSIFFI	+++
53	SLLSHVIVA	+++
54	FINPKGNWLL	+++
55	IASAIVNEL	++
56	KILDLTRVL	++
57	VLISSTVRL	++
58	ALDDSLTSL	++
59	ALTKILAEI	+++
60	FLIDTSASM	++
61	HLPDFVKQL	++
62	SLFNQEVQI	+++
63	TLSSERDFAL	+

Seq ID	Sequence	Peptide exchange
64	GLSSSSYEL	++
65	KLDGICWQV	+++
66	FITDFYTTV	+++
67	GVIETVTSL	++
69	GIYDGILHSI	+++
70	GLFSQHFNL	+++
71	GLITVDIAL	+++
72	GMIGFQVLL	+++
74	ILDETLENV	++
75	ILDNVKNLL	+++
76	ILLDESNFNHFL	+++
77	IVLSTIASV	+++
78	LLWGHPRVA	+++
79	SLVPLQILL	++++
80	TLDEYLTYL	+++
81	VLFLGKLLV	++
82	VLLRVLIL	++
83	ELLEYLPQL	+++
84	FLEEEITRV	+++
85	STLDGSLHAV	+++
87	YLTEVFLHVV	+++
88	ILLNTEDLASL	+++
89	YLVAHNLLL	+++
90	GAVAEVLSSI	+
91	SSLEPQIQPV	+
92	LLRGPPVARA	++
93	SLLTQPIFL	+++
321	SLWFKPEEL	+++
322	ALVSGGVAQA	+++
323	ILSVVNSQL	+++
324	AIFDFCPSV	++++
325	RLLPKVQEV	++
326	SLLPLVWKI	+++
327	SIGDIFLKY	+++
328	SVDSAPAAV	++
329	FAWEPSFRDQV	++
330	FLWPKEVEL	+++
331	AIWKELISL	+++
333	GTFLEGVAK	+++
334	GRADALRVL	+++
335	VLLAAGPSAA	++
336	GLMDGSPHFL	++

Seq ID	Sequence	Peptide exchange
337	KVLGKIEKV	+++
338	LLYDGKLSSA	++
339	VLGPGPPPL	++
340	SVAKTILKR	++

Table 14: MHC class I binding scores. Binding of HLA-class I restricted peptides to HLA-A*24 was ranged by peptide exchange yield: <20 % = +; 20 % - 49 % = ++; 50 % - 75 % = +++; >= 75 % = ++++

Seq ID	Sequence	Peptide exchange
96	YYTQYSQTI	++++
97	TYTFLKETF	++++
98	VFPRLHNVLF	+++
99	QYILAVPVL	++++
100	VYIESRIGTSTSF	+++
102	VYPFENFEF	+++
103	NYIPVKNGKQF	+++
104	SYLTWHQQI	++++
105	IYNETITDLL	+++
106	IYNETVRDLL	+++
107	KYFPYLVVI	+++
108	PYLVVIHTL	+++
109	LFITGGQFF	++++
110	SYPKIIEEF	+++
111	VYVQILQKL	+++
112	IYNFVESKL	+++
113	IYSFHTLSF	+++
114	QYLDGTWSL	++++
115	RYLNKSFVL	+++
116	AYVIAVHLF	++++
117	IYLSDLTYI	+++
118	KYLNSVQYI	+++
119	VYRVYVTTF	+++
120	GYIEHFSLW	++++
121	RYGLPAAWSTF	+++
122	EYQARIPEF	+++
123	VYTPVLEHL	++
124	TYKDYVDLF	+
125	VFSRDFGLLVF	+++
127	QYFTGNPLF	+++
128	VYPFDWQYI	++++

Seq ID	Sequence	Peptide exchange
129	KYIDYLMTW	++++
131	EYLDRIQLFF	+++
132	RYPALFPVL	++++
133	KYLEDMKTYF	+++
134	AYIPTPIYF	+++
135	VYEAMVPLF	++++
136	IYPEWPVFF	+++
137	EYLNCSYF	++++
138	VYNAVSTSF	++
139	IFGIFPNQF	+++
140	RYLINSYDF	++++
141	SYNGHLTIWF	+++
142	VYVDDIYVI	+++
143	KYIFQLNEI	+++
144	VFASLPGFLF	++++
145	VYALKVRTI	+++
146	NYYERIHAI	+++
147	LYLAFPLAF	+++
148	SYGTVSQIF	++++
149	SYGTVSQI	++++
152	KFFDDLGDLELF	++
153	VYVPFGGKSMITF	++++
154	VYGVPTPHF	++++
155	IYKWITDNF	++++
156	YYMELTKLLL	++++
157	DYIPASGFALF	+++
158	IYEETRGVLKVF	+++
159	IYEETRGVL	+++
160	RYGDGGSSF	+++
161	KYPDIVQQF	+++
162	KYTSYILAF	++
163	RYLTISNLQF	++++
164	HYVPATKVF	+++
165	EYFTPLLSGQF	+++
166	FYTLPFHLI	++++
167	RYGFYYVEF	+++
168	RYLEAALRL	+++
169	NYITGKGDVF	+++
170	QYPFHVPLL	++++
171	NYEDHFPLL	+++
172	VFIFKGNEF	++++
173	QYLEKYYNL	++++

Seq ID	Sequence	Peptide exchange
174	VYEKNGYIYF	+++
175	LYSPVPFTL	+++
176	FYINGQYQF	+++
177	VYFKAGLDVF	+++
178	NYSSAVQKF	+++
179	TYIPVGLGRLL	+++
180	KYLQVVGMF	+++
181	VYPPYLNLY	+++
182	AYAQLGYLLF	++++
183	PYLQDV PRI	+++
184	IYSVGAFENF	++++
185	QYLVHVNDL	++++
186	VFTTSSNIF	++++
187	AYAANVHYL	++++
188	GYKTFFNEF	+++
190	LYSELTETL	+++
191	TYPDGTYTGRIF	+++
192	RYSTFSEIF	+++
193	LYLENNAQTQF	+++
194	VYQSLSNSL	+++
195	AYIKGGWIL	+++
196	GYIRGSWQF	++++
197	IFTDIFHYL	++++
198	DYVGFTLKI	++
199	SYLNHLNNL	+++
200	VFIHHL PQF	+++
201	GYNPNRVFF	+++
202	RYVEGIVSL	+++
204	EYLSTCSKL	+++
205	VYPVVLNQI	+++
206	NYLDVATFL	++++
207	LYSDAFKFIVF	+++
208	TYLEKIDGF	++++
209	AFIETPIPLF	++++
210	IYAGVGEFSF	++++
211	VFKSEGAYF	++++
212	SYAPPS EDLF	++
213	SYAPPS EDLFL	++
214	KYLMELTLI	+++
215	SYVASFFLL	++
216	FYVNVKEQF	+++
217	IYISNSIYF	++++

Seq ID	Sequence	Peptide exchange
218	LYSELNKWSF	+++
219	SYLKAVFNL	+++
220	SYSEIKDFL	++++
221	KYIGNLDLL	++++
223	TFITQSPLL	++++
224	PYFFANQEF	+++
225	TYTNTLERL	+++
226	MYLKLVLQF	++
227	IYRFITERF	+++
228	IYQYVADNF	+++
229	IYQFVADSF	+++
230	TYGMVMVTF	+++
231	AFADVSVKF	++++
232	YYLSDSPLL	+++
233	QYLTAALHNL	+++
234	SYLPAIWLL	+++
235	VYKDSIYYI	+++
236	VYLPKIPSW	+++
237	KYVGQLAVL	+++
239	VYAIFRILL	+++
240	YYFFVQEKI	+++
241	SYVKVLHHL	+++
242	VYGEPRELL	+++
243	SYLELANTL	+++
244	VHFEDTGKTLLF	+++
245	LYPQLFVVL	+++
246	KYLSVQLTL	++
247	SFTKTSPNF	+++
248	AFPTFSVQL	++++
249	RYHPTTCTI	++++
250	KYPDIASPTF	++
251	VYTKALSSL	+++
252	AFGQETNVPLNNF	++++
253	IYGFFNENF	+++
254	KYLESSATF	+++
255	VYQKIILKF	+++
256	VFGKSAYLF	+++
257	IFIDNSTQPLHF	+++
258	AYAQLGYLL	+++
259	YFIKSPPSQLF	++
260	VYMNVMTRL	++++
261	GYIKLINFI	++++

Seq ID	Sequence	Peptide exchange
262	VYSSQFETI	++++
263	RYILENHDF	+++
264	LYTETRLQF	++++
265	SYLNEAFSF	++++
266	KYTDWTEFL	+++
267	SFLNIEKTEILF	++
268	IFITKALQI	++
269	QYPYLQAFF	+++
270	YYSQESKVLYL	+++
271	RFLMKSYSF	++++
272	RYVFPLPYL	++++
273	IYGEKLQFIF	+++
274	KQLDIANYELF	++++
275	KYGTLDVTF	++++
276	QYLDVLHAL	++++
277	FYTFPFQQL	+++
279	VWLPASVLF	+++
280	TYNPNLQDKL	++++
281	NYSPGLVSLIL	+++
282	NYLVDPVTI	+++
283	EYQEIFQQL	+++
284	DYLKDPVTI	+++
285	VYVGDALLHAI	+++
286	SYGTILSHI	++++
287	IYNPNLLTASKF	+++
288	VYPDTVALTF	++
289	FFHEGQYVF	++++
290	KYGDFKLLEF	++++
291	YYLGSGRETF	+++
292	FYPQIINTF	++++
293	VYPHFSTTNLI	++++
294	RFPVQGTVTF	+++
295	SYLVIHERI	+++
296	SYQVIFQHF	++++
297	TYIDTRTVF	++++
298	AYKSEVVYF	++++
299	KYQYVLNEF	+++
300	TYPSQLPSL	+++
301	KFDDVTMLF	++++
302	LYLPVHYGF	+++
303	LYSVIKEDF	+++
304	EYNEVANLF	+++

Seq ID	Sequence	Peptide exchange
305	NYENKQYLF	++++
306	VYPAEQPQI	+++
307	GYAFTLPLF	+++
308	TFDGHGVFF	+++
309	KYYRQTLLF	++
310	IYAPTLLVF	+++
311	EYLQNLNHI	++++
312	SYTSVLSRL	+++
313	KYTHFIQSF	++++
314	RYFKGDYSI	+++
315	FYIPHVPVSF	+++
316	VYFEGSDFKF	+++
317	VFDTSIAQLF	+++
318	TYSNSAFQYF	+++
319	KYSDVKNLI	++++
341	SYLTQHQRI	+++
342	NYAFLHRTL	+++
343	NYLGGTSTI	+++
344	EYNSDLHQF	+++
345	EYNSDLHQFF	+++
347	VYAEVNSL	+++
348	IYLEHTESI	+++
349	QYSIISNVF	+++
350	KYGNFIDKL	+++
351	IFHEVPLKF	+++
352	QYGGDLTNTF	+++
353	TYGKIDLGF	+++
354	VYNEQIRDLL	+++
355	IYVTGGHLF	+++
356	NYMPGQLTI	++++
357	QFITSTNTF	++++
358	YYSEVPVKL	+++
359	NYGVLHVTF	++++
360	VFSPDGHLF	+++
361	TYADIGGLDNQI	+++
362	VYNYAEQTL	++
363	SYAELGTTI	++
364	KYLNENQLSQL	+++
365	VFIDHPVHL	++++
366	QYLELAHSL	+++
367	LYQDHMQYI	++
368	KYQNVKHNH	+++

Seq ID	Sequence	Peptide exchange
369	VYTHEVVTL	+++
370	RFIGIPNQF	+++
371	AYSHLRYVF	++
372	VYVIEPHSMEF	+++
373	GYISNGELF	+++
374	VFLPRVTEL	++
375	KYTDYILKI	+++
376	VYTPVASRQSL	+++
377	QYTPHSHQF	+++
378	VYIAELEKI	+++
379	VFIAQGYTL	++++
380	VYTGIDHHW	++++
381	KYPASSSVF	+++
382	AYLPPLQQVF	+++
383	RYKPGEPITF	+++
384	RYFDVGLHNF	+++
385	QYIEELQKF	+++
386	TFSDVEAHF	+++
387	KYTEKLEEI	+++
388	IYGEKTYAF	+++

EXAMPLE 6

Absolute quantitation of tumor associated peptides presented on the cell surface

The generation of binders, such as antibodies and/or TCRs, is a laborious process, which may be conducted only for a number of selected targets. In the case of tumor-associated and –specific peptides, selection criteria include but are not restricted to exclusiveness of presentation and the density of peptide presented on the cell surface. In addition to the isolation and relative quantitation of peptides as described in Example 1, the inventors did analyze absolute peptide copies per cell as described. The quantitation of TUMAP copies per cell in solid tumor samples requires the absolute quantitation of the isolated TUMAP, the efficiency of TUMAP isolation, and the cell count of the tissue sample analyzed.

Peptide quantitation by nanoLC-MS/MS

For an accurate quantitation of peptides by mass spectrometry, a calibration curve was generated for each peptide using the internal standard method. The internal

standard is a double-isotope-labeled variant of each peptide, i.e. two isotope-labeled amino acids were included in TUMAP synthesis. It differs from the tumor-associated peptide only in its mass but shows no difference in other physicochemical properties (Anderson et al., 2012). The internal standard was spiked to each MS sample and all MS signals were normalized to the MS signal of the internal standard to level out potential technical variances between MS experiments.

The calibration curves were prepared in at least three different matrices, i.e. HLA peptide eluates from natural samples similar to the routine MS samples, and each preparation was measured in duplicate MS runs. For evaluation, MS signals were normalized to the signal of the internal standard and a calibration curve was calculated by logistic regression.

For the quantitation of tumor-associated peptides from tissue samples, the respective samples were also spiked with the internal standard, the MS signals were normalized to the internal standard and quantified using the peptide calibration curve.

Efficiency of peptide/MHC isolation

As for any protein purification process, the isolation of proteins from tissue samples is associated with a certain loss of the protein of interest. To determine the efficiency of TUMAP isolation, peptide/MHC complexes were generated for all TUMAPs selected for absolute quantitation. To be able to discriminate the spiked from the natural peptide/MHC complexes, single-isotope-labeled versions of the TUMAPs were used, i.e. one isotope-labeled amino acid was included in TUMAP synthesis. These complexes were spiked into the freshly prepared tissue lysates, i.e. at the earliest possible point of the TUMAP isolation procedure, and then captured like the natural peptide/MHC complexes in the following affinity purification. Measuring the recovery of the single-labeled TUMAPs therefore allows conclusions regarding the efficiency of isolation of individual natural TUMAPs.

The efficiency of isolation was analyzed in a low number of samples and was comparable among these tissue samples. In contrast, the isolation efficiency differs between individual peptides. This suggests that the isolation efficiency, although determined in only a limited number of tissue samples, may be extrapolated to any other

tissue preparation. However, it is necessary to analyze each TUMAP individually as the isolation efficiency may not be extrapolated from one peptide to others.

Determination of the cell count in solid, frozen tissue

In order to determine the cell count of the tissue samples subjected to absolute peptide quantitation, the inventors applied DNA content analysis. This method is applicable to a wide range of samples of different origin and, most importantly, frozen samples (Alcoser et al., 2011; Forsey and Chaudhuri, 2009; Silva et al., 2013). During the peptide isolation protocol, a tissue sample is processed to a homogenous lysate, from which a small lysate aliquot is taken. The aliquot is divided in three parts, from which DNA is isolated (QiaAmp DNA Mini Kit, Qiagen, Hilden, Germany). The total DNA content from each DNA isolation is quantified using a fluorescence-based DNA quantitation assay (Qubit dsDNA HS Assay Kit, Life Technologies, Darmstadt, Germany) in at least two replicates.

In order to calculate the cell number, a DNA standard curve from aliquots of single healthy blood cells, with a range of defined cell numbers, has been generated. The standard curve is used to calculate the total cell content from the total DNA content from each DNA isolation. The mean total cell count of the tissue sample used for peptide isolation is extrapolated considering the known volume of the lysate aliquots and the total lysate volume.

Peptide copies per cell

With data of the aforementioned experiments, the inventors calculated the number of TUMAP copies per cell by dividing the total peptide amount by the total cell count of the sample, followed by division through isolation efficiency. Copy cell number for selected peptides is shown in Table 15.

Table 15: Absolute copy numbers. The table lists the results of absolute peptide quantitation in tumor samples. The median number of copies per cell are indicated for each peptide: <100 = +; >=100 = ++; >=1,000 +++; >=10,000 = +++. The number of samples, in which evaluable, high quality MS data are available is indicated.

SEQ ID No.	Peptide Code	Copies per cell (median)	Number of samples
70	DNMT3B-001	++	16

323	KIAA0226L-002	++	19
325	ZNF-003	++	14

Reference List

- Aalto, Y. et al., Leukemia **15** (2001): 1721-1728
- Abaan, O. D. et al., Cancer Res **73** (2013): 4372-4382
- Accardi, L. et al., Int.J Cancer **134** (2014): 2742-2747
- Adams, D. J. et al., Mol.Cell Biol **25** (2005): 779-788
- Agha-Hosseini, F. et al., Med.J Islam Repub.Iran **29** (2015): 218
- Agostini, M. et al., Oncotarget. **6** (2015): 32561-32574
- Akiyama, Y. et al., Oncol.Rep. **31** (2014): 1683-1690
- Al-haidari, A. A. et al., Int.J Colorectal Dis. **28** (2013): 1479-1487
- Alcoser, S. Y. et al., BMC.Biotechnol. **11** (2011): 124
- Allison, J. P. et al., Science **270** (1995): 932-933
- Alonso, C. N. et al., Leuk.Res. **36** (2012): 704-708
- Amaro, A. et al., Cancer Metastasis Rev **33** (2014): 657-671
- American Cancer Society, (2015), www.cancer.org
- Ammirante, M. et al., Nature **464** (2010): 302-305
- Ampie, L. et al., Front Oncol. **5** (2015): 12
- An, C. H. et al., Hum.Pathol. **43** (2012): 40-47
- Andersen, R. S. et al., Nat.Protoc. **7** (2012): 891-902
- Anderson, N. L. et al., J Proteome.Res **11** (2012): 1868-1878
- Appay, V. et al., Eur.J Immunol. **36** (2006): 1805-1814
- Arai, E. et al., Int.J Cancer **137** (2015): 2589-2606
- Armitage, J. O., Blood **110** (2007): 29-36
- Armstrong, C. M. et al., Am.J Clin Exp.Urol. **3** (2015): 64-76
- Asahara, S. et al., J Transl.Med. **11** (2013): 291

- Atcheson, E. et al., Biosci.Rep. **31** (2011): 371-379
- Avigan, D. et al., Clin Cancer Res. **10** (2004): 4699-4708
- Azevedo, R. et al., J Control Release **214** (2015): 40-61
- Back, J. M. et al., Biochem.Biophys.Res Commun. **461** (2015): 334-341
- Baker, M. et al., PLoS.One. **8** (2013): e62516
- Banchereau, J. et al., Cell **106** (2001): 271-274
- Bankovic, J. et al., Lung Cancer **67** (2010): 151-159
- Barlin, J. N. et al., Neoplasia. **17** (2015): 183-189
- Batliner, J. et al., Mol.Immunol. **48** (2011): 714-719
- Battistella, M. et al., J Cutan.Pathol. **41** (2014): 427-436
- Beatty, G. et al., J Immunol **166** (2001): 2276-2282
- Becker, M. A. et al., Mol.Cancer Ther. **14** (2015): 973-981
- Beggs, J. D., Nature **275** (1978): 104-109
- Benada, J. et al., Biomolecules. **5** (2015): 1912-1937
- Benjamini, Y. et al., Journal of the Royal Statistical Society.Series B (Methodological), **Vol.57** (1995): 289-300
- Bentz, S. et al., Digestion **88** (2013): 182-192
- Berard, A. R. et al., Proteomics. **15** (2015): 2113-2135
- Berman, R. S. et al., National Cancer Institute: PDQ(R) Colon Cancer Treatment (2015a)
- Berman, R. S. et al., National Cancer Institute: PDQ(R) Rectal Cancer Treatment (2015b)
- Berndt, S. I. et al., Nat Commun. **6** (2015): 6889
- Bie, L. et al., PLoS.One. **6** (2011): e25631
- Bill, K. L. et al., Lab Invest (2015)
- Binsky-Ehrenreich, I. et al., Oncogene **33** (2014): 1006-1016
- Black, J. D. et al., Toxins.(Basel) **7** (2015): 1116-1125
- Bo, H. et al., BMC.Cancer **13** (2013): 496
- Bockelman, C. et al., Cancer Biol Ther. **13** (2012): 289-295
- Boeva, V. et al., PLoS.One. **8** (2013): e72182

- Bogdanov, K. V. et al., *Tsitologiya* **50** (2008): 590-596
- Bogni, A. et al., *Leukemia* **20** (2006): 239-246
- Boldt, H. B. et al., *Endocrinology* **152** (2011): 1470-1478
- Bormann, F. et al., *Mol.Genet.Genomics* **286** (2011): 279-291
- Boulter, J. M. et al., *Protein Eng* **16** (2003): 707-711
- Braumuller, H. et al., *Nature* (2013)
- Bray, F. et al., *Int J Cancer* **132** (2013): 1133-1145
- Brenner, S. et al., *Cancer Lett.* **356** (2015): 517-524
- Bridgewater, J. et al., *J Hepatol.* **60** (2014): 1268-1289
- Brocker, E. B. et al., *Int.J Cancer* **41** (1988): 562-567
- Brossart, P. et al., *Blood* **90** (1997): 1594-1599
- Bruckdorfer, T. et al., *Curr.Pharm.Biotechnol.* **5** (2004): 29-43
- Bryant, N. L. et al., *J Neurooncol.* **101** (2011): 179-188
- Burgess, A. W. et al., *Exp.Cell Res* **317** (2011): 2748-2758
- Butler, J. E. et al., *J Immunol.* **182** (2009): 6600-6609
- Butterfield, L. H. et al., *Clin Cancer Res* **12** (2006): 2817-2825
- Butterfield, L. H. et al., *Clin Cancer Res* **9** (2003): 5902-5908
- Byrd, J. C. et al., *N.Engl.J Med.* **369** (2013): 32-42
- Byrns, M. C. et al., *J Steroid Biochem.Mol.Biol* **125** (2011): 95-104
- Cai, C. J. et al., *Sichuan.Da.Xue.Xue.Bao.Yi.Xue.Ban.* **41** (2010): 941-945
- Camos, M. J. et al., *PLoS.One.* **7** (2012): e49819
- Cao, S. et al., *J Virol.* **89** (2015): 713-729
- Cao, W. et al., *J Biol Chem* **282** (2007): 18922-18928
- Carballido, E. et al., *Cancer Control* **19** (2012): 54-67
- Carbonnelle-Puscian, A. et al., *Leukemia* **23** (2009): 952-960
- Card, K. F. et al., *Cancer Immunol Immunother.* **53** (2004): 345-357
- Carlsten, M. et al., *Cancer Res* **67** (2007): 1317-1325
- Carr, J. C. et al., *Surgery* **152** (2012): 998-1007

- Carr, J. C. et al., *Ann.Surg.Oncol* **20 Suppl 3** (2013): S739-S746
- Cassoni, P. et al., *J Neuroendocrinol*. **16** (2004): 362-364
- Catellani, S. et al., *Blood* **109** (2007): 2078-2085
- Cavard, C. et al., *J Pathol*. **218** (2009): 201-209
- Chae, Y. K. et al., *Oncotarget*. **6** (2015): 37117-37134
- Chang, Y. S. et al., *Cancer Chemother.Pharmacol*. **59** (2007): 561-574
- Chanock, S. J. et al., *Hum.Immunol*. **65** (2004): 1211-1223
- Chapiro, J. et al., *Radiol.Med*. **119** (2014): 476-482
- Che, J. et al., *Tumour.Biol* **36** (2015): 6559-6568
- Chen, H. S. et al., *Zhonghua Gan Zang.Bing.Za Zhi*. **11** (2003): 145-148
- Chen, H. W. et al., *Mol.Carcinog* **52** (2013): 647-659
- Chen, J. et al., *Cancer Chemother.Pharmacol*. **75** (2015): 1217-1227
- Chen, R. S. et al., *Oncogene* **28** (2009): 599-609
- Chen, W. L. et al., *BMC.Cancer* **12** (2012): 273
- Chen, Y. et al., *Am.J Physiol Lung Cell Mol.Physiol* **306** (2014): L797-L807
- Cheong, S. C. et al., *Oral Oncol* **45** (2009): 712-719
- Chinwalla, V. et al., *Oncogene* **22** (2003): 1400-1410
- Chisholm, K. M. et al., *PLoS.One*. **7** (2012): e30748
- Choi, H. H. et al., *Oncotarget*. **6** (2015a): 19721-19734
- Choi, H. H. et al., *Oncotarget*. **6** (2015b): 11779-11793
- Chudnovsky, Y. et al., *Cell Rep*. **6** (2014): 313-324
- Cicek, M. et al., *PLoS.One*. **6** (2011): e17522
- Cipriano, R. et al., *Oncotarget*. **4** (2013): 729-738
- Cipriano, R. et al., *Mol.Cancer Res* **12** (2014): 1156-1165
- Cohen, C. J. et al., *J Mol Recognit*. **16** (2003a): 324-332
- Cohen, C. J. et al., *J Immunol* **170** (2003b): 4349-4361
- Cohen, S. N. et al., *Proc.Natl.Acad.Sci.U.S.A* **69** (1972): 2110-2114
- Cohen, Y. et al., *Hematology*. **19** (2014): 286-292

- Coligan, J. E. et al., Current Protocols in Protein Science (1995)
- Colombetti, S. et al., J Immunol. **176** (2006): 2730-2738
- Coosemans, A. et al., Anticancer Res **33** (2013): 5495-5500
- Cotterchio, M. et al., PLoS.One. **10** (2015): e0125273
- Counter, C. M. et al., Blood **85** (1995): 2315-2320
- Courtial, N. et al., FASEB J **26** (2012): 523-532
- Crawford, H. C. et al., Curr.Pharm.Des **15** (2009): 2288-2299
- Cribier, B. et al., Br.J Dermatol. **144** (2001): 977-982
- Cui, D. et al., Oncogene **33** (2014): 2225-2235
- Dahlman, K. B. et al., PLoS.One. **7** (2012): e34414
- Dai, X. et al., J Virol. **88** (2014): 12694-12702
- de Kruijf, E. M. et al., BMC.Cancer **12** (2012): 24
- De, S. et al., Cancer Res **69** (2009): 8035-8042
- Dedes, K. J. et al., Sci.Transl.Med. **2** (2010): 53ra75
- Dengjel, J. et al., Clin Cancer Res **12** (2006): 4163-4170
- Denkberg, G. et al., J Immunol **171** (2003): 2197-2207
- Dhanoa, B. S. et al., Hum.Genomics **7** (2013): 13
- Ding, M. et al., Oncotarget. **6** (2015): 7686-7700
- Donnard, E. et al., Oncotarget. **5** (2014): 9199-9213
- Drayton, R. M. et al., Clin Cancer Res **20** (2014): 1990-2000
- Drutskaya, M. S. et al., IUBMB.Life **62** (2010): 283-289
- Du, C. et al., Gastric.Cancer **18** (2015): 516-525
- Du, H. et al., Protein Pept.Lett. **16** (2009): 486-489
- Duffy, M. J. et al., Clin Cancer Res **15** (2009): 1140-1144
- Dufour, C. et al., Cancer **118** (2012): 3812-3821
- Economopoulou, P. et al., Ann.Transl.Med. **4** (2016): 173
- Ehlken, H. et al., Int.J Cancer **108** (2004): 307-313
- Eichhorst, B. F. et al., Blood **107** (2006): 885-891

- Eijssink, J. J. et al., *Int.J Cancer* **130** (2012): 1861-1869
- Eisele, G. et al., *Brain* **129** (2006): 2416-2425
- Elbelt, U. et al., *J Clin Endocrinol.Metab* **100** (2015): E119-E128
- Elsnerova, K. et al., *Oncol Rep.* (2016)
- Emens, L. A., *Expert.Rev.Anticancer Ther.* **12** (2012): 1597-1611
- Engelmann, J. C. et al., *PLoS.Comput.Biol* **11** (2015): e1004293
- Enguita-German, M. et al., *World J Hepatol.* **6** (2014): 716-737
- Er, T. K. et al., *J Mol.Med.(Berl)* (2016)
- Eruslanov, E. et al., *Clin.Cancer Res.* **19** (2013): 1670-1680
- Espiard, S. et al., *Endocrinol.Metab Clin North Am.* **44** (2015): 311-334
- Estey, E. H., *Am.J Hematol.* **89** (2014): 1063-1081
- Etcheverry, A. et al., *BMC.Genomics* **11** (2010): 701
- Faget, J. et al., *Oncoimmunology* **2** (2013): e23185
- Falk, K. et al., *Nature* **351** (1991): 290-296
- Fang, M. et al., *Mol.Cell Biol* **33** (2013): 2635-2647
- Fang, Y. et al., *Tumour.Biol* **33** (2012): 2299-2306
- Farrell, A. S. et al., *Mol.Cancer Res* **12** (2014): 924-939
- Ferlay et al., *GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No.11* [Internet], (2013), <http://globocan.iarc.fr>
- Fernandez-Calotti, P. X. et al., *Haematologica* **97** (2012): 943-951
- Fevre-Montange, M. et al., *J Neuropathol.Exp.Neurol.* **65** (2006): 675-684
- Finocchiaro, G. et al., *Ann.Transl.Med.* **3** (2015): 83
- Fiorito, V. et al., *Biochim.Biophys.Acta* **1839** (2014): 259-264
- Fokas, E. et al., *Cell Death.Dis.* **3** (2012): e441
- Fong, L. et al., *Proc.Natl.Acad.Sci.U.S.A* **98** (2001): 8809-8814
- Ford-Hutchinson, A. W., *Eicosanoids* **4** (1991): 65-74
- Forsey, R. W. et al., *Biotechnol.Lett.* **31** (2009): 819-823
- Fremont, S. et al., *EMBO Rep.* **14** (2013): 364-372

- Fritz, P. et al., *Pathol.Res Pract.* **208** (2012): 203-209
- Fuge, O. et al., *Res Rep.Urol.* **7** (2015): 65-79
- Fujita, H. et al., *J Histochem.Cytochem.* **63** (2015): 217-227
- Fukuyama, R. et al., *Oncogene* **27** (2008): 6044-6055
- Furman, R. R. et al., *N.Engl.J Med.* **370** (2014): 997-1007
- Furukawa, T. et al., *Sci.Rep.* **1** (2011): 161
- Gabrielson, M. et al., *Biochem.Biophys.Res Commun.* **469** (2016): 1090-1096
- Gabrielson, M. et al., *Oncol Rep.* **29** (2013): 1268-1274
- Gabrilovich, D. I. et al., *Nat Med.* **2** (1996): 1096-1103
- Galazis, N. et al., *Gynecol.Endocrinol.* **29** (2013): 638-644
- Gandhi, A. V. et al., *Ann Surg.Oncol* **20 Suppl 3** (2013): S636-S643
- Gao, M. et al., *Diagn.Pathol.* **8** (2013): 205
- Garbe, C. et al., *J Invest Dermatol.* **100** (1993): 239S-244S
- Garcia-Irigoyen, O. et al., *Hepatology* **62** (2015): 166-178
- Gattinoni, L. et al., *Nat Rev.Immunol* **6** (2006): 383-393
- Gazy, I. et al., *Mutat.Res Rev Mutat.Res* **763** (2015): 267-279
- Gelsi-Boyer, V. et al., *Mol.Cancer Res* **3** (2005): 655-667
- Ghosh, A. et al., *Int.J Biol Sci.* **12** (2016): 30-41
- Giannopoulos, K. et al., *Leukemia* **24** (2010): 798-805
- Giannopoulos, K. et al., *Int.J Oncol* **29** (2006): 95-103
- Gnjatic, S. et al., *Proc Natl.Acad.Sci.U.S.A* **100** (2003): 8862-8867
- Godkin, A. et al., *Int.Immunol* **9** (1997): 905-911
- Goede, V. et al., *N.Engl.J Med.* **370** (2014): 1101-1110
- Gonda, T. J. et al., *Expert.Opin.Biol Ther.* **8** (2008): 713-717
- Goni, M. H. et al., *Anticancer Res* **13** (1993): 1155-1160
- Granziero, L. et al., *Blood* **97** (2001): 2777-2783
- Green, J. et al., *Cochrane.Database.Syst.Rev* (2005): CD002225
- Green, M. R. et al., *Molecular Cloning, A Laboratory Manual* **4th** (2012)

- Greenfield, E. A., Antibodies: A Laboratory Manual **2nd** (2014)
- Grimm, M. et al., J Transl.Med. **12** (2014): 208
- Grinberg-Rashi, H. et al., Clin Cancer Res **15** (2009): 1755-1761
- Grivas, P. D. et al., Semin.Cancer Biol **35** (2015): 125-132
- Gruel, N. et al., Breast Cancer Res **16** (2014): R46
- Gunawardana, C. et al., Br.J Haematol. **142** (2008): 606-609
- Guo, P. et al., Onco.Targets.Ther. **8** (2015a): 73-79
- Guo, T. et al., Int.J Cancer (2016)
- Guo, Z. et al., Tumour.Biol **36** (2015b): 3583-3589
- Guo, Z. et al., Tumour.Biol **36** (2015c): 4777-4783
- Guyonnet, Duperat, V et al., Biochem.J **305 (Pt 1)** (1995): 211-219
- Hallek, Michael et al., ASH Annual Meeting Abstracts **112** (2008): 325
- Halon, A. et al., Arch.Gynecol.Obstet. **287** (2013): 563-570
- Handkiewicz-Junak, D. et al., Eur.J Nucl.Med.Mol.Imaging (2016)
- Hapgood, G. et al., Blood **126** (2015): 17-25
- Harig, S. et al., Blood **98** (2001): 2999-3005
- Hayette, S. et al., Oncogene **19** (2000): 4446-4450
- He, H. et al., Diagn.Mol.Pathol. **21** (2012): 143-149
- He, M. et al., J Dig.Dis. **12** (2011): 393-400
- Heerma van Voss, M. R. et al., Histopathology **65** (2014): 814-827
- Heishima, K. et al., PLoS.One. **10** (2015): e0137361
- Hill, S. J. et al., Genes Dev. **28** (2014): 1957-1975
- Hinrichs, C. S. et al., Nat.Biotechnol. **31** (2013): 999-1008
- Hirahata, M. et al., Cancer Med. (2016)
- Hirano, Y. et al., Genes Cells **11** (2006): 1295-1304
- Hlavac, V. et al., Medicine (Baltimore) **93** (2014): e255
- Holla, S. et al., Mol.Cancer **13** (2014): 210
- Holtl, L. et al., Clin.Cancer Res. **8** (2002): 3369-3376

- Hong, L. et al., Hum.Pathol. **45** (2014): 2423-2429
- Honore, B. et al., Exp.Cell Res **294** (2004): 199-209
- Horig, H. et al., Cancer Immunol Immunother. **49** (2000): 504-514
- Hu, X. T. et al., Zhonghua Zhong.Liu Za Zhi. **30** (2008): 515-518
- Hu, X. T. et al., Oncol Rep. **22** (2009): 1247-1252
- Huang, P. Y. et al., Leuk.Lymphoma **55** (2014): 2085-2092
- Huang, Y. et al., Clin Epigenetics. **8** (2016): 9
- Huang, Y. et al., PLoS.One. **8** (2013a): e82519
- Huang, Y. et al., Cell Biosci. **3** (2013b): 16
- Huang, Y. X. et al., Nan.Fang Yi.Ke.Da.Xue.Xue.Bao. **29** (2009): 1329-1332
- Hubertus, J. et al., Oncol Rep. **25** (2011): 817-823
- Huisman, C. et al., Mol.Ther. (2015)
- Huisman, C. et al., Mol.Oncol **7** (2013): 669-679
- Hung, C. F. et al., Immunol.Rev **222** (2008): 43-69
- Hus, I. et al., Oncol Rep. **20** (2008): 443-451
- Hussein, S. et al., Sci.Rep. **5** (2015): 15752
- Huu, N. T. et al., FEBS J **282** (2015): 4727-4746
- Hwang, M. L. et al., J Immunol. **179** (2007): 5829-5838
- Ihn, H. J. et al., Exp.Biol Med.(Maywood.) **240** (2015): 1690-1697
- Ilm, K. et al., Mol.Cancer **14** (2015): 38
- Imai, K. et al., Br.J Cancer **104** (2011): 300-307
- Inoue, K. et al., Subcell.Biochem. **85** (2014): 17-40
- Ishida, T. et al., Leukemia **20** (2006): 2162-2168
- Ishizone, S. et al., Cancer Sci. **97** (2006): 119-126
- Iunusova, N. V. et al., Izv.Akad.Nauk Ser.Biol (2014): 448-455
- Iunusova, N. V. et al., Izv.Akad.Nauk Ser.Biol (2013): 284-291
- Iwakawa, R. et al., Carcinogenesis **36** (2015): 616-621
- Jager, D. et al., Cancer Res **60** (2000): 3584-3591

- Jaiswal, A. S. et al., *Bioorg.Med.Chem Lett.* **24** (2014): 4850-4853
- Januchowski, R. et al., *Biomed.Pharmacother.* **67** (2013): 240-245
- Januchowski, R. et al., *Biomed.Pharmacother.* **68** (2014): 447-453
- Jelinek, J. et al., *PLoS.One.* **6** (2011): e22110
- Jenne, D. E. et al., *Am.J Hum.Genet.* **69** (2001): 516-527
- Jiang, H. et al., *Int.J Mol.Med.* **35** (2015a): 1374-1380
- Jiang, H. et al., *Exp.Ther.Med.* **8** (2014a): 769-774
- Jiang, H. N. et al., *PLoS.One.* **8** (2013): e67637
- Jiang, L. et al., *Cell Cycle* **14** (2015b): 2881-2885
- Jiang, L. et al., *Oncotarget.* **5** (2014b): 7663-7676
- Jiang, Y. et al., *Mol.Cell* **53** (2014c): 75-87
- Jiao, X. L. et al., *Eur.Rev Med.Pharmacol.Sci.* **18** (2014): 509-515
- Johnson, M. A. et al., *Growth Horm.IGF.Res* **24** (2014): 164-173
- Jones, R. T. et al., *Urol.Clin North Am.* **43** (2016): 77-86
- Ju, W. et al., *Oncol.Res.* **18** (2009): 47-56
- Jung, G. et al., *Proc Natl Acad Sci U S A* **84** (1987): 4611-4615
- Junttila, M. R. et al., *Cell Cycle* **7** (2008): 592-596
- Kachakova, D. et al., *J BUON.* **18** (2013): 660-668
- Kadeh, H. et al., *Asian Pac.J Cancer Prev.* **16** (2015): 6609-6613
- Kalikin, L. M. et al., *Genomics* **57** (1999): 36-42
- Kalos, M. et al., *Sci.Transl.Med.* **3** (2011): 95ra73
- Kang, Y. K. et al., *Cancer Res* **68** (2008): 7887-7896
- Kanthan, R. et al., *J Oncol* **2015** (2015): 967472
- Kanzaki, H. et al., *Oncol Rep.* **18** (2007): 1171-1175
- Kanzaki, H. et al., *J Cancer Res Clin Oncol* **134** (2008): 211-217
- Kanzawa, M. et al., *Pathobiology* **80** (2013): 235-244
- Karim, H. et al., *Biochem.Biophys.Res Commun.* **411** (2011): 156-161
- Karrman, K. et al., *Br.J Haematol.* **144** (2009): 546-551

- Kasiappan, R. et al., Mol.Cancer **9** (2010): 311
- Katkoori, V. R. et al., PLoS.One. **7** (2012): e30020
- Kato, S. et al., Int.J Oncol **29** (2006): 33-40
- Kaufman, H. L. et al., Clin Cancer Res **14** (2008): 4843-4849
- Kayser, G. et al., Pathology **43** (2011): 719-724
- Kelavkar, U. et al., Curr.Urol.Rep. **3** (2002): 207-214
- Kelavkar, U. P. et al., Prostaglandins Other Lipid Mediat. **82** (2007): 185-197
- Khanna, A. et al., Int.J Cancer **138** (2016): 525-532
- Khanna, A. et al., Cancer Res **73** (2013): 6548-6553
- Khatamianfar, V. et al., BMJ Open. **2** (2012)
- Kibbe, A. H., Handbook of Pharmaceutical Excipients **rd** (2000)
- Kim, D. S. et al., J Proteome.Res **9** (2010a): 3710-3719
- Kim, H. S. et al., Korean J Intern.Med. **25** (2010b): 399-407
- Kim, J. et al., J Biol Chem **286** (2011): 43294-43300
- Kim, J. H. et al., J Prev.Med.Public Health **49** (2016): 61-68
- Kim, J. W. et al., Cancer Sci. **100** (2009): 1468-1478
- Kim, J. Y. et al., BMB.Rep. **47** (2014a): 451-456
- Kim, K. et al., Mol.Cancer Res **6** (2008): 426-434
- Kim, S. M. et al., Int.J Cancer **134** (2014b): 114-124
- Kim, Y. D. et al., Int.J Mol.Med. **29** (2012): 656-662
- Kindla, J. et al., Cancer Biol Ther. **11** (2011): 584-591
- Kirschner, L. S. et al., Horm.Cancer **7** (2016): 9-16
- Kitchen, M. O. et al., Epigenetics. **11** (2016): 237-246
- Kiyomitsu, T. et al., Mol.Cell Biol **31** (2011): 998-1011
- Kleylein-Sohn, J. et al., J Cell Sci. **125** (2012): 5391-5402
- Klopfleisch, R. et al., J Proteome.Res **9** (2010): 6380-6391
- Knollman, H. et al., Ther.Adv.Urol. **7** (2015a): 312-330
- Knollman, H. et al., Ther.Adv.Urol. **7** (2015b): 312-330

- Kocer, B. et al., *Pathol.Int.* **52** (2002): 470-477
- Kohnz, R. A. et al., *ACS Chem Biol* **10** (2015): 1624-1630
- Kohonen-Corish, M. R. et al., *Oncogene* **26** (2007): 4435-4441
- Koido, S. et al., *World J Gastroenterol.* **19** (2013): 8531-8542
- Kong, D. S. et al., *Oncotarget.* (2016)
- Krackhardt, A. M. et al., *Blood* **100** (2002): 2123-2131
- Krieg, A. M., *Nat Rev.Drug Discov.* **5** (2006): 471-484
- Kronenberger, K. et al., *J Immunother.* **31** (2008): 723-730
- Krupenko, S. A. et al., *Cell Growth Differ.* **13** (2002): 227-236
- Kubota, T. et al., *Cell Cycle* **12** (2013): 2570-2579
- Kuchenbaecker, K. B. et al., *Nat Genet.* **47** (2015): 164-171
- Kuefer, M. U. et al., *Oncogene* **22** (2003): 1418-1424
- Kumar, A. et al., *Cell Biochem.Biophys.* **67** (2013): 837-851
- Kumar, R. et al., *DNA Repair (Amst)* **15** (2014): 54-59
- Kunimoto, K. et al., *J Cell Physiol* **220** (2009): 621-631
- Kuwada, M. et al., *Cancer Lett.* **369** (2015): 212-221
- Landi, D. et al., *Cancer* **118** (2012): 4670-4680
- Lanier, M. H. et al., *Mol.Biol Cell* **26** (2015): 4577-4588
- Lee, D. G. et al., *Curr.Cancer Drug Targets.* **11** (2011): 966-975
- Lee, J. H. et al., *Ann.Surg.* **249** (2009a): 933-941
- Lee, K. Y. et al., *Yonsei Med.J* **50** (2009b): 60-67
- Lee, M. A. et al., *BMC.Cancer* **14** (2014a): 125
- Lee, S. Y. et al., *Eur.J Cancer* **50** (2014b): 698-705
- Lee, W. C. et al., *J Immunother.* **28** (2005): 496-504
- Lei, N. et al., *Oncol Rep.* **32** (2014): 1689-1694
- Leitlinie Endometriumkarzinom, **032/034**, (2008)
- Leitlinie Magenkarzinom, **032-009OL**, (2012)
- Leitlinien für Diagnostik und Therapie in der Neurologie, **030/099**, (2014)

- Leonetti, M. D. et al., Proc.Natl.Acad.Sci.U.S.A **109** (2012): 19274-19279
- Leung, J. et al., Immune.Netw. **14** (2014): 265-276
- Li, J. et al., Mol.Biol Rep. **41** (2014): 8071-8079
- Li, J. et al., Zhongguo Fei.Ai.Za Zhi. **18** (2015a): 16-22
- Li, J. et al., Tumour.Biol (2016)
- Li, J. F. et al., Zhonghua Wei Chang Wai Ke.Za Zhi. **15** (2012a): 388-391
- Li, L. et al., Pharmacogenet.Genomics **22** (2012b): 105-116
- Li, W. Q. et al., Carcinogenesis **34** (2013): 1536-1542
- Li, Y. et al., Cancer Biol Ther. **16** (2015b): 1316-1322
- Li, Y. et al., Cancer Epidemiol. **39** (2015c): 8-13
- Li, Y. F. et al., Int.J Biol Sci. **8** (2012c): 1168-1177
- Liang, Y. C. et al., Oncotarget. **6** (2015): 38046-38060
- Liao, W. et al., Oncotarget. **5** (2014): 10271-10279
- Liddy, N. et al., Nat Med. **18** (2012): 980-987
- Lin, C. et al., Oncotarget. **6** (2015): 8434-8453
- Lin, J. C. et al., RNA. **20** (2014): 1621-1631
- Lin, Y. W. et al., Eur.J Cancer **45** (2009): 2041-2049
- Lin, Z. et al., Diagn.Pathol. **8** (2013): 133
- Lindqvist, B. M. et al., Epigenetics. **7** (2012): 300-306
- Linhares, N. D. et al., Eur.J Med.Genet. **57** (2014): 643-648
- Linher-Melville, K. et al., Mol.Cell Biochem. **405** (2015): 205-221
- Linkov, F. et al., Eur.Cytokine Netw. **20** (2009): 21-26
- Listerman, I. et al., Cancer Res **73** (2013): 2817-2828
- Liu, C. et al., Int.J Clin Exp.Pathol. **8** (2015): 7446-7449
- Liu, L. et al., Biochem.J **451** (2013a): 55-60
- Liu, M. et al., Asian Pac.J Cancer Prev. **14** (2013b): 6281-6286
- Liu, Q. et al., Med.Oncol **31** (2014a): 882
- Liu, T. et al., DNA Repair (Amst) **11** (2012): 131-138

- Liu, W. J. et al., Leuk.Lymphoma **55** (2014b): 2691-2698
- Liu, X. et al., Mol.Biol Rep. **41** (2014c): 7471-7478
- Ljunggren, H. G. et al., J Exp.Med. **162** (1985): 1745-1759
- Lleonart, M. E. et al., Oncol Rep. **16** (2006): 603-608
- Llovet, J. M. et al., N.Engl.J Med. **359** (2008): 378-390
- Lobito, A. A. et al., J Biol Chem **286** (2011): 18969-18981
- Loddo, M. et al., J Pathol. **233** (2014): 344-356
- Lollini, P. L. et al., Int.J Cancer **55** (1993): 320-329
- Longenecker, B. M. et al., Ann N.Y.Acad.Sci. **690** (1993): 276-291
- Lonsdale, J., Nat.Genet. **45** (2013): 580-585
- Lu, G. et al., Cancer Cell **26** (2014): 222-234
- Lucas, S. et al., Int.J Cancer **87** (2000): 55-60
- Luhrig, S. et al., Cell Div. **8** (2013): 3
- Luis, Espinoza J. et al., Cancer Sci. **104** (2013): 657-662
- Lukas, T. J. et al., Proc.Natl.Acad.Sci.U.S.A **78** (1981): 2791-2795
- Lukka, H. et al., Clin Oncol (R Coll.Radiol.) **14** (2002): 203-212
- Luna, B. et al., Mol.Neurobiol. **52** (2015): 1341-1363
- Lundblad, R. L., Chemical Reagents for Protein Modification **3rd** (2004)
- Ma, J. et al., Pathol.Oncol Res **19** (2013a): 821-832
- Ma, L. D. et al., Zhongguo Shi Yan.Xue.Ye.Xue.Za Zhi. **21** (2013b): 1429-1434
- Ma, T. et al., Zhonghua Yi.Xue.Za Zhi. **94** (2014): 3005-3007
- Maggioni, A. et al., Protein Expr.Purif. **101** (2014): 165-171
- Mahomed, F., Oral Oncol **47** (2011): 797-803
- Mantel, A. et al., Exp.Dermatol. **23** (2014): 573-578
- Mantia-Smaldone, G. M. et al., Hum.Vaccin.Immunother. **8** (2012): 1179-1191
- Marchio, C. et al., J Clin Pathol. **63** (2010): 220-228
- Marechal, R. et al., Clin Cancer Res **15** (2009): 2913-2919
- Marine, J. C., Nat Rev Cancer **12** (2012): 455-464

- Markus, M. A. et al., Genomics **107** (2016): 138-144
- Marten, A. et al., Cancer Immunol.Immunother. **51** (2002): 637-644
- Martin, R. W. et al., Cancer Res **67** (2007): 9658-9665
- Martinez, I. et al., Eur.J Cancer **43** (2007): 415-432
- Marzec, K. A. et al., Biomed.Res Int. **2015** (2015): 638526
- Mason, C. C. et al., Leukemia (2015)
- Massari, F. et al., Cancer Treat.Rev. **41** (2015): 114-121
- Massoner, P. et al., PLoS.One. **8** (2013): e55207
- Matsueda, S. et al., World J Gastroenterol. **20** (2014): 1657-1666
- Matsuura, N. et al., Nihon Rinsho **53** (1995): 1643-1647
- Maus, M. V. et al., Blood **123** (2014): 2625-2635
- Mayr, C. et al., Exp.Hematol. **34** (2006): 44-53
- Mayr, C. et al., Blood **105** (2005): 1566-1573
- McGilvray, R. W. et al., Int.J Cancer **127** (2010): 1412-1420
- Medeiros, A. C. et al., Cancer Epidemiol.Biomarkers Prev. **3** (1994): 331-333
- Mehta, J. et al., PLoS.One. **10** (2015): e0120622
- Mei, J. Z. et al., Nan.Fang Yi.Ke.Da.Xue.Xue.Bao. **27** (2007): 887-889
- Mencia, N. et al., Biochem.Pharmacol. **82** (2011): 1572-1582
- Mendoza-Maldonado, R. et al., PLoS.One. **5** (2010): e13720
- Meziere, C. et al., J Immunol **159** (1997): 3230-3237
- Migliorini, D. et al., J Clin Invest **121** (2011): 1329-1343
- Milutin, Gasperov N. et al., PLoS.One. **10** (2015): e0129452
- Missero, C. et al., Exp.Dermatol. **23** (2014): 143-146
- Miyagi, Y. et al., Clin Cancer Res **7** (2001): 3950-3962
- Miyamoto, K. et al., Int.J Cancer **116** (2005): 407-414
- Mohanraj, L. et al., Recent Pat Anticancer Drug Discov **6** (2011): 166-177
- Mohelnikova-Duchonova, B. et al., Cancer Chemother.Pharmacol. **72** (2013): 669-682
- Molina, J. R. et al., Mayo Clin Proc. **83** (2008): 584-594

- Morgan, R. A. et al., Science **314** (2006): 126-129
- Mori, M. et al., Transplantation **64** (1997): 1017-1027
- Morin, P. J., Cancer Res **65** (2005): 9603-9606
- Morita, T. et al., Int.J Cancer **109** (2004): 525-532
- Mortara, L. et al., Clin Cancer Res. **12** (2006): 3435-3443
- Moser, J. J. et al., J Neurosci.Res **85** (2007): 3619-3631
- Mou, X. et al., Sci.Rep. **4** (2014): 6138
- Moulton, H. M. et al., Clin Cancer Res **8** (2002): 2044-2051
- Mueller, L. N. et al., J Proteome.Res **7** (2008): 51-61
- Mueller, L. N. et al., Proteomics. **7** (2007): 3470-3480
- Mukhopadhyay, P. et al., Biochim.Biophys.Acta **1815** (2011): 224-240
- Muller, M. R. et al., Blood **103** (2004): 1763-1769
- Mumberg, D. et al., Proc.Natl.Acad.Sci.U.S.A **96** (1999): 8633-8638
- Nagashio, R. et al., Sci.Rep. **5** (2015): 8649
- Naito, T. et al., J Biol Chem **290** (2015): 15004-15017
- Nakajima, H. et al., Cancer Sci. **105** (2014): 1093-1099
- Nakano, K. et al., Exp.Cell Res **287** (2003): 219-227
- Nakarai, C. et al., Clin Exp.Med. **15** (2015): 333-341
- Nakashima, A. et al., Biochem.Biophys.Res Commun. **361** (2007): 218-223
- National Cancer Institute, (5-6-2015), www.cancer.gov
- Nguyen, M. H. et al., Int.J Oncol **41** (2012): 1285-1296
- Ni, I. B. et al., Hematol.Rep. **4** (2012): e19
- Ni, L. et al., J Cell Biochem. **106** (2009): 920-928
- Nobusawa, S. et al., Brain Tumor Pathol. **31** (2014): 229-233
- O'Brien, S. et al., Lancet Oncol **15** (2014): 48-58
- O'Geen, H. et al., PLoS.Genet. **3** (2007): e89
- Obama, K. et al., Clin Cancer Res **14** (2008): 1333-1339
- Oehler, V. G. et al., Blood **114** (2009): 3292-3298

- Ogasawara, N. et al., J Biochem. **149** (2011): 321-330
- Ogbomo, H. et al., Neoplasia. **10** (2008): 1402-1410
- Ogiso, Y. et al., Cancer Res **62** (2002): 5008-5012
- Oh, Y. et al., J Biol.Chem **287** (2012): 17517-17529
- Okabe, N. et al., Int.J Oncol **46** (2015): 999-1006
- Okuno, K. et al., Exp.Ther Med. **2** (2011): 73-79
- Olkhanud, P. B. et al., Cancer Res **69** (2009): 5996-6004
- Olszewski-Hamilton, U. et al., Biomark.Cancer **3** (2011): 31-40
- Orentas, R. J. et al., Front Oncol **2** (2012): 194
- Orzol, P. et al., Histol.Histopathol. **30** (2015): 503-521
- Ouyang, M. et al., BMC.Cancer **15** (2015): 132
- Ozawa, H. et al., Ann.Surg.Oncol **17** (2010): 2341-2348
- Ozeki, N. et al., Int.J Mol.Sci. **17** (2016)
- Palma, M. et al., Cancer Immunol Immunother. **57** (2008): 1705-1710
- Palmer, D. H. et al., Hepatology **49** (2009): 124-132
- Palomba, M. L., Curr.Oncol Rep. **14** (2012): 433-440
- Pan, J. et al., Leuk.Res **36** (2012): 889-894
- Pannu, V. et al., Oncotarget. **6** (2015): 6076-6091
- Parikh, R. A. et al., Genes Chromosomes.Cancer **53** (2014): 25-37
- Parikh, S. A. et al., Blood **118** (2011): 2062-2068
- Parisi, M. A., Am.J Med.Genet.C.Semin.Med.Genet. **151C** (2009): 326-340
- Park, E. et al., Mol.Cell **50** (2013): 908-918
- Park, M. J. et al., Immunol.Invest **40** (2011): 367-382
- Park, Y. R. et al., Cancer Genomics Proteomics. **13** (2016): 83-90
- Parplys, A. C. et al., DNA Repair (Amst) **24** (2014): 87-97
- Pasmant, E. et al., Mol.Med. **17** (2011): 79-87
- Patil, A. A. et al., Oncotarget. **5** (2014): 6414-6424
- Pattabiraman, D. R. et al., Leukemia **27** (2013): 269-277

- Pawar, S. et al., J Ovarian.Res **7** (2014): 53
- Payne, S. R. et al., Prostate **69** (2009): 1257-1269
- Peng, B. et al., Mol.Biosyst. **11** (2015): 105-114
- Pequeux, C. et al., Cancer Res **62** (2002): 4623-4629
- Perrais, M. et al., J Biol Chem **276** (2001): 15386-15396
- Petrini, I., Ann.Transl.Med. **3** (2015): 82
- Phan, G. Q. et al., Cancer Control **20** (2013): 289-297
- Phe, V. et al., BJU.Int. **104** (2009): 896-901
- Piasecka, D. et al., Postepy Biochem. **61** (2015): 198-206
- Pinheiro, J. et al., nlme: Linear and Nonlinear Mixed Effects Models (<http://CRAN.R-project.org/package=nlme>) (2015)
- Plebanski, M. et al., Eur.J Immunol **25** (1995): 1783-1787
- Porta, C. et al., Virology **202** (1994): 949-955
- Porter, D. L. et al., N.Engl.J Med. **365** (2011): 725-733
- Potapenko, I. O. et al., Mol.Oncol **9** (2015): 861-876
- Przybyl, J. et al., Int.J Biochem.Cell Biol **53** (2014): 505-513
- Qian, M. X. et al., Cell **153** (2013): 1012-1024
- Qiu, J. et al., Leukemia **17** (2003): 1891-1900
- Quinn, D. I. et al., Urol.Oncol. (2015)
- Qureshi, R. et al., Cancer Lett. **356** (2015): 321-331
- Rainer, J. et al., Mol.Endocrinol. **26** (2012): 178-193
- Raja, S. B. et al., J Cell Sci. **125** (2012): 703-713
- Rajadhyaksha, A. M. et al., Am.J Hum.Genet. **87** (2010): 643-654
- Rajkumar, T. et al., BMC.Cancer **11** (2011): 80
- Rakic, M. et al., Hepatobiliary.Surg.Nutr. **3** (2014): 221-226
- Rammensee, H. G. et al., Immunogenetics **50** (1999): 213-219
- Ramsay, R. G. et al., Expert.Opin.Ther.Targets. **7** (2003): 235-248
- RefSeq, The NCBI handbook [Internet], Chapter 18, (2002), <http://www.ncbi.nlm.nih.gov/books/NBK21091/>

- Reid-Lombardo, K. M. et al., Cancer Epidemiol.Biomarkers Prev. **20** (2011): 1251-1254
- Reinisch, W. et al., J Immunother. **25** (2002): 489-499
- Reinmuth, N. et al., Dtsch.Med.Wochenschr. **140** (2015): 329-333
- Religio, A. et al., PLoS.Genet. **10** (2014): e1004338
- Rendon-Huerta, E. et al., J Gastrointest.Cancer **41** (2010): 52-59
- Resende, C. et al., Helicobacter. **16 Suppl 1** (2011): 38-44
- Richards, S. et al., J Natl.Cancer Inst. **91** (1999): 861-868
- Ricke, R. M. et al., Cell Cycle **10** (2011): 3645-3651
- Rincon, R. et al., Oncotarget. **6** (2015): 4299-4314
- Rini, B. I. et al., Curr.Opin.Oncol. **20** (2008): 300-306
- Rini, B. I. et al., Cancer **107** (2006): 67-74
- Riordan, J. D. et al., PLoS.Genet. **9** (2013): e1003441
- Ritter, A. et al., Cell Cycle **14** (2015): 3755-3767
- Robak, T. et al., Expert.Opin.Biol.Ther **14** (2014): 651-661
- Roca, H. et al., PLoS.One. **8** (2013): e76773
- Rock, K. L. et al., Science **249** (1990): 918-921
- Rodenko, B. et al., Nat Protoc. **1** (2006): 1120-1132
- Rodini, C. O. et al., Int.J Oncol **40** (2012): 1180-1188
- Rodriguez, F. J. et al., J Neuropathol.Exp.Neurol. **67** (2008): 1194-1204
- Romanuik, T. L. et al., BMC.Med.Genomics **3** (2010): 43
- Ronchi, C. L. et al., Neoplasia. **14** (2012): 206-218
- Rouanne, M. et al., Crit Rev Oncol Hematol. **98** (2016): 106-115
- Rucki, A. A. et al., World J Gastroenterol. **20** (2014): 2237-2246
- Rudland, P. S. et al., Am.J Pathol. **176** (2010): 2935-2947
- Rutkowski, M. J. et al., Mol Cancer Res **8** (2010): 1453-1465
- Ryu, B. et al., PLoS.One. **2** (2007): e594
- S3-Leitlinie Exokrines Pankreaskarzinom, **032-010OL**, (2013)
- S3-Leitlinie Lungenkarzinom, **020/007**, (2011)

- S3-Leitlinie maligne Ovarialtumore, **032-035OL**, (2013)
- S3-Leitlinie Mammakarzinom, **032-045OL**, (2012)
- S3-Leitlinie Melanom, **032-024OL**, (2013)
- S3-Leitlinie Prostatakarzinom, **043/022OL**, (2014)
- S3-Leitlinie Zervixkarzinom, **032/033OL**, (2014)
- Sadeque, A. et al., BMC.Med.Genomics **5** (2012): 59
- Sacki, M. et al., PLoS.One. **8** (2013): e67326
- Safarpour, D. et al., Arch.Pathol.Lab Med. **139** (2015): 612-617
- Saiki, R. K. et al., Science **239** (1988): 487-491
- Salim, H. et al., Genes Chromosomes.Cancer **52** (2013): 895-911
- Salman, B. et al., Oncoimmunology. **2** (2013): e26662
- Sandoval, J. et al., J Clin Oncol **31** (2013): 4140-4147
- Sangro, B. et al., J Clin Oncol **22** (2004): 1389-1397
- Sankaranarayanan, P. et al., PLoS.One. **10** (2015): e0121396
- Santarlaschi, V. et al., Eur.J Immunol. **44** (2014): 654-661
- Sarma, S. N. et al., Environ.Toxicol.Pharmacol. **32** (2011): 285-295
- Sasao, T. et al., Reproduction. **128** (2004): 709-716
- Satija, Y. K. et al., Int.J Cancer **133** (2013): 2759-2768
- Sato, N. et al., Genes Chromosomes.Cancer **49** (2010): 353-367
- Savaskan, N. E. et al., Ann.Anat. **192** (2010): 309-313
- Savaskan, N. E. et al., Curr.Neuropharmacol. **13** (2015): 258-265
- Sawada, G. et al., Oncol Rep. **30** (2013): 1971-1975
- Schetelig, J. et al., J Clin Oncol **26** (2008): 5094-5100
- Scheurer, B. et al., Immunopharmacology **38** (1997): 167-175
- Schmidt, S. M. et al., Cancer Res **64** (2004): 1164-1170
- Schreiber, M. et al., J Biol Chem **273** (1998): 3509-3516
- Seeger, F. H. et al., Immunogenetics **49** (1999): 571-576
- Seidl, C. et al., Invest New Drugs **28** (2010): 49-60

- Seppanen, M. et al., *Acta Obstet.Gynecol.Scand.* **87** (2008): 902-909
- Shareef, M. M. et al., *Arab.J Gastroenterol.* **16** (2015): 105-112
- Sharma, R. K. et al., *Clin Exp.Metastasis* **33** (2016): 263-275
- Sharpe, D. J. et al., *Oncotarget.* **5** (2014): 8803-8815
- Shen, C. et al., *Cancer Res* **73** (2013): 3393-3401
- Shen, Y. et al., *Oncotarget.* **6** (2015a): 20396-20403
- Shen, Y. et al., *Cancer Cell Microenviron.* **2** (2015b)
- Sherman, F. et al., *Laboratory Course Manual for Methods in Yeast Genetics* (1986)
- Sherman, S. K. et al., *Surgery* **154** (2013): 1206-1213
- Shi, M. et al., *World J Gastroenterol.* **10** (2004): 1146-1151
- Shi, Z. et al., *Tumour.Biol* **36** (2015): 8519-8529
- Shimizu, F. et al., *Lab Invest* **83** (2003): 187-197
- Shioji, G. et al., *J Hum.Genet.* **50** (2005): 507-515
- Showel, M. M. et al., *F1000Prime.Rep.* **6** (2014): 96
- Siegel, S. et al., *Blood* **102** (2003): 4416-4423
- Siew, Y. Y. et al., *Int.Immunol.* **27** (2015): 621-632
- Silva, L. P. et al., *Anal.Chem.* **85** (2013): 9536-9542
- Silvestris, F. et al., *Adv.Exp.Med.Biol* **714** (2011): 113-128
- Singh, V. et al., *Curr.Cancer Drug Targets.* **13** (2013): 379-399
- Singh-Jasuja, H. et al., *Cancer Immunol.Immunother.* **53** (2004): 187-195
- Skawran, B. et al., *Mod.Pathol.* **21** (2008): 505-516
- Small, E. J. et al., *J Clin Oncol.* **24** (2006): 3089-3094
- Smetsers, S. et al., *Fam.Cancer* **11** (2012): 661-665
- Smith, P. et al., *Clin Cancer Res* **13** (2007): 4061-4068
- Sohrabi, A. et al., *Asian Pac.J Cancer Prev.* **15** (2014): 6745-6748
- Song, H. R. et al., *Mol.Carcinog* **52 Suppl 1** (2013): E155-E160
- Sonora, C. et al., *J Histochem.Cytochem.* **54** (2006): 289-299
- Spaner, D. E. et al., *Cancer Immunol Immunother.* **54** (2005): 635-646

- Srivastava, N. et al., Cancer Manag.Res. **6** (2014): 279-289
- Stacey, S. N. et al., Nat Commun. **6** (2015): 6825
- Stahl, M. et al., Ann.Oncol. **24 Suppl 6** (2013): vi51-vi56
- Stangel, D. et al., J Surg.Res **197** (2015): 91-100
- Stein, U., Expert.Opin.Ther.Targets. **17** (2013): 1039-1052
- Steinberg, R. L. et al., Urol.Oncol (2016a)
- Steinberg, R. L. et al., Urol.Oncol (2016b)
- Steinway, S. N. et al., PLoS.One. **10** (2015): e0128159
- Stenman, G. et al., Cell Cycle **9** (2010): 2986-2995
- Stevanovic, S. et al., J Clin Oncol **33** (2015): 1543-1550
- Stintzing, S., F1000Prime.Rep. **6** (2014): 108
- Stratakis, C. A. et al., DNA Seq. **9** (1998): 227-230
- Struyf, S. et al., Am.J Pathol. **163** (2003): 2065-2075
- Sturm, M. et al., BMC.Bioinformatics. **9** (2008): 163
- Su, Z. et al., Cancer Res. **63** (2003): 2127-2133
- Subhash, V. V. et al., BMC.Cancer **15** (2015): 550
- Sui, Y. et al., Oncogene **26** (2007): 822-835
- Sukocheva, O. A. et al., World J Gastroenterol. **21** (2015): 6146-6156
- Sun, S. et al., Gene **584** (2016): 90-96
- Sun, W. et al., World J Gastroenterol. **19** (2013): 2913-2920
- Sutherland, C. L. et al., Blood **108** (2006): 1313-1319
- Suzuki, N. et al., J Orthop.Res **32** (2014): 915-922
- Tabares-Seisdedos, R. et al., Mol.Psychiatry **14** (2009): 563-589
- Takahashi, M. et al., Int.J Oncol **27** (2005): 1483-1487
- Takatsu, H. et al., J Biol Chem **286** (2011): 38159-38167
- Takayama, M. A. et al., Genes Cells **5** (2000a): 481-490
- Takayama, T. et al., Cancer **68** (1991): 2391-2396
- Takayama, T. et al., Lancet **356** (2000b): 802-807

- Taketani, T. et al., *Cancer Res* **62** (2002): 33-37
- Tang, C. et al., *Int.J Clin Exp.Pathol.* **7** (2014): 4782-4794
- Tatenhorst, L. et al., *J Neuropathol.Exp.Neurol.* **63** (2004): 210-222
- Taverniti, V. et al., *Nucleic Acids Res* **43** (2015): 482-492
- Taylor, M. et al., *Breast Cancer Res* **9** (2007): R46
- Terabayashi, T. et al., *PLoS.One.* **7** (2012): e39714
- Teufel, R. et al., *Cell Mol Life Sci.* **62** (2005): 1755-1762
- Thakkar, J. P. et al., *Cancer Epidemiol.Biomarkers Prev.* **23** (2014): 1985-1996
- Tian, Y. et al., *Diagn.Pathol.* **9** (2014): 42
- Ting, L. et al., *DNA Repair (Amst)* **9** (2010): 1241-1248
- Toda, M. et al., *Meta Gene* **2** (2014): 686-693
- Toomey, P. G. et al., *Cancer Control* **20** (2013): 32-42
- Torelli, G. F. et al., *Haematologica* **99** (2014): 1248-1254
- Tran, E. et al., *Science* **344** (2014): 641-645
- Tsujikawa, T. et al., *Int.J Cancer* **132** (2013): 2755-2766
- Tumova, L. et al., *Mol.Cancer Ther.* **13** (2014): 812-822
- Urata, Y. N. et al., *Sci.Rep.* **5** (2015): 13676
- Ushiku, T. et al., *Histopathology* **61** (2012): 1043-1056
- Utrera, R. et al., *EMBO J* **17** (1998): 5015-5025
- Vainio, P. et al., *Am.J Pathol.* **178** (2011a): 525-536
- Vainio, P. et al., *Oncotarget.* **2** (2011b): 1176-1190
- Valque, H. et al., *PLoS.One.* **7** (2012): e46699
- van de Klundert, M. A. et al., *PLoS.One.* **7** (2012): e48940
- Van Ginkel, P. R. et al., *Biochim.Biophys.Acta* **1448** (1998): 290-297
- van Muijen, G. N. et al., *Recent Results Cancer Res* **139** (1995): 105-122
- Van, Seuningen, I et al., *Biochem.J* **348 Pt 3** (2000): 675-686
- Vater, I. et al., *Leukemia* **29** (2015): 677-685
- Ventela, S. et al., *Oncotarget.* **6** (2015): 144-158

- Verreman, K. et al., *Biochem.J* **439** (2011): 469-477
- Vici, P. et al., *J Exp.Clin Cancer Res* **33** (2014): 29
- Von Hoff, D. D. et al., *N.Engl.J Med.* **369** (2013): 1691-1703
- von Rundstedt, F. C. et al., *Transl.Androl Urol.* **4** (2015): 244-253
- Wallrapp, C. et al., *Ann.Oncol* **10 Suppl 4** (1999): 64-68
- Walsh, M. D. et al., *Mod.Pathol.* **26** (2013): 1642-1656
- Walter, S. et al., *J Immunol* **171** (2003): 4974-4978
- Walter, S. et al., *Nat Med.* **18** (2012): 1254-1261
- Walton, E. L. et al., *Biology.(Basel)* **3** (2014): 578-605
- Wan, W. et al., *World J Surg.Oncol* **12** (2014): 185
- Wang, C. et al., *Nucleic Acids Res* **43** (2015a): 4893-4908
- Wang, C. Q. et al., *Oral Surg.Oral Med.Oral Pathol.Oral Radiol.* **117** (2014a): 353-360
- Wang, D. et al., *Chin Med.Sci.J* **14** (1999a): 107-111
- Wang, G. et al., *Tumour.Biol* **36** (2015b): 1055-1065
- Wang, G. H. et al., *Oncol Lett.* **5** (2013a): 544-548
- Wang, H. et al., *Carcinogenesis* **30** (2009a): 1314-1319
- Wang, J. et al., *Ann.Surg.Oncol* **22** (2015c): 685-692
- Wang, J. et al., *J Exp.Clin Cancer Res* **34** (2015d): 13
- Wang, J. W. et al., *Oncogene* **23** (2004): 4089-4097
- Wang, L. et al., *J Cutan.Pathol.* **42** (2015e): 361-367
- Wang, L. et al., *Mol.Biol Rep.* **38** (2011a): 229-236
- Wang, L. et al., *Diagn.Pathol.* **8** (2013b): 190
- Wang, N. et al., *Arch.Gynecol.Obstet.* **283** (2011b): 103-108
- Wang, Q. et al., *Cell* **138** (2009b): 245-256
- Wang, Q. et al., *BMC.Cancer* **11** (2011c): 271
- Wang, Q. et al., *Onco.Targets.Ther.* **8** (2015f): 1971-1977
- Wang, Q. et al., *PLoS.One.* **8** (2013c): e61640
- Wang, R. et al., *Mol.Cell Biochem.* **405** (2015g): 97-104

- Wang, S. et al., J Cell Sci. **120** (2007): 567-577
- Wang, W. Z. et al., J Exp.Clin Cancer Res **29** (2010): 140
- Wang, X. W. et al., Gut Liver **8** (2014b): 487-494
- Wang, X. Z. et al., Oncogene **18** (1999b): 5718-5721
- Wang, Y. et al., Cancer Cell **26** (2014c): 374-389
- Wang, Y. P. et al., Ai.Zheng. **27** (2008): 243-248
- Wang, Z. et al., J Cancer Res Clin Oncol **141** (2015h): 1353-1361
- Wang, Z. et al., Oncotarget. (2016)
- Wang, Z. et al., Glycobiology **22** (2012): 930-938
- Watanabe, N. et al., J Biol Chem **278** (2003): 26102-26110
- Watts, C. A. et al., Chem Biol **20** (2013): 1399-1410
- Wells, J. et al., J Biol Chem **284** (2009): 29125-29135
- Weng, Y. R. et al., Carcinogenesis **35** (2014): 1389-1398
- Wheler, J. J. et al., BMC.Cancer **15** (2015): 442
- Whitaker, H. C. et al., Oncogene **33** (2014): 5274-5287
- Wierda, W. G. et al., Blood **118** (2011): 5126-5129
- Wierinckx, A. et al., Endocr.Relat Cancer **14** (2007): 887-900
- Wilhelm, S. M. et al., Cancer Res **64** (2004): 7099-7109
- Willcox, B. E. et al., Protein Sci. **8** (1999): 2418-2423
- Williams, G. L. et al., Cell Cycle **6** (2007): 1699-1704
- Wilson, P. M. et al., Nat Rev.Clin Oncol **11** (2014): 282-298
- Wilzen, A. et al., Int.J Oncol **34** (2009): 697-705
- Wittig, B. et al., Hum.Gene Ther. **12** (2001): 267-278
- Wlcek, K. et al., Cancer Biol Ther. **11** (2011): 801-811
- Wong, R. P. et al., Pigment Cell Melanoma Res **25** (2012): 213-218
- World Cancer Report, (2014)
- World Health Organization, (2014), <http://www.who.int/en/>
- Wu, J. et al., ACS Chem Biol **8** (2013): 2201-2208

- Wu, Y. et al., Cancer Lett. **356** (2015): 646-655
- Xie, B. et al., Pathol.Oncol Res **19** (2013): 611-617
- Xie, C. et al., Biochem.Biophys.Res Commun. **445** (2014): 263-268
- Xiong, D. et al., Carcinogenesis **33** (2012): 1797-1805
- Xu, X. et al., Oncogene **26** (2007): 7371-7379
- Xu, X. et al., J Biol Chem **289** (2014): 8881-8890
- Xue, J. H. et al., Acta Pharmacol.Sin. **32** (2011): 1019-1024
- Yamada, T. et al., Br.J Cancer **108** (2013): 2495-2504
- Yamashita, J. et al., Acta Derm.Venereol. **92** (2012): 593-597
- Yamazoe, S. et al., J Exp.Clin Cancer Res **29** (2010): 53
- Yan-Chun, L. et al., Appl.Immunohistochem.Mol.Morphol. (2015)
- Yan-Fang, T. et al., PLoS.One. **10** (2015): e0126566
- Yang, J. J. et al., Haematologica **99** (2014a): e11-e13
- Yang, L. et al., J Biol Chem **291** (2016): 3905-3917
- Yang, L. et al., PLoS.One. **10** (2015a): e0133896
- Yang, T. T. et al., Sci.Rep. **5** (2015b): 14096
- Yang, Y. et al., Oncol Lett. **9** (2015c): 1833-1838
- Yang, Y. et al., PLoS.One. **9** (2014b): e97578
- Yang, Y. M. et al., Cancer Sci. **102** (2011): 1264-1271
- Yao, Y. et al., Cell Physiol Biochem. **35** (2015): 983-996
- Ye, B. G. et al., Oncotarget. (2016)
- Yeh, I. et al., Nat.Comm. **6** (2015): 7174
- Yeh, S. et al., Proc.Natl.Acad.Sci.U.S.A **97** (2000): 11256-11261
- Yonezawa, S. et al., Pathol.Int. **49** (1999): 45-54
- Yoshimaru, T. et al., Nat Commun. **4** (2013): 2443
- Yoshimaru, T. et al., Sci.Rep. **4** (2014): 7355
- Young, A. et al., BMC.Cancer **14** (2014): 808
- Yu, C. J. et al., Int.J Cancer **69** (1996): 457-465

- Yu, H. et al., *Nat Chem Biol* **11** (2015a): 847-854
- Yu, T. et al., *Cell Res* **24** (2014): 1214-1230
- Yu, X. et al., *Tumour.Biol* **36** (2015b): 967-972
- Yuan, M. et al., *Oncotarget*. **5** (2014): 2820-2826
- Zaganjor, E. et al., *Proc.Natl.Acad.Sci.U.S.A* **111** (2014): 10568-10573
- Zamuner, F. T. et al., *Mol.Cancer Ther.* **14** (2015): 828-834
- Zaremba, S. et al., *Cancer Res.* **57** (1997): 4570-4577
- Zavala-Zendejas, V. E. et al., *Cancer Invest* **29** (2011): 1-11
- Zekri, A. R. et al., *BMC.Res Notes* **1** (2008): 106
- Zeng, B. et al., *Curr.Cancer Drug Targets.* **13** (2013a): 103-116
- Zeng, S. et al., *Eur.J Cancer* **49** (2013b): 3752-3762
- Zeng, X. et al., *Ai.Zheng.* **26** (2007): 1080-1084
- Zeng, X. X. et al., *Eur.Rev Med.Pharmacol.Sci.* **19** (2015): 4353-4361
- Zhan, W. et al., *PLoS.One.* **10** (2015): e0142596
- Zhang, B. et al., *J Huazhong.Univ Sci.Technolog.Med.Sci.* **30** (2010a): 322-325
- Zhang, G. et al., *BMC.Cancer* **14** (2014): 310
- Zhang, J. et al., *Theor.Biol Med.Model.* **9** (2012a): 53
- Zhang, Q. et al., *Zhongguo Fei.Ai.Za Zhi.* **13** (2010b): 612-616
- Zhang, W. et al., *Clin Cancer Res* **7** (2001): 822s-829s
- Zhang, W. et al., *Biochem.J* (2016)
- Zhang, X. et al., *EMBO J* **30** (2011): 2177-2189
- Zhang, X. et al., *Med.Oncol* **32** (2015): 148
- Zhang, X. et al., *Int.J Med.Sci.* **10** (2013a): 1795-1804
- Zhang, Y. et al., *Gene* **497** (2012b): 93-97
- Zhang, Y. et al., *J Ovarian.Res* **6** (2013b): 55
- Zhao, J. et al., *Int.J Med.Sci.* **11** (2014a): 1089-1097
- Zhao, J. G. et al., *FEBS Lett.* **588** (2014b): 4536-4542
- Zhen, T. et al., *Oncotarget.* **5** (2014): 3756-3769

- Zheng, M. et al., Breast Cancer Res Treat. **148** (2014): 423-436
- Zheng, M. Z. et al., J Transl.Med. **5** (2007): 36
- Zhong, M. et al., Mol.Cancer Res **8** (2010): 1164-1172
- Zhong, T. et al., Biomed.Pharmacother. **69** (2015): 317-325
- Zhou, X. et al., J Cancer Res Clin Oncol **141** (2015): 961-969
- Zhou, Y. et al., Front Biosci.(Landmark.Ed) **16** (2011): 1109-1131
- Zhou, Z. et al., Gastroenterology **147** (2014): 1043-1054
- Zhu, H. H. et al., Asian Pac.J Trop.Med. **7** (2014): 488-491
- Zhu, J. et al., Int.J Clin Exp.Pathol. **8** (2015a): 9479-9486
- Zhu, P. et al., Oncol Lett. **10** (2015b): 1487-1494
- Zighelboim, I. et al., J Clin Oncol **27** (2009): 3091-3096
- Zimmerman, K. M. et al., Mol.Cancer Res **11** (2013): 370-380
- Zocchi, M. R. et al., Blood **119** (2012): 1479-1489
- Zou, J. X. et al., Mol.Cancer Res **12** (2014): 539-549
- Zou, T. T. et al., Oncogene **21** (2002): 4855-4862

CLAIMS

1. A peptide comprising an amino acid sequence selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 240, SEQ ID No. 242 to SEQ ID No. 322 and SEQ ID No. 324 to SEQ ID No. 388, and variant sequences thereof that are at least 88% homologous to SEQ ID No. 1 to SEQ ID No. 240, SEQ ID No. 242 to SEQ ID No. 322 and SEQ ID No. 324 to SEQ ID No. 388, and wherein said variant binds to molecule(s) of the major histocompatibility complex (MHC) and/or induces T cells cross-reacting with said variant peptide; and a pharmaceutical acceptable salt thereof, wherein said peptide is not a full-length polypeptide.
2. The peptide according to claim 1, wherein said peptide has the ability to bind to an MHC class-I or –II molecule, and wherein said peptide, when bound to said MHC, is capable of being recognized by CD4 and/or CD8 T cells.
3. The peptide or variant thereof according to claim 1 or 2, wherein the amino acid sequence thereof comprises a continuous stretch of amino acids according to any one of SEQ ID No. 1 to SEQ ID No. 240, SEQ ID No. 242 to SEQ ID No. 322 and SEQ ID No. 324 to SEQ ID No. 388.
4. The peptide or variant thereof according to any of claims 1 to 3, wherein said peptide or variant thereof has an overall length of from 8 to 100, preferably from 8 to 30, and more preferred from 8 to 16 amino acids, and most preferred wherein the peptide consists or consists essentially of an amino acid sequence according to any of SEQ ID No. 1 to SEQ ID No. 240, SEQ ID No. 242 to SEQ ID No. 322 and SEQ ID No. 324 to SEQ ID No. 388.
5. The peptide or variant thereof according to any of Claims 1 to 4, wherein said peptide is modified and/or includes non-peptide bonds.
6. The peptide or variant thereof according to any of Claims 1 to 5, wherein said peptide is part of a fusion protein, in particular comprising N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii).

7. A nucleic acid, encoding a peptide or variant thereof according to any one of claims 1 to 6, optionally linked to a heterologous promoter sequence.
8. An expression vector capable of expressing the nucleic acid according to claim 7.
9. A recombinant host cell comprising the peptide according to any one of claim 1 to 6, the nucleic acid according to claim 7 or the expression vector according to claim 8, wherein said host cell preferably is an antigen presenting cell, such as a dendritic cell.
10. The peptide or variant thereof according to any one of claims 1 to 6, the nucleic acid according to claim 7, the expression vector according to claim 8, or the host cell according to claim 9 for use in medicine.
11. A method for producing the peptide or variant thereof according to any one of claims 1 to 6, the method comprising culturing the host cell according to claim 9 that presents the peptide according to claim 1 to 6, or expresses the nucleic acid according to claim 7 or expresses the expression vector according to claim 8, and isolating the peptide or variant thereof from the host cell or its culture medium.
12. An *in vitro* method for producing activated T lymphocytes, the method comprising contacting *in vitro* T cells with antigen loaded human class I or II MHC molecules expressed on the surface of a suitable antigen-presenting cell or an artificial construct mimicking an antigen-presenting cell for a period of time sufficient to activate said T cells in an antigen specific manner, wherein said antigen is a peptide according to any one of claims 1 to 4.
13. An activated T lymphocyte, produced by the method according to claim 12, that selectively recognizes a cell which presents a polypeptide comprising an amino acid sequence given in any one of claims 1 to 4.
14. A method for killing target cells in a patient which target cells present a polypeptide comprising an amino acid sequence given in any one of claims 1 to 4, the

method comprising administering to the patient an effective number of activated T cells as defined in claim 13.

15. An antibody, in particular a soluble or membrane-bound antibody, that specifically recognizes the peptide or variant thereof according to any of claims 1 to 5, preferably the peptide or variant thereof according to any of claims 1 to 5 when bound to an MHC molecule.
16. Use of a peptide according to any one of claims 1 to 6, the nucleic acid according to claim 7, the expression vector according to claim 8, the cell according to claim 9, the activated T lymphocyte according to claim 13 or the antibody according to claim 15 for use in diagnosis and/or treatment of cancer, or for use in the manufacture of a medicament against cancer.
17. The use according to claim 16, wherein said cancer is selected from the group of glioblastoma, breast cancer, colorectal cancer, renal cell carcinoma, chronic lymphocytic leukemia, hepatocellular carcinoma, non-small cell and small cell lung cancer, Non-Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, pancreatic cancer, prostate cancer, esophageal cancer including cancer of the gastric-esophageal junction, gallbladder cancer and cholangiocarcinoma, melanoma, gastric cancer, testis cancer, urinary bladder cancer, or uterine cancer. and other tumours that show an overexpression of a protein from which a peptide SEQ ID No. 1 to SEQ ID No. 240, SEQ ID No. 242 to SEQ ID No. 322 and SEQ ID No. 324 to SEQ ID No. 388 is derived from.
18. A kit comprising:
 - (a) a container comprising a pharmaceutical composition containing the peptide(s) or the variant according to any one of claims 1 to 6, the nucleic acid(s) according to claim 7, the expression vector(s) according to claim 8, the cell(s) according to claim 10, the activated T lymphocyte(s) according to claim 13 or the antibody according to claim 15, in solution or in lyophilized form;
 - (b) optionally, a second container containing a diluent or reconstituting solution for the lyophilized formulation;
 - (c) optionally, at least one more peptide selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 240, SEQ ID No. 242 to SEQ ID No. 322 and SEQ ID No. 324 to SEQ ID No. 417, and

- (d) optionally, instructions for (i) use of the solution or (ii) reconstitution and/or use of the lyophilized formulation.
19. The kit according to claim 18, further comprising one or more of (iii) a buffer, (iv) a diluent, (v) a filter, (vi) a needle, or (v) a syringe.
20. The kit according to claim 18 or 19, wherein said peptide is selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 240, SEQ ID No. 242 to SEQ ID No. 322 and SEQ ID No. 324 to SEQ ID No. 388.
21. A method for producing a personalized anti-cancer vaccine or a compound-based and/or cellular therapy for an individual patient, said method comprising:
- a) identifying tumour-associated peptides (TUMAPs) presented by a tumour sample from said individual patient;
 - b) comparing the peptides as identified in a) with a warehouse of peptides that have been pre-screened for immunogenicity and/or over-presentation in tumours as compared to normal tissues
 - c) selecting at least one peptide from the warehouse that matches a TUMAP identified in the patient; and
 - d) formulating the personalized vaccine or compound-based or cellular therapy based on step c).
22. The method according to claim 21, wherein said TUMAPs are identified by:
- a1) comparing expression data from the tumour sample to expression data from a sample of normal tissue corresponding to the tissue type of the tumour sample to identify proteins that are over-expressed or aberrantly expressed in the tumour sample; and
 - a2) correlating the expression data with sequences of MHC ligands bound to MHC class I and/or class II molecules in the tumour sample to identify MHC ligands derived from proteins over-expressed or aberrantly expressed by the tumour.
23. The method according to claim 21 or 22, wherein the sequences of MHC ligands are identified by eluting bound peptides from MHC molecules isolated from the tumour sample, and sequencing the eluted ligands.

24. The method according to any of claims 21 to 23, wherein the normal tissue corresponding to the tissue type of the tumour sample is obtained from the same patient.
25. The method according to any one of claims 21 to 24, wherein the peptides included in the warehouse are identified based on the following steps:
 - aa. Performing genome-wide messenger ribonucleic acid (mRNA) expression analysis by highly parallel methods, such as microarrays or sequencing-based expression profiling, comprising identify genes that over-expressed in a malignant tissue, compared with a normal tissue or tissues;
 - ab. Selecting peptides encoded by selectively expressed or over-expressed genes as detected in step aa, and
 - ac. Determining an induction of in vivo T-cell responses by the peptides as selected comprising *in vitro* immunogenicity assays using human T cells from healthy donors or said patient; or
 - ba. Identifying HLA ligands from said tumour sample using mass spectrometry;
 - bb. Performing genome-wide messenger ribonucleic acid (mRNA) expression analysis by highly parallel methods, such as microarrays or sequencing-based expression profiling, comprising identify genes that over-expressed in a malignant tissue, compared with a normal tissue or tissues;
 - bc. Comparing the identified HLA ligands to said gene expression data;
 - bd. Selecting peptides encoded by selectively expressed or over-expressed genes as detected in step bc;
 - be. Re-detecting of selected TUMAPs from step bd on tumour tissue and lack of or infrequent detection on healthy tissues and confirming the relevance of over-expression at the mRNA level; and
 - bf. Determining an induction of in vivo T-cell responses by the peptides as selected comprising *in vitro* immunogenicity assays using human T cells from healthy donors or said patient.
26. The method according to any of claims 21 to 25, wherein the immunogenicity of the peptides included in the warehouse is determined by a method comprising in vitro immunogenicity assays, patient immunomonitoring for individual HLA

binding, MHC multimer staining, ELISPOT assays and/or intracellular cytokine staining.

27. The method according to any of claims 21 to 26, wherein said warehouse comprises a plurality of peptides selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 240, SEQ ID No. 242 to SEQ ID No. 322 and SEQ ID No. 324 to SEQ ID No. 417.
28. The method according to any of claims 21 to 27, further comprising identifying at least one mutation that is unique to the tumour sample relative to normal corresponding tissue from the individual patient, and selecting a peptide that correlates with the mutation for inclusion in the vaccine or for the generation of cellular therapies.
29. The method according to claim 28, wherein said at least one mutation is identified by whole genome sequencing.
30. A T-cell receptor, preferably soluble or membrane-bound, that is reactive with an HLA ligand, wherein said ligand has at least 75% identity to an amino acid sequence selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 240, SEQ ID No. 242 to SEQ ID No. 322 and SEQ ID No. 324 to SEQ ID No. 388.
31. The T-cell receptor according to claim 30, wherein said amino acid sequence is at least 88% identical to SEQ ID No. 1 to SEQ ID No. 240, SEQ ID No. 242 to SEQ ID No. 322 and SEQ ID No. 324 to SEQ ID No. 388.
32. The T-cell receptor according to claim 30 or 31, wherein said amino acid sequence consists any of SEQ ID No. 1 to SEQ ID No. 240, SEQ ID No. 242 to SEQ ID No. 322 and SEQ ID No. 324 to SEQ ID No. 388 .
33. The T-cell receptor according to any of claims 30 to 32, wherein said T-cell receptor is provided as a soluble molecule and optionally carries a further effector function, such as an immune stimulating domain or toxin.
34. A nucleic acid, encoding for a TCR according to any one of claims 30 to 33, optionally linked to a heterologous promoter sequence.

35. An expression vector capable of expressing the nucleic acid according to claim 34.
36. A host cell comprising the nucleic acid according to claim 34 or the nucleic acid encoding an antibody according to claim 15 or the expression vector according to claim 35, wherein said host cell preferably is a T cell or NK cell.
37. A method for producing the T cell receptor according to any claims 30 to 33, said method comprising culturing a host cell according to Claim 36, and isolating said T cell receptor from said host cell and/or its culture medium.
38. A pharmaceutical composition comprising at least one active ingredient selected from the group consisting of
 - a) the peptide selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 240, SEQ ID No. 242 to SEQ ID No. 322 and SEQ ID No. 324 to SEQ ID No. 388;
 - b) a T-cell receptor reactive with a peptide and/or the peptide-MHC complex according to a);
 - c) a fusion protein comprising a peptide according to a), and the N-terminal amino acids 1 to 80 of the HLA-DR antigen-associated invariant chain (II);
 - d) a nucleic acid encoding for any of a) to c) or an expression vector comprising said nucleic acid,
 - e) a host cell comprising the expression vector of d,
 - f) an activated T-lymphocyte, obtained by a method comprising contacting in vitro T cells with a peptide according to a) expressed on the surface of a suitable antigen presenting cell for a period of time sufficient to activate said T cell in an antigen specific manner, as well as a method to transfer these activated T cells into the autologous or other patients;
 - g) an antibody, or soluble T-cell receptor, reactive to a peptide and/or the peptide – MHC complex according to a) and/or a cell presenting a peptide according to a), and potentially modified by fusion with for example immune-activating domains or toxins,
 - h) an aptamer recognizing a peptide selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 240, SEQ ID No. 242 to SEQ ID No. 322 and SEQ

ID No. 324 to SEQ ID No. 388 and/or a complex of a peptide selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 240, SEQ ID No. 242 to SEQ ID No. 322 and SEQ ID No. 324 to SEQ ID No. 388 with a MHC molecule,

i) a conjugated or labelled peptide or scaffold according to any of a) to h) and a pharmaceutically acceptable carrier, and optionally, pharmaceutically acceptable excipients and/or stabilizers.

39. An aptamer that specifically recognizes the peptide or variant thereof according to any of claims 1 to 5, preferably the peptide or variant thereof according to any of claims 1 to 5 that is bound to an MHC molecule.